Guidance on Cancer Services

Improving Outcomes in Children and Young People with Cancer

The Evidence Review

August 2005

Developed by the National Collaborating Centre for Cancer
Guidance on Cancer Services

Improving Outcomes in Children and Young People with Cancer

The Evidence Review
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Presentation, Referral &amp; Diagnosis</td>
<td>9</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td></td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>27</td>
</tr>
<tr>
<td>Surgery</td>
<td>44</td>
</tr>
<tr>
<td>Neurosurgery</td>
<td>57</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>67</td>
</tr>
<tr>
<td><strong>Supportive Care</strong></td>
<td></td>
</tr>
<tr>
<td>Febrile Neutropenia</td>
<td>78</td>
</tr>
<tr>
<td>Central Venous Access</td>
<td>93</td>
</tr>
<tr>
<td>Blood Product Support</td>
<td>111</td>
</tr>
<tr>
<td>Pain Management</td>
<td>113</td>
</tr>
<tr>
<td>Management of Nausea and Vomiting</td>
<td>119</td>
</tr>
<tr>
<td>Nutrition</td>
<td>122</td>
</tr>
<tr>
<td>Oral &amp; Dental Care</td>
<td>125</td>
</tr>
<tr>
<td><strong>Rehabilitation</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>129</td>
</tr>
<tr>
<td><strong>Psychosocial Care</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>132</td>
</tr>
<tr>
<td><strong>Long Term Follow Up/Sequelae</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>138</td>
</tr>
<tr>
<td><strong>Palliative Care</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>150</td>
</tr>
<tr>
<td><strong>Bereavement</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>164</td>
</tr>
<tr>
<td><strong>Delivery of Care</strong></td>
<td></td>
</tr>
<tr>
<td>Multidisciplinary Teams/Care</td>
<td>168</td>
</tr>
<tr>
<td>Section</td>
<td>Page</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Continuity of Care</td>
<td>174</td>
</tr>
<tr>
<td>Protocol Based Care</td>
<td>183</td>
</tr>
<tr>
<td>Place of Care</td>
<td>189</td>
</tr>
<tr>
<td>Communication/Information</td>
<td>212</td>
</tr>
<tr>
<td>Research</td>
<td>219</td>
</tr>
<tr>
<td>Appendix A</td>
<td>229</td>
</tr>
<tr>
<td>Appendix B</td>
<td>232</td>
</tr>
<tr>
<td>Appendix C</td>
<td>235</td>
</tr>
<tr>
<td>Appendix D</td>
<td>236</td>
</tr>
<tr>
<td>Appendix E</td>
<td>313</td>
</tr>
<tr>
<td>Appendix F</td>
<td>329</td>
</tr>
<tr>
<td>Appendix G</td>
<td>340</td>
</tr>
<tr>
<td>Appendix H</td>
<td>343</td>
</tr>
<tr>
<td>Appendix I</td>
<td>356</td>
</tr>
<tr>
<td>Appendix J</td>
<td>375</td>
</tr>
<tr>
<td>Appendix K</td>
<td>406</td>
</tr>
<tr>
<td>Appendix L</td>
<td>437</td>
</tr>
</tbody>
</table>
Introduction

This document contains a summary of the evidence reviewed for the production of the recommendations in Guidance for Commissioning Cancer Services – Improving Outcomes in Children and Young People with Cancer - The Manual. As with previous documents in this series, the topic areas are dealt with in the same order as in the Manual to facilitate cross referencing.

The purpose of the review is to determine the current evidence on interventions and models of care to guide and improve service provision for children and young people with cancer. The association between such evidence and patient outcomes is frequently lacking and in many instances it has been necessary to assume that improvement of health care service delivery and practice should enhance patient outcomes.

Methodology

- Searching for evidence

There are 3 stages to the identification and retrieval of evidence:

(i) Clinical question development

The members of the Guidance Development Group (GDG) were asked to consider the issues covered in the project scope and to submit clinical questions covering these issues. A total of 180 questions were submitted to the National Collaborating Centre for Cancer (NCC-C). It was clearly not possible to carry out full literature searches on each question, due to time limitations. The clinical questions were therefore prioritised by the NCC-C Director/Lead Researcher/Chair/Clinical Lead for full searching (Appendix A) or 'high level' searching (Appendix B) and subsequent critical appraisal. The questions are presented in the evidence tables in the initial free form structure. These questions were converted to more
structured questions for searching using the Population Intervention Comparison Outcome (PICO) format.

(ii) Literature searching

**Systematic.** A systematic search strategy to identify published evidence for each clinical question was developed by the NCC-C Information Specialists (Appendix A). The search period ended on the 6th December 2004.

**High level searching:** The wide range of topic areas for consideration for children and young people with cancer necessitated the use of a pragmatic approach to searching for evidence in order to achieve production of the guidance within the timescales for delivery. It is clear that there had to be a balance between timeliness and rigour. Such an approach was also necessary to try and identify the type of literature relevant to service delivery. It is well known that the classical databases for medical literature, such as Medline, do not adequately index such literature. The Lead Researcher used validated methods that involved the use of meta-search engines and other databases for ‘high level’ searching to quickly identify relevant evidence (Appendix B).

Identified titles and abstracts were initially screened for relevance to the clinical question by the Information Specialist and Researcher. Definite inclusion/exclusion criteria were not employed for articles, because of the nature and variability of the literature on service delivery. Only articles in English, French, German and Spanish were selected for critical appraisal. In some instances help from a member of the GDG was enlisted to verify the relevance of selected articles and as a supplementary check on the completeness of the search. In general no formal contact was made with the authors for each paper identified, but occasionally communication was made for clarification of specific points.
(iii) Critical appraisal
The full papers were critically appraised using the methodology from the *NICE Guideline Development Methods* manual and the data relevant to the question was entered into an evidence table. Owing to practical limitations the final selection, critical appraisal and data extraction were undertaken by a single Researcher. All tables were circulated to the GDG members for comments. References were also supplied by the GDG members and some stakeholder evidence was used. Both sources were always appraised for quality.

- Synthesising evidence
There were very few randomised controlled trials (RCTs) relevant to the majority of the clinical questions. This is a widely acknowledged problem with health service research and every effort was made to maximise the retrieval of relevant high quality literature. Where available, evidence from good quality systematic reviews was appraised and included in the evidence tables; not all studies in the reviews were individually appraised.

Evidence for each topic was extracted into tables and summarised in the form of a considered judgement form (modified from the Scottish Intercollegiate Guideline Network methodology). The tables recommended for use in the NICE methodology manual were modified to accept the type of studies identified for service guidance. The quality of evidence was graded using the NICE hierarchy of evidence and the quality checklists. Evidence was usually rejected if graded as poor quality, apart from where it had been cited in the expert position papers and/or was of Level 1 type and was highly relevant to the question (Appendix C).

- Expert position papers
The GDG identified areas where there was a requirement for expert input. These areas were addressed by the production of a position paper by a recognised
expert. Such experts were identified by contacting the relevant registered stakeholder and asking for a suitable nomination to deal with a particular topic area. A ‘high level’ search was performed to supplement these position papers, but there was usually no formal assessment of the papers cited within. These papers were presented at the GDG meetings for discussion. The papers that made a substantial contribution to the evidence are included in Appendices F-K.

Key strategic documents pertinent to paediatric oncology and/or child and young people’s health were also identified as sources of evidence (Appendix A, The Manual). Relevant national and international guidelines were referred to during the guidance development process (Appendix A, The Manual). Where feasible the guidelines were appraised for quality using the Appraisal of Guidelines Research and Evaluation tool (AGREE).

- **Health economic evidence**
  Economic evidence was extracted from the evidence tables, where it existed and was supplemented with searches performed by the Centre for the Economics of Health, University of Wales, Bangor.

- **Complementary research**
  One complementary piece of research was commissioned to elicit children and young people’s views about cancer service provision. The National Children’s Bureau performed this study, the full results of which are given in Appendix D.

  The results of a survey of teenagers (age range 14-23 years) views on the provision of cancer services from a conference organised by the Teenage Cancer Trust in 2004 were also used to provide information on the specific requirements of this age group (Appendix E).
• **Drafting recommendations**
The GDG members were allocated specific topic areas and asked to review the evidence tables pertaining to the topic and draft recommendations for the service guidance. At the 10th GDG meeting of the 12 during the development phase, the GDG members participated in an event that involved external facilitation. This resulted in a list of three types of recommendations that were classified as essential, desirable and potential. The resulting recommendations were then examined by the Chair and Clinical Lead prior to writing the first draft of the guidance.

• **Agreeing recommendations**
Once an early draft of the guidance was produced, the GDG members were asked to review the draft document and consider whether:

a) there appeared to be any major gaps in the synthesised evidence.

b) the recommendations were justified from the evidence presented and whether they were sufficiently practical and precise so that health service commissioners and the relevant front line health care professionals could implement them.

During the development of this guidance no formal consensus methods were used. Consensus was achieved by informal means during GDG meetings and correspondence outside the meetings.

The absence of high quality evidence for the majority of the clinical questions/topic areas made the grading of the recommendations impractical.

• **Writing of the guidance**
The first formal draft version of the guidance was coordinated by the Chair and Clinical Lead of the GDG in accordance with the decisions of the GDG. The draft guidance was circulated for consultation according to the formal NICE stakeholder consultation and validation process prior to publication.
Presentation, Referral & Diagnosis

The Question:

What is the evidence for delays in presentation, referral and diagnosis in children and young people with cancer?

Nature of the evidence

During the guidance development period the NICE clinical guidelines for general practitioners on *Referral for Suspected Cancer* were released for consultation and some of the evidence contained in them was used, after critically appraising the articles.

Data was extracted from:

- 10 historical case series, 1 of good quality; 5 of fair quality; 4 of fair to poor quality
- 1 retrospective comparative study with historical control of fair to poor quality
- 1 qualitative study of fair to poor quality
- 2 surveys, 1 of good quality; 1 of fair to poor quality
- 1 audit of fair to poor quality

Summary of the supporting evidence for the recommendations

- There was consensus from the GDG members that implementation of the NICE GP referral guidelines for cancer should improve delays in referrals, but that training and resources would be required.
- The evidence from one historical case series indicated that 32% of patients with brain tumours are diagnosed within 30 days. The delay is
contributed to by parental and physician delays and are caused by failure to recognise signs and symptoms \(^4\).

- One survey of incidence rates of childhood cancer indicated that it was rare and that because of the rarity, guidelines for GPs were required \(^8\).
- One historical case series demonstrated that the delay for brain stem tumours was greater than for other brain tumours. No effect of age or sex could be shown \(^12\).
- Evidence from one historical case series demonstrated that age was significantly correlated with lag time. There was no correlation between lag time and outcome \(^16\).
- Parental delays were shown to be shorter in one case series for children with acute lymphatic leukaemia (ALL) compared with brain tumours, doctor delays were the same \(^17\).
- Evidence from one historical case series demonstrated that age, parental education level and lack of social security assistance affected time to diagnosis. Delays were greatest for Hodgkin’s disease, retinoblastoma & unspecified neoplasms and shortest for leukaemia \(^7\).
- The risk of local tumour invasion was increased with diagnostic delay in one historical case series. Primary healthcare professionals require education about the importance of ocular symptoms, especially squint, in paediatric patients \(^10\).
- A review of qualitative studies concluded that there is a need for training in communication skills \(^1\).
- Evidence from one historical case series of patients with retinoblastoma (RB) indicated that delays in diagnosis did not affect outcomes. There was a trend towards eye loss in bilateral RB \(^2\).
- There was evidence from one historical case series that younger children (0-2 yrs) are diagnosed more quickly than older children \(^5\).
- In one comparative study the results showed that children < 5 yrs were diagnosed more quickly. The delay was greatest for brain tumours compared with acute lymphoblastic leukaemia and Wilm’s tumours \(^9\).
Evidence from 1 historical case series suggests that the greatest delay in diagnosis is the failure of the family to recognise symptoms in patients with retinoblastoma. There was evidence of age correlation with lag time from one large historical case series for all solid tumour types except Hodgkin’s disease. The preliminary results of an audit indicated that the 2 week referral method is not appropriate for childhood cancer. The results of the survey performed in 2004 by the Teenage Cancer Trust indicated that there are particular problems with delays in referral for older children and young people.

There was a scarcity of papers that evaluated the reasons behind diagnostic delays. Furthermore the studies did not always distinguish between primary and secondary care related delays. Diagnostic delays do however appear to be correlated with age and the older the child, the longer the delay between presentation and diagnosis. For some cancers there is a lack of awareness by parents of the warning signs and symptoms. Delays are also contributed towards by difficulties that general practitioners have in recognising symptoms that may be vague and occur in other less serious illnesses.
## EVIDENCE FOR DELAYS IN PRESENTATION, REFERRAL AND DIAGNOSIS IN CHILDREN AND YOUNG PEOPLE WITH CANCER

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
</table>
• Exercising choice  
• Referral pathways  
• Withdrawal of trust from medical practitioners | Interviews were performed with members of 98 (133 were identified as eligible; 74% response rate) families of children with cancer. 278 adults with RSI were interviewed. The evidence suggests:-  
• that the parents of children with cancer and adults with RSI felt that their experiences and knowledge were disregarded by doctors during the process of diagnosis.  
• There is a need for additional training in communication skills and occupational health problems. | Reviews studies by Sloper 1996. Insufficient details of qualitative analysis methods used. | Review of selected qualitative studies | 3 +/- |
| 2. Butros LJ, Abramson DH, Dunkel IJ (2002) Delayed diagnosis of retinoblastoma: analysis of degree, cause, and potential consequences. Pediatrics 109:1-5. | 57 patients with retinoblastoma diagnosed between November 1993 – January 1998. US. | Assessment of degree, cause and consequences of delays in diagnosis. | Adverse effects of delayed diagnosis, such as eye loss. | The median time from presenting signs to diagnosis was 1.5 months (unilateral disease) and 2.25 months (bilateral disease). 77% of patients delayed seeking treatment. Primary care physicians delayed referral in 30% of | Recall bias possible. Small sample size. No p values stated. No discussion of reasons for patient attrition. | Historical case series. | 3 +/- |

1 See Appendix C for explanation of evidence levels and quality grading
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Dixon-Woods M, Findlay M, Young B et al. (2001) Parents' accounts of obtaining a diagnosis of childhood cancer. Lancet 357:670-4.</td>
<td>20 parents whose children (aged 4-18 yrs) had a confirmed diagnosis of cancer (leukaemia) or brain or solid tumours UK.</td>
<td>Semi-structured interviews.</td>
<td>The feelings of parents about the diagnosis process. Whether the narratives had implications for early diagnosis and referral.</td>
<td>Response rate 95%. There was good consistency between parent’s accounts and the medical records. Data were analysed by the constant comparison method. The signs and symptoms of younger children were first noticed by parents. Parents of older children and adolescents often had to be told of problem. Early symptoms often vague. There were disputes in 7/20 families with the GP.</td>
<td>The study is limited to 1 paediatric oncology unit. There were few examples of the types of tumour that can be prone to delays in diagnosis. Communication or information issues not addressed.</td>
<td>Qualitative</td>
<td>3</td>
</tr>
<tr>
<td>4. Dobrovoljac M, Hengartner H, Boltshauser E et al. (2002) Delay in the diagnosis of paediatric brain tumours. European Journal of Paediatrics 161:663-7.</td>
<td>252 children with primary brain tumours diagnosed between 1980 – December 1999. Switzerland.</td>
<td>Identification of reasons for delay in diagnosis.</td>
<td>Pre-diagnostic symptomatic interval (PSI) defined as interval between onset of signs/symptoms and the time of diagnosis by imaging.</td>
<td>The median pre-diagnostic symptomatic interval [PSI] (defined as the interval between onset of signs/symptoms and the time of diagnosis by imaging) was 60 days (range 0-8.2 years) with a parental delay of 14 days (range 0-6.3 yrs) and a doctor’s delay of 30 days (range 0-8.2 yrs). 81 (32%) of the tumours were diagnosed within 30 days</td>
<td>Well described study with appropriate use of statistics. No distinction between delays in primary care and secondary care</td>
<td>Historical case series</td>
<td>3</td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review 13
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Edgeworth J, Bullock P, Bailey AM et al. (1996)</td>
<td>74 children (0-16 yrs) with primary brain tumours admitted during 1990-1994 to a neurosurgical unit, UK.</td>
<td>Examination of the duration and characteristics of symptoms and signs and the nature of consultations before diagnosis.</td>
<td>after symptom onset. Patients with raised intracranial pressure (ICP) had a statistically shorter PSI (median 60 versus 152 days; p = 0.007, Mann-Whitney test) and shorter doctor’s delays (median 20 versus 60 days; p = 0.02, Mann-Whitney test) when compared with the children without increased ICP. However the parental delays for these two groups of patients were similar. Gender did not correlate with PSI, parental delay or doctor’s delay. In 75 (45%), the doctor’s delay was more than 30 days indicating misinterpretation of signs and/or symptoms. Common diagnostic difficulties included the correct interpretation of headache, nausea/vomiting, seizures, behavioural changes and squint/diplopia.</td>
<td>No examination of causal relationship. Some methodological problems with analysis of the qualitative interview data.</td>
<td>Historical case series Questionnaire survey</td>
<td>3 +/-</td>
<td></td>
</tr>
</tbody>
</table>
## STUDY

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. Eiser C, Parkyn T, Havermans T et al. (1994) Parents’ recall on the diagnosis of cancer in their child. <em>Psychooncology</em> 3:197-203.</td>
<td>30 families with a child diagnosed with cancer (ALL, lymphomas, solid tumours and brain tumours).</td>
<td>Determination of information parents’ recall being given on diagnosis and assessment of information they would have liked.</td>
<td>In 20 cases mothers were told by the GP or local hospital before they received fuller information at the oncology unit or regional centre. 2/20 mothers reported that this initial explanation was incomplete. No real criticism of the way information was given at the oncology unit or regional centre. Policy in both centres was that children &gt; 8 were told of diagnosis.</td>
<td>Some relevance to question. Insufficient details given for appraisal</td>
<td>Qualitative 3</td>
</tr>
<tr>
<td>7. Fajardo-Gutierrez A, Sandoval-Mex AM, Mejia-Arangure JM et al. (2002) Clinical and social factors</td>
<td>4940 children with cancer referred to secondary care. Mexico.</td>
<td>Estimation of delays in diagnosis and factors involved.</td>
<td>The time to diagnosis for all types of cancer ranged from 1 to 5 months. The shortest was for leukaemia.</td>
<td>Health service different in Mexico compared with UK.</td>
<td>Historical case series 3</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>Medical and Pediatric Oncology 39:25-31.</td>
<td></td>
<td></td>
<td></td>
<td>(median = one month) and the longest for Hodgkin’s disease, retinoblastoma and unspecified malignant neoplasms (median = five months). When grouped by age in years as &lt; 1 (the reference age), 1-4, 5-9, and 10-14; the risk of a delayed time to diagnosis increased with age ($\chi^2 = 29.12; p = 0.0001$), the highest being for the 10-14 group (OR = 1.8; 95% CI = 1.4-2.3). Gender did not significantly affect time to diagnosis (OR = 1.1; 95% CI = 1.0-1.3). Parental educational level also influenced time to delay, and there was risk of delayed time to diagnosis in the lower compared to the higher educational level group (OR = 1.4; 95% CI = 1.1-1.8 for fathers, and OR = 1.5; 95% CI = 1.2-2.1 for mothers). The population without National Social Security had greater risk of delayed time to diagnosis (OR = 1.3; 95% CI = 1.1-1.4). The risk of delayed time to diagnosis varied among the different cancer types, but in general, age at diagnosis was the variable with greatest influence.</td>
<td></td>
</tr>
<tr>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>8. Feltbower RG, Lewis IJ, Picton S et al. (2004)</td>
<td>1215 children &lt; 15 yrs, diagnosed with cancer 1999-2001.</td>
<td>Calculation of incidence rates across 2 strategic health authorities in Yorkshire (25 PCTs).</td>
<td>Rates of cancer for each PCT. Standardised morbidity ratios (SMRs).</td>
<td>The demographic and socioeconomic profiles of the PCTs in Yorkshire were highly representative of England and Wales: the median childhood population counts were 26,700 in Yorkshire compared with 27,400 in the rest of England &amp; Wales. No significant heterogeneity in SMRs across PCTs (p=0.09). The PCTs could expect 3-5 resident children to be newly diagnosed with cancer/yr. Based on the number of registered practitioners (defined as unrestricted principals &amp; equivalents) [n=2050], a single GP will see a child diagnosed with cancer once every 3 years on average. The authors conclude that childhood cancer is rare and therefore referral guidelines are required. There is also a need for availability of GP paediatricians i.e. GPs with a special interest.</td>
<td>Useful data in view of comparability with rest of England &amp; Wales.</td>
</tr>
<tr>
<td>9. Flores LE, Williams DL, Bell BA et al. (1986)</td>
<td>79 children (&lt; 20 yrs) with primary brain tumours, diagnosed between 1976-1984. 45 patients with Wilm's tumours and 123</td>
<td>Comparison of the interval from symptom onset to diagnosis in children with primary brain tumours with children with Wilm's tumours and ALL.</td>
<td>The mean diagnostic delay in patients with brain tumours was 26 weeks, with a median of six weeks. Patients less than 5 years of age who had infratentorial tumours and</td>
<td>Inadequate description of statistics. Small sample with inadequate power. Does not consider whether diagnostic</td>
<td>Retrospective comparative study</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| | Parents of 100 children (with retinoblastoma treated between 1993-1996). 34 patients had bilateral disease and 66 unilateral. UK. | Determination of extent of diagnostic delay and associated factors and the effect on treatment outcome. | Parents were asked to recall the sequence of events from the time they first noted "something wrong" with their child's eye(s) to the diagnosis of retinoblastoma.  
- Lag 1 = the time interval between the date the first symptom was noted and the date of first consultation with a primary healthcare professional (PHP) (parental delay).  
- Lag 2 = the time interval between Leucocoria was the initial symptom in 52/100 patients. Squint, was the first symptom noted in 29 patients. The parents of 10 patients noted change in the appearance of their child's eye(s). In nine patients the first symptom noted related to decreased visual acuity. The median age at first symptom of patients with bilateral tumours was 5.0 (0-33) months. Patients with unilateral tumours were significantly older (p <0.001) with a median age of 18.0 (1-95) months at first symptom. Although 49% of patients | | | |
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>11. Haik BG, Siedlecki A, Elisworth RM et al. (1985) Documented delays in the diagnosis of retinoblastoma. <em>Annals of Ophthalmology</em> 17:731-2.</td>
<td>250 cases of retinoblastoma referred to ophthalmic oncology centre between 1974 and 1983.</td>
<td>Investigation of whether delays occur in diagnosis and referral.</td>
<td>• Time from birth to first symptoms. • Time from first symptom to examination in primary care. • Time to subsequent referral to ophthalmologist.</td>
<td>28 patients (11%) had a family history of retinoblastoma. The median age at diagnosis was 6 months for such patients compared with 19 months for those with no family history. The longest interval was median time elapsed to treatment with primary enucleation was not increased by diagnostic delay. There were no deaths during the study period. The authors conclude that primary healthcare professionals require education about the importance of ocular symptoms, especially squint, in paediatric patients.</td>
<td>Poor description of statistics.</td>
</tr>
</tbody>
</table>

**DESIGN**

**EVIDENCE LEVEL/QUALITY**

3 +/-
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;i&gt;italics=reviewers comments&lt;/i&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>first discernable symptom (4 months with positive family history [range 1-18 months], and 15 months without [range 1-115 months]). The next longest interval was median time elapsed from the primary care physician to referral to an ophthalmologist (five [range 1-32 weeks] and nine weeks [range 1-128 weeks], respectively). Significant percentages of primary care physicians (47% for children with no positive family history, and 25% for children with positive family history) delayed referral for a significant period of time (19 weeks for both groups). The mean time from first symptom to seeking the opinion of a primary care physician was 2 weeks (range 1-8 weeks) for children with a positive family history, and 5 weeks (range 1-100 weeks) for children with a negative family history. The authors conclude that the greatest delay in diagnosis is the failure of the patient’s family to appreciate the significance of first symptoms.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>12. Mehta V, Chapman A, McNeely PD et al. (2002)</td>
<td>104 patients (&lt; 17 years) diagnosed with brain tumours between 1995 and 2000. Canada.</td>
<td>Investigation of time required for diagnosis and factors involved in this diagnosis.</td>
<td>Median time from symptom onset to diagnosis.</td>
<td>The mean time from the onset of symptoms to diagnosis was 7.3 months (95% CI, 4.99-9.67 months) and only 41% of cases were correctly diagnosed within 3 visits to various doctors; 30% of children required &gt; 7 visits. Sex or age did not affect time to diagnosis. Delays in diagnosis were significantly greater for brainstem tumours compared with those located elsewhere (mean = 11.76 months [95% CI, 3.13-20.39 months] versus 6.57 months [95% CI, 4.20-8.95 months], p = .014). Patients with medulloblastoma exhibited significantly shorter diagnostic times, compared with other pathological subtypes (mean = 3.78 months [95% CI, 1.97-5.59 months] versus 8.35 months [95% CI, 5.40-11.3 months], p = 0.006).</td>
<td>Recall bias. Well described and designed study. The authors examined medical records and performed structured interviews. Appropriate use of statistics.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Historical case series</td>
<td>3/4 ++</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
</tr>
<tr>
<td>14. Poirier V, Foot A, Walsh J et al. (2004) Paediatric cancer – defining the pathway for children in the South West. SWCIS unpublished.</td>
<td>Children diagnosed with a malignancy.</td>
</tr>
<tr>
<td>15. Pollock BH, Krischer JP, Vietti TJ (1991) Interval between symptom onset and diagnosis of paediatric solid tumours. Journal of Paediatrics 119:725-32.</td>
<td>2665 children with solid tumours diagnosed between 1982-1988. (children were entered into POG therapeutic protocols). US.</td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review
### RESULTS

Multivariate regression analysis was performed separately for each diagnostic group. With the exception of the Hodgkin’s disease group, age remained a significant independent predictor of lag time for all diagnostic groups ($p < 0.05$). Consistent with the univariate analysis, gender remained significantly associated with lag time for non-Hodgkin’s lymphoma ($p = 0.02$). The multivariate analysis also revealed a significant association between gender and lag time for Ewing’s sarcoma ($p = 0.02$). The association differed in these two tumour groups; girls had longer lag times in the non-Hodgkin lymphoma group but shorter lag times in the Ewing’s sarcoma group.

Also consistent with the univariate analysis, race maintained a statistically significant association with lag time only for osteosarcoma ($p = 0.02$). Signs and symptoms were compared for shorter (not more than the median) lag time and longer (greater than the median) lag time groups within each diagnostic category. Patients with shorter lag...
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>16. Saha V, Love S, Eden T et al. (1993) Determinants of symptom interval in childhood cancer. <em>Archives of Disease in Childhood</em> 68:771-4.</td>
<td>236 children (0-15 years) diagnosed with cancer from 1982-1990. UK.</td>
<td>Identification of the determinants of lag time within multiple diagnostic groups and with age, sex and extent of disease. The study was designed to examine first the relation of lag time within multiple cancer diagnostic groups and with age, gender, and extent of disease in a cohort from the UK, and then compare the results with those of previous studies.</td>
<td>A child was considered to be symptomatic from the day that unrelieved symptoms that could be directly attributed to a malignancy were first recorded. The lag time was calculated from the date of onset of symptoms until the date of diagnosis to the nearest week, its relationship with patient demographic and clinical data was then examined.</td>
<td>The mean lag time varied from 2.8 weeks for nephroblastoma to 13.3 weeks in brain tumour. One way analysis of variance showed diagnostic group to be significant for length of lag time, F(6,161) = 5.5, p &lt;0.001. There was no significant difference in the lag time between males and females. Age was a significant predictor for lag time, F(1,182) = 24.1, p &lt;0.001, with older children having a longer lag time.</td>
<td>Small numbers in each diagnostic category. Study does not assess directly the role of physician or parent. Recall bias possible.</td>
<td>Historical case series</td>
<td>3</td>
</tr>
</tbody>
</table>

Time for brain tumour had a 67% frequency of gait abnormalities and ataxia, compared with 59% for those with a longer lag time (p = 0.13), but were similar with respect to other common symptoms of brain tumour. For neuroblastoma, abdominal masses were more common in patients with shorter lag times (31.5 vs 9.6%; p = 0.037). Patients with shorter lag time for non-Hodgkin lymphoma had a higher frequency of abdominal masses (13% vs 5%; p = 0.06) and of breathing difficulty and coughing (32% vs 15%, p = 0.007).
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>17. Thulesius H, Pola J, Hakanson A (2000) Diagnostic delay in pediatric malignancies – a population based study. Acta Oncologica 39:873-876.</td>
<td>64 children, mean age 7.8 yrs (0-16 yrs) with cancer (leukaemia &amp; brain tumours) diagnosed between 1984-1995.</td>
<td>Investigation of the diagnostic process of childhood malignancies from the viewpoint of the GP, with the focus on the time course from initial symptoms until diagnosis and start of treatment.</td>
<td>Parental delay was defined as the interval from first symptoms to first consultation with a physician, and a doctor's delay as the time from first consultation to diagnosis. Treatment delay was the period from diagnosis to start of treatment. Lag time was the time from first symptoms to diagnosis.</td>
<td>Both age, F(1,160) = 16.96, p &lt;0.001 and diagnostic group, F(6,160) = 4.41, p &lt;0.001 remained individually significant after multivariate analysis. The difference in lag time for children with acute leukaemia was not significantly related to a presenting white cell count of ( \geq 50 \times 10^9/l ) compared to those presenting with a lesser count. The difference in lag time between the stages in all diagnostic cancer groups was not significant either. The authors failed to find a positive correlation between lag time and outcome. Insufficient details of statistics. Swedish medical system different from UK in that the GPs do not have a gatekeeper role, patients can see a specialist without a referral. Authors discuss the potential for bias in their study.</td>
<td>Historical case series</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

Parent's delay was shorter than 4 weeks in 22 of 25 children with leukaemia, compared with 9 of 20 children with brain tumours (\( x^2 = 9.59, p = 0.002 \)). For two children with leukaemia, parental delay was 3 months or more. The doctor's delay was <2 weeks for 17 of 25 children with leukaemia, compared with 7 of 21 children with a brain tumour (\( x^2 = 5.50, p = 0.019 \)). Lag time was 4 weeks or less for 19 of 25 children with leukaemia, compared with 6 of 20.
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>children with a brain tumour ($x^2 = 9.52, p = 0.002$). Median lag time also was 3 weeks (range 0-15) for children with leukaemia, and 9 weeks (range 1-199) for children with brain tumours (mean lag time was 3.8 [SD = 3.8] and 19.8 weeks [SD = 43.0], respectively). The mean number of visits to a GP in the year prior to tumour diagnosis was 2.3 for the children with leukaemia and 1.5 for the children with brain tumour (visits leading to diagnosis were included), and 0.2 and 0.6, respectively, the year after diagnosis. In the control group, the mean number of visits to a GP was 1.0 in both years. Diagnostic delays are longer for children with brain tumours compared with children with leukaemia.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Chemotherapy

The Questions:

1. Does the place of administration and management of chemotherapy (CT) affect outcome?
2. What evidence is there that community delivered chemotherapy is delivered more safely and effectively by nursing staff than by parents?
3. Are there reliable methods to monitor chemotherapy treatment compliance?
4. Are protocol compliance and effectiveness greater when treatment is performed by a shared care centre compared with a tertiary care centre?
5. What evidence is there for non-compliance with cancer therapy in children and young people?

Nature of the evidence

Q.1
2 randomised trials of fair to poor quality
4 systematic reviews, 3 of good quality; 1 of fair to poor quality

Q.2
2 systematic reviews of good quality
2 historical case series, 1 of fair quality; 1 of fair to poor quality

Q.3 & 4
3 case series, 1 of fair quality; 2 of fair to poor quality
1 review of good quality
Q.5
1 systematic review of randomised controlled trials of good quality
1 non randomised controlled trial of fair quality
2 qualitative studies of poor quality*
1 historical case series of fair to poor quality
1 guideline of fair quality
1 literature review of fair to poor quality
1 review of fair quality
1 expert opinion of poor quality*
1 expert position paper (Appendix F)

Summary of the supporting evidence for the recommendations

Q.1
• The results of the two randomised controlled trials should be interpreted with caution because of methodological problems. One study 3 found no difference in patient satisfaction or quality of life in patients treated at home. The other trial findings suggest that home treatment may be feasible under some circumstances 4.
• The results of 1 systematic review (all patients with cancer) conclude that there is insufficient evidence on the clinical effectiveness of home versus non-home settings 5. There is some evidence to show that home treatment delivery is safe, although patient selection and training are pivotal. 1 systematic review concluded that there is no evidence for patient acceptability or preferences 1.
• 1 systematic review indicated the requisite criteria for successful delivery of home CT 2.
• No conclusions on the clinical effectiveness of home CT could be made because of the variability of studies in 1 systematic review 5.

* Included as forms part of the evidence in expert position paper
• A review of the effect of home treatment on quality of life concluded that the evidence was inconclusive.

Q.2

• There was no evidence from 1 systematic review on the superiority of nurses versus parents.
• No conclusions could be drawn from 1 systematic review.
• The results from one small case series indicated that parents were enthusiastic about home CT treatment.
• 1 small historical case series demonstrated that parents could be trained to administer IV chemotherapy; no CT related adverse events.

N.B. There were no studies directly comparing nurses versus parents.

Q.3 & 4

• The evidence from 1 historical case series demonstrated that haemoglobin and weight changes were poor parameters for measuring compliance to prednisone.
• The evidence for the assessment of compliance to prednisone and penicillin by metabolite assays was poor.
• Assays of 6 mercaptopurine (6-MP) metabolites were used in 1 very small historical case series to measure compliance.
• The conclusions from 1 review were that the usefulness of urinary steroid assays was limited. Assays of 6-MP and its metabolites only provide information on short term compliance. Evidence from 1 study indicates that assays of RBC 6-TGNs and MeMPs allow early identification of non-compliance.

There was no evidence for shared care versus tertiary care with respect to superiority for compliance.
Q.5

- The evidence from 1 systematic review indicated that there were no RCTs that fulfilled the inclusion criteria and the evidence on compliance was poor \(^4\).
- The evidence from 1 non RCT for the effectiveness of 1 type of patient information leaflet was inconclusive \(^3\).
- The evidence from 2 poor quality qualitative studies had some implications for communication between healthcare professionals and patients and the beliefs of patients and how they affect compliance \(^5\).
- 1 historical case series demonstrated that younger patients preferred a more participatory role \(^2\).
- 1 review (6 studies of relevance to children and adolescents) indicated that non compliance in children was between 2-50%; adolescents were the least compliant \(^6\).
- 1 guideline from SIOP gives the major reasons for non compliance in children and adolescents \(^8\).
- 1 literature review indicated that the evidence on compliance was poor \(^1\).
- 1 expert opinion suggested that patient information leaflets do not provide adequate help to patients and carers \(^7\).

There was insufficient evidence on place of delivery of chemotherapy and its effect on outcomes and on the feasibility of home delivery of chemotherapy, although there was some evidence to indicate that home delivery produces improved quality of life for patients and carers.

The importance of suitable facilities and the presence of appropriately trained staff were confirmed by some Level 3 evidence.

There was evidence indicating that compliance is a particular problem in teenagers and young people. Electronic transfer of prescriptions (ETP) does appear to reduce prescribing errors, but there was no evidence specific for
children and young people. Data is lacking for the effect of ETP on compliance in children and young people with cancer.
## Q.1 DOES THE PLACE OF ADMINISTRATION AND MANAGEMENT OF CHEMOTHERAPY AFFECT OUTCOME?

### HOSPITAL vs COMMUNITY

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Agence d’Evaluation des Technologies et des Modes d’Intervention en Sante (AETMIS) (2001) Home chemotherapy - systematic review (project). Agence d’Evaluation des Technologies et des Modes d’Intervention en Sante (AETMIS).</td>
<td>Adults and children with cancer.</td>
<td>Review of literature on home chemotherapy for cancer patients. Qualitative interviews with service providers in Quebec and Ontario.</td>
<td>Clinical effectiveness, QOL, implications for health care system, ethical, legal &amp; social implications, alternatives.</td>
<td>The authors conclude that there is insufficient evidence on the clinical effectiveness of home chemotherapy (CT) compared with non-home settings. There is more evidence to show that home treatment can be delivered safely, although patient selection &amp; training is paramount. Evidence was poor for improvements in patient QOL with home CT. A total of 17 interviews were performed between May 2001 and March 2002. These interviews revealed variable delivery of home CT and the need for well integrated collaborative teams of health care professionals.</td>
<td>Well designed and comprehensive review of literature on home chemotherapy. Clear description of clinical questions and review methods. Valid conclusions drawn from available evidence. Highly relevant to CT questions. The authors make recommendations for conditions which are a prerequisite for home CT.</td>
<td>Systematic review</td>
<td>2++</td>
</tr>
<tr>
<td>2. L’Agence Nationale d’Accréditation et d’Évaluation en Santé (2003) Critères d’éligibilité des patients à une chimiothérapie anticancéreuse à domicile. Consensus</td>
<td>Cancer patients, receiving chemotherapy.</td>
<td>Development of criteria for selecting patients who may be eligible to receive CT at home.</td>
<td>The authors conclude after a review of the literature that the following conditions must be satisfied for CT to be delivered at home: • Written therapeutic protocol. • Patient preference and</td>
<td>Good review of literature and presentation of evidence based statements.</td>
<td>Systematic review</td>
<td>2’’</td>
<td>++</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/ QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td>3. King MT, Hall J, Caleo S et al. (2000) Home or hospital? An evaluation of the costs, preferences, and outcomes of domiciliary chemotherapy. International Journal of Health Services 30:557-579.</td>
<td>46 patients with breast cancer, 27 with colorectal cancer and 1 with head neck cancer.</td>
<td>Comparison of home CT with outpatient or day care administration of CT.</td>
<td>Questionnaire determination of preference, satisfaction, unmet need &amp; QOL.</td>
<td>40/74 patients, completed the study. Home based care more expensive that inpatient treatment due to extra nurse time. No difference was found between patient satisfaction or QOL in the 2 settings.</td>
<td>Good validation of questionnaire but study methodology poor. No details of how randomisation was performed. Patient selection bias. No intention to treat analyses. In Australia most CT is provided on an outpatient basis or day care. Not relevant to question.</td>
<td>Prospective randomised controlled trial</td>
<td>1- +/-</td>
</tr>
<tr>
<td>STUDY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| POPULATION |
| To compare adult day hospital care with usual inpatient care for cancer patients. 2 year single centre study. Total no of patients: 442. Adult Day Hospital (ADH): n=229; Inpatient: n=213. Eligible patients required: 4-8 hour treatment plan, including chemotherapy, and other long-term intravenous treatments; stable cardiovascular status; mental competence; no skilled overnight nursing; helper to assist with home care. Patients ineligible if standard outpatient treatment possible. USA. |

| INTERVENTION |
| Adult Day Hospital: 12-bed pilot unit included nursing core, treatment room; 2 follow-up rooms, education centre, satellite pharmacy, waiting lounge & administrative offices. Designed to create relaxing & comfortable environment facilitating communication among patients, families and staff. Physician director responsible for clinical management of unit. Patients dealt with by own physician. No house staff signed to unit. Telephone access to nurse 24hrs/day, 7 days/week. No overnight accommodation; patients unable to return home for medical reasons admitted to hospital. |

| OUTCOMES |
| Clinical, psychosocial and cost outcomes evaluated over 60day period. |

| RESULTS |
| No statistically significant (p<0.05) differences found between ADH and inpatient care in medical or psychosocial outcomes over 60-day study period. During study period 28 (6.3%) patients died (13 (5.7%) ADH patients; 15 (7%) Inpatients). Treatment stratas differed as did survival rates in treatment stratas. Patients interviewed for psychosocial status of patients and family: (ADH 198/229 (87%); inpatient 188/213 (88%)). Patient Evaluation of ADH (ADH vs inpatient). Scale of 1= worst; 7= best. Rated nurses self-care instruction (5.9 vs 4.5; p<0.001); helpfulness of staff (6.6 vs 5.3; p<0.001); access to follow-up care and attractiveness of the environment significantly (6.7 vs 6.1; p<0.001) higher than inpatients. No difference found in number of family provided direct hours of care, subjectively assessed family disruption, or reported time lost from work. No observed |

| COMMENTS |
| Few patients within child & adolescent age range. Authors conclude study demonstrates that day hospital care of medical oncology patients is clinically equivalent to inpatient care, causes no negative psychosocial effects and costs less than inpatient care. Findings support trend toward dehospitalisation of medical treatment. Analyses of cost, clinical & psychosocial outcomes performed on different sub samples of 442 randomised cases. Cost analyses included patients who died or removed from study. Other analyses seemed to "lose" patients, not include all data etc. Study conducted some time ago. |

| DESIGN |
| RCT |

<p>| EVIDENCE LEVEL/QUALITY |
| 1- |</p>
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. Smeenk FW, van Haastregt JC, de Witte LP et al. (1996) Effectiveness of home care programmes for patients with incurable cancer on their quality of life and time spent in hospital: systematic review. <em>British Medical Journal</em> 316:1939-1944.</td>
<td>All patients with incurable cancer, receiving home care programmes.</td>
<td>To investigate the literature on the superiority, in terms of QOL and reduction in readmission, of home care programmes compared with standard care.</td>
<td>QOL; readmission to hospital.</td>
<td>9/358 prospective randomised controlled trials of moderate quality were identified that fulfilled the inclusion criteria. The evidence was inconclusive for the effectiveness of home care programmes.</td>
<td>Not possible to determine patient characteristics. Well designed and reported study with clear description of inclusion criteria and search strategies. Not of relevance to question.</td>
<td>Systematic review</td>
<td>2++</td>
</tr>
</tbody>
</table>
Q.2 WHAT EVIDENCE IS THERE THAT COMMUNITY DELIVERED CHEMOTHERAPY IS DELIVERED MORE SAFELY AND EFFECTIVELY BY NURSING STAFF THAN BY PARENTS?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Adults and children with cancer.</td>
<td>Review of literature on home chemotherapy for cancer patients. Qualitative interviews with service providers in Quebec and Ontario.</td>
<td>Clinical effectiveness, QOL, implications for health care system, ethical, legal &amp; social implications, alternatives.</td>
<td>The authors conclude that there is insufficient evidence on the clinical effectiveness of home chemotherapy (CT) compared with non-home settings. There is more evidence to show that home treatment can be delivered safely, although patient selection &amp; training is paramount. Evidence was poor for improvements in patient QOL with home CT. A total of 17 interviews were performed between May 2001 and March 2002. These interviews revealed variable delivery of home CT and the need for well integrated collaborative teams of health care professionals.</td>
<td>Well designed and comprehensive review of literature on home chemotherapy.</td>
<td>Systematic review</td>
<td>2++</td>
</tr>
<tr>
<td>2.</td>
<td>35 paediatric oncology patients in 1 UKCCSG centre.</td>
<td>Parents views on acceptability of home (IV antibiotics) treatment of FNP. Two groups of children received home antibiotic therapy: an early discharge group following hospital Admission to hospital.</td>
<td>During study period there were 83 patient episodes of infection or FNP requiring admission. In 36 episodes, the course of antibiotics was completed at home. 16 episodes were managed at home. In the early discharge group 4 patients</td>
<td>Small numbers.</td>
<td>Case series</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review 36
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Jayabose S, van Haastregt JC, de Witte LP et al (1992) Home chemotherapy for children with cancer. <em>Cancer</em> 69:574-579.</td>
<td>Parents of 20 children with cancer receiving CT (most frequently cytosine arabinoside) at home. US.</td>
<td>Establishment of a home training programme for home delivery of intravenous CT.</td>
<td>Adverse events.</td>
<td>The only criteria used for patient selection was: • Frequent visits for CT to clinic • 3 parents of poor socio-economic status were excluded. No CT related adverse events were noted. The authors conclude that home based CT is a safe and cost effective alternative to hospital or clinic based CT.</td>
<td>Small study. Difficult to determine if patients were truly unselected.</td>
</tr>
<tr>
<td>4. Parker G, Bhakta P, Lovett CA et al. (2002) A systematic review of the costs and effectiveness of different models of paediatric home care. <em>Health Technology Assessment</em> 6: issue 35.</td>
<td>Children with all diseases receiving home treatment.</td>
<td>Review of the literature on costs and effectiveness of home care.</td>
<td>Costs.</td>
<td>The variability in and quality of the studies reporting costs of home CT were so great that no conclusions could be drawn about the relative costs of home and hospital-based CT. No conclusions could be made on clinical effectiveness.</td>
<td>Well designed and reported review of world literature.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Historical case series</td>
<td>3 +/-</td>
</tr>
<tr>
<td>Systematic review</td>
<td>2++</td>
</tr>
</tbody>
</table>
**Q.3 ARE THERE RELIABLE METHODS TO MONITOR CHEMOTHERAPY TREATMENT COMPLIANCE?**

**Q.4 ARE PROTOCOL COMPLIANCE AND EFFECTIVENESS GREATER WHEN TREATMENT IS PERFORMED BY A SHARED CARE CENTRE COMPARED WITH A TERTIARY CARE CENTRE?**

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
</table>
Usefulness of urinary steroid assays as an assessment of compliance is limited. Assays of 6-MP and its metabolites only provide information about short-term compliance. Assay of RBC 6-TGNs and MeMPs allow early identification of non-compliance (1 study only). | Reviews major studies on compliance with ALL therapy and methods for detecting compliance. | Review | 3/4 ++ |
<p>| 2. Festa RS, Tamaroff MH, Chasalow F (1992) Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment. Journal of Pediatrics 120:807-811. | 21 patients (15.6 yrs ± 2.2yrs) 15 with ALL and 6 with HD who were taking prednisone. 29 patients (19.1 yrs ± 4.1 yrs) with HD whose CT been stopped and taking penicillin. | Laboratory assessment of outpatient adherence to CT (prednisone) and penicillin therapy. | Non adherence to therapy assessed by assays of metabolites. | 11 patients (52%) nonadherent to prednisone treatment. 14 (48%) nonadherent to penicillin treatment. | Only deals with prednisone and penicillin adherence. No discussion on validity of assay methods. No discussion of controls. | Case series | 3 |
| 3. Lancaster D, Lennard L, Lilleyman JS (1997) Profile of non-compliance in lymphoblastic leukaemia. Archives of Disease in Childhood 76:365-366. | 496 children with acute lymphoblastic leukaemia prescribed 6-mercaptopurine (6-MP). | Assays of 6-MP to indicate compliance with therapy. | Levels of 6-MP. 2 outcomes = remission. | 9 children (2%) had undetectable 6-MP metabolites. 5/9 were adolescents. 7/9 continue to be in remission. | Small study. Follow up period not defined. | Historical case series | 3 |</p>
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Partridge AH, Avorn J, Wang PS et al (2002) Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute 94:652-661.</td>
<td>All patients with cancer.</td>
<td>Review of published studies.</td>
<td>Non-compliance with anti-neoplastic agents.</td>
<td>Six studies were identified of children and adolescents with leukaemia or non Hodgkin’s lymphoma, acute lymphoblastic leukaemia or Hodgkin’s disease. The studies reviewed indicated that there was poor compliance in children with cancer. Non compliance ranged from 2 – 50%. Measures and definitions of compliance varied between studies. Adolescents were the least compliant. Those most at risk had poorer understanding of their illness and raised levels of denial compared with those who were compliant. The relationship between the involvement of parents and compliance were important.</td>
<td>All observational historical studies with associated biases but some identified child &amp; adolescent studies of adequate quality.</td>
<td>Review</td>
<td>4</td>
</tr>
</tbody>
</table>
### Q.5 WHAT EVIDENCE IS THERE FOR NON-COMPLIANCE WITH CANCER THERAPY IN CHILDREN AND YOUNG PEOPLE

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Carter S, Taylor D, Levenson R (2003) <em>A question of choice - compliance in medicine taking</em> London: Medicines Partnership 87p.</td>
<td>Cancer patients.</td>
<td></td>
<td>The authors conclude that the evidence on medication compliance is limited because most treatment is administered under the direct supervision of health professionals. Most research on compliance has been performed in the context of clinical trials and uses drop out rates as the measure of compliance. The paper by Partridge et al. (2002) revealed poor compliance in the paediatric oncology population (see below). The paper by Spinetta et al. (2002) was also identified (see below).</td>
<td></td>
<td>Literature review</td>
<td>Good quality search but articles not appraised for quality.</td>
</tr>
<tr>
<td>2.</td>
<td>Cassileth BR, Zupkis RV, Sutton-Smith K et al. (1980) <em>Information and participation preferences among cancer patients. Annals of Internal Medicine</em> 92:832-6.</td>
<td>256 cancer patients, (type unspecified), all ages.</td>
<td>Use of information styles questionnaire and the Beck Hopelessness Scale to examine the degree to which patients, prefer to become informed about and to participate in their medical care.</td>
<td>Patents expressed views.</td>
<td>The younger the patients the more closely they conformed to the well informed participant standard of patient behaviour. The older the patients the more likely they were to prefer the older nonparticipatory patient role.</td>
<td>Historical case series</td>
<td>Insufficient details about patients.</td>
</tr>
<tr>
<td>3.</td>
<td>Dickinson D, Raynor DK, Duman P (2001) *Patient information leaflets for medicines: using consumer testing to determine the most two matched groups of 20 consumers given either the European Commission leaflet (based on Comparison of consumers’ ability to use 2 different patient information leaflets.</td>
<td>Two matched groups of 20 consumers given either the European Commission leaflet (based on Comparison of consumers’ ability to use 2 different patient information leaflets.</td>
<td>The groups were required to find and understand 15 pieces of information in the leaflets.</td>
<td>The target that each question should be answered correctly by 16/20 consumers was achieved for 3/15 points in the EC leaflet compared with 8 in the Mark II leaflet. Open indicates the importance of consumer testing. Not specific for cancer.</td>
<td>Non randomised controlled trial</td>
<td>Indicates the importance of consumer testing. Not specific for cancer.</td>
<td>2 +/-</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>effective design. <em>Patient Education and Counselling</em> 43:147-159.</td>
<td>‘prescriptive’ model for leaflets) or the Mark II leaflet (based on best practice in information design)</td>
<td></td>
<td></td>
<td>questioning confirmed the problems with the EC leaflet.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Haynes RB, McDonald H, Garg AX et al. (2002) Interventions for helping patients to follow prescriptions for medications. <em>The Cochrane Database of Systematic Reviews</em>: Issue 2.</td>
<td>Patients with any medical condition requiring drug prescription.</td>
<td>Evaluation of the results of published RCTs on interventions to improve compliance with medications.</td>
<td>Original data concerning medication adherence. One or more measures of treatment outcome. At least 6 month follow up from time of patient entry.</td>
<td>No RCTs concerning cancer patients fulfilled the inclusion criteria. For short term treatments 1/3 interventions reported in 3 RCTs showed an effect on both adherence and outcome. 18/36 interventions reported in 30 RCTs were associated with improvement in adherence but only 16 interventions led to improved treatment outcomes. The effective interventions were complex; improvements were not large.</td>
<td>Not directly relevant to child &amp; adolescent cancer. Good review with adequate description of methodology and limitations of included studies such as lack of concealment allocation, presence of confounding factors.</td>
<td>Systematic review of RCTs</td>
<td>1+</td>
</tr>
<tr>
<td>5. Horne R, Weinman J (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. <em>Journal of Psychosomatic Research</em> 47:555-567.</td>
<td>Patients with asthma, cardiac conditions, chronic renal failure and cancer patients.</td>
<td>Investigation of whether patients beliefs and perceptions of their illness and treatment affected compliance.</td>
<td>Factors influencing compliance with therapy.</td>
<td>Specific beliefs about medicines were a strong predictor of compliance (19% of observed variance). Demographic variables were less significant. The authors conclude that it is important to address patients’ beliefs when considering compliance.</td>
<td>No patients within child &amp; adolescent range. Limited relevance. Small numbers.</td>
<td>Qualitative; interviews</td>
<td>3</td>
</tr>
<tr>
<td>6. Partridge AH, Avorn J, Wang PS et al. (2002) Adherence to therapy with oral antineoplastic agents. <em>Journal of the National Cancer Institute</em> 94:652-661.</td>
<td>All patients with cancer.</td>
<td>Review of published studies.</td>
<td>Non-compliance with anti-neoplastic agents.</td>
<td>Six studies were identified of children and adolescents with leukaemia or non Hodgkin’s lymphoma, acute lymphoblastic leukaemia or Hodgkin’s disease. The studies reviewed indicated that there was poor compliance in children with All observational historical studies with associated biases but some identified child &amp; adolescent studies of adequate quality.</td>
<td>Review</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review 41
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>7. Raynor DK, Savage I, Knapp PR et al. (2004) We are the experts: people with asthma talk about their medicine information needs. <em>Patient Education and Counselling</em> 53:167-174.</td>
<td>Patients with asthma.</td>
<td>Effect of the provision of patient information leaflets.</td>
<td>The results indicate that patient information leaflets do not provide adequate help to patients and carers. This is a particular issue with paediatric prescriptions, where the drugs are often prescribed outside their licensed indications.</td>
<td>Not directly relevant to child &amp; adolescent cancer.</td>
<td>Expert opinion</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>8. Spinetta JJ, Masera G, Eden T et al. (2002) Refusal, non-compliance, and abandonment of treatment in children and adolescents with cancer: A report of the SIOP Working Committee on psychosocial issues in pediatric oncology. <em>Medical and Pediatric Oncology</em> 38:114-117.</td>
<td>Children and adolescents with cancer.</td>
<td>Consideration of: • the causes of refusal, non-compliance and abandonment of treatment • the prevention of above • judicial intervention, when essential.</td>
<td>The major reasons for refusal, non-compliance and abandonment of oncology therapy in children and adolescents include: • poor communication of diagnosis and treatment regimens • fear of side effects • poor understanding of the seriousness of the illness • physical discomfort • frustration with length of treatment • lack of knowledge about benefits of therapy</td>
<td>Report of SIOP Psychosocial Working Group. Literature reviewed but no details given on how recommendations are formed.</td>
<td>Guidelines</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
|       |            |              |          | • increased availability of alternative medicine  
|       |            |              |          | • availability of social support services.   |

**ITALICS** = reviewers comments

<table>
<thead>
<tr>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Surgery

The Question:

Does specialist (surgical) care improve outcomes for children and young people with cancer?

Nature of the evidence

2 systematic reviews, 1 of good quality; 1 of fair quality
3 guidelines of good quality
2 reviews of good quality
4 expert opinions, 2 of good quality; 2 of fair quality

Summary of the supporting evidence for the recommendations

- The paediatric studies did not meet the inclusion criteria in one systematic review and in the second review the evidence from the paediatric studies reviewed was inconclusive for the benefits of specialisation.
- UK guidelines recommended specialist surgeons and anaesthetists for the treatment of children and young people with cancer (no evidence given).
- The literature reviews provided evidence that survival in paediatric cancer was improved with specialist care, but the studies reviewed were generally of poor quality.
- The expert opinions concluded that there was evidence for improved outcomes with specialist surgeons and anaesthetists.

There is general consensus that specialisation is associated with improved patient outcomes, but there is a lack of good evidence to support this. The requirements to provide optimum surgical treatment are specified in a number of
UK guidelines and strategic documents (Appendix 1 – The Manual). There is some observational evidence that specialisation is required in anaesthetic and pathology service provision (see evidence table below).
### Does Specialist (Surgical) Care Improve Outcomes for Children and Young People with Cancer?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Arul GS, Spicer RD (1998) Where should paediatric surgery be performed? <em>Archives of Disease in Childhood</em> 79:65-72.</td>
<td>Paediatric surgery</td>
<td>Discussion and review of evidence for: • role of specialist paediatric surgery centre • provision of non-specialist paediatric surgery in district general hospitals (DGHs).</td>
<td>The authors conclude: • There are arguments for and against large regional specialist paediatric centres. If specialist paediatric emergency transport is available the benefits of centralisation outweigh the adverse effects of the need to transport children to such a regional centre. • There is clear evidence that all neonatal surgery and anaesthesia should be conducted by specialists. • There is debate about the critical mass necessary to maintain specialist expertise in surgery. • There is lack of data from DGHs on the set up of paediatric surgical services. Debate continues about the benefits of properly trained paediatric surgeons taking over surgery at a DGH.</td>
<td>Good review of evidence for organisation of paediatric surgical services.</td>
<td>Expert opinion</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

**Expert opinion**

- **++** indicates a high level of evidence.
- **+** indicates a lower level of evidence.
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Regional paediatric centre.**

There are some surveys of perioperative complications post anaesthesia in children from UK, France & Canada, the results of which suggest the requirement for centralisation of paediatric anaesthesia (and intensive care) services.

- The NCEPOD report highlighted the dangers of insufficient critical mass for paediatric surgery, but did not define the limits.
- One solution may be the referral of all children < 3 yrs old to a specialist centre.


**Response to the Kennedy report.**

The BAPS state:

- They strongly agree that where a small number of centres offer a specialist service, the requirements of quality and safety should prevail over ease of access.
- The designation of supra-regional units must be based on performance and outcome measures and not their geographical situation.
- Centres must be constantly monitored by the designating authority to ensure that their continuing status as a

**Important to take note of in any paediatric service issues.**

**Expert opinion**

<table>
<thead>
<tr>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
</tr>
</tbody>
</table>

**+**
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>supra-regional unit is justified.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Children’s acute hospital services ideally should be located in a children’s hospital close to an acute general hospital.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• The report does not distinguish between specialist paediatric surgery provided in specialist centres and general paediatric surgery provided by appropriately trained surgeons at DGHs.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• The provision of specialist paediatric surgery services on split sites is not acceptable.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• The recommendation that all surgeons who operate on children must obtain a recognised professional qualification requires clarification.</td>
<td></td>
</tr>
</tbody>
</table>


Paediatric surgical services. Recommendations for purchasers.

The authors consider:
• The definitions of the spectrum of paediatric surgery.
• The provision of paediatric surgical services. The best clinical outcomes are achieved when the number of patients being treated in a unit is sufficient for a high level of surgical & nursing expertise to be maintained.

Guidelines 4 ++
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>italic= reviewers comments</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Specialist paediatric surgery must be provided in a specialist paediatric surgery unit.

The requirements are:
- Trained and accredited paediatric surgeons and paediatric anaesthetists.
- A full range of specialist services for children including paediatrics, neonatology, paediatric intensive care, radiology, neurosurgery, nephrology, cardiology, oncology & pathology.
- Nursing staff trained in paediatric nursing and paediatric critical care nursing.
- Support services catering for the specific needs of children, including dieticians, social workers, play leaders and teachers.
- Facilities designed for children, including the accident and emergency department, outpatient department, wards, operating theatres, day case unit, radiology suite and laboratory services.
- Accommodation for parents, who should have unrestricted access to their children.
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Italic= reviewers comments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Popoulatiion Base:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>There should be 1 specialist surgeon/500,000 population. It is unrealistic to plan a department with &lt; 4 paediatric surgeons and 1 paediatric urologist. Thus 2.5 million is the minimum population required to ensure a sufficient critical mass. Strict adherence to this figure would increase the burden of travel in some rural areas and specialist paediatric surgery should be provided at a regional unit.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Detailed description of standards and manpower requirements and service arrangements.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expert opinion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>++</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review
### STUDY

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. Grilli R, Minozzi S, Tinazzi A et al. (1998) Do specialists do it better? The impact of specialization on the processes and outcomes of care for cancer patients. <em>Annals of Oncology</em> 9:365-374.</td>
<td>Patients with cancer receiving specialist care.</td>
<td>Assess the impact of specialisation on processes and outcomes of care for cancer patients.</td>
<td>Mortality, morbidity. Process outcomes e.g. specialisation of treating clinician, numbers of patients treated.</td>
<td>47/189 potential studies met the inclusion criteria. 12/24 (50%) studies provided information on process and 17/32 (53%) information on outcomes. Overall results were in favour of specialised clinicians/centres and were generally statistically significant. The study quality was however low.</td>
<td>Well described and designed study. Note is taken of the need to adjust in comparisons for case mix. The authors discuss the possibility of publication bias, influence of methodological flaws, use of observational studies causing an over estimate of effect size. The aims and inclusion criteria were well defined. Care is required in concluding that there is good evidence for the apparent superiority of specialist versus non-specialist care.</td>
<td>Review</td>
<td>++</td>
</tr>
<tr>
<td>7. Harding M, Lord J, Littlejohns P et al. (2002) A systematic review of the evidence relating process</td>
<td>Patients with cancer.</td>
<td>Assessment of difference in outcome between treatment in specialist and non-</td>
<td>Survival.</td>
<td>The authors conclude that there was insufficient high quality evidence to indicate that specialist care affected</td>
<td>High quality study. No studies in paediatric cancer met the inclusion criteria.</td>
<td>Systematic review</td>
<td>1</td>
</tr>
</tbody>
</table>

Notes:
- **DESIGN:** *systematic review*
- **EVIDENCE LEVEL/ QUALITY:** *4*

---

Improving outcomes in children and young people with cancer: evidence review
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>of care or outcome to treatment in specialist and non-specialist hospital settings. London: St George’s Hospital Medical School 208p.</td>
<td>specialist centres.</td>
<td>outcomes in cancer patients.</td>
<td>criteria. Publication bias significant.</td>
<td></td>
<td></td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>8. Hillner BE, Smith TJ, Desch CE (2000) Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. Journal of Clinical Oncology 18:2327-2340.</td>
<td>All types of cancer care.</td>
<td>Evidence to support that hospital or physician volume or specialty affects outcome of cancer care.</td>
<td>A consistent literature was identified that support a volume-outcome relationship for cancers treated with technically complex surgical procedures. These studies identified 30-day mortality and used the hospital as the unit of analysis. For cancer treated with low-risk surgery there were fewer studies and there was only an association for colorectal and breast cancer.</td>
<td>Search limited to Medline 1988-1999. Indirect relevance to question.</td>
<td>Systematic review</td>
<td>2'</td>
<td></td>
</tr>
<tr>
<td>9. Parkes SE, Muir KR, Cameron AH et al. (1997) The need for specialist review of pathology in paediatric cancer. British Journal of Cancer 75:1156-1159.</td>
<td>Histopathology of 2104 biopsies of paediatric solid tumours.</td>
<td>Assessment of variability in diagnosis of childhood cancer by paediatric and general pathologists. Confirmation of diagnosis was made independently by 3 specialist pathologists.</td>
<td>Analysis of conformity by percentage agreement, kappa statistic &amp; weighted kappa.</td>
<td>Birch Marsden classification was used. 348 (16.5%) of the 2104 original diagnoses were amended by the review panel. 23 cases originally diagnosed as malignant were reclassified as non-malignant. The panel confirmed the original diagnosis of paediatric pathologists in 89% of cases (kappa = 0.76; w kappa = 0.78) compared with 78% (kappa = 0.59; w kappa 0.54) for general pathologists.</td>
<td>Reasonable evidence to support sub specialisation of pathologists.</td>
<td>Historical case series</td>
<td>3</td>
</tr>
<tr>
<td>10. Pheby DFH, Bray FJ (1998) Review of studies designed to explain variations in cancer</td>
<td>Patients with ICD9 diagnosis 140-208 of cancer, of any age.</td>
<td>Review of studies on variations in cancer outcomes in relation to variations in patterns</td>
<td>Survival.</td>
<td>4 papers dealing with childhood cancer fulfilled inclusion criteria. There were data problems, but overall the</td>
<td>Comprehensive literature review and discussion of the literature and</td>
<td>Review</td>
<td>4</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td>11. Royal College of Anaesthetists (2001) Guidance on the provision of paediatric anaesthetic services. Royal college Anaesthetists Bulletin 8:355-359.</td>
<td>Paediatric anaesthetic services.</td>
<td>The authors conclude: • Anaesthesia for children requires specially trained medical and nursing staff &amp; special facilities. • The service should be led at all times by consultants who anaesthetise children regularly. • Adequate assistance to the anaesthetist by staff with paediatric training &amp; skills must be available. • Paediatric anaesthetic equipment must be available where children are treated and staff must receive regular retraining in paediatric life support. • There should be properly funded acute pain services.</td>
<td>Detailed guidance for provision of paediatric anaesthetic services. Covers staffing, education organisation &amp; administration.</td>
<td>Guidelines 4</td>
<td>++</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2001.doc

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>and adults and adult neurosurgeons may provide an appropriate degree of care and level of skill. Certain paediatric neurosurgical conditions are rare and it is generally accepted that they would be best managed by neurosurgeons with the appropriate paediatric specialist training and expertise. Neurosurgical units providing specialist paediatric neurosurgical services should have sufficient facilities and resources to allow immediate transfer, urgent same day admission or admission within 48 hours as necessary. Specialist paediatric services must have appropriate support facilities including access to Paediatric Intensive and High Dependency Care. Neurosurgeons providing specialist paediatric neurosurgical expertise should have a regular defined commitment to paediatric neurosurgery, including the necessary theatre and outpatient clinic time within their weekly timetable. The neurosurgical training programme will give every</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Trainee neurosurgeon exposure to paediatric neurosurgery and specific training in the management of paediatric neurosurgical emergencies sufficient to enable them to manage an emergency when on call.
- In certain neurosurgical units which provide paediatric services some further subspeciality expertise may develop.
- The management of children with childhood brain and spinal tumours is best accomplished by those with a subspecialty interest and expertise using a multidisciplinary approach. Accordingly neurosurgical units which undertake the management of paediatric brain and spinal tumours must have access to paediatric oncologists who are members of or affiliated to the UK Children's Cancer Study Group.

Neurosurgical units which undertake paediatric work should be responsible for the development and dissemination of agreed guidelines for patient management and for their
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>regular up-dating and perform regular audit.</td>
</tr>
</tbody>
</table>
Neurosurgery

The Question:

Do specialist paediatric neuro-oncology surgeons produce improved outcomes for children and young people with cancer?

Nature of the evidence

1 historical case series of fair quality
4 guidance/guidelines/policy documents, 2 of good quality; 2 of fair quality
2 commentaries/expert opinions of fair quality
1 overview of fair quality

Summary of the supporting evidence for the recommendations

- The evidence from 1 historical case series indicated that tumour resection was maximal with specialist paediatric neurosurgeons. Complication rates were less with accredited neurosurgeons.
- One policy document provides recommendations for safe neurosurgery.
- One guidance predating the above policy document makes recommendations for safe neurosurgery.
- Clear recommendations for paediatric neurosurgery are given in one guideline.
- Specialist neurosurgical units for paediatric brain tumours are recommended in one guidance.
- One commentary concludes that there is good evidence to support specialisation in paediatric neurosurgery.
- No definite recommendations for specialisation, specifically in the care of patients with gliomas, are made in one commentary.
- One overview makes no recommendations on specialisation.
There is evidence from expert opinion and formal consensus that care of children and young people with brain tumours should be delivered in the context of multidisciplinary teams (MDTs).
## DO SPECIALIST PAEDIATRIC NEUROONCOLOGY SURGEONS PRODUCE IMPROVED OUTCOMES FOR CHILDREN AND YOUNG PEOPLE WITH CANCER?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Albright AL, Sposto R, Holmes E et al. (2000) Correlation of neurosurgical subspecialisation with outcomes in children with malignant brain tumors. <em>Neurosurgery</em> 47:879-885.</td>
<td>732 children, 485 with medulloblastoma/pri mitive neuroectodermal tumours and 247 with malignant gliomas. US.</td>
<td>Evaluation of association between the type of neurosurgeon (general or paediatric) and outcomes.</td>
<td>Extent of tumour removal. Neurological complications.</td>
<td>Operations were performed by 269 neurosurgeons (NS) (213 general NS, 29 designated paediatric NS and 27 ASPN members). The mean number of operations/surgeon was 1.8, 4.9 and 7.6 for general, paediatric and ASPN respectively. There was a significant relationship between the extent of tumour resection and the type of neurosurgeon. Designated paediatric NS and ASPN members were more likely to remove &gt; 90% of the tumour than were general NS (p&lt;0.05). The probability of extensive tumour removal also correlated with the number of operations the neurosurgeon performed (p&lt;0.01). Neurological complications occurred in 23% of cases operated upon by a general NS; 32% designated paediatric NS and 18% ASPN.</td>
<td>Relevance of US practice to UK? Historical case series</td>
</tr>
</tbody>
</table>

**Strengthened by studies with a lower level of evidence.**
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Chumas P, Hardy D, Hockley A et al. (2002) Safe paediatric neurosurgery 2001. <em>British Journal of Neurosurgery</em> 16:208-210.</td>
<td>Paediatric neurosurgery.</td>
<td>Update to 1998 policy document from SBNS.</td>
<td></td>
<td>The authors conclude:  - The management of children with brain and spinal tumours is best accomplished by those with subspecialty interest and using a multidisciplinary approach.  - Neurosurgical units managing paediatric brain and spinal tumours must have access to paediatric oncologists who are members or affiliated to the UKCCSG.  - Cross referral from other neurosurgeons to these specialised services to be encouraged.  - Specialised neurosurgical units will need to develop clinical networks.  - Guidelines should be developed and audit of activity performed.</td>
<td>No supporting evidence.</td>
<td>Policy document 4</td>
<td></td>
</tr>
<tr>
<td>3. Gerrard GE, Prestwich RJ, Franks KN et al. (2003) Neuro-oncology practice in the UK. <em>Clinical Oncology</em> 15:478-484.</td>
<td>All cancer centres in UK.</td>
<td>Questionnaire survey to determine current practice (July 2000) by UK clinical oncologists specialising in neuro-oncology. Workshops in 2000 and 2002.</td>
<td></td>
<td>41/54 (76%) response rate. There were marked variations in practice. Results were obtained for controversial areas of management such as adults with high grade glioma, adults with grade II glioma, ependymomas, meningiomas, primary adenomas &amp; multiple brain metastases. The authors conclude that there are many controversial areas in</td>
<td>Good document to highlight controversial areas of neurosurgical oncological treatment.</td>
<td>Overview 4</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/ QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recommendations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>4. Society of British Neurological Surgeons (1998) Safe paediatric neurosurgery London: Society of British Neurological Surgeons.</td>
<td>Paediatric neurosurgery.</td>
<td>Recommendations</td>
<td>The recommendations are: • High quality children’s care should be delivered by appropriate staff and facilities. • Paediatric neurosurgery should offer at the very minimum, the same quality, degree of care and level of expertise regarded as a norm for adult neurosurgical practice. • Neurosurgical units offering a paediatric service must be capable of delivering a full comprehensive 24-hour service. This will require a minimum of 2 consultant WTEs and middle grade cover consisting of both neurosurgical and paediatric staff. • The minimal requirement of a comprehensive 24hr service is paediatric beds, PICU, paediatric neuro-anaesthesia, paediatric nurses and on-site CT scanning. The need for specialist services in neuro-radiology and</td>
<td>Contains specifications for workforce, training facilities etc. The 2001 update does not provide amendments to these data.</td>
<td>Guidance</td>
<td>4 +</td>
<td></td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Society of British Neurological Surgeons (2001) Safe paediatric neurosurgery</td>
<td>Paediatric neurosurgery</td>
<td>Standards</td>
<td>• All neurosurgical units providing care for neurological emergencies should have clinicians with the necessary experience and training to undertake the immediate care of neurosurgical emergencies occurring in children. If separate facilities for children are not available then children should not be housed in adult facilities for longer than is required for their safe neurosurgical management and the child should be transferred to appropriate paediatric facilities as soon as is practicable. • Units undertaking the emergency care of children with neurosurgical problems</td>
<td>neuropathology is recognised. Paediatric neurologists and general paediatric support is essential. • Audit is essential. • In some regions there needs to be an assessment of the delivery of paediatric neurosurgery with some degree of rationalisation and co-ordination between departments.</td>
<td>Guidelines</td>
<td>4 ++</td>
<td></td>
</tr>
</tbody>
</table>

5. Society of British Neurological Surgeons (2001) Safe paediatric neurosurgery

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>ITALICS</strong>= reviewers comments</td>
</tr>
</tbody>
</table>

must have access to CT and MR scanning.
- Neurosurgical units providing specialist paediatric neurosurgical services should have sufficient facilities and resources to allow immediate transfer, urgent same day admission or admission within 48 hours as necessary.
- Specialist paediatric services must have appropriate support facilities including access to Paediatric Intensive and High Dependency Care. Such facilities should be supported by specialist neuroradiologists, neuropathologists and Anaesthetists with the necessary expertise. Access to CT and MR imaging is essential. Paediatric neurologists should also be available. The Consultant medical team must be supported by properly trained and qualified nurses including theatre staff and professionals in allied disciplines. The specialist paediatric neurosurgical unit should have a paediatric environment able to support the social requirements of children.
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
• Most progress in the treatment of childhood cancer has been due to improved survival from entry into trials.  
• Treatment abroad is not supported by evidence for clinical benefit. Innovation in treatment is necessary.  
• Arguments for specialist referral are compelling. Only 62% of all children with tumours of the CNS diagnosed in the UK between 1991-1993 were | Commentary |

and family, e.g. play area, schooling and family accommodation.  
• In certain neurosurgical units which provide paediatric services some further subspeciality expertise may develop. The development of such ultra-specialised paediatric neurosurgical expertise will normally require a further period of specialist training and experience.  
• Accordingly neurosurgical units which undertake the management of paediatric brain and spinal tumours must have access to paediatric oncologists who are members of or affiliated to the UK Children’s Cancer Study Group.

64
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
- Existing referral patterns in the UK have not been clearly defined.  
- In line with the Calman/Hine report it is proposed that a network of UKCCSG centres be established which specialise in treatment of children and young people with brain tumours.  
- All children and young people with suspected brain or spinal tumours should be treated in a unit where clinical services meet standards in DoH guidance documents about services for children and young people.  
- It is hoped that concentration of expertise will lead to improved standards of care. Quality of care will be further enhanced through audit & research. | referred to designated paediatric oncology centres in contrast with 90% of children with leukaemia and 79% with other forms of malignant disease. | |


Guidance 4

++
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
- Gliomas are the most difficult of all paediatric tumours to treat because of problems with diagnosis, lack of effective treatments and consensus between specialists.  
- Modern neuroimaging techniques now facilitate diagnosis.  
- Lack of appreciation of presenting symptoms lead to delays in diagnosis.  
- Surgery and/or radiotherapy are treatment options.  
- There is no standard chemotherapy regime.  
- There should be specific recommendations developed for supportive care. | Key review of management of gliomas. Some recommendations dated (1999). | Commentary | 4 |

Radiotherapy

The Questions:

1. Do delays in radiotherapy (RT) and quality of radiotherapy affect patient outcomes in children and young people with cancer?
2. What evidence is there for the provision of specialist radiotherapy facilities producing improved outcomes?

Q.1 & 2
Nature of the evidence

3 randomised controlled trials, 2 of fair quality; 1 of fair to poor
2 retrospective cohort studies of good quality
1 systematic review of good quality
4 historical case series, 1 of fair quality; 3 of fair to poor quality
1 literature review of fair to poor quality

Summary of the supporting evidence for the recommendations

- One RCT of children with medulloblastoma concluded that there was no significant difference in overall survival or event free survival (EFS) starting radiotherapy within 42 days of surgery.
- The evidence from 1 RCT of patients with Wilms’ tumours indicated that delays in RT were associated with tumour control.
- The evidence from 1 systematic review indicated that delaying RT in patients with high grade gliomas may affect outcomes.
- There is evidence from 2 retrospective cohort studies that demonstrate delays in RT affect tumour control in patients with sarcoma.
- One historical case series demonstrated that in patients (> 3yrs) with medulloblastoma that delays in RT did not affect outcome.
• Multivariate analyses from 1 historical case series (Grade III or IV gliomas) demonstrated that increased time from presentation to the RT department was associated with reduced survival\(^2\).
• The evidence from 1 historical case series showed that tumour recurrence rates of Wilms’ tumours were not affected by delays in RT\(^3\).
• The evidence from 1 historical case series of patients with Ewing’s sarcoma did not indicate a significant effect of RT delays on outcomes\(^5\).
• A recent literature review provides evidence for the effect of RT delays on high grade gliomas\(^7\).

There appears to be a lack of consistent evidence for the effect of delays of radiotherapy on outcomes.

The recommendations for the provision of specialist RT facilities are in agreement with a move to sub specialisation in clinical oncology as outlined in the Calman Hine report and the publications from the royal colleges. The resource requirements are also specified in guidance from the UKCCSG and there is emphasis on the need to provide age appropriate facilities in line with the general recommendation in the children’s National Service Framework.
**Q.1 DO DELAYS IN RADIOTHERAPY & QUALITY OF RADIOTHERAPY AFFECT PATIENT OUTCOMES IN CHILD AND YOUNG PEOPLE CANCER PATIENTS?**

**Q.2 WHAT EVIDENCE IS THERE FOR THE PROVISION OF SPECIALIST RADIOTHERAPY FACILITIES PRODUCING IMPROVED OUTCOMES?**

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| 1. DelCharco JO, Bolek TW, McCollough WM et al. (1998) Medulloblastoma: Time-dose relationship based on a 30-year review. *International Journal of Radiation Oncology, Biology, Physics* 42:147-154. | 53 patients with medulloblastoma. Age range 3 to 77 years (7 children < 3 years were excluded from analysis). Country: USA. | Postoperative craniospinal radiotherapy given with curative intent between 1963 and 1993 at one centre. Dose ranged from 23.3 to 45.6 Gy. Different fractionation regimes were used. 7 patients (13%) had biopsy alone; 28 patients (53%) had subtotal excision; 18 patients (34%) had gross total excision. 11 patients had adjuvant chemotherapy. | Relationship between the following factors and survival (5 and 10 years), freedom from relapse and disease control in the posterior fossa were examined. Radiotherapy (dose to craniospinal axis and posterior fossa), fractionation, time from surgery to radiotherapy and duration of radiotherapy. | Absolute survival rates were 68% at 5 years and 64% at 10 years. Freedom from relapse rates were 61% at 5 years and 52% at 10 years. Rates of disease control in the posterior fossa were 79% at 5 years and 68% at 10 years. Only results pertaining to time between surgery and radiotherapy are reported below:  
- The time between surgery and the start of radiotherapy was not significantly associated with posterior fossa disease (p = 0.115); freedom from relapse (p = 0.311) or overall survival (p not reported).  
The authors conclude that radiotherapy treatment for more than 45 days increased freedom from relapse and improved posterior fossa disease control. Time from surgery | Small sample size. Range of time between surgery and start of radiotherapy was not reported. Not restricted to children and adolescents. Results from 30 year period during which radiotherapy treatment regimes changed. | Historical case series | 3 +/- |
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL /QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Do V, Gebksi V, Barton MB (2000)</td>
<td>182 patients with grade III/IV gliomas</td>
<td>Radiotherapy delays.</td>
<td>Survival.</td>
<td>3/182 survived at the end of the study. Median survival of the whole group = 8.5 months. Multivariate analysis indicated that reduced survival associated with older age, reduced dose and prolonged PWT. The hazard of death increased by 2% per day of PWT (p=0.03). Two waiting time variables were examined: • time from biopsy to start of radiotherapy (BWT) • time from presentation to RT department (PWT). Poor prognostic variables such as age, surgery, dose, ECOG were not associated with longer PWTs.</td>
<td>Authors acknowledge the known limitations of their study – selection bias, uncontrolled patient and tumour factors and treatment bias. Median age 57 years, few patients in age range for children and young people guidance.</td>
<td>Historical case series</td>
<td>3 +/-</td>
</tr>
<tr>
<td>3. Kalapurakal JA, Li SM, Breslow NE et al. (2003)</td>
<td>Total 1226 patients with Stage II, III or IV favourable histology (FH) Wilms' tumour who received flank or abdominal radiation therapy (RT) study guidelines. Male (567); Female (659). Randomised: eligible if between 1 &amp; 15 yrs</td>
<td>RT delay; Category 1: 0-9 days; Category 2 ≥10 days. Flank recurrence: recurrent disease in operative bed. Abdominal recurrence: infradiaphragmatic.</td>
<td>Mean RT delay was 10.9 days; median delay was 9 days (range: 1-227 days). RT delay was in the range of 8 to 12 days after nephrectomy in 59% patients. RT delay did not vary substantially with patient's gender, race, age, tumour stage or treatment regimen.</td>
<td>No patient characteristics given. Part of a larger study. Methods section mentions &quot;randomised&quot;; &quot;switched&quot; &amp; &quot;followed&quot; as categories but no explanation given in study of if/how these applied.</td>
<td>Historical case series</td>
<td>3 +</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td></td>
<td>inclusive &amp; not received treatment for nephrectomy for unilateral disease. Switched: if assigned regimen changed later in study. Followed: included those not randomised but treated according to one of the arms of study. Exclusions: received preoperative chemotherapy, bilateral (Stage V) tumours, tumours arising from fused kidney, extrarenal Wilms', or adult Wilms' (age ≥16). Country: USA</td>
<td>Details of chemotherapy regimens not supplied in this report (referred to previous reports). Excluded: Tumour recurrence in liver. Tumour recurrence in opposite kidney.</td>
<td>matic tumour recurrences, including flank recurrences.</td>
<td>Univariate &amp; multivariate analysis did not reveal RT delay of ≥10 days to significantly influence flank and abdominal tumour recurrence rates in NWTS-3 or NWTS-4. Flank recurrence: N=18/1226 (1.5%). Abdominal tumour recurrence: 59/1226 (4.8%). Median follow-up for 1,070 was 12 yrs (range 0.1-22 yrs). Median time to death for 156 deceased patients was 1.75 yrs from diagnosis. 8 yr flank tumour recurrence risk of 0-9 days was 1.9% and ≥10 days was 1.2% (5 recurrences vs 7.2 recurrences expected) (p=0.3). 8 yr abdominal tumour recurrence rates for 0-9 days were 4.8% and ≥10 days were 5.3% (25 recurrences vs 23.6 recurrences expected) (p=0.7).</td>
<td>italics = reviewers comments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL /QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Italics = reviewers comments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Study reports Median RT delay for NWTS 1 to 4:  
• 1: 4  
• 2: 8  
• 3: 9  
• 4: 9  
Authors concluded that RT delay of ≥10 days did not significantly influence flank or abdominal tumour recurrence rates among children with FH tumours treated on NWTS-3 and NWTS-4. However unable to test for meaningful difference as concentration of RT delay close to 10 days. |
95 patients (median age 6 yrs) with nonorbital cranial parameningeal sarcoma comprised the preintensive treatment group (RT began 6 weeks after start of CT) and 68 patients (median age 5 yrs) the intensive treatment group (RT started at day 0).  
Comparison of CT and nonintensive RT with intensive RT.  
Remission rate. Tumour free survival.  
The remission rate in the preintensive group was 65/95 patients (68%) and 52/68 (76%) in the intensive group (p <0.25). The authors attribute the better results to the early institution of wide-field RT for those patients with risk of meningeal extension. |
| Well designed and described study with appropriate analyses. |
| Retrospective cohort study |
| 2 |
Age Range: 3 to 33 Male (94); Female (59).  
Surgery, chemotherapy, radiotherapy.  
Patients received different regimen of chemotherapy.  
Local and combined relapse as first event. Local or combined relapse as second event.  
Median interval between surgery & irradiation was 79 days.  
Group 1: 46 patients: postoperative radiation started ≤60 days after surgery (9 patients ≤30 days).  
Results not specifically for children/adolescents. Results include patients from other trials – unclear as to which patients were on what. |
| Historical case series |
| 3 |
| +/- |

Improving outcomes in children and young people with cancer: evidence review
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients were part of other ongoing trials reported elsewhere. Germany.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Median follow-up 70 mths (range 7 to 169 mths).</td>
<td></td>
<td>First events: local relapse, systemic relapse, death for any reason and secondary neoplasm.</td>
<td>Combined and local systemic relapse as first event: 1/46 (2%).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Postoperative radiotherapy applied either in conventional fractionation or in hyperfractionated accelerated split course. Dose dependent on intraoperative resection margins and on response to initial chemotherapy.</td>
<td></td>
<td></td>
<td>Local or combined relapse as second event: 3/46 (6.5%).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patients with wide resection, poor response to chemotherapy or with marginal resection and good response to chemotherapy received 45 Gy.</td>
<td></td>
<td></td>
<td>Freedom of local and combined local and systemic relapses after 5 yrs for &gt;30 days ≤60 days was 98%. Patients ≤30 days was 100%. Event free survival for both subgroups was identical (p=0.7085).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patients with intralesional resection or marginal resection, poor response to chemotherapy received 54 Gy.</td>
<td></td>
<td></td>
<td>Group 2: 107 patients ≥60 days after surgery (51 patients ≥90 days).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>After completion of local therapy systemic therapy continued for patients.</td>
<td></td>
<td></td>
<td>Local relapse as first event: 5/105 (5%).</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Combined relapse as first event: 4/107 (5%).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Local or combined relapse as second event: 1/107 (0.9%).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Freedom of local and combined local and systemic relapses after 5 yrs was 92%. For subgroups ≤90 days &amp; ≥90 days no difference in local control &amp; event free survival (p=0.7447).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>chemotherapy regimens etc.</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>6. Schwartz DL, Einck J, Hunt K et al. (2002) The effect of delayed postoperative irradiation on local control of soft tissue sarcomas of the extremity and torso. <em>International Journal of Radiation Oncology, Biology, Physics</em> 52:1352-1359.</td>
<td>102 patients, median age 50 yrs (14-76) with soft tissue sarcomas of the extremity and torso.</td>
<td>Radiotherapy timing. The group was dichotomised according to time interval from definitive resection to the start of adjuvant radiation. 26 patients delay of ≤ 4 months and 32 patients long delay of ≥ 4 months.</td>
<td>Local relapse free survival.</td>
<td>No substantial difference between groups concerning risk factors for local failure and survival. No statistically significant difference in event free survival between groups: 64% after 5 yrs. Authors conclude patients with early onset of postoperative irradiation show a trend for improved local control compared to patients with later onset; difference is statistically not significant. This trend has no influence on survival. Authors consider bias. Only 2 factors differed between the group – age and study period. Both factors had no effect on local control and event free survival.</td>
<td>Retrospective cohort study</td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review

74
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>7. Seel M, Foroudi F (2002) Waiting for radiation therapy: does it matter? Australasian Radiology 46:275-279.</td>
<td>All cancers.</td>
<td>Radiation therapy.</td>
<td>Multiple.</td>
<td>Great majority of the research concentrates on radical RT. Breast – multiple studies High grade gliomas – 1 study Head &amp; neck – many studies Oesophagus – 1 study Lung – 4 studies Prostate – 0 articles Cervix -0 articles Evidence exists for head and neck cancer, small-cell lung cancer and high grade gliomas that tumour control might be adversely affected by delaying RT.</td>
<td>Where there were papers, the evidence suggested that delays in RT did have an adverse effect on outcomes. Details of searching process inadequate – time period, inclusion &amp; exclusion criteria not specified.</td>
<td>Literature review</td>
<td>4 +/-</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>-----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td>9. Taylor RE, Bailey CC, Robinson K et al. (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s cancer Study group PNET-3 Study. <em>Journal of Clinical Oncology</em> 21:1581-1591. &lt;br&gt;217 patients median age 7.67 yrs (range 3 – 16 years) with nonmetastatic medulloblastoma (Chang stage M0-1). Median follow up 5.4 years.</td>
<td>Patients randomised to preradiation chemotherapy or radiotherapy.</td>
<td>Overall survival, event free survival.</td>
<td>179/217 patients were eligible for analysis (CT + RT: 90 patients; RT alone: 89 patients). It was recommended that RT should commence within 28 days of surgery. 12 patients (13.5%) achieved this. The interval between surgery and RT was 24-42 days for 46 patients (51.7%) and &gt; 42 days for 28 patients. There was no significant difference in OS (p=0.2113) or event free survival (p=0.1263) for those patients, starting RT within 42 days of surgery compared with those starting &gt; 42 days after surgery.</td>
<td>Adequate details of randomisation process. Problems with recruitment to trial resulted in reduction in power of study. Good multicentre study with adequate details of methods etc.</td>
<td>Randomised controlled trial</td>
<td>1+</td>
<td></td>
</tr>
<tr>
<td>10. Thomas PRM, Tefft M, Compaan PJ et al. (1991) Results of two radiation therapy randomizations in the third National Wilms’ tumor Study. <em>Cancer</em> 68:1703-1707. Note: Also co-author of Kalapuraka study which also reports results from NWTS 3 &amp; 4.</td>
<td>Children with Stage II and Stage III favourable histologic type (FH) tumours. 268 patients Stage II FH Wilms’ tumour; 277 patients Stage III FH Wilms’ tumour. US.</td>
<td>To resolve some issues raised in NWTS 1 &amp; 2, incorporated RT randomisations for patients with Stage II &amp; Stage III (residual abdominal disease) FH Wilms’ tumours. Stage II-Surgery and then 2 groups: Group 1: no radiotherapy or 2000 cGy radiotherapy and chemotherapy of dactinomycin (AMD), Vincristine (VCR) and Survival and intra-abdominal relapses.</td>
<td>10/15 patients who experienced an abdominal relapse had delays of &gt; 10 days after surgery before initiation of RT. A comparison of the 10 relapses in 103 patients, with the 5 relapses in 174 patients whose RT started within 10 days is significant (continuity-corrected Pearson chi-squared test, 4.664; two-sided p=0.03). No other overall effect of RT delay was demonstrated. Authors conclude delay of start of RT seems to have been implicated in the</td>
<td>Insufficient details of patient characteristics, randomisation methods, statistical analyses, attribution. Without details of randomisation study could be a nested case control study. Controversy exists about use of continuity corrected Pearson chi tests.</td>
<td>Randomised controlled trial?</td>
<td>1-</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL /QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>-------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Doxorubicin (ADR) for 15 mths. OR Group 2: no radiotherapy and intensive AMD + VCR for 15mths. Patients on radiotherapy arm of trial required to receive RT to operative bed (excised tumour plus kidney). Stage III-Surgery and then 2 groups: Group 1: either 1000 cGY or 2000 cGY and AMD+VCR+ADR for 15mths or 1000 cGY or 2000 cGY plus intensive AMD+VCR for 15 mths.</td>
<td>development of abdominal relapse. Factors such as slower recovery from surgery in patients with more extensive tumours may contribute to this. NWTS-4 (next stage of study) mandates RT start &lt;10 days of surgery.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Febrile Neutropenia

The Questions:

1. Does the place of treatment of febrile neutropenia (FNP) episodes for children and young people with cancer affect outcome?
2. Are there safe and reliable methods for selecting and treating children and young people with FNP in an outpatient setting?

Nature of the evidence

Q.1
3 randomised controlled trials of fair quality
1 guideline of good quality
1 literature review of fair quality

Q.2
1 systematic review of good quality
1 prospective case series of fair quality
1 prospective cohort of fair quality
2 guidelines, 1 of good quality; 1 of fair quality
2 historical case series of fair quality

Summary of the supporting evidence for the recommendations

Q.1
- The conclusions from one RCT are that oral antibiotics and early hospital discharge for patients who remain stable >24 hours of inpatient monitoring offers an alternative to conventional management of low risk FNP.
- The evidence from one RCT indicated that children can be managed as outpatients providing they meet certain criteria.
• The evidence from one RCT indicates that the safety of outpatient treatment requires further research \(^1\).

• The conclusions from one guideline are that some selected patients may be treated as outpatients \(^3\).

• The evidence from 1 literature review suggests that there is a sub-population of children who can be managed as outpatients \(^2\).

Q.2

• One systematic review concluded that FNP cancer patients can be considered low risk if they are clinically well with evidence of marrow recovery and no disqualifying comorbidities \(^4\).

• The authors of one prospective cohort conclude that clinical and laboratory parameters can be used to select children in an outpatient setting but that formal evaluation is required \(^6\).

• One prospective case series indicates which criteria can be used to select children \(^5\).

• One historical case series provides indications for selection criteria for low risk children \(^2\).

• One guideline provides partially evidence-based indications for selection criteria \(^1\).

• One guideline describes the Multinational Scoring System for Identification of low Risk FNP cancer patients \(^3\).

The guidelines that exist are from the United States and there is consensus that there is an urgent need for UK guidelines on the management of FNP. As yet there is insufficient high quality evidence to determine whether it is safe to treat FNP in an outpatient setting.
Q.1 DOES THE PLACE OF TREATMENT OF FEBRILE NEUTROPENIA (FNP) EPISODES FOR CHILDREN AND YOUNG PEOPLE WITH CANCER AFFECT OUTCOME?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>

232 episodes (in 163 patients, aged between 5 to 74yrs) of neutropenia with an estimated projection to last no more than 10 days and no coexisting medical conditions.

Comparison oral amoxicillin-clavulanate plus ciprofloxacin with IV cefazidine. Patients hospitalised.

Treatment failure. From May 1992-1997, 211 patients had a total of 284 episodes of fever & neutropenia. 52 episodes not evaluated. The authors conclude that oral antibiotics are effective as IV treatment but the safety of outpatient treatment requires further research.

The use of a double blind design with a dummy IV or oral treatment eliminated bias toward modifying therapy earlier in the oral therapy group. The size of the sample provided an 80% probability that the upper 95% CI for the true difference in the success rates for oral treatment and IV treatment was > than 15%. The observed difference was 3% in favour of oral medications. A confounding factor is that 200/232 episodes of fever & neutropenia were treated with CSFs. According to ASCO guidelines low risk patients do not need treatment with growth factors. Suggests that patients were not truly low risk. No QoL measures.

<table>
<thead>
<tr>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double blind, randomised controlled trial</td>
<td>1+</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
</tr>
<tr>
<td>2. Holdsworth M, Hanrahan J, Albanese B et al. (2003)</td>
<td>Children with cancer.</td>
</tr>
<tr>
<td>3. Hughes WT, Armstrong D, Bodey GP et al. (2002)</td>
<td>Update of 1997 guidelines.</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
</tr>
<tr>
<td>in neutropenic patients with cancer. \textit{Clinical Infectious Diseases} 43:730-751.</td>
<td>the treatment of carefully selected patients with oral antibiotics alone. Some patients may receive their therapy as outpatients, although the majority of studies that have supported treatment with oral antibiotics have been performed in hospitals. Vigilant observation and prompt access to 24h per day / 7 days a week medical care must be in place. The factors favouring low risk for severe infection in patients with neutropenia are:</td>
</tr>
<tr>
<td></td>
<td>• ANC $\geq$ 100 cells/mm$^2$</td>
</tr>
<tr>
<td></td>
<td>• AMC $\geq$ 100 cells/mm$^2$</td>
</tr>
<tr>
<td></td>
<td>• Normal findings on a chest X-ray</td>
</tr>
<tr>
<td></td>
<td>• Nearly normal results of hepatic &amp; renal function tests</td>
</tr>
<tr>
<td></td>
<td>• Duration of neutropenia $&lt;$ 7 days</td>
</tr>
<tr>
<td></td>
<td>• Resolution of neutropenia expected in $&lt;$ 10 days</td>
</tr>
<tr>
<td></td>
<td>• No intravenous catheter-site infection</td>
</tr>
<tr>
<td></td>
<td>• Early evidence of bone marrow recovery</td>
</tr>
<tr>
<td></td>
<td>• Malignancy in remission</td>
</tr>
<tr>
<td></td>
<td>• Peak temperature of $&lt;$ 39.0$^\circ$C</td>
</tr>
<tr>
<td></td>
<td>• No neurological or mental changes</td>
</tr>
<tr>
<td></td>
<td>• No appearance of illness</td>
</tr>
</tbody>
</table>

The evidence from which the recommendations are made is graded. The up to date nature of the guidelines and their evidence base make them useful to the question of criteria for patient selection for OP/shared care treatment.
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>102 patients undergoing conventional dose cytotoxic chemotherapy representing 126 episodes of fever associated with neutropenia. Clinical symptoms at randomisation were mild to moderate. Age range: 18 to 78 yrs. Female 61.9%. Majority episodes occurred in women reflecting underlying diagnoses of breast cancer &amp; small-cell lung cancer. Patients could be entered in study more than once following randomisation.</td>
<td>Assessment of efficacy and safety of oral antibiotics in conjunction with early hospital discharge in comparison with standard in-patient intravenous antibiotics in patients with low-risk neutropenic fever. Compared oral and early hospital discharge with inpatient IV antibiotics. Oral arm: oral regimen of ciprofloxacin 750mg/12hrs plus amoxicillin 500mg+ clavulanate 175mg every 8hrs for total of 5 days. Patients eligible for discharge following 24h hospitalisation if clinically stable and symptomatically improved and according to criteria as described for oral arm.</td>
<td>Primary outcomes: success and safety. “Success” defined as lysis of fever and resolution of symptoms and signs with no modification to initial antibiotic regimen and with no recurrence within 7 days. “Safety” assessed by frequency of serious medical complications and deaths. Secondary outcomes: total duration of hospital admission, frequency of readmission, toxicity of treatment and resource utilisation.</td>
<td>Oral arm: 66 episodes (51 first episodes). Intravenous Arm: 60 episodes (51 first episodes). Total of 36.5% had no symptoms other than fever. Efficacy &amp; Safety: Success rate to initial antibiotic therapy similar in both groups. Intravenous: Successful 90% of episodes (95%CI: 82.4 to 97.6%) Oral: 84.8%; p=0.55: absolute differences between groups 5.2%; 95%CI for difference minus 7 to 17.3% Success rates of 102 first episodes: Intravenous: 45/51 (82%); Oral: 43/51 (84.3%); p=0.77.</td>
<td>Small sample. Study states retrospectively scored patients’ baseline characteristics at randomisation. Some retrospective analysis done due to publication of “risk scales” during study period.</td>
<td>Prospective randomised controlled single centre study (retrospective scoring of baseline characteristics) Randomisation: consecutively drawn sealed envelopes.</td>
<td>++</td>
<td></td>
</tr>
</tbody>
</table>
### STUDY

Improving outcomes in children and young people with cancer: evidence review

### POPULATION

Subsequent episodes of febrile neutropenia. Patients required to be haemodynamically stable with no signs or symptoms requiring intravenous fluid support. Adequate renal function and ability to maintain satisfactory oral intake required. Responsible adult to act as carer.

### INTERVENTION/AIMS

**AIMS**

- To patient’s wishes.
- Patients supplied with diary to record temp at 6h intervals and associated symptoms.
- Telephone contact maintained with clinical research team. Oral & written instructions and 24h contact no. of specialist centre, emphasising need for early reporting of symptomatic deterioration. After discharge patients reviewed 7-10 days later in Oncology Outpatient Dept. If not discharged after 24h reassessed daily.
- Intravenous arm:
  - Intravenous regimen of gentamicin 80mg every 8hrs and dose adjusted according to therapeutic levels plus tazocin (piperacillin) 4g+tazobactam 500mg every 8hrs until hospital discharge.
- Patients eligible for discharge when afebrile for 24h with a rising neutrophil count (irrespective of absolute value). Patients did not routinely receive antibiotics on discharge.

### OUTCOMES

- to patient’s wishes.
- Patients supplied with diary to record temp at 6h intervals and associated symptoms.
- Telephone contact maintained with clinical research team. Oral & written instructions and 24h contact no. of specialist centre, emphasising need for early reporting of symptomatic deterioration. After discharge patients reviewed 7-10 days later in Oncology Outpatient Dept. If not discharged after 24h reassessed daily.
- Intravenous arm:
  - Intravenous regimen of gentamicin 80mg every 8hrs and dose adjusted according to therapeutic levels plus tazocin (piperacillin) 4g+tazobactam 500mg every 8hrs until hospital discharge.
- Patients eligible for discharge when afebrile for 24h with a rising neutrophil count (irrespective of absolute value). Patients did not routinely receive antibiotics on discharge.

### RESULTS

**Failure:**

- **Intravenous arm:**
  - Death (1) not attributed to treatment.
  - Persistence of fever with microbiological evidence of resistance (2); without microbiological evidence of resistance (3);
- **Oral arm:**
  - Serious complication or clinical deterioration while in-patient (1); Intolerance of antibiotics due to vomiting (1); due to severe oesophagitis (2);
  - Persistence of fever without microbiological evidence of resistance (6). All 9 failures converted to intravenous antibiotic regimens. 5 patients readmitted to hospital, 4 described above; 1 with pulmonary embolism.

**Toxicity:**

- Both arms well tolerated. Oral: 1 episode (0.8%) severe toxicity, CTC grade 3. Other: mild-moderate gastrointestinal toxicity not requiring change to regimen: 14 (21%) patients CTC grade 1-2 diarrhoea; 5 (7.6%) grade 1-2 nausea/vomiting;
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Mullen CA, Petropoulos D, Roberts WM et al. (1999) Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 86:126-34.</td>
<td>73 episodes of fever and neutropenia in 41 children receiving chemotherapy for cancer. Aged 3 to 20 years. Children had to have</td>
<td>Aim: to assess the safety of treating low risk paediatric patients with FNP as outpatients. Children and parents attended for baseline clinical evaluation, blood samples.</td>
<td>Number of episodes treated entirely as outpatients. Duration of raised temperature and treatment. Proportion of episodes managed as outpatients.</td>
<td>Overall, 63/73 (86%) of episodes were managed as outpatients. There was no statistically significant difference between oral and intravenous antibiotics in Episodes rather than children were randomised and analysed. Small number of children. Children had to fulfil certain criteria such as &lt; 1 hr from</td>
<td>Episodes rather than children were randomised and analysed. Small number of children. Children had to fulfil certain criteria such as &lt; 1 hr from</td>
<td>RCT</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>+</td>
</tr>
</tbody>
</table>

Intravenous: no episodes of toxicity CTC grade >1.

**Median in-patient stay:**
- Intravenous: 4 (range 2-8) days;
- Oral: 2 (range 1-16 days);

**p<0.0005.** Overall oral antibiotic policy resulted in reduction of 66 in-patient days (199 compared to 265).

**Resource utilisation:**
Overall costs over £19,000 less in oral arm compared with intravenous arm. Authors conclude that oral antibiotics in conjunction with early hospital discharge for patients who remain stable after a 24hr period of in-patient monitoring offers a feasible and cost-effective alternative to conventional management of low-risk neutropenic fever.

Authors urge caution when applying findings outside setting of a single specialist centre. Also suggest larger trials needed to further evaluate policy.
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>This RCT compares oral and intravenous antibiotics in outpatients.</td>
<td>reliable caretakers and be &lt; 1 hour from hospital. Absolute neutrophil count &lt; 500 cells/microL or &lt; 1000 cells/microL and declining. Oral temp &gt; 38.5°C once or &gt; 38°C on three occasions over 6 hrs. USA.</td>
<td>All given single dose ceftazidime (50 mg/kg) then randomised to intravenous ceftazidime (50 mg/kg/dose every 8 hrs via portable pump) or oral ciprofloxacin (12.5 mg/kg/dose every 12 hrs). Children returned to clinic for daily evaluation till afebrile for 48 hrs.</td>
<td>episodes requiring change of initial antibiotic. Description of problems encountered for episodes requiring hospitalisation. Deaths, ICU transfers, serious complications.</td>
<td>the proportion of episodes treated entirely as outpatients (31/33 with IV ceftazidime versus 32/40 with oral ciprofloxacin, p = 0.10) Mean duration of: • Raised temp was 2.7 days; • antibiotic treatment was 4.7 days. 77% of episodes required no change of initial antibiotic. 10 children were hospitalised (4 had prolonged fever; 3 had emesis; 1 deteriorating condition; 1 parents non-compliance; 1 protocol violation). There were no deaths, ICU transfers or serious complications. 60% of children presenting with febrile neutropenic episodes were not eligible for outpatient treatment. The authors concluded that carefully selected children with fever and neutropenia can be safely treated as outpatients provided they are evaluated every day.</td>
<td></td>
</tr>
</tbody>
</table>

hospital, reliable carer etc and attend clinical every day.
### Q.2 ARE THERE SAFE AND RELIABLE METHODS FOR SELECTING AND TREATING CHILDREN AND YOUNG PEOPLE WITH FNP IN AN OUTPATIENT SETTING?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| 1. Hughes WT, Armstrong D, Bodey GP et al. (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clinical Infectious Diseases* 43:730-751. | Update of 1997 guidelines. | Level of Risk for Oral Antibiotics and Outpatient Management = The guideline panel consider there is good evidence for the treatment of carefully selected patients with oral antibiotics alone. Some patients may receive their therapy as outpatients, although the majority of studies that have supported treatment with oral antibiotics have been performed in hospitals. Vigilant observation and prompt access to 24h per day/7 days a week medical care must be in place. The factors favouring low risk for severe infection in patients with neutropenia are:  
- ANC ≥100 cells/mm²  
- AMC ≥100 cells/mm²  
- Normal findings on a chest X-ray  
- Nearly normal results of hepatic & renal function tests  
- Duration of neutropenia < 7 days  
- Resolution of neutropenia expected in < 10 days  
- No intravenous catheter-site infection  
- Early evidence of bone marrow recovery | The guidelines are partially evidence based, but rely heavily on expert consensus opinion. The evidence from which the recommendations are made is graded. The up to date nature of the guidelines and their evidence base make them useful to the question of criteria for patient selection for OP/shared care treatment. | Guidelines | 3/4 ++ |

---

**Improving outcomes in children and young people with cancer: evidence review**

87
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
</table>
• Peak temperature of < 39.0°C  
• No neurological or mental changes  
• No appearance of illness  
• No abdominal pain  
• No comorbidity complications.  
As an alternative to initial outpatient treatment early discharge with continued outpatient therapy for selected patients may be considered after a brief inpatient admission during which IV therapy is initiated, a fulminant infection is excluded and the status of initial culture specimens is ascertained. | Good quality study. Appropriate use of statistics. | Historical case series | 3 ++ |

Improving outcomes in children and young people with cancer: evidence review 88
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Orudjev E, Lange B (2002) Evolving concepts of management of febrile neutropenia in children with cancer, Medical &amp; Pediatric Oncology 2002:39:77-85.</td>
<td>27 prospective trials and 5 reviews of febrile neutropenia in paediatric cancer patients. Aged 0 to 18 years. Studies of adult patients were included in the assessment of different antibiotic strategies.</td>
<td>Aim: to determine risk factors in identifying low-risk paediatric patients for outpatient treatment of fever and neutropenia, to assess alternative antibiotic regimens and create an algorithm for managing patients. The review included the studies by Sahu, Rackoff, Petrilli Shemesh and Santolaya. Various oral and intravenous antibiotic regimens. Treatments took place in hospital, home, outpatient departments. Some regimens involved early discharge.</td>
<td>The association between the following factors and treatment failure: • comorbidities at presentation; • absolute neutrophil count (ANC); • absolute monocyte count (AMC) and fever; • therapeutic strategies (site of care, route of administration of antibiotics and the duration of antibiotic treatment). 1/3 to ½ of children with febrile neutropenia are at low risk of life threatening complications. Low risk patients can be identified by an experienced nurse or physician, physical examination and complete blood count. The review presents a list of specific comorbidities. Children who are well and have evidence of marrow recovery (rising ANC or AMC; children in relapse from leukaemia require an APC$\geq$100 x $10^9$) are low risk and are suitable for outpatient treatment or early discharge. Studies of antibiotic regimens generally used 1 or more doses of intravenous broad spectrum antibiotics followed by observation plus daily assessment. Continuation of treatment with oral and</td>
<td>Search date not stated. Primary sources: Medline, references. Validity of studies was not assessed. No details of methods used to conduct the review.</td>
<td>Systematic review</td>
<td>2+ ++</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION/ AIMS</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/ QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>--------------------</td>
<td>----------</td>
<td>---------</td>
<td>-----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td>5. Rackoff WR, Gonin R, Robinson C et al. (1996) Predicting the risk of bacteraemia in children with fever and neutropenia. <em>Journal of Clinical Oncology</em> 14:919-924.</td>
<td>115 episodes of fever and neutropenia in 72 children with cancer treated in hospital. Age 9 months to 18 years. Children had solid tumours or haematological malignancies. Fever was defined as temperature of 38°C on 3 occasions over 24 hours or single. Study aim: To identify factors in children with cancer who present with fever and neutropenia at admission that predict bacteraemia. Treated in hospital. Study setting: Children’s Medical Centre, Indiana, USA.</td>
<td>The following predictors of bacteraemia were examined:  - diagnosis;  - disease status;  - type of central venous access device;  - admission clinical signs</td>
<td>intravenous had similar treatment failure rates. Standard inpatient treatment is required for outpatients with bacterial infection, fever for &gt; 4 days, clinical deterioration, and intolerance of therapy or non compliance. Up to 25% may experience treatment failure. The authors concluded that febrile neutropenic paediatric cancer patients can be considered low risk if they are clinically well with evidence of marrow recovery and no disqualifying comorbidities. The authors report that one study stated that results reported in trials may not generalise to settings outside clinical trials. A treatment algorithm is presented. Only the absolute monocyte count (AMoC) and temperature on admission were significant predictors of bacteraemia. Bacteraemia was significantly increased for high risk episodes compared with low risk episodes. OR 4.4 (95% CI: 1.6, 12.9). Risk classification was validated using data from 57 prospective case series</td>
<td>Prospective case series</td>
<td>3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review 90
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>temperature recording ≥38.5°C. Neutropenia was defined as absolute neutrophil count (ANC) &lt; 500/µL. Bacteraemia was defined as positive blood culture using BACTEC. Country: USA</td>
<td>and symptoms; • prophylactic antibiotics; • use of G-CSF; • admission blood count and picture; • need for IV resuscitation; and chest • X-ray. Episodes of fever and neutropenia were classified as low risk (AMoC ≥100 µ/L), intermediate (AMoC &lt; 100 µ/L and temp &lt; 39°C) and high risk (AMoC &lt;100µ/L and temp ≥39°C) for bacteraemia.</td>
<td>different episodes of fever and bacteraemia. The authors concluded that three levels of risk were defined using the AMoC and temperature at admission. They suggest future studies could examine the safety of abbreviated antibiotic therapy in children at low or intermediate risk of bacteraemia.</td>
<td>Authors note generalisability of study findings may be limited since: various regimes used in children with cancer; different underlying disease; year to year and site specific variation in rate and type of infection.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Santolaya ME, Alvarez AM, Becker A et al. (2001) Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children (IBI) with cancer, neutropenia, and fever. Journal of Clinical Oncology 19:3415-3421.</td>
<td>447 episodes of febrile neutropenia in 257 children with cancer. Aged 6 months to 18 years. Most had acute lymphocytic leukaemia. All were receiving chemotherapy. Fever defined as ≥38.5°C once or ≥38°C twice. Neutropenia defined as absolute</td>
<td>Aim: to determine factors that predict the presence of invasive bacterial infection (IBI) in paediatric cancer patients with acute fever and neutropenia. Setting: 5 hospitals in Santiago, Chile. All children were hospitalised and</td>
<td>Five variables were independent risk factors for IBI: CRP ≥ 90 mg/L (RR 4.2); hypotension (RR 2.7); relapse of leukaemia (RR 1.8); platelet count ≤ 50,000/mm³ (RR 1.7); ≤ 7 days since last chemotherapy (RR 1.3). 95% CIs were reported for the above RR. Results were similar for demonstrable IBI and</td>
<td>Prospective cohort</td>
<td>2-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION/AIMS</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>-------------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>monocyte count (AMC) ≤500/mm³. Country: Chile</td>
<td>received intravenous broad spectrum antibiotics. Monitored daily in hospital till fever settles and AMC &gt; 500 mm³.</td>
<td>episode variables • admission clinical and laboratory variables. Demonstrable IBI defined as confirmed bacteraemia and positive bacterial culture from usually sterile site. Probable IBI defined as no positive culture but clinical and lab signs suggestive of sepsis plus focal organ involved.</td>
<td>probable IBI when analysed separately and in analysis using only the first episode per child. The authors concluded that clinical and laboratory admission parameters can help predict the risk of invasive bacterial infection. The authors state that validation of this predictive model is required before it can be adopted for use. The authors state that they are currently conducting such a validation.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Central Venous Access

The Question:

What is the evidence for the optimum method of central venous catheter (CVC) insertion in children and young people with cancer?

Nature of the evidence

1 randomised controlled trial of fair quality
1 non-randomised controlled study of poor quality
2 systematic reviews, 1 of fair to poor quality; 1 of poor quality
1 prospective cohort study of fair quality,
1 retrospective comparative study of poor quality
2 guidelines; 1 of good quality; 1 of fair quality
1 audit of fair to poor quality
1 non-systematic literature review of poor quality

Summary of the supporting evidence for the recommendations

- There is evidence from both randomised trials and non randomised trials to support the view that trained clinical nurse specialists can provide high quality CVC care \(^2\)\(^4\).
- The systematic and non systematic review evidence indicated that there was a lack of high quality evidence to indicate the optimum method for CVC insertion but that there are some simple measures that are effective in reducing complications \(^5\)\(^6\)\(^8\).
- The cohort study aimed to determine risk factors for infection but the results were not separated for children and young people. The study provided indirect evidence that the insertion of CVCs should be performed in an operating theatre or clean special procedure room \(^8\).
• Ultrasound locating devices can improve the insertion success rate and reduce complications – NICE technology appraisal 7.

• The audit study demonstrated that there was a wide variation in insertion techniques used in the UKCCSG centres. The authors concluded that such variations make any interpretation of data difficult 9.

No randomised evidence specific for child or adolescent cancer patients was identified. No clear evidence was found to indicate the best model of care for CVC insertion in children and young people with cancer.
### WHAT IS THE EVIDENCE FOR THE OPTIMUM METHOD FOR CENTRAL VENOUS CATHETER (CVC) INSERTION IN CHILDREN & YOUNG PEOPLE WITH CANCER?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
</table>
- Suggests intrinsic factors affecting LA-BSI rates represented by Transplant (TR), Mechanical Ventilation (MV) or Pulmonary Oedema (PE)  
- Independent Extrinsic risk factors: inserting a CL outside an operating room (SPR), using Total Parenteral nutrition (TPN) and keeping CL 312 days.  
- Line insertion outside a special procedure room or operating room (SPR) odds ratio (OR) =2.5; (95% CI: 1.6 to 4.0)  
- Total parenteral nutrition (TPN) OR=2.3; (95%CI: 1.7 to 3.0)  
- Duration of CL 312 days OR=1.8 (95%CI: 1.3 to2.6);  
- Mechanical ventilation (MV) OR=2.5; (95%CI: 1.7 to 3.9) | No results separately for children and adolescents with cancer. Numbers of patients not given, nor any other patient characteristics. | Prospective multicentre cohort surveillance study. | 2^+ |
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Boland A, Haycox A, Bagust A et al. (2003) A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. <em>Health Technology Assessment</em> 7:1-99.</td>
<td>470 adult (&gt;18 years) cancer patients due to have a Hickman line insertion who were clinically and physically compliant with specified protocols. 80% patients of normal physical state; 75% had Karnofsky performance score from 80% to 100%; 54% had gastrointestinal cancer; 66% treated as inpatients.</td>
<td>To compare the clinical and cost-effectiveness of image guided Hickman line insertion with blind Hickman line insertion undertaken by nurses in adult cancer patients. Setting: large acute cancer hospital in Manchester. Blind versus guided insertion of Hickman line by nurses (1 trainer and 2 trainees). Both treatments involved blind venipuncture of the subclavian vein. Lines inserted by 3 trained nurses. 74% were single lumen Hickman lines. Blind insertion of a Hickman line at the patients’ bedside: Hickman line routinely inserted without the use of image guidance at any point in the primary clinical outcome measure: catheter-tip misplacement. For comparison of skill level of the trainer and the trainees, pneumothorax was the primary clinical outcome. Secondary outcomes were: arterial puncture, haematoma; infection; failed insertion; and assistance from other healthcare professionals.</td>
<td>Pulmonary Oedema (PE) OR=2.0; (95% CI: 1.3 to 3.1) Transplant patient (TR) OR=2.6; (95% CI: 1.2 to 4.7) Catheter-tip misplacement was significantly higher with blind insertion (14% [32/235] v 1% [1/235], p &lt; 0.001). This was the only significant difference. No significant difference between blind and image guided in: arterial puncture (6% v 5%), pneumothorax (3% v 1%), haematoma (1% v 2%), line infection (4% v 6%), tunnel infection (5% v 2%). Significantly higher proportion of lines were inserted without complications or help from other staff using image guided method (81% with image guided v 67% with blind, p &lt; 0.001). Only 3 patients were transferred from the bedside to X-ray unit during insertion. <strong>Time</strong> Blind: mean 38 mins (95% CI: 36, 39 mins); Range 15 to 90 mins.</td>
<td>Few patients, of relevance to child and adolescent group. Treatment groups comparable at baseline. Detailed report. Lots of background information including types of CVCs; methods of insertion of Hickman lines; choice of access site; choice of operator; complications; analysis of empirical evidence (1980 to 2000); comparison of Hickman with other types of CVC; different settings, operators and techniques;</td>
<td>RCT</td>
<td>1+</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION/ AIMS</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/ QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>-------------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td>3. British Committee for Standards in Haematology (1997) Guidelines on the insertion and management of central</td>
<td>All patients with skin tunnelled catheters.</td>
<td>Development of recommendations for insertion and management.</td>
<td>Major recommendations (relevant to question): • Single lumen catheters cause fewer problems. • Fully implantable catheters more suitable</td>
<td>Image-guided: mean 40 mins (95% CI: 38, 42 mins); Range 20 to 150 mins. There was no significant difference between the two trainees combined and the trainer for pneumothorax, catheter tip misplacement; arterial puncture; haematoma; line infection; tunnel infection; successful insertion; nurse assistance; oncologist assistance; radiologist assistance. Trainees were significantly more likely to require the assistance of another nurse than the trainer (13% v 4%, p = 0.002). Authors concluded that: Nurses previously inexperienced in the procedure can be trained to insert Hickman lines successfully both at the bedside and under image guidance within a 3-month period. Authors concluded that the insertion of Hickman lines is safe and effective for most adults with cancer.</td>
<td>review of health economics literature (reviews 8 papers); summary of published literature.</td>
<td>review of health economics literature (reviews 8 papers); summary of published literature.</td>
<td>3/4</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION/ AIMS</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/ QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>-------------------</td>
<td>----------</td>
<td>---------</td>
<td>-----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Italic= reviewers comments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**AIMS**
- Lines should be inserted in children by paediatric specialists.
- Imaging facilities must be available.
- Line insertion should take place in an operating theatre or similar clean environment.
- Thrombosis and infection must be diagnosed promptly. Both complications may require line removal.
- Catheters should be removed only by experienced personnel. Catheter breakage requires radiological intervention.
- Patients should receive clear and comprehensive information and be encouraged to look after their own lines.
- Units should audit complication rates and use the data to develop preventative measures.

**OUTCOMES**

**DESIGN**

**EVIDENCE LEVEL/ QUALITY**

<p>| 4. Cardella JF, Cardella K, Bacci N, et al. (1996) Cumulative experience with 1,273 peripherally inserted central catheters at a single institution. Journal of Vascular Interventional Radiology 7:5-13 | Total of 869 peripherally inserted central catheters (PICCs) inserted in 655 patients. Mean age 49.7 yrs (range 1 to 93 yrs). | To compare bedside insertion of PICCs by nurses with insertion by radiologists. (Group A) Nurses (N) performed 327 (37.6%) bedside insertions with Technical success; Service Interval Complications | Follow-up information available for 808 of 869 (93%) PICCs inserted; 50 of 61 PICCs lost to follow up did have identifiable removal date. Outcome of insertion attempts: Technical Success: | No results separately for children and adolescents with cancer. PICC : Each group used own preferred Vendor of PICC. | Non randomised controlled study with non-comparative control group | 2 |</p>
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 2 of study (Phase 1 previously reported elsewhere).</td>
<td>No statistically significant difference in patient ages between groups. <strong>Sex:</strong> 51% male (n=340); 48.1% female (n=315)  <strong>Group A (Nurses):</strong> 51% male  41.9% female  <strong>Group B (Radiologists):</strong> 48.2% male; 51.8% female. Statistically significant difference in sex (p=0.004)  <strong>Indication for PICC insertion:</strong>  Antibiotic therapy: Nurses: n=198 (45.4%)  Radiologists: n=324 (52.3%)  Difference NS  <strong>Hyperalimentation</strong>  Nurses n=85 (14.9%)  Radiologists n=190 (30.7%)  p&lt;0.001  <strong>Hydration:</strong>  Nurses n=107 (24.5%)  Radiologists n=39 (6.3%)</td>
<td>Palpatory, through-the-needle technique in 301 patients. (3 PICCs inserted by nurses under guidance of interventional radiologists in fluoroscopy suite for training purposes.)  <strong>(Group B)</strong>  Radiologists performed 542 (62%) insertions with a venographic-fluoroscopic direct puncture &amp; sheath technique in 354 patients.  Radiologists required for difficult initial insertions, PICC salvage and PICC exchange.  From 14 May 1992 to 31 December 1994.</td>
<td>Nurses: 327/396 (82.8%)  Radiologists: 542/555 (98.2%)  <strong>Failure:</strong>  • Inability to cannulate: Nurses: 31/89 (44.9%)  Radiologists: 10/10 (100%)  • Inability to thread: Nurses: 26/89 (37.7%)  Radiologists: 0/10 (0%)  • Errant threading (to wrong site)Nurses: 12/89 (17.4%)Radiologists: 0/10 (0%)  In all cases of failed attempts by nurses, PICCS were successfully inserted by radiologists.  All failed attempts at PICC insertion in radiology dept occurred in patients (n=63) referred directly by nurses.  Overall mean service interval for PICC insertions was: Nurses: 21.0 days (range 0 to 288 days)  Radiologists: 32.2 days (range, 0-432 days)  p=0.002.  <strong>Size &amp; Type of catheter:</strong> No statistically significant difference between Nurses group and Radiologists Group with regard to PICC type or size.</td>
<td>Groups different at baseline.  Radiologists were assigned more difficult patients. Not stated how patients were selected for reporting. Not stated that consecutive patients were treated.</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION/ AI MS</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>---------------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| p<0.001 | **Chemotherapy:**
Nurses n=13 (3.0)
Radiologists n= 14 (2.3%)
Difference NS |
| | **Plain Medication:**
Nurses n=14 (3.2%)
Radiologists n=6 (1.0%)
p=0.003 |
| | **Immunosuppress- ive Therapy:**
Nurses n=0
Radiologists n=16 (2.6%)
p<0.001 |
| | **Other:**
Nurses n=39 (8.9%)
Radiologists n=30 (4.6%)
P=0.001 |
| | Due to different insertion strategies there were significant differences in preferred insertion site (p<0.001) and final tip position (p=0.001) between Groups A & B. |
| | Patient Status at end of study period: Difference in patient status between groups not statistically significant. 695/869 PICCS were alive; 85/869 PICCS (9.8%) died 28/869 PICCS (3.2%) still in use 61/869 PICCs (7%) lost to follow up. |
| | Reasons for removal of PICC: There were no statistically significant differences between Nurses and Radiologists groups with regard to reasons for PICC removal. |
| | Complications: 
**Death:**
Nurses: 0
Radiologists: 0 |
| | **Thrombophlebitis:**
Nurses: 13/301 patients (4.3%)
Radiologists: 12/354 (3.4%)
p=0.133 |
| | **Infection:**
Nurses: 2/301 (0.7%) |

Due to different insertion strategies there were significant differences in preferred insertion site (p<0.001) and final tip position (p=0.001) between Groups A & B.

Patient Status at end of study period: Difference in patient status between groups not statistically significant. 695/869 PICCS were alive; 85/869 PICCS (9.8%) died 28/869 PICCS (3.2%) still in use 61/869 PICCs (7%) lost to follow up.

Reasons for removal of PICC: There were no statistically significant differences between Nurses and Radiologists groups with regard to reasons for PICC removal.

Complications:
**Death:**
Nurses: 0
Radiologists: 0

**Thrombophlebitis:**
Nurses: 13/301 patients (4.3%)
Radiologists: 12/354 (3.4%)
p=0.133

**Infection:**
Nurses: 2/301 (0.7%)
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.</td>
<td>People having long term intravenous therapy.</td>
<td>Appears to be methods aimed at preventing infection.</td>
<td>Not explicitly stated. Appears to be infection.</td>
<td><strong>Dressing:</strong> One study found that cleansing the end of a Hickman catheter with 70% alcohol, placing in sterile finger cot and sealing with tape covering at least 2 inches of the cap resulted in no further episodes of <em>S. epidermidis</em> catheter infection. <strong>Hygiene:</strong> One study found that intensive training in strict hygiene and hand washing reduced infection rates in a children’s hospital from 40% to 8%. <strong>Antibiotics:</strong> One study found that exit site infections respond to intravenous antibiotics and that removal of the catheter is not required. One study recommended catheter removal for tunnel infection with <em>Pseudomonas</em>. <strong>The exit site:</strong> Three studies found that skin cleansing with chlorhexidine in spirit reduces infection compared with alcohol or povidone iodine. One study found that dry dressings reduce infection compared with Tegaderm or Opsite. Two studies found that dressings like IV3000 are better at preventing accumulation of moisture under the dressing than Tegaderm.</td>
<td>Inclusion criteria not stated in terms of population. Inclusion criteria not stated in terms of interventions. No results separately for children and adolescents with cancer. No defined inclusion criteria for review, no stated search strategy, no details of methods used to select studies, assess validity, extract data. Inadequate reporting of individual studies included in this report. Study design and number of patients/ catheters not mentioned. High risk of bias. Unable to assess the quality of the evidence.</td>
<td>Non-systematic literature review</td>
<td>4</td>
</tr>
</tbody>
</table>

Radiologists: 11/354 (3.1%) p=0.147

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Securing the catheter**: No studies reported. Just comments.
- **Pyrexia**: No studies reported. Just comments.
- **Prevention of thrombosis**: One study reported that most hospitals heparinised catheters daily when in use. **Treatment of thrombosis**: Two studies recommended that catheters be flushed with Hepsal once weekly when in use. One study recommended more frequent flushing in children with small lumen catheters. One study found that suction of blood into the catheter tip may be prevented by clamping catheter while the last ml of heparin is given. One study found that Exoparin is effective in treating and preventing venous thrombosis in bone marrow transplant patients. One study suggested that low dose warfarin may prevent venous thrombosis in high risk patients. One study found that clots could be removed from Hickman catheters if care were taken. Two studies found that the length of time urokinase has to remain in place is controversial. One study found that using an algorithm for the management of occluded
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
</table>

Catheters helps and can be used as a teaching tool. As a result of the review the following aspects of catheter care were changed: **Cleansing solution:** changed from saline to chlorhexide in spirit. **Hygiene:** bacterial cultures taken from nursing and medical staff to highlight need for hygiene. **Bungs:** change to bungs rather than membrane caps and use Bionectors. **Reporting Audit:** reporting infection rates to surgeons and monitoring infection rates. **Surveillance:** collection of information on catheters with annual audit. Audit sooner if increase in infection. Need to consider most effective tool for collecting information. **Communication:** Monthly multidisciplinary clinical haematology audit meetings.

Search date: 1999
Primary sources: Medline; conference proceedings; reference lists; contact with primary authors. Included RCTs where these were available, if
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>from percutaneously drawn blood cultures that matched microbial growth from catheter.</td>
<td>Warfarin and Heparin Prophylaxis</td>
<td>Prophylaxis with very-low-dose warfarin should be strongly considered for patients with long-term, indwelling intravascular catheters [IIa]. Prophylactic heparin should be administered to patients with short-term central venous catheters [I]. Site of Insertion</td>
<td>No randomised trials have assessed the risk for infection associated with catheter insertion into the subclavian, internal jugular, or femoral vein. Insertion into a subclavian vein is preferred to reduce the risk of infection [III] (4 observational studies). Femoral venous catheterisation should be limited to circumstances that prevent the use of alternative sites [III]. Subcutaneously Tunneled Catheters</td>
</tr>
</tbody>
</table>

**Design**

- Grade I: Evidence from a well-designed meta-analysis of randomised, controlled trials;
- Grade IIa: evidence from at least one randomised, controlled trial;
- Grade IIb: evidence from at least 1 RCT that allowed catheter exchange over guide wires into old sites;
- Grade III: evidence from at least one well-designed clinical trial without randomisation;
- Grade IV: evidence from opinions of authorities in the field based on clinical experience, descriptive studies or expert opinion.

**Evidence Level/Quality**

- Grade I: Evidence from a well-designed meta-analysis of randomised, controlled trials;
- Grade IIa: evidence from at least one randomised, controlled trial;
- Grade IIb: evidence from at least 1 RCT that allowed catheter exchange over guide wires into old sites;
- Grade III: evidence from at least one well-designed clinical trial without randomisation;
- Grade IV: evidence from opinions of authorities in the field based on clinical experience, descriptive studies or expert opinion.
<table>
<thead>
<tr>
<th>STUDY POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>committee reports.</td>
<td>where approved, or skin preparation before catheter insertion [IIa]. Tincture of iodine is superior to povidone-iodine as a cutaneous antiseptic and should be considered for preparation of intravascular sites [IV].</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sterile Barrier Precautions</td>
<td>Full barrier precautions should be the standard of care during central venous catheter insertion [IIa] and should be considered during insertion of midline and artery catheters [IV].</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Catheter Dressing</td>
<td>On the basis of all available evidence, the choice of central venous catheter dressing may be a matter of thin preference and cost [IIb]; however, gauze dressings are preferred if blood is oozing from the catheter insertion site [IIb].</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ointments</td>
<td>Applying triple antibiotic ointment (polymyxin, bacitracin, neomycin) to the catheter insertion is not recommended [IIa]. Mupirocin ointment should not be applied to catheter insertion sites [IV]. Applying povidone-iodine ointment to insertion sites of...</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION/AIMS</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>------------------</td>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td>7. National Institute of Clinical Excellence (2002) Guidance on the use of ultrasound locating devices for placing central venous catheters. NICE Technology Appraisal Guidance No. 49. London: National Institute of Clinical Excellence. Available from: <a href="http://www.nice.org.uk">www.nice.org.uk</a></td>
<td>Patients requiring CVCs.</td>
<td>Two types of Real-time ultrasound guidance: two-dimensional (2D) imaging ultrasound guidance and audio-guided Doppler ultrasound guidance. Evaluated against a venepuncture method known as &quot;landmark method&quot;.</td>
<td>Major recommendations on use of ultrasound locating devices for placing CVCs.</td>
<td>Two Dimensional (2D) imaging ultrasound guidance recommended: 1) as preferred method for insertion of CVCs into internal jugular vein (IJV) in adults and children in elective situations. 2) should be considered in most clinical circumstances where CVC insertion is necessary either electively or in emergency situations.</td>
</tr>
</tbody>
</table>

nontunneled, long-term central venous catheters in immunocompromised patients with heavy *S. aureus* carriage (such as patients with AIDS, or cirrhosis) should be considered [IV].

Contamination-Shielded Pulmonary Artery Catheters
A contamination shield should be used for all pulmonary artery catheters [Iia].

There were also additional recommendations for catheter maintenance.

Authors concluded that simple interventions can reduce the risk for serious catheter-related infections. Adequately powered RCTs are required.
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3) that all those involved in placing CVCs using 2D imaging should undertake appropriate training to achieve competence. Audio-guided Doppler ultrasound guidance not recommended for CVC insertion.</td>
<td>ultrasound against landmark method: 13 evaluated 2D ultrasound guidance against landmark method. 1 evaluated both Doppler &amp; 2D against landmark method. No trials compared ultrasound against surgical cut-down method. None addressed PICCs or ports. Procedure carried out by anaesthetists in 7 studies &amp; other medical staff in 4 studies. None of the studies involved nurses. Only 3 trials for 2D ultrasound and one for Doppler ultrasound using internal jugular vein evaluated effect of guidance on infants.</td>
<td>See Comment by Carey CR, Stenz R. (2003) Paediatric central venous catheter insertions Anaesthesia, 58: 1127-1128</td>
<td>++</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION/ AIMS</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>-------------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Randolph AG, Cook DJ, Gonzales CA et al. (1996) Ultrasound guidance for placement of central venous catheters: a meta-analysis of the literature. Critical Care Medicine 24:2053-8.</td>
<td>493 patients requiring 513 placements of central venous catheters (CVCs). Only one study specified children included. No numbers or patient details provided.</td>
<td>To evaluate effect of real-time ultrasound guidance using regular or Doppler ultrasound technique for placement of CVCs compared with landmark placement.</td>
<td>Rapidity of placement, Number of attempts before successful placement, Success of placement rate of complications, Rate of success after failure by landmark method.</td>
<td>Rapidity of placement: Results comparing ultrasound guidance vs landmark technique were heterogeneous (p&lt;0.0001). Some showed it took less time, some more. Mean difference was 9 seconds (95%CI: –80 to 62.2). Number of attempts before successful placement: Ultrasound guidance significantly decreases requirement of multiple placement attempts. Overall relative risk for ultrasound guidance 0.60 (95%CI: 0.45 to 0.79). Success of placement: Ultrasound guidance significantly decreases relative risk of catheter placement failure compared with landmark placement. Overall relative risk of 0.32 (95% CI: 0.28 to 0.55). Catheters placed in internal jugular vein (IJV) (relative risk 0.38; 95%CI: 0.21 to 0.71); Subclavian vein (SCV) (relative risk 0.15; 95%CI: 0.04 to 0.53). 1 RCT for infants showed reduced number of attempts to success. Rate of complications: Frequency rate of...</td>
<td>Experience of operators varied. Settings for CVC insertion varied. Only 1 study detailed results on children and states due to their smaller vessel size may be beneficial for children but requires further investigation under controlled settings. All studies unblended: assessor bias. Variable definition of failed catheter placement. Provided search details of included studies, evaluation of evidence.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic review – meta analysis</td>
<td>1+/-</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
</tr>
</tbody>
</table>
• Identification of variations in aftercare practice.  
• Survey opinion of diagnosis of CVC sepsis among multiple centres belonging to a single cooperative group. | | complications during placement significantly decreased using ultrasound guidance (relative risk 0.22; 95%CI: 0.10 to 0.45); IJV (relative risk 0.26; 95%CI: 0.11 to 0.58); SCV (relative risk 0.11; 95%CI: 0.02 to 0.56).  
Rate of success after failure by landmark method:  
Not all trials reported results. Success rates where reported ranged from 33% to 100% with ultrasound guidance following failure by landmark method. | No age or diagnosis data given but authors state that these were representative of the prevalence of individual centres in the UK. | Cross sectional audit | 3 +/- |
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>flush associated rigor, fever were considered pathognomic. The authors conclude that the variations highlight the difficulties in interpreting the published data on CVC efficacy.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**COMMENTS**

Italics = reviewers comments

**DESIGN**

**EVIDENCE LEVEL/ QUALITY**
Blood Product Support

Nature of the evidence

3 national guidelines of fair quality
1 national surveillance report of fair quality
1 expert position paper (Appendix G)

Summary of the supporting evidence for the recommendations

- The three guidelines and the expert position paper recommended the use of agreed protocols although there was no supporting evidence specific for children and young people with cancer\(^1\) \(^2\) \(^4\).
- The results of the national surveillance of adverse incidents indicated that medical and nursing and laboratory staff should be aware of the specific transfusion requirements of children\(^3\).

The expert position paper was accepted by the GDG as providing advice on this topic and a detailed literature search was not performed.
### BLOOD PRODUCT SUPPORT

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Serious Hazards of Transfusion. Annual Report 2003.</td>
<td>Description of adverse incidents occurring during blood transfusion.</td>
<td>The commonest error in 2003 was the failure to request irradiated blood appropriately.</td>
<td></td>
<td>Guidelines 3/4</td>
<td>+</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Pain Management

The Question:

What are effective methods for pain management in children and young people with cancer?

Nature of the evidence

1 systematic review of fair quality
2 guidelines, 1 of good quality; 1 of fair quality
1 government policy of fair quality
1 expert opinion of fair quality

Summary of the supporting evidence for the recommendations

- There is evidence from a systematic review that relaxation and cognitive behavioural therapy (CBT) are effective in reducing effects of headache\(^2\).
- There are guidelines on the management of pain control that has implications for service provision and emphasises the importance of protocols for the safe and effective use of analgesia\(^4\).
- The Children’s NSF states the importance of effective pain management and staff training\(^1\).
- 1 expert opinion concludes that effective pain management should be high priority in service provision and that there should be adequate numbers of paediatric oncology nurses\(^3\).

It was clear from the evidence that multidisciplinary protocols should be in place for pain assessment and treatment and all children should have access to play specialists.
## WHAT ARE EFFECTIVE METHODS FOR PAIN MANAGEMENT IN CHILDREN AND YOUNG PEOPLE WITH CANCER?²

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
</table>


² Cross refer to palliative care evidence table
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION/AIMS</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>------------------</td>
<td>----------</td>
<td>---------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
|       |            |                  |          | **cancer care should be educated and trained in assessing pain as well as in the principles of its control.**  
- Patients should be given information and instruction about pain and pain management and be encouraged to take an active role in their pain management.  
- Analgesia for continuous pain should be prescribed on a regular basis not 'as required. Breakthrough analgesia should be administered at any time outwith regular analgesia if the patient is in pain.  
- All staff using syringe drivers, including community based health care professionals, must be fully trained in their correct use.  
- Safe systems for use and management of syringe drivers must be in place as detailed in guidance issued by the Scottish Executive Department of Health.  
- All professionals looking after patients with pain from cancer should be aware of the range of neurosurgical and anaesthetic techniques. | |
|       |            |                  |          | **COMMENTS**  
*italics= reviewers comments* | |
<p>|       |            |                  |          | <strong>DESIGN</strong> |
|       |            |                  |          | <strong>EVIDENCE LEVEL/QUALITY</strong> |</p>
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>available for the relief of pain.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• All professionals looking after patients with pain from cancer should have access to a specialist pain relief service, able to offer the techniques described above.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• If a patient's pain is not controlled by other measures, then the advice of a specialist in pain relief should be sought with a view to performing one of the above procedures.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pre-registration curricula for health care professionals should place greater emphasis on pain management education.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Continuing pain management education programmes should be available to all health care professionals caring for patients with cancer.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• All patients with cancer should have access to a health care professional appropriately qualified to offer advice and information, both verbal and written, regarding pain and effective pain management.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Patients with cancer pain</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>should be given an opportunity to be trained in some form of relaxation as an adjunct to pharmacological pain control.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Family members should be offered information and education regarding the principles of pain and its management in order to address their lack of knowledge and concerns regarding analgesic administration, tolerance and addiction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A thorough assessment of the patient's psychological and social state should be carried out. This should include assessment of anxiety and, in particular, depression, as well as the patient's beliefs about pain.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patients with cancer pain should be given an opportunity to be trained in some form of relaxation as an adjunct to pharmacological pain control.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Comments**

Italics = reviewers comments
Management of Nausea and Vomiting

The Question:

What is the evidence for the optimum management of nausea and vomiting?

Nature of the evidence

1 quasi randomised controlled trial of fair to poor quality
3 guidelines, 2 of good quality; 1 of fair quality
1 expert opinion of fair quality

Summary of the supporting evidence for the recommendations

- The results of the quasi RCT on the use of evidence based guidelines on the symptoms of nausea and vomiting showed that such guidelines do improve control of nausea and vomiting.
- Data from one US and two UK guidelines give detailed information on protocol use to treat nausea, vomiting and diarrhoea. The evidence for the guidelines was considered however to be poor and in some instances the recommendations are formed from expert consensus.
- An expert opinion provides a review of the current evidence for management of nausea and vomiting in children with cancer.
EVIDENCE FOR THE OPTIMUM MANAGEMENT OF NAUSEA AND VOMITING

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/ QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>-------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td>4. Kearney N, Miller M, Weir-Hughes D et al. (2004) <em>Wisecare+: Final Report</em>  <a href="http://www.cancercare.stir.ac.uk/projects/wisecare-final-report.pdf">www.cancercare.stir.ac.uk/projects/wisecare-final-report.pdf</a></td>
<td>Patients (&gt; 18 years) with cancer undergoing chemotherapy. Pilot project of 11 patients aged between 13 and 20 years (mean age 16 yrs).</td>
<td>To assess the influence of the integration of patient symptom assessment and the promotion of evidence based guidelines on the symptoms of nausea and vomiting. Two groups, one group received additional self-care information. Both groups received evidence based guidelines. Both groups then received evidence based care. Data collection was over 20 months.</td>
<td>Results were available for 235 patients. All symptoms measured except fatigue improved following the introduction of evidence based intervention. The authors conclude that the introduction of structured patient assessment and evidence based guidelines significantly improves patients’ symptoms during chemotherapy. 10/11 patients returned the questionnaire in the pilot project. The modifications of the questionnaire were considered by most teenagers to be adequate for symptom assessment.</td>
<td>No details of randomisation process. Exclusion criteria well described. Useful evidence.</td>
<td>Quasi randomised controlled trial</td>
<td>1</td>
<td>+/-</td>
</tr>
<tr>
<td>5. National Comprehensive Cancer Network (2004). <em>Practice Guidelines in Oncology. Antiemesis. Version 1.</em></td>
<td>All cancer patients. US</td>
<td>Development of evidence based guidelines.</td>
<td>The guidelines present flow diagrams with the different methods to treat emesis.</td>
<td>The evidence for the guidelines was considered to be of low quality. The statements were based on NCCN consensus, based on this evidence.</td>
<td>Guidelines</td>
<td>3/4</td>
<td>++</td>
</tr>
</tbody>
</table>
Nutrition

The Question:

What is the evidence for the optimum method of provision of nutritional support for children and young people with cancer?

Nature of the evidence

1 historical case series of fair quality
1 guideline of fair quality
2 expert opinions, 1 of fair quality; 1 of fair to poor quality
1 expert position paper (Appendix H)

Summary of the supporting evidence for the recommendations

- The evidence from one historical case series indicates that children who were malnourished at diagnosis have poorer outcomes compared with well nourished children\(^3\).
- The guideline provides information for optimum artificial nutritional support but is not specific to children with cancer\(^2\).
- The expert opinions emphasise that it is necessary to understand the metabolic changes that occur in cancer patients and that nutritional support is vital in children with cancer\(^1\)\(^4\).

The expert position paper was accepted by the GDG as providing advice on this topic and a detailed literature search was not performed.
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Andrassy RJ (1998) <em>Nutritional support of the paediatric oncology patient.</em> Nutrition 14: 124-129.</td>
<td>Paediatric oncology patients.</td>
<td>Description of nutritional support interventions.</td>
<td>The author emphasises that it is necessary to understand the metabolic alterations occurring in cancer patients that cause nutritional depletion.</td>
<td>Expert opinion</td>
<td>4 +/-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>-------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>survival. International Journal of Cancer [supp] 11:66-18.</td>
<td>quality of life and survival.</td>
<td>support should be given with appropriate tumour directed therapy if curative intent is the goal of treatment.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Italics = reviewers' comments

Improving outcomes in children and young people with cancer: evidence review
Oral & Dental Care

The Question:

What is the evidence for the optimum method of provision of oral and dental care for children and young people with cancer?

Nature of the evidence

1 systematic review of good quality
2 historical case series of fair quality
1 survey of fair quality
2 guidelines, 1 of fair quality; 1 of fair to poor quality
1 expert opinion

Summary of the supporting evidence for the recommendations

- The results of one systematic review indicated that there was a lack of high quality evidence for effective treatment for oral infections and mucositis 7.
- It was demonstrated in one historical case series that root surface area of mandibular teeth is reduced in long term survivors of paediatric cancer 2.
- Untreated decay and problems accessing dental care was shown in one historical case series of children with cancer 1.
- One survey of all 22 UKCCSG centres revealed variation in service provision for oral and dental care 4.
- Two guidelines provided some recommendations for oral care 5 6.
- The author of one expert opinion concluded that the development and implementation of evidence based guidelines could improve the oral and dental care of children and young people with cancer 3.
WHAT IS THE EVIDENCE FOR THE OPTIMUM METHOD OF PROVISION OF ORAL AND DENTAL CARE FOR CHILDREN AND YOUNG PEOPLE WITH CANCER?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Clarkson JE, Eden OB (1998) Dental health in children with cancer. Archives of Diseases in Childhood. 78:560-561.</td>
<td>60 children with cancer 1-14 years (mean age 6.2 yrs).</td>
<td>Assessment of dental health 4-6 months post diagnosis.</td>
<td>Presence of infection and dental problems.</td>
<td>Untreated decay was diagnosed in 26 children and 20 children had visible plaque with gingivitis. 8 patients had problems gaining access to dental care. 25 children had received preventive dental advice. 21 children required urgent dental treatment. The authors conclude that the results highlight the need to improve the integration of dental services into the medical care structure.</td>
<td></td>
<td>Historical case series</td>
<td>3</td>
</tr>
<tr>
<td>2. Duggal MS (2003) Root surface areas in long-term survivors of childhood cancer. Oral Oncology 39:178-183</td>
<td>69 long-term survivors of paediatric cancer.</td>
<td>Quantification of root surface area (RSA) of mandibular teeth in long term survivors of childhood cancer.</td>
<td>Comparison of RSA of cancer survivors with normal controls.</td>
<td>RSA of mandibular teeth was significantly smaller in survivors of cancer patients than in normal controls. There was no relation between the RSA and the age at which cancer was diagnosed.</td>
<td></td>
<td>Historical case series</td>
<td>3</td>
</tr>
<tr>
<td>4. Glenny AM, Gibson F Auld E et al. (2004) A survey of current practice with regard to oral care for children being treated for Paediatric oncology patients being treated at 22 UKCCSG centres.</td>
<td>Establishment of current UK oral care practice by telephone survey of 22 UKCCSG centres.</td>
<td>19/22 centres (86%) of the centres used protocols/guidelines for mouth care. There was wide variation in the use of</td>
<td></td>
<td></td>
<td>Survey</td>
<td>3/4</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer. European Journal of Cancer. 40:1217-1224.</td>
<td></td>
<td></td>
<td>preventive oral care therapies. Only at 8/22 centres (36%) did children undergo dental check ups before the commencement of cancer treatment. There was little variation in advice given to parents/patients on basic oral hygiene. The authors stress the need to establish evidence based strategies for oral and dental care.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Worthington HV, Clarkson JE, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. The Cochrane Database Of Systematic Reviews. Issue 2.</td>
<td>All cancer patients.</td>
<td>Any intervention for the treatment of oral mucositis or its associated pain.</td>
<td>Mucositis; days to heal; oral pain scores; dysphagia; systemic infection incidence; analgesia; LOS; cost of oral care &amp; QOL.</td>
<td>Only 1 RCT met the inclusion criteria. The authors conclude that there is weak and unreliable evidence that allopurinol mouthwash; vitamin E, immunoglobulin or human placental extract improve or eradicate mucositis. There is The reviewers also mention that there is no good evidence to support the use of antimicrobial agents for reducing oral mucositis.</td>
<td>Systematic review</td>
<td>1-</td>
<td></td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review 127
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>no evidence that patient controlled analgesia is better than continuous infusion method for controlling pain. Further well designed trials are required.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Rehabilitation

The Question:

What is the most effective strategy to provide effective rehabilitation services for children and young people with cancer?

Nature of the evidence

1 systematic review of good quality
1 systematic review of fair quality (head injury in children)
1 literature review of fair to poor quality

Summary of the supporting evidence for the recommendations

- The NICE guidance on Improving Outcomes in Palliative and Supportive Care for Adults with Cancer contains evidence from a systematic review on general rehabilitation services for cancer patients ².
- There is good evidence from the systematic review on the literature for traumatic brain injury in children on the effectiveness of rehabilitation of children and adolescents ¹.
- The results of 1 literature review on the effectiveness of occupational therapy indicate that they have a positive role in providing psychosocial support, maximisation of function and family assistance ³.

There is a lack of good quality evidence for children and young people with cancer. Consensus opinion exists that adequate allied health professional input is vital and that timing of commencement of rehabilitation is important.
### WHAT IS THE MOST EFFECTIVE STRATEGY TO PROVIDE EFFECTIVE REHABILITATION SERVICES FOR CHILDREN AND YOUNG PEOPLE WITH CANCER?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Agency for Healthcare Research and Quality (1999) 2S. Supplement. Rehabilitation for traumatic brain injury in children and adolescents. Available from: <a href="http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter.2633">http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter.2633</a></td>
<td>Children and adolescents with head injury.</td>
<td>Systematic review of the literature.</td>
<td>There is no good evidence on the effectiveness of rehabilitation for children and adolescents with head injury. Certain models for social skills training and cognitive rehabilitation have been shown to be ineffective in people who have similar disabilities, yet these models are still being used in children and adolescents with head injury. Interventions must be tested with experimental designs that incorporate concepts of child and adolescent development.</td>
<td>The requirements of children and adolescents with head injury have some similarities to those of children and adolescents with cancer. Useful for type of questions and outcomes that should be formulated. Of relevance to children and adolescents with neurological tumours.</td>
<td>Systematic review</td>
<td>2’++</td>
</tr>
<tr>
<td>3. Strong J (1987) Occupational therapy and cancer rehabilitation. British Journal of Occupational Therapy 50:4-6.</td>
<td>Cancer patients.</td>
<td>Role of occupational therapy in rehabilitation.</td>
<td>Review of the paediatric literature indicates that the occupational therapist’s role has been advocated as largely one of psychosocial intervention and support, in</td>
<td></td>
<td>Review of literature</td>
<td>4 +/-</td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review
addition to maximisation of function, assistance with developmental tasks and provision of assistance to families on environmental matters. The psychosocial area is very important in paediatric oncology and play therapy is often used to help children with terminal cancer deal with their feelings.
Psychosocial Care

The Question:

What is the evidence for the best model of psychosocial care for children and young people with cancer?

Nature of the evidence

2 systematic reviews of fair quality
1 overview survey of good quality
1 questionnaire study of fair quality
1 expert opinion of fair to poor quality
1 expert position paper (Appendix I)

Summary of the supporting evidence for the recommendations

- 1 systematic review concluded that for children and adolescents with cancer the evidence for the best model of psychosocial provision was poor ³.
- 1 systematic review for mixed cancer patients including children and adolescents concluded that the published evidence was poor but that there was some evidence to suggest that group therapy, education, counselling, cognitive behaviour therapy, relaxation therapy and guided imagery were of benefit ⁵.
- 1 questionnaire study examining unmet needs illustrated that for cancer patients (few patients, in child and adolescent age range) these needs were variable particularly with age and social class ⁴.
- 1 detailed overview and survey of UKCCSG centres gives current levels of service provision and makes suggestions for future developments ².
- 1 expert opinion makes recommendations that are not evidence backed ¹.
Whilst high quality evidence was lacking on the optimum psychosocial service provision, the NICE guidance on *Improving Outcomes in Palliative and Supportive Care for Adults with Cancer* recommended that cancer networks have an important role in coordinating service improvement to meet the demonstrated unmet need for psychosocial input.
WHAT IS THE EVIDENCE FOR THE BEST MODEL OF PSYCHOSOCIAL CARE FOR CHILDREN AND YOUNG PEOPLE WITH CANCER?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Children’s Cancer Centre Royal Children’s Hospital, Melbourne (2003) Psychosocial care in paediatric oncology. Towards best practice at the Royal Children’s Hospital. Melbourne: Royal Children’s Hospital.</td>
<td>Service users of a paediatric oncology psychosocial care department. Australia.</td>
<td>• Parent focus groups and survey.  • Audit.  • Staff consultation.  • Benchmarking.  • Consultation with community based cancer support organisations.</td>
<td>The authors conclude that:  • There must be a commitment to and vision of psychosocial service development within the Centre.  • Engagement of expertise within the hospital, and where indicated external agencies, to assist in the development of services.  • Substantial funding for additional psychosocial services.</td>
<td>Recommendation for service improvement but specific to the Melbourne hospital. Can extrapolate to UK for ideal components of service provision. Useful.</td>
<td>Review/expert opinion</td>
<td>4 +/-</td>
<td></td>
</tr>
<tr>
<td>2. Clarke S, Mitchell W, Sloper P et al. (2003) Current patterns of provision of psychosocial support and practical support services at NHS paediatric oncology treatment centres in the UK: an overview. York: University of York.</td>
<td>21 UKCCSG treatment centres, including their associated Teenage Cancer Trust (TCT) units. The 2 TCTs not based at a UKCCSG centre were also surveyed.</td>
<td>Questionnaire survey to investigate the provision of psychosocial and practical support services.</td>
<td>All 21 centres completed the questionnaire and 2/3 separate TCTs replied.  • The number of children and teenagers registered as new patients, per year varied from 250-15, with a mean of 97.  • Data is available on age distribution and expertise at the centres.  • 15/23 centres share care with other hospitals.  • 21/22 centres employed social workers, the majority of posts were funded by the voluntary sector.  • 11/20 centres employed psychologists.  • 8/22 employed a psychiatrist</td>
<td>Excellent questionnaire survey with good questionnaire design and reporting of results.</td>
<td>Overview/Questionnaire survey</td>
<td>3 ++</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 1/21 centres employed a counsellor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 19/20 employed a play therapist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 21/22 employed at least 1 full time POONS.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• All 23 centres had family accommodation.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Data was available from 22 centres on patient and family facilities, hospital transport and teenage facilities.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Formal psychological assessments of patients are not routinely made. Patients, usually assessed by social worker, psychologist or nurse.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Support groups can be accessed from 21/23 centres.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 17/23 centres have formal bereavement support.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 12/23 centres offer some form of complementary therapy.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 23 centres provide informal support.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Data available on cultural needs, information and transition support.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 22/23 centres provide an outreach service for families within their local community.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 18/23 centres have procedures for transition of care from hospital to home.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Eiser C, Hill JJ, Vance YH (2000) Examining the psychological consequences of surviving childhood cancer: systematic review as a research method in pediatric psychology. <em>Journal of Pediatric Psychology</em> 25:449-460.</td>
<td>Children and adolescent survivors with cancer.</td>
<td>Results of a systematic review of literature on psychological consequences of surviving childhood cancer.</td>
<td>Psychological consequences.</td>
<td>20 studies were identified, 17 from the US. Anxiety depression or low self esteem were not significantly different in child cancer survivors compared with population norms or matched controls. The studies were of poor quality and no definite conclusions can be drawn from the results.</td>
<td>Well designed and described study with adequate description of inclusion and exclusion criteria.</td>
</tr>
</tbody>
</table>

- 20/23 centres have a designated person responsible for assisting patients to return to school.
- There was a lack of consensus & information in relation to hand over of care from paediatric to adult services.
- 11/23 centres provide psychosocial support for long-term survivors.
- For palliative care all 23 centres offer a combination of care in the home, hospital and hospice.

The gaps in service provision most frequently reported were psychology support (11/23), social work support (9/23), provision of age appropriate facilities, support for survivors/long-term follow up, communication and duplication between statutory and voluntary sector.

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. McIlmurray MB, Thomas C, Francis B et al. (2001) The psychosocial needs of cancer patients: findings from an observational study. European Journal of Cancer Care 10:261-269.</td>
<td>1000 patients &gt; 18 years, with breast, colorectal, lymphoma and lung cancer.</td>
<td>Assess and identify the prevalence of psychosocial need.</td>
<td>Unmet need for psychosocial care using a 48 point inventory.</td>
<td>Response rate 40%. Logistic regression analysis indicated that the statistically significant variables of need vary by both clinical and social characteristics. Results however do indicate the range of psychosocial needs required by cancer patients.</td>
<td>Few patients, in age range of children and adolescents. Clear patient selection bias</td>
<td>Cross sectional questionnaire study</td>
<td>4 ++</td>
</tr>
<tr>
<td>5. Newell SA, Sanson-Fisher RW, Savolainen NJ (2002) Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. Journal of the National Cancer Institute 94:558-584.</td>
<td>All cancers. Only 1 study in which population stated to be children. All other studies either adult or mixed ages.</td>
<td>Systematic review of literature on psychological therapies.</td>
<td>Effectiveness of interventions targeting anxiety, depression, hospitality, stress, QOL, coping skills, domestic adjustment, social relationships, nausea, vomiting, pain and survival.</td>
<td>627 relevant papers were identified that reported on 329 intervention trials. Only 1 trial was rated as good for its methodology. Using effectiveness results from 34 trials with psychosocial outcomes, 28 trials with side effect outcomes, 10 trials with survival or immune outcomes, the authors suggest that the following have a positive effect on outcome: • Group therapy, education, structured counselling &amp; CBT. • Relaxation therapy and guided imagery for side effects.</td>
<td>Comprehensive review of the literature with good methodology. The authors stress the poor quality of published literature.</td>
<td>Systematic review</td>
<td>2' ++</td>
</tr>
</tbody>
</table>
Long Term Follow Up/Sequelae

The Questions:

1. What is the evidence for the most effective strategy to provide long term follow up (FU) for children and young people with cancer?
2. What is the evidence for the optimum type of late effects services for children and young people with cancer?
3. Should fertility (cryo) preservation strategies be routinely offered to all young people deemed at significant risk of infertility and competent to consent?

Nature of the evidence

Q.1
1 historical case series of fair quality
1 guideline of good quality
1 questionnaire survey of fair quality
1 expert opinion of fair quality
1 review of fair to poor quality
1 qualitative study of fair to poor quality
1 expert position paper (Appendix J)

Q.2
1 retrospective cohort study of fair to poor quality
1 cross sectional study of fair to poor quality
1 expert opinion of fair quality
1 expert position paper (Appendix J)

Q.3
1 audit of fair quality
1 questionnaire survey of fair quality
Summary of the supporting evidence for the recommendations

Q.1
- The evidence from 1 large historical case series indicates the extent of chronic medical problems and that compliance with follow up was good 3.
- Three levels of follow up care are described in 1 guideline 2 and there are recommendations for GP and patient/carer information. Further issues, not dealt with specifically in the SIGN guideline are addressed in the position paper (Appendix J).
- The evidence from the questionnaire survey demonstrates the pattern of FU arrangements for UKCCSG patients 4.
- One expert opinion emphasised the important role for nurses in FU and that UK arrangements lack coordination and evaluation 1.
- One evidence based review summarises the clinical effects of childhood cancers and their treatments. The authors highlight the need for further research and the cost implications 5.
- One qualitative (US) study examined the barriers to FU 6.

Q.2
- The results of the US cohort study and historical case series demonstrated the problems with establishing a comprehensive late effects service and the authors recommend a national policy for adult survivors of childhood cancer 4 6.
- The US cross sectional study again indicated the problems with late effects services and noted the lack of outcomes based research to evaluate the components of follow up 5.
- The authors of 1 expert opinion conclude that follow up strategies are made empirically due to limited evidence and stress the importance of late sequelae 3.
Q.3

- The report of the audit of current provision of fertility services and the development of service guidance makes a series of recommendations for the development of comprehensive fertility services\(^1\).

- The questionnaire survey provides information on the decision process surrounding sperm storage but makes no recommendations about whether fertility preservation strategies should routinely be offered to adolescents\(^2\).

- The expert position paper provides recommendations and evidence for providing endocrine and fertility services for children and young people with cancer.
Q.1 WHAT IS THE MOST EFFECTIVE STRATEGY TO PROVIDE LONG TERM FOLLOW UP FOR CHILDREN AND YOUNG PEOPLE WITH CANCER?3

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
</table>
• Importance of physical, social and emotional adjustment.  
• Role of nurse providing structured and continuing follow-up.  
• Establishing re-entry into school.  
• UK arrangements often informal, lack of co-ordination and evaluation.  
• Can some patients be discharged from follow-up?  
For continuing care – by whom and in what setting? | Important for UK practice. Nurses are interested in LTFU – to provide health education programmes and support in hospital based clinics and as nurse practitioners running nurse led clinics as occurs in USA. | Expert opinion | 4 |
• All survivors of childhood cancer should be actively followed up.  
• At the end of a course of cancer therapy, patients, their carers and GPs should be given a summary of the treatment and a list of signs of late effects to lookout for.  
• Each patient should have access to an appropriate designated key worker to coordinate care.  
• With appropriate training, | Well designed guidelines with good AGREE score. Some issues not covered. | Guidelines | 3/4 |

3 Cross refer to late effects question
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
</table>
- Endocrine  
- Fertility  
- Sensory  
- Neuropsychological  
- Organ toxicity  
- Mobility  
- Cosmetic | 800 patients (62%) had survived 5 years from first diagnosis but 67 (6%) died later. 290 patients attending the long term follow up clinic were available for investigation. 34 (12%) had survived treatment for relapse. Overall 169 (58%) had at least one chronic medical problem and 93 (32%) had two or more. Infertility problems (14%); nephrectomy (11%), thyroid hormone replacement therapy (9%) and visual handicap were the most common problems. Compliance with long term follow up was good and the audit of unselected sub group of all the survivors in the study showed that 84% had attended for surveillance. The results of the study confirm that the sequelae of cure are not trivial. | Well described study with important results for service provision. Outcomes could not be related to specific modalities of treatment. | Historical case series | 3 + |
- Discharge policy arrangements before and after 5 years from Clinicians were divided into paediatric oncologists and other specialists. Completed questionnaires were received from 71 clinicians in 21/22 centres, a response rate of 77%. | | Questionnaire survey | 3/4 + |
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
</table>
- Second primary tumours  
- Cardiovascular disease  
- Fertility  
- Education, psychosocial and quality of life issues  
- Growth, bone mineral density and body composition. | Evidence based on retrospective studies. The authors summarise the clinical effects of childhood cancers and their treatments. They highlight the need for research, such as the British Childhood Cancer Survivor Study, to provide an evidence base. The authors also highlight the financial implications of following all childhood cancer survivors for life. | Review | 4 | +/- |

<table>
<thead>
<tr>
<th>POPULATION</th>
<th>INTERVENTION/AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| 20 young adult (median age 38; range 21-51) survivors of childhood cancer. US. | Identification of barriers to the utilisation of follow up care using the Delphi technique. | Major barriers to health care. | The barriers could be grouped in to 4 categories:  
Survivor related barriers  
Psychological barriers  
Provider related barriers  
Insurance or system related barriers. | | Qualitative | 4 |

**Q.2 WHAT IS THE EVIDENCE FOR THE OPTIMUM TYPE OF LATE EFFECTS SERVICE FOR CHILDREN AND YOUNG PEOPLE WITH CANCER?**

Q.3 SHOULD FERTILITY (CRYO) PRESERVATION STRATEGIES BE ROUTINELY OFFERED TO ALL YOUNG PEOPLE DEEMED AT SIGNIFICANT RISK OF INFERTILITY AND COMPETENT TO CONSENT?


<table>
<thead>
<tr>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
</tr>
</tbody>
</table>
- Paediatric Oncology Centres  
- Assisted Conception Units | Questionnaire surveys of oncology centres and assisted conception units.  
Face to face interviews with  
- Professionals  
- Young men  
- Parents  
Pediatric oncology centres  
- Storage services  
- Written guidelines  
- Service provision  
- Information provision and consent  
- Psychosocial support  
Assisted conception units  
- Storage services  
- Screening  
- Service provision  
- Consent  
- Psychosocial support. | Paediatric oncology centres  
- 40% have written guidelines regarding fertility preservation in adolescent males  
- 55% have written information  
- 55% Did not know which consent form to use  
- 90% response rate from oncology centres.  
- 19/20 centres would welcome the introduction of national guidelines for adolescent male fertility preservation.  
Assisted conception units  
- 23 units currently offered storage facilities for sperm and/or testicular tissue.  
- 61% screened for HIV  
- 56% screened for Hepatitis B  
- 60% screened for Hepatitis C  
- 4% screened for Syphilis  
- 4% of units had sperm stored for adolescent males. | Well designed and reported study. | Questionnaire survey | 3/4 ++ |
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
</tr>
</thead>
</table>
• 87% would welcome the introduction of national guidelines.  
Young men's issues  
• Choice  
• Information  
• Communication  
• Consent  
Young men understood the need for quick decision making about fertility preservation issues.  
Parent's issues  
• Role  
• Information  
• Communication  
• Coping with feelings  
Author's comments:  
• Survival rates now so good, quality of life increasingly important.  
• Need to maintain survival rates while minimising adverse sequelae.  
• Evidence limited by changes in treatment schedules and supportive care guidelines.  
• Increasing importance of late sequelae:  
  - Cardiotoxicity  
  - Endocrine function  
Useful for UK practice. | Expert Opinion | 4 | + |

**Comments**

- Italic = reviewers comments

**DESIGN**

**EVIDENCE LEVEL/QUALITY**
### STUDY

Improving outcomes in children and young people with cancer: evidence review

<table>
<thead>
<tr>
<th>STUDY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improving outcomes in children and young people with cancer: evidence review</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POPULATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INTERVENTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subset of the retrospective cohort study randomly selected and sent an 88 item questionnaire.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OUTCOMES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health care visit, in previous 2 years, related to cancer treatment.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RESULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCSS study 41% RWJ Barriers study 26%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased attendance associated with:</td>
</tr>
<tr>
<td>• Increasing age</td>
</tr>
<tr>
<td>• Male gender</td>
</tr>
<tr>
<td>• College education</td>
</tr>
<tr>
<td>• Lack of medical insurance</td>
</tr>
<tr>
<td>• Lack of concern about future health</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DESIGN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retrospective cohort study</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
</tr>
</tbody>
</table>


1. Childhood Cancer Survivor Study (CCSS). A retrospective cohort study of 14,000 adult survivors aged 16 and older. Information available for 9434 adults.

2. The RWJ Barriers study was a subset of 1600 patients from the CCSS cohort.

The author highlighted the growing population of childhood cancer ‘survivors’ who are vulnerable to the late effects of disease and therapies.

Author’s recommendations:
- National Health Care Policy for adult survivors of childhood cancer.
- Evidence based guidelines for screening and surveillance (research required).
- Minimise barriers to care and maximise enablers.

Only 67% of the original cohort represented in the CCSS study results.

70% response rate to the RWJ Barriers study questionnaire. The results reported are preliminary findings. Both studies use self-reported data.
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Oeffinger KC, Eshelman DA, Tomlinson GE et al. (1998)</td>
<td>Members of the Children’s Cancer Group and the Paediatric Oncology Group 219 participants. USA.</td>
<td>16 item questionnaire.</td>
<td>4 categories of questions: • Existence of a programme to follow-up young adults. • Setting of the programme. • Routine activities of the programme. • Commonly encountered barriers to care.</td>
<td>44% of institutions had a mechanism for following up adult survivors. 93% lead by paediatric oncologist. 13% had assistance from an adult oncologist. 8% had primary care physician input. 70% had nurse clinician or nurse practitioner involvement. Problems routinely followed-up included: • Employment • Cardiac function • Educational attainment • Fertility • Insurability • Other psychosocial measures • Quality of life measures The authors noted the lack of outcomes based research to evaluate the value and components of follow-up. Patients were said to be uncertain about follow-up or unwilling to attend, particularly in the paediatric clinic setting. The authors suggest a need for purposeful, planned</td>
<td>Response rate 83%.</td>
<td>Cross sectional study</td>
<td>3</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>----------------</td>
</tr>
</tbody>
</table>
General physical examination. 
Cancer related medical visit. 
Medical visit to a cancer centre. | 87% reported general medical contact, 71.4% a general physical examination, 41.9% a cancer related visit and 19.2% a visit to a cancer centre. The authors conclude that primary care doctors provide health care for most of this increasing high risk population. Communication is vital between primary care and cancer centres. Univariate analyses were performed to assess the associations of demographic and cancer-related variables with the medical outcome measures. | Well designed and described study. Authors discuss the limitations of the study design such as self reporting, survivors' perceptions of the reason for the medical visit. Selection bias, ethnic groups were under reported. | Historical case series | 3 ++ |
Palliative Care

The Question:

For children and young people with cancer what is the evidence for the requirements for a comprehensive palliative care service?

Nature of the evidence

1 systematic review of good quality
1 guideline of good quality
4 questionnaire surveys, 1 of fair quality; 3 of fair to poor
7 expert opinions, 2 of fair quality; 5 of fair to poor quality
1 expert position paper (Appendix K)
1 strategic document of fair quality

Summary of the supporting evidence for the recommendations

- The evidence for child and adolescent cancer palliative care service requirements from one comprehensive systematic review was poor. The authors stress the difficulties in evaluating the palliative care team because of lack of measurable outcomes. Possible benefits of effective palliative care teams are reduced time in hospital, improved symptom control and increased carer satisfaction 10.

- The NICE guidance provides evidence based recommendations for the requirements for palliative care and supportive care services for adults with cancer; many of these can be extrapolated to children’s services 13.

- The surveys provide information on audit of GP referral patterns and service requirements 7; coordination of palliative care in shared care settings 9 and the role of the specialist palliative care clinical nurse in service provision 11; symptoms and management of children with
progressive malignant disease and practice within the 22 UKCCSG centres in 1997.

- The guidance/expert opinion from Addenbrooke’s hospital provides details of their structures for community and shared care palliative care.
- The Association for Children with Life Threatening Conditions and their Families have recommendations for palliative care services specifically for young people aged 13-24 years and following a UK needs assessment recommendations for commissioners.
- Two expert opinions stress the importance of specialist nurses in the provision of palliative care in the community.
- The position statement provided estimates the numbers of children requiring palliative care in the UK and recommendations for service provision.
- The Norfolk Children and Young People’s Palliative Care Group performed a local needs assessment and produced a local strategy for palliative care service provision based on this assessment and in response to national guidance.
- The document from the Children’s Hospital in Melbourne gives recommendations for best practice for children requiring palliative care.
- The strategic document (Wales) addresses palliative care for all ages but addresses the specific requirements of children.

There is a considerable amount of observational evidence on the requirements for effective palliative care service provision to children and young people with cancer. Outcome measurement is difficult and there is a need for well designed high quality studies to evaluate different models of service provision.
## FOR CHILDREN & YOUNG PEOPLE WITH CANCER WHAT IS THE EVIDENCE FOR THE REQUIREMENTS FOR A COMPREHENSIVE PALLIATIVE CARE SERVICE?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/ QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
</tbody>
</table>
| Children with Life-threatening or Terminal Conditions and their Families 69p. | decision making.  • Undertake needs assessment.  • Flexibility of teams important but need a named key worker.  • Joint planning health and social services.  • Plan for transition to adult care.  • Increase training. | The numbers of young people receiving palliative care is not known as data is not collected routinely. There are increasing numbers of clients attending children’s hospices.  
In late adolescence / early adulthood there is a higher proportion of individuals requiring palliative care.  
There is also an increasing number of survivors of childhood cancer reaching adulthood.  
Issues raised by young people:  • Involvement in decision making.  • Psychological needs.  • Transition from child to adult health services.  • Inexperience of adult health services.  • Concerns about parents and siblings. | consultation. Consensus document based upon limited research literature and written and oral submissions from:  • Professionals  • Voluntary organisations  • Young people’s forum  • Parents  • Families | + |
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Association for \nChildren with Life-Threatening or Terminal Conditions and their Families, The Royal College of Paediatrics and Child Health (2003) A guide to the development of children’s palliative care services. Bristol: Association for Children with Life-threatening or Terminal Conditions and their Families 53p.</td>
<td>UK. Children with cancer requiring palliative care.</td>
<td>Definition of palliative care as including an active and total approach to care: • Physical • Emotional • Social • Spiritual Need: • 8 per 50,000 children die annually • 60-85 per 50,000 have life limiting conditions with some palliative care needs. Recommended model of care: • Locally based multidisciplinary team. • Ready access to children’s hospice and specialist palliative care advice. • Most day to day care in the community. • Key worker. • Flexibility. • Specific needs of adolescents and young adults.</td>
<td>Guidance including needs assessment, review of existing services and recommendations for commissioners.</td>
<td>Expert opinion/Guidance</td>
<td></td>
</tr>
</tbody>
</table>

**DESIGN**

**EVIDENCE LEVEL/QUALITY**

- 3/4
- +
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Beardsmore S (2002) Palliative care in paediatric oncology. <em>European Journal of Cancer</em> 38:1900-1907.</td>
<td>UK. Paediatric palliative care.</td>
<td>Development of protocol for doctors and nursing staff in specialised units and in the community.</td>
<td>Authors conclude: 1) Transition to palliative care complicated by: • Prognosis difficult to accept for patient, staff and family. • Desire for second opinion. • Participation in phase 1 trials. 2) Phase 1 trials can benefit by: • Stabilising progression of disease. • Alleviate symptoms. • Psychological benefit. • Potential gains for future patients. • Adult trials not an adequate predictor. Authors recommend: • A flexible response. • Paediatric outreach</td>
<td>respite and palliative care are familial, raising the need for family support and guidance. • Good information available on cancers, particularly in children. Less information on other conditions. • Needs of minority, ethnic communities must be recognised. • Locally based registers might be helpful.</td>
<td>Expert opinion 4 +/-</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
</tbody>
</table>

nurses and 24 hour access to specialist advice and information. WHO guidelines for cancer pain relief and palliative care are directly applicable in the paediatric setting.
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.</td>
<td>UK. Palliative care services, all ages.</td>
<td>Audit of GPs referring to hospice, inpatient, outpatient and day care facilities (child and adult).</td>
<td>Response: 137 GPs (60%) from 74 practices (85%).  • 91% used planned inpatient admission  • 4% used paediatric services (small numbers)  • 20% used palliative medicine clinic  • 78% of GPs didn’t know whether more or less services were needed. This reflects the rare occurrence and therefore limited experience for individual practitioners.</td>
<td>Questionnaire survey</td>
<td>3 +/-</td>
</tr>
<tr>
<td>8.</td>
<td>UK. Paediatric palliative care.</td>
<td>An estimated 12,000 children in England and Wales require palliative care. 120 likely to die from the condition. A proportion of these deaths will be due to malignancy, but not all. Recommendations:  • Sound community children’s nursing infrastructure.  • Skilled medical support from general practitioners with an interest and some training in paediatric palliative care and from tertiary specialists.  • Expansion of consultant-led tertiary services.  • Expansion of teaching and research.</td>
<td>The document also includes longer-term goals such as increased respite provision and the development of adolescent and young people’s palliative care services.</td>
<td>Expert opinion (based on a regional research project and published guidance)</td>
<td>4 ++</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>9. Harris N, Myers P (2003) Palliative care provision by paediatric oncology teams in the Southwest – a regional survey. San Antonio: Southwest Paediatric Oncology Palliative Care Network 6p.</td>
<td>UK. 8 Paediatric oncology shared care units and the regional centre in Bristol.</td>
<td>Regional survey; two part questionnaire. 1. General section covering workload, team organisation and training over the previous three years. 2. Confidential section examining aspects of personal involvement in palliative care.</td>
<td>8 out of 9 units responded. Most palliative care for children dying from cancer taking place in the community, but is co-ordinated and provided by hospital based paediatric oncology palliative care teams. Deaths: • 19% in hospital • 78% at home • 3% in hospice or other setting. Areas of concern: • Pain control • Symptom control • Information for parents Support for staff</td>
<td>Authors commented that hospital staff underestimate the potential assistance to families from local primary care teams.</td>
<td>Questionnaire survey</td>
</tr>
<tr>
<td>10. Higginson IJ, Finlay IG (2003) Improving palliative care for cancer. Lancet Oncology 4:73-74.</td>
<td>UK. Palliative care, all ages.</td>
<td>Hospital based palliative care teams.</td>
<td>Process or outcomes of care for patients and families at the end of life. • Symptoms • Quality of life • Time in hospital • Total length of time in palliative care</td>
<td>Results suggest possible benefits: • Reduced time in hospital. • Improved symptom control. • Increased carer satisfaction. • Influence on prescribing of opioids and non-steroidal anti-inflammatory analgesics. Ten databases searched. Hospital setting, mainly UK and large teaching hospitals, though including studies from Sweden, Canada, Argentina, France and Italy. One randomised controlled trial.</td>
<td>Systematic literature review; qualitative meta-synthesis and quantitative meta-analysis.</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>11.</td>
<td>Jack B, Oldham J, Williams A (2003) A stakeholder evaluation of the impact of the palliative care clinical nurse specialist upon doctors and nurses, within an acute hospital setting. <em>Palliative Medicine</em> 17:283-288.</td>
<td>UK. Palliative care, all ages</td>
<td>A stakeholder evaluation of the role of the palliative care clinical nurse specialist in the acute hospital setting. 31 semi-structured interviews giving opinions from: • Senior nurses • Consultants • Junior doctors Nurses of different Clinical nurse specialist appointments in palliative care.</td>
<td>Emerging themes: • Core components of the role include expert practice, education, consultation and research. • Colleagues value support and advice. • Education is particularly welcomed by senior nursing staff and doctors. • Clinical nurse specialists identify education as an important part of their role</td>
<td>Only three studies included a control group. No adjustment for confounding. Effect sizes generally small. The authors comment on the “poor quality of studies”. The effectiveness of the palliative care team, working as unit, is difficult to measure. Standardised outcome measures would be valuable for practice and research.</td>
</tr>
<tr>
<td>12.</td>
<td>Leeson J (2002) <em>Norfolk palliative care strategy for children and young people</em> (aged &lt; 19)</td>
<td>UK authors. Children and young people (aged &lt; 19)</td>
<td>Morbidity 10-12 children per 10,000 population. Mortality 1.1 per 10,000 child</td>
<td>Local strategy and recommendations based on a local</td>
<td>Expert opinion</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>young people, Norwich: Norfolk Children and Young People’s Palliative Care Group 24p. Available from: <a href="http://www.cancernw.com/content/palliative_care/palliative_care_strategy_children.doc">www.cancernw.com/content/palliative_care/palliative_care_strategy_children.doc</a></td>
<td>years) in Norfolk requiring palliative care.</td>
<td>population. Children’s palliative care different because: • Small numbers requiring the service • Many rare diagnoses specific to paediatrics • Genetic illnesses - issues for family members • Families directly involved in care Issues raised by the needs assessment: • Poor co-ordination of services • Lack of bereavement support / training • Patchy provision of respite care • Inequality of access to services • Lack of good practice guidelines • Lack of consistent key worker for families • Little support for siblings Recommendations: • Locally based services • Named key worker • Individual care plan for each family • Strengthen arrangements for tertiary services • Education and information</td>
<td>health needs assessment and in response to national guidance.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ITALICS: reviewers comments

DESIGN LEVEL/ QUALITY +/-
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>14. Royal Children’s Hospital, Melbourne (2002) <em>Best practice in palliative care</em>. Royal Children’s Hospital: Melbourne. Internet Communication.</td>
<td>Australia. Paediatric palliative care.</td>
<td>The site cites the Royal College of Paediatrics and Child Health (UK) description of best practice, with essential components: • Assessment and care plan • Key worker • Local clinicians and nurses skilled in paediatric palliative care • 24 hour support • Regular respite • Emotional support • Provision of medication and equipment • Financial assistance Barriers described: • Rarity of conditions • Only 40% child deaths due to malignant conditions • Difficult to develop and maintain skills • Dual role for parents of care givers and decision makers • Developmental factors in children affect</td>
<td>Expert opinion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DESIGN**

1. Guidelines/Systematic review
2. Evidence
3. Expert opinion
4. +/-

**EVIDENCE LEVEL/QUALITY**

1++
2++
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>15. United Kingdom Children's Cancer Study Group. Paediatric Oncology Nursing Forum. <em>Survey of signs and symptoms. Symptoms and management of children with progressive malignant disease. Draft.</em> Leicester: United Kingdom Children’s Cancer Study Group, Paediatric Oncology Nursing Forum 14p.</td>
<td>Children and young people with cancer.</td>
<td>Prospective survey of 22 UKCCSG centres May 1997-November 1997.</td>
<td>Symptoms; current management and variation in service delivery.</td>
<td>Study documents frequency of symptoms in children with CNS tumours; leukaemia; neuroblastoma; soft tissue sarcoma; nephroblastoma; osteosarcoma; lymphoma. The study showed symptomology differences between tumour types. The authors discuss the difficulties of evaluating palliative care services and suggest that by using symptoms that these are proxy measures of quality of life.</td>
<td>Useful preliminary data for UKCCSG patients.</td>
<td>Questionnaire survey</td>
<td>3/4</td>
</tr>
<tr>
<td>16. Welsh Assembly Government (2003) A strategic direction for palliative care services in Wales. Cardiff: Welsh Assembly Government 26p.</td>
<td>Wales. Palliative care, all ages.</td>
<td></td>
<td>The Strategy recognises that paediatric palliative care requires a specific needs assessment and strategy. The document covers issues relevant to palliative care at all ages: • Pain control • Patient involvement • Out of hours services • Barriers to co-ordinated care • GP knowledge • Work force planning • Education and training - Undergraduate - Postgraduate • Voluntary sector issues • Carer support</td>
<td>The document addresses palliative care services for all ages, though there is a short section on palliative care for children. Reference is made to other documents, such as The Calman Hine report, Cancer Services in Wales and Paediatric Palliative Care in Wales.</td>
<td>Strategy document</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review

162
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Recommendations are made for:</strong>&lt;br&gt;- Generic services&lt;br&gt;- Primary care&lt;br&gt;- Secondary care&lt;br&gt;- Tertiary care&lt;br&gt;- Palliative care services.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Italics= reviewers comments
Bereavement

The Question:

What is the evidence for best practice in the provision of bereavement services for children and young people with cancer, their families and carers?

Nature of the evidence

1 systematic review of good quality
1 draft guideline of fair quality
1 questionnaire survey of good quality
1 questionnaire survey of fair quality

Summary of the supporting evidence for the recommendations

- A systematic review on palliative and supportive care gives general recommendations for bereavement care.
- 1 draft guideline from the newly set up National Child Bereavement group gives preliminary guidance on child bereavement services.
- The evidence from 1 questionnaire survey provides an up to date picture of current childhood bereavement services in the UK.
- The evidence from 1 questionnaire survey illustrates the problems of one health authority in providing bereavement services (not paediatric specific).

There is a lack of evidence on what constitutes an effective bereavement service but there is consensus on the need for key worker support and that each treatment centre should provide bereavement support for a suitable period depending on the needs of individual families. Good communication skills and the provision of adequate information are vital in providing bereavement support.
**WHAT IS THE EVIDENCE FOR BEST PRACTICE IN THE PROVISION OF BEREAVEMENT SERVICES FOR CHILDREN AND YOUNG PEOPLE WITH CANCER AND THEIR FAMILIES AND CARERS?**

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. National Institute for Clinical Excellence (2004) Guidance on cancer services - improving supportive and palliative care for adults with cancer – the manual. London: National Institute of Clinical Excellence. Available from: <a href="http://www.nice.org.uk">www.nice.org.uk</a></td>
<td>All patients with cancer.</td>
<td>Review of evidence on bereavement care for families and carers.</td>
<td>Differing forms of support are available for those experiencing bereavement, ranging from information, through befriending and self-help groups to more formalised psychological interventions such as counselling. There is inequitable distribution of bereavement services and the quality varies. Families and carers may never undergo screening to assess their level of vulnerability. Professionals are often not adept at assessing, predicting and responding to families’ and carers’ bereavement needs, both before and after death.</td>
<td>Good review of evidence, but very little specific to child and adolescent age range.</td>
<td>Systematic review</td>
<td>2** ++</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/ QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td>3.</td>
<td>All subjects requiring bereavement support.</td>
<td>Interviews with health professionals (primary, secondary and community care) who had experience of working with the bereaved.</td>
<td>Level of bereavement support provided by health professionals for a specific health authority in Yorkshire.</td>
<td>The study indicated that bereavement services provided within the hospital setting were reactive not proactive. The use of an assessment tool was not reported and bereavement need was identified informally through contacts with the bereaved. There appeared to be insufficient bereavement policy statements. There were significant communication problems between secondary and primary care systems.</td>
<td>Illustrates problems within a typical health authority for provision of a bereavement service.</td>
<td>Questionnaire survey</td>
<td>3/4 ++</td>
</tr>
<tr>
<td>4.</td>
<td>Bereaved children</td>
<td>Identification of current provision of bereavement services in the UK.</td>
<td>A questionnaire was sent to 127 services that were either solely dedicated to childhood bereavement or offered a service within a host organisation. The response rate was 85% (108/127 services). The findings identified that 85% of bereavement services are located within the voluntary sector; 14% are dedicated childhood bereavement services. 44% of host organisations are hospices. 73% of services relied on both paid and unpaid staff with 11% relying entirely on paid staff and 14% of services entirely on unpaid staff.</td>
<td>Good review of current UK service provision of bereavement services.</td>
<td>Questionnaire survey</td>
<td>3/4 ++</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/ QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Interventions were offered to children and young people (&lt;18yrs) by 86% of the services.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The authors conclude that the number of variables that need to be held constant between services makes the use of RCTs or other comparative research methods difficult as tools of service evaluation.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Italics= reviewers comments**
Multidisciplinary Teams/Care

The Question:

What is the evidence for the role of the multidisciplinary team (MDT) on the outcomes of care of children and young people with cancer?

Nature of the evidence

1 good quality randomised controlled trial
2 case series of fair to poor quality
2 expert opinions of fair to poor quality
1 survey of fair to poor quality
1 guide/guidance of fair to poor quality
1 consensus of fair quality

Summary of the supporting evidence for the recommendations

- The advantages of multidisciplinary care for young people were demonstrated in one good quality RCT performed in Denmark. There were improvements in patients’ attitudes to the healthcare system but quality of life scores were not significantly different.
- There was indirect evidence from two case series on multidisciplinary treatment of paediatric Hodgkin’s disease and medulloblastoma and its beneficial effect on quality of life.
- The expert opinions conclude that multidisciplinary care offers the best opportunity for improved outcomes.
- The survey gives an estimate of the number of MDTs in a small sample of NHS trusts as less than 30%.
- The guide and consensus document provides standards and quality measures for cancer MDTs.
In children and young people with cancer there is a lack of high quality evidence that directly supports the positive effect of multidisciplinary care on survival. Observational evidence suggests that such care leads to improved quality of life for patients.
### WHAT IS THE EVIDENCE FOR THE ROLE OF THE MULTIDISCIPLINARY TEAM ON THE OUTCOMES OF CARE OF CHILDREN AND YOUNG PEOPLE WITH CANCER?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Commission for Health Improvement, Audit Commission (2002) National Service Framework assessments: No.1 – NHS cancer care in England and Wales. Supporting data: 5 Multidisciplinary team working. London: Commission for Health Improvement and the Audit Commission 18p.</td>
<td>NHS Cancer Care in England and Wales.</td>
<td>Survey MDT working in 22 NHS trusts (within 9 networks) in England &amp; Wales.</td>
<td>Less than 30% of trusts reported regular patient-planning MDTs for neurological/brain and CNS patients. Where an MDT was present the percentage membership was: Lead physician/surgeon 100% Pathologist 83% Non-surgical oncologist 81% Other surgeon/physician specialising in same cancer 78% Nurse specialist 74% Radiologist 69% Palliative care nurse 34% Palliative care doctor 31% Medical trainees 23% Therapy radiographer 10% Information specialist 9% Service manager 9% Dietitian 9% Ward nurses 7% Speech therapist 4% Physiotherapist 4% Social worker 4% Trials/audit 1% Pharmacist 1% OT 1%</td>
<td>Small sample, difficult to draw conclusions.</td>
<td>Survey</td>
</tr>
</tbody>
</table>

Small sample, difficult to draw conclusions. +/−
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Donaldson SS, Whitaker SJ, Plowman PN et al. (1990) Stage I-II pediatric Hodgkin's disease: long-term follow-up demonstrates equivalent survival rates following different management schemes. Journal of Clinical Oncology B:1128-1137.</td>
<td>All patients were 15 years of age or younger with stage I-II Hodgkin's disease. Patients were treated between 1971 and 1985. The case series included 100 patients from the first centre (USA) and 71 from the second (UK). 171 children (&lt;15yrs) with stage I-II Hodgkin's disease from two institutions with differing approaches to management.</td>
<td>To compare the prognosis of children with stage I-II Hodgkin's disease.</td>
<td>Actuarial survival and freedom from relapse (calculated using Kaplan-Meier technique). Prognostic factors were also analyzed using Cox regression.</td>
<td>The first centre (USA) used an aggressive approach: pathologic staging, extended-field radiation alone or involved-field radiation plus combination chemotherapy. The second centre (UK) used a less aggressive approach: clinical staging only and involved/regional-field radiotherapy. Combined modality therapy was used in both institutions in some cases. The 17 year survival of the entire group was 87% and 17 year freedom from relapse was 87%. Actuarial survival (91% at 10 years in both centres) and freedom from relapse (90% at 10 years USA, 83% UK) showed no significant difference between the 2 institutions. Authors’ conclusions: Treatment strategies should be directed toward the long-term goal of cure of disease with maximal quality of life. A multidisciplinary management philosophy undertaken at a</td>
<td>Case series / prognosis study</td>
<td>3</td>
<td>+/-</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>7. Nielsen JD, Palshof T, Mainz J et al. (2003) Randomised controlled trial of a shared care</td>
<td>248 cancer patients, &gt; 18 years.</td>
<td>To determine the effect of a multidisciplinary shared care</td>
<td>QOL &amp; performance status. Patients attitudes to</td>
<td>Shared care is defined as: when the responsibility for the health care of the patient is shared between individuals or</td>
<td>Well designed and described study. Non-blinded. Power of study</td>
<td>Randomised controlled trial</td>
<td>1</td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review 172
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>programme for newly referred cancer patients: bridging the gap between general practice and hospital. Quality &amp; Safety in Health Care 12:263-272.</td>
<td>programme on the attitudes of newly referred cancer patients. The shared care programme included transfer of knowledge from the oncologist to the GP, improved communication between the parties and active patient involvement.</td>
<td>healthcare system and GPs.</td>
<td>teams who are part of separate organisations, or where substantial organisational boundaries exist. It implies personal communication and organised transfer of knowledge from hospital doctors to GPs and patient involvement. 48 patients dropped out of study (24 from each group); 17 had died. The shared care programme had a positive effect on patient evaluation of cooperation between primary &amp; secondary care. The effect was particularly significant (p=0.003) in young (18-49) men. There were no differences in QOL.</td>
<td>discussed and adequate to detect a difference. Appropriate statistical analyses. Good discussion about limitations of study – power, bias etc.. Only relevant to upper age group patients for question.</td>
<td></td>
</tr>
</tbody>
</table>

++
Continuity of Care

The Questions:

1. How can the transition from paediatric to adult services best be managed to ensure quality services for teenagers and young people?
2. What is the evidence for the role of the key worker in the care of children and young people with cancer?

Nature of the evidence

Q.1
1 review of good quality
2 formal consensus papers of fair quality
2 expert opinion papers of fair quality

Q.2
1 randomised controlled trial of fair quality
1 policy document
1 questionnaire survey of fair quality
1 literature review of fair to poor quality
1 guidance/resource pack

Summary of the supporting evidence for the recommendations

Q.1
- The conclusions of one literature review describing current UK provision of services for young adults were that there is a dearth of high quality evidence to indicate the best service model to ensure continuity of care.
- 1 formal consensus provides useful recommendations on service structure. A UK formal consensus concluded that further research is
required to determine service provision and gives current recommendations \(^1\) \(^3\).

- Two expert opinions, specific for young people with cancer provide overviews of issues and recommendations for successful transition of care \(^4\) \(^5\).

Q.2

- The evidence from one randomised controlled trial did not provide evidence directly about the role of a key worker but indicated that a nurse coordinator acting in a key worker role significantly improved the coordination of palliative care for terminally ill patients (all ages) \(^5\).

- A questionnaire survey to providers of care to disabled children in the UK indicated that there was considerable variation in the provision of key worker schemes. Thirty schemes were in operation in the UK in 2004 \(^2\).

- Evidence from a review of the literature suggested that where key worker schemes were used in the treatment of disabled children that quality of life for families was improved \(^3\). A further review produced a resource pack for key worker schemes for disabled children \(^4\).

- An expert opinion concluded that there is no evidence on whether one profession is better than another in the key worker role \(^6\).

No evidence from high level research was identified to indicate the optimum model of service provision to ensure continuity of care for children and young people with cancer; this also applied to disabled children.

The Children Act \(^1\) states the importance of the key worker in coordinating the care of children. Observational evidence supports the role of the key worker in successful coordination in the transition of care.
### Q.1 HOW CAN THE TRANSITION FROM PAEDIATRIC TO ADULT SERVICES BEST BE MANAGED TO ENSURE QUALITY SERVICES FOR TEENAGERS AND YOUNG PEOPLE?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. American Academy Pediatrics (2002) A consensus statement on health care transitions for young adults with special health care needs. <em>Pediatrics</em> 110:1304.</td>
<td>Young adults with special healthcare needs.</td>
<td>Improving the transition of health care for young adults.</td>
<td>The authors consider: • What is meant by healthcare transitions. • Why planning for healthcare transitions are important. They recommend: • All children have an identified healthcare professional. • Core skills and knowledge of healthcare professionals are identified to develop healthcare transition services. • Portable up-to-date medical summary for each child. • Written healthcare plan for each child by age 14. • The same guidelines for primary &amp; preventative care should be applied for all adolescents &amp; young adults. Ensure all young people with healthcare needs have health insurance coverage which is affordable &amp; continuous.</td>
<td>Not specific to cancer.</td>
<td>Formal consensus</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>NHS Service Delivery and Organisation R&amp;D Programme (2002) The transition from child to adult health and social care. London: NHS</td>
<td>Young adults with disabilities or chronic diseases.</td>
<td>Improving the transition of health care for young adults.</td>
<td>The authors review current practice and provide a review of literature (they note that little high-level research is available). Four main models of</td>
<td>Comprehensive literature review. Good critical appraisal and good questionnaire survey. Not specific to cancer.</td>
<td>Review of current practice</td>
<td>4</td>
<td>++</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Rosen DS, Blum RW, Britto M et al. (2003) Transition to adult health care for adolescents and young adults with chronic conditions. Position paper of the Society for Adolescent Medicine. Journal of Adolescent Health 33:309-311.</td>
<td>Young adults with special healthcare needs.</td>
<td>Improving the transition of health care for young adults.</td>
<td>transition services were identified.</td>
<td>Outlined principles of transition that authors believe have been nearly universally endorsed. Endorses the American Academy Pediatrics document: A consensus statement on health care transitions for young adults with special health care needs (2002). Additional recommendations from the Society for Adolescent Medicine: • Primary care provider should be responsible for coordinating appropriate services • Ongoing education for all concerned about the importance of appropriate transition • All adults should receive adult-orientated primary health care • Adult health care sector be encouraged to make adult-orientated services available to adolescents and young adults with chronic health conditions • Continued collaborative development of best practices for management of adults with diseases of childhood</td>
<td>Not specific to cancer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DESIGN**

Formal consensus/position paper

**EVIDENCE LEVEL/QUALITY**

4 +
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
• A policy on timing of transfer  
• A preparation period and education programme  
• A co-ordinated transfer process  
• An interested and capable adult service  
• Administrative support  
• Primary care involvement  
Potential models are briefly discussed. The gold standard model for long term follow up is a seamless clinic which begins in childhood or adolescence and continues into adulthood with both paediatric and adult professionals providing ongoing life-long care as appropriate. Alternatively dedicated long-term follow up services may be set up within an adult setting, but without paediatric input. In this situation more detailed attention to transition planning is required. |  
• Removal of restrictions/barriers preventing timely transition  
• Further research in the area of transition to adult health care. | Expert opinion | 4 | + |
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
</table>
| 4. Viner R (1999) Transition from paediatric to adult care. bridging the gaps or passing the buck? Archives of Disease in Childhood 81:271-275. | Young adults with special healthcare needs. |  |  | Recommendations:  
- Transition preparation is essential  
- All paediatric general and specialty clinics should have a transition policy  
- Young adults should be taught skills to function in an adult setting  
- An identified person should be responsible for transition e.g. clinical nurse specialist  
- Management links developed between hospitals/adult & paediatric services  
- Large children’s services develop a transition map | Not specific to cancer. | Expert opinion | 4 + |
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Italics= reviewers comments</td>
<td>Italics= reviewers comments</td>
<td>Italics= reviewers comments</td>
<td>Italics= reviewers comments</td>
<td>Italics= reviewers comments</td>
<td>Italics= reviewers comments</td>
</tr>
</tbody>
</table>

### Q.2 WHAT IS THE EVIDENCE FOR THE ROLE OF THE KEY WORKER IN THE CARE OF CHILDREN AND YOUNG PEOPLE WITH CANCER?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Italics= reviewers comments</td>
<td>Italics= reviewers comments</td>
<td>Italics= reviewers comments</td>
<td>Italics= reviewers comments</td>
<td>Italics= reviewers comments</td>
<td>Italics= reviewers comments</td>
</tr>
</tbody>
</table>

   - All children.
   - States about the coordination of care for children that there should be a named person i.e. key worker.

   - 225 disabled children. UK.
   - Postal survey to determine the prevalence and nature of care coordination and key worker services.
   - The response rate was 70% (159/225 questionnaires). Thirty five areas (22%) reported having a coordination scheme, 26 in England, 5 in Scotland, 4 in Wales and 0 in Northern Ireland. Thirty schemes provided key workers to families.
   - The authors conclude that there was considerable variation in service models and little is known on how such variations affect outcomes for children and families.
   - The authors address the problems with questionnaire surveys and emphasise that the survey gives a small picture of care coordination in the UK.

   - Identification from the literature of major issues in managing
   - Development of information guides for parents,
   - Where a key worker system is present the QOL of families with disabled children is
   - Limited search of non medical databases. Some of the
   - Review of the literature

---

Improving outcomes in children and young people with cancer: evidence review

180
### STUDY

<table>
<thead>
<tr>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>disabilities and development of information guides for parents, children and professionals. Cardiff: Wales Office of Research &amp; Development/Barnardos 41p.</td>
<td>key worker systems, the key worker’s role and families needs and requirements for a successful service.</td>
<td>children and professionals.</td>
<td>improved. The model is only available to a third of families in the UK. Key worker systems focus on parents’ needs rather than the needs of services.</td>
<td>conclusions cannot be substantiated by the evidence presented.</td>
</tr>
<tr>
<td>4. Mukherjee S, Sloper P, Beresford B et al. (2000) A resource pack: developing a key worker service for families with a disabled child. York: University of York, Social Policy Research Unit 67p.</td>
<td>Disabled children. Resource pack for implementing a key worker system for families with disabled children.</td>
<td>Review of the evidence for effectiveness of key worker systems indicates that: • Families with key workers have less unmet needs and improved relationships with professionals • A key worker service needs to be located within a formal key worker service • A key worker service should contain the following elements – proactive regular contact, supportive open relationship, family centred as opposed to a child centred approach, working across agencies, working with families’ strengths and working for the family not the agency.</td>
<td>Care required in extrapolating to children and adolescents with cancer. Statements in evidence review not always backed by references.</td>
<td>Guidance/resource pack</td>
</tr>
<tr>
<td>5. Raftery JP, Addington-Hall JM, MacDonald, LD et al. (1996) A randomized controlled trial of the cost-effectiveness of a district co-ordinating service for terminally ill cancer patients. Palliative Medicine 10:151-161.</td>
<td>167 terminally ill cancer patients with a prognosis of less than one year, in a single health authority. UK.</td>
<td>To compare the cost effectiveness of a coordination service with standard services for terminally ill cancer patients with a prognosis of less than one year.</td>
<td>Survival at the end of the study, inpatient days, and cost per patient.</td>
<td>Stratified cluster randomization was used (the GP with which the patients were registered) but analysis was done on an individual basis. Could spuriously overestimate the</td>
</tr>
</tbody>
</table>

---

Improving outcomes in children and young people with cancer: evidence review
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>Sloper P, Jones L, Triggs S et al. (2003) Multi-agency care co-ordination and key worker services for disabled children. <em>Journal of Integrated Care</em> 11:9-15.</td>
<td>Disabled children.</td>
<td>Optimisation of coordination of care and key worker services. Review of evidence for effectiveness of key workers.</td>
<td>There is some observational evidence for the effectiveness of the key worker model for families of disabled children and also the staff working with them. There is no evidence on whether one profession is better than other in the key worker role. The authors report on a number of projects being performed in the UK.</td>
<td></td>
<td>Expert opinion</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Protocol Based Care

The Question:

What is the evidence that protocol driven treatment improves outcomes for children and young people with cancer?

Nature of the evidence

1 systematic review of good quality
1 prospective cohort study of fair quality
2 historical case series, 1 of fair quality; 1 of fair to poor quality
1 literature review of fair quality

Summary of the supporting evidence for the recommendations

• There is evidence from one systematic review that there is some evidence for the positive effect of protocols on outcomes ¹.
• One prospective cohort study provides some evidence, with methodological problems, for positive effect of protocol on outcomes for children with nephroblastoma ².
• The evidence from 1 historical case series indicates that children can be successfully treated on a protocol at a non specialist cancer centre i.e. it is the protocol not the centre that is important ³.
• The evidence from 1 large historical case series indicated a positive protocol effect ⁷.
• One literature review concludes that there is no evidence for a positive protocol effect on survival ⁶.
## WHAT IS THE EVIDENCE THAT PROTOCOL DRIVEN TREATMENT IMPROVES OUTCOMES FOR CHILDREN AND YOUNG PEOPLE WITH CANCER?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Edwards S, Lilford RJ, Braunholtz DA et al. (1998) Ethical issues in the design and conduct of randomised controlled trials. Health Technology Assessment 2:1-96.</td>
<td>Systematic review of literature on ethical issues and randomised controlled trials.</td>
<td></td>
<td>636 articles containing ethical issues relating to RCTS were identified. 17 of these examined the effects of participating in clinical trials on patient outcomes, including the effect of protocol entry. 10 articles involved cancer therapy and examined the effect of trial entry on survival/disease free survival, of which 4 involved childhood cancer. There were few relevant studies and these were of variable quality. The results however support the belief that treatment protocols benefit patients. There are two options to redress the balance between trial and non-trial patients. The first is based on the so called ‘treatment effect’ and in this case all eligible patients are offered entry into trials. The second assumes that the ‘trial’ effect is really a ‘protocol effect’ and therefore all treatments whether trial or non trial should be performed under protocol regimes.</td>
<td>Good quality review with adequate description of methodology. Extensive search, limited to English language.</td>
<td>Systematic review</td>
</tr>
<tr>
<td>2. Lennox EL, Draper GJ, Sanders BM (1975) Retinoblastoma: a study of natural history and UK. 313 children diagnosed with nephroblastoma in 1970.</td>
<td>98 children were entered into the MRC nephroblastoma study between October 1970</td>
<td>3 year survival</td>
<td>The 3 year survival rate was 58%. The rate in the children entered into the trial (77%) was significantly better than Trial participants and non trial controls were not matched for</td>
<td></td>
<td>Prospective cohort study</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>1.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Meadows AT, Kramer S, Hopson R et al. (1983)</td>
<td>Survival in childhood acute lymphocytic leukaemia: effect of protocol and placement. Cancer Investigation 1:49-55.</td>
<td>327 children &lt; 15 yrs with ALL diagnosed between 1970-1975. USA</td>
<td>Effect of treatment protocol and place of treatment.</td>
<td>Survival</td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Norum J, Nordoy T, Wist E (1995) Testicular cancer treated in a minor general oncology department. European Journal of Cancer Part A: General Topics 31:293-295.</td>
<td>98 patients, with testicular cancer. Norway.</td>
<td>Evaluation of outcomes in patients treated at a district general hospital oncology department.</td>
<td>Remission; survival.</td>
<td>All 98 patients obtained complete remission. The 5 year cancer corrected cumulative survivals according to Kaplan-Meier method were 0.9787 and 0.9804 in the seminoma and non-seminoma groups, respectively. These results were similar to those reported from major oncological centres. In Norway almost all treatment centres treat their patients, according to the same protocols. The use of protocols means that patients can be successfully treated in non-specialist oncology centres.</td>
<td>Few patients in child and adolescent age range. Insufficient details to assess quality.</td>
<td>Historical case series</td>
<td>3</td>
</tr>
<tr>
<td>6. Shochat SJ, Fremgen AM, Murphy SB et al. (2001) Childhood cancer: patterns of protocol participation in a national survey. CA: A Cancer Journal for Clinicians 51:119-130.</td>
<td>200 cancer registries in US. 2208 children and adolescents (&lt; 21 years) DIAGNOSED IN 1987 AND 2293 DIAGNOSED IN 1992.</td>
<td>Assessment of patterns of protocol.</td>
<td>Protocol participation.</td>
<td>53.8% of children were treated on protocols in paediatric centres compared with 25.1% treated at other institutions. In general the younger the patients, the more likely the chance of being treated in a protocol (paediatric centres 63.7%; others 42.0%) with very poor adolescent protocol participation (paediatric centres 34.8%; others 42.0%). The authors conclude that measures must be taken to increase participation in protocols.</td>
<td>Results not directly applicable to UK. Not of direct relevance to question. Concentrates on inequality of protocol participation between children and adolescents and between specialist and no specialist centres.</td>
<td>Survey</td>
<td>3/4</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>7. Stiller CA (1994) Centralised treatment, entry to trials and survival. <em>British Journal of Cancer</em> 70:352-362.</td>
<td>All cancer patients</td>
<td>Review of published literature from 1984-1993 (Medline, Embase) on patterns of care.</td>
<td>Survival</td>
<td>Children entered into MRC trials had a significantly higher survival rate. Trial entry had little effect on survival at high volume centres. For children with acute non-lymphoblastic leukaemia entry to a trial and treatment at a teaching hospital were both associated with a higher survival rate. In 2 studies of children with retinoblastoma survival rate was highest at the national referral centre. For children with Wilms’ tumour survival rates were higher for those included in MRC trials than those who were eligible but not included. Patients, who had surgery at a specialist centre had higher survival rates. The author concludes there is no evidence that referral or treatment according to protocols leads to improved survival rates.</td>
<td>The papers are not critically appraised. The author discusses the possible sources of bias. Other possible outcome measures are discussed. Some of the studies reviewed predate the introduction of current treatment methods.</td>
<td>Literature review</td>
<td>3/4</td>
</tr>
<tr>
<td>8. Youngson JHAM, Jones JM, Chang JG et al. (1995) Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. <em>British Journal of Cancer</em> 72:757-765.</td>
<td>1663 patients, entered into a specialist population based (cases 15 years) registry in North West England of patients, with lymphoid leukaemia and non Hodgkin’s lymphoma. Cases diagnosed between Jan 1983-</td>
<td>Estimation of treatment variations.</td>
<td>Survival</td>
<td>RESULTS OF RELEVANCE TO PROTOCOL: 1009 patients were analysed. 159/1003 patients were entered into clinical trials of which 111 were managed at a specialist oncology centre. Patients were unlikely to have been entered into a trial unless they had been treated at a specialist oncology centre.</td>
<td></td>
<td>Historical case series</td>
<td>3</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>December 1986.</td>
<td></td>
<td></td>
<td></td>
<td>Whether treatment had followed a recognised protocol was a significant factor affecting survival. The importance of the use of an appropriate protocol was marked for patients managed at 'other hospitals'. CLL patients had particularly poor survival when not treated on a protocol.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Place of Care

The Questions:

1. What evidence is there for the optimum place of treatment for children and young people with cancer?
2. What evidence is there for the effects of accessibility and centralisation of cancer services for children and young people?
3. Is there evidence for an association between the number of cases of children and young people with cancer seen and outcome?
4. Is there evidence that shared care improves patient outcomes?

Nature of the evidence

Q.1
1 non randomised controlled trial of poor quality\(^4\).
1 systematic review of good quality.
1 retrospective cohort study of fair to poor quality
3 reviews, 2 of good quality; 1 of fair quality
6 historical case series, 2 of good quality; 4 of fair quality
1 guidance of fair quality
1 dissertation/evidence review of fair quality
1 expert opinion of fair quality

Q.2
2 systematic reviews 1 of fair quality; 1 fair to poor quality
1 thesis/expert opinion of fair quality
1 literature review of fair quality
1 survey of fair quality

\(^4\) Retained despite methodological problems - highest level of evidence available with relevance to the question.
Q.3
2 systematic reviews of fair quality, no specific paediatric papers
1 literature review of fair quality with specific paediatric papers
4 historical case series, 3 of good quality; 1 of fair quality

Q.4
1 randomised controlled trial of good quality
1 systematic review of fair quality
2 qualitative studies of fair to poor quality
1 review of fair quality
3 reports/guidance, 1 of good quality; 2 of fair quality
1 expert opinion of fair quality

Summary of the supporting evidence for the recommendations

Q.1
- No difference in outcomes was demonstrated in one non RCT with treatment in the community versus specialist centre. This trial had methodological problems 5.
- A systematic review indicated that there was insufficient evidence to recommend specialist treatment. The paediatric cancer papers reviewed did not meet the inclusion criteria 4.
- In adolescents with acute lymphoblastic leukaemia (ALL) one retrospective cohort study concluded that they should be treated in a paediatric setting 1.
- One review of the literature concluded that survival was improved in children with ALL, acute non-lymphoblastic leukaemia, non Hodgkin’s lymphoma (NHL), retinoblastoma and Wilms’ tumours when treated in a specialist cancer centre/teaching hospital department. Two other reviews
of all types of cancer patients were also in favour of specialist treatment.

- Another historical case series demonstrated that survival for children with acute non-lymphoblastic leukaemia, NHL, Ewing’s sarcoma, rhabdomyosarcoma and osteosarcoma was improved at paediatric oncology centres compared with non-UKCCSG centres.

- The evidence from one historical case series indicated that survival for children with ALL did not vary between paediatric oncology centres and other hospitals.

- For adolescents with ALL and acute myeloid leukaemia (AML) survival rates were similar at teaching and non-teaching hospitals in one historical case series.

- A difference in survival for patients with medulloblastoma and rhabdomyosarcoma treated in a cancer centre versus a non cancer centre was seen in one historical case series; this difference was not seen in Wilms’ tumour patients.

- The evidence from one historical case series indicated that for children with ALL, survival in the non-protocol group was improved at specialist paediatric cancer centres. For children treated on protocols there was little variation with type of centre.

- For children with Wilms’ tumours, evidence from one historical case series demonstrated that survival was reduced when patients were treated at non UKCCSG centres compared with paediatric oncology centres.

- The evidence from a dissertation/review of the evidence for the improvement in outcomes with dedicated adolescent units was equivocal.

- An expert opinion concluded that referral to a specialist centre was not always indicated.
Q.2

- Evidence from 1 systematic review suggested that shared care was a safe option for cancer patients. The review was not specific for child and adolescent patients.

- The evidence from 1 systematic review was poor and no conclusions could be drawn about the relationship between distance and mortality and morbidity for cancer patients. The 2 paediatric studies did not meet the inclusion criteria.

- The conclusions from a thesis/expert opinion that studied paediatric cancer patients indicated that travel was not an issue for the decentralised group but that the parents using the more centralised service identified several problems with travel.

- Evidence from 1 literature review was contradictory for the burden of travel, but suggests that it is an inconvenience for patients, and may be a barrier for compliance. Not specific for child and adolescent age range.

- The results of one survey showed that there was no significant correlation between travel times for treatment and overall radiotherapy uptake.

Q.3

- The conclusions from one systematic review were that whilst the evidence from the published literature does support the volume/outcome association it is possible that different case mix and processes of care between high and low volume providers may partially explain the results. There were no specific child and adolescent cancer studies.

- One systematic review provided evidence for the volume/outcome (30 day mortality) association for cancers that require complex surgical interventions compared with those patients treated with low risk surgery. No specific child and adolescent cancer studies.

- Evidence for improved survival for children with ALL, acute non-lymphoblastic leukaemia, retinoblastoma and Wilms' tumours treated at high volume hospitals was provided from one literature review.
• There was evidence from one historical case series that survival of children with acute nonlymphoblastic leukaemia, non Hodgkin’s lymphoma, Ewing’s sarcoma and osteosarcoma was better in high volume treatment centres\(^3\).

• Survival of children with ALL and AML did not vary with case load in one historical case series\(^4\).

• One historical case series provided evidence that survival was significantly higher for children with ALL treated at high volume hospitals and entered into clinical trials\(^3\).

Q.4

• Randomised controlled trial evidence indicated that shared care had a positive effect on patients’ views of cooperation between primary and secondary care; there was no difference in quality of life. There were no patients less than 18 years old in the trial\(^6\).

• The safety of shared outreach care was supported by evidence from one systematic review\(^2\).

• Qualitative studies indicated that parents had problems with shared care in district general hospitals and that parents thought shared care promoted the security of the whole family\(^5\) \(^7\).

• The problems with agreeing a standard definition of shared care were discussed in one review\(^4\).

• 3 reports/guidance provided information on requirements and standards for a UK shared care centre\(^1\) \(^8\) \(^9\).

• The conclusions of an expert opinion were that centralised care can have negative outcomes for families and shared care requires efficient organisation\(^3\).

There is limited good quality evidence to suggest the optimum place of treatment for children and young people with cancer. The choice of outcome measures is difficult and survival has most frequently been used, with no conclusive
supporting evidence being found. Other measures such as quality of life and patient satisfaction are also important and several studies have addressed these outcomes. The evidence for shared care improving outcomes appears to depend on whether the care is well coordinated with good communication methods.
Q.1 WHAT EVIDENCE IS THERE FOR THE OPTIMUM PLACE OF TREATMENT FOR CHILDREN AND YOUNG PEOPLE WITH CANCER?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Boissel N, Auclerc M-F, Lhéritier V et al. (2003) Should adolescents with acute lymphoblastic leukaemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. Journal of Clinical Oncology 21:774-780.</td>
<td>Adolescents with acute lymphocytic leukaemia (ALL) aged 15 to 20 years. 77 treated in paediatric FRALLE-93 trial (1993 to 1999). 107 treated in adult LALA-94 trial (1994 to 2000). 100 with complete follow-up were analysed.</td>
<td>To compare treatment of adolescents with ALL using paediatric and adult protocols. Adolescents diagnosed by paediatricians are treated in paediatric trials. Adolescents diagnosed by GPs or internists are treated in adult departments. Treatment regimens for both trials were reported. Higher doses of all major ALL drugs were given in FRALLE-93 within shorter time period compared with LALA-94. Country: France.</td>
<td>Complete remission (CR); disease free survival (DFS); event free survival (EFS); relapse free survival (RFS). Predictors of EFS at 5 years.</td>
<td>Treatment with the paediatric protocol (FRALLE-93) significantly improved CR rates compared with the adult protocol (LALA-94) especially for patients with BCP-ALL; CR for ALL: 94% with FRALLE versus 83% with LALA, p = 0.04. CR for BCP-ALL: 98% with FRALLE versus 81% with LALA, p = 0.002. Treatment with the paediatric protocol (FRALLE-93) significantly improved EFS and DFS at 5 years compared with the adult protocol; EFS: 67% with FRALLE versus 41% with LALA, p &lt; 0.0001. DFS: 72% with FRALLE versus 49% with LALA, p = 0.0004. The only prognostic factors for EFS were white blood cell count (p &lt; 0.0001) and the trials (p = 0.004).</td>
<td>The authors concluded that adolescents with ALL should be treated with intensive paediatric protocols. Treatment groups were not randomly allocated to treatment. The authors did compare baseline characteristics between groups and found groups to be similar.</td>
<td>Retrospective cohort with control group</td>
<td>2</td>
</tr>
<tr>
<td>2. Foreman NK, Thorne RN, Mott MG (1996) Variation in survival of children with cancer within a region of the United Kingdom. Cancer 77:785-90.</td>
<td>678 children &lt; 15 yrs with cancer.</td>
<td>Quality of primary and hospital based care. Large versus small hospital size.</td>
<td>Survival by diagnosis period &amp; type of cancer, survival by county &amp; cancer.</td>
<td>At 5 years patients with CNS tumours experienced a 58% survival rate in large hospitals and a 41% survival rate in small hospitals (p=0.03). The rate of entrance into trials was similar for each of the trials (p = 0.004).</td>
<td>Well designed study. Appropriate statistical analyses. Provides evidence that children treated at larger hospitals likely to</td>
<td>Historical case series</td>
<td>+/−</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/ QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td>3. Grilli R, Minozzi S, Tinazzi A et al. (1998) Do specialists do it better? The impact of specialization on the processes and outcomes of care for cancer patients. <em>Annals of Oncology</em> 9:365-374.</td>
<td>Patients with cancer receiving specialist care.</td>
<td>Assess the impact of specialisation on processes &amp; outcomes of care for cancer patients.</td>
<td>Mortality, morbidity. Process outcomes e.g. specialisation of treating clinician, numbers of patients treated.</td>
<td>47/189 potential studies met the inclusion criteria. 12/24 (50%) studies provided information on process and 17/32 (53%) information on outcomes. Overall results were in favour of specialised clinicians/centres and were generally statistically significant. The study quality was however low.</td>
<td>Well described and designed study. Note is taken of the need to adjust in comparisons for case mix.</td>
<td>Review</td>
<td>4</td>
</tr>
<tr>
<td>Harding M, Lord J, Littlejohns P et al. (2002) A systematic review of the evidence relating process of care or outcome to treatment in specialist and non-specialist hospital settings. London: St George’s Hospital Medical School 208p.</td>
<td>Patients with cancer.</td>
<td>Assessment of difference in outcome between treatment in specialist and non specialist centres.</td>
<td>Survival.</td>
<td>The authors conclude that there was insufficient high quality evidence to indicate that specialist care affected outcomes in cancer patients.</td>
<td>High quality study. No studies in paediatric cancer met the inclusion criteria. Publication bias significant.</td>
<td>Systematic review</td>
<td>1</td>
</tr>
<tr>
<td>4. Kisker CT, Strayer F, Wong K et al. (1980) Health outcomes of a community-based therapy program for children with cancer – a shared management approach. <em>Pediatrics</em> 66:900-906.</td>
<td>24 children receiving shared care and 22 who received specialist care. Both centres used the same treatment protocols.</td>
<td>Evaluation of medical outcomes when care is provided by a shared care system.</td>
<td>Febrile episodes, infections, drug toxicities, neutropenia, thrombocytopenia. Physician performance (protocol compliance)</td>
<td>Results presented on 46/82 patients. No significant differences were reported in febrile episodes &amp; infections, drug toxicity, blood dyscrasias or protocol compliance.</td>
<td>Study power not reported, but likely to be low (small number of patients). Patient characteristics &amp; severity of disease at diagnosis not described.</td>
<td>Non randomised controlled trial</td>
<td>2</td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.</td>
<td>Kramer S, Meadows AT, Pastore G et al. (1984) Influence of place of treatment on diagnosis, treatment and survival in three paediatric solid tumours. <em>Journal of Clinical Oncology</em> 2:917-923.</td>
<td>147 patients with Wilms' tumours, 87 with rhabdomyosarcoma and 76 with medulloblastoma.</td>
<td>Determination of effect of place of treatment between cancer centres (CC) and non-cancer centres (NCC).</td>
<td>Disease free survival (DFS).</td>
<td>Differences in 3yr DFS between CC and NCC were noted for medulloblastoma (52% v 24%) and rhabdomyosarcoma (48% v 10%), but not for Wilms' tumours (79% v 68%). The principle management contrast found in rhabdomyosarcoma was that multiagent CT was used less often in NCC. Wilms' tumour patients were evaluated and treated similarly in the CC and NCC, except for surgical approach and follow up.</td>
<td>Incomplete adjustment for confounding factors. High likelihood of bias.</td>
<td>Historical case series 3</td>
</tr>
<tr>
<td>7.</td>
<td>Pheby DFH, Bray FI (1998) Review of studies designed to explain variations in cancer disease outcome.</td>
<td>Patients with ICD9 diagnosis 140-208 of cancer of any age.</td>
<td>Review of studies on variations in cancer outcomes in relation to variations in patterns of practice.</td>
<td>4 papers dealing with childhood cancer fulfilled inclusion criteria. There were data problems but overall the studies indicated that survival</td>
<td>Indicates that it is protocol that is important not centre effect.</td>
<td>Comprehensive literature review and discussion of the literature and factors affecting</td>
<td>Review 4</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>particularly in relation to variations in patterns of practice. Bristol: University of the West of England 161p. Available from: <a href="http://www.uwe.ac.uk/fas/uare/cancer3.pdf">www.uwe.ac.uk/fas/uare/cancer3.pdf</a></td>
<td>30 Wilms' tumour patients diagnosed 1980-1982 not treated in centres in the UK Children's Cancer Study Group (UKCCSG)</td>
<td>What is the treatment regimen for children with Wilms' tumour outside of paediatric oncology centres?</td>
<td>Disease type by treatment given, 3-year survival rate by centre type.</td>
<td>10 of 20 children studied at these centres received more treatment than the authors would recommend. The 3-year survival rate was significantly lower in non-UKCCSG centres compared with that of paediatric oncology centres. Authors recommend that patients should be included in multicentre studies after establishment of prognosis, care should be shared with a paediatric oncology centre.</td>
<td>++</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stiller CA (1994) Centralised treatment, entry to trials and survival. British Journal of Cancer 70:352-362.</td>
<td>All cancer patients.</td>
<td>Review of published literature from 1984-1993 (Medline, Embase) on patterns of care.</td>
<td>Survival</td>
<td>For children with ALL, there was a significant trend towards higher survival rates in children being treated at high volume centres. Children entered into MRC trials had a significantly higher survival rate. Trial entry had little effect on survival at high volume centres. For children with acute non-lymphoblastic leukaemia entry to a trial and treatment at a teaching hospital were both associated with a higher survival rate. In 2 studies of children with retinoblastoma, survival rate was highest at the national referral centre. For children with Wilms’ tumour, survival rates were higher for those included in MRC trials than those who were eligible but not included. Patients, who had surgery at a specialist centre had higher survival rates.</td>
<td>The papers are not critically appraised. The author discusses the possible sources of bias. Other possible outcome measures are discussed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Stiller CA, Eatock EM (1999) Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994. Archives of Disease In Childhood 81:202-208.</td>
<td>4998 children aged between 0 and 14 years.</td>
<td>Effect of patterns of care.</td>
<td>Survival. Hospitals were classified as: • Mean annual number of new patients aged 15-29 with ALL &amp; AML • As teaching or non-teaching hospitals.</td>
<td>5 year survival improved from 67% in 1980-84 to 81% in 1990-94. The authors conclude that survival did not vary systematically with hospital case load or between paediatric oncology centres and other hospitals. Trial entry had an effect on survival.</td>
<td>Large well designed multicentre study.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/ QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td>13. Stiller CA, Benjamin S, Cartwright RA et al. (1999) Patterns of care and survival for adolescents and young adults with acute leukaemia-a population-based study. <em>British Journal of Cancer</em> 79:658-665.</td>
<td>879 patients, aged 15-29 years with acute leukaemia during 1984-1994.</td>
<td>Effect of patterns of care.</td>
<td>Survival. Hospitals were classified as: • Mean annual number of new patients aged 15-29 with ALL &amp; AML • As teaching or non-teaching hospitals.</td>
<td>For ALL actuarial survival rates were 43% at 5 years after diagnosis and 37% at 10 years. Survival improved significantly between 1984-88 and 1989-94 for those aged 15-19 at diagnosis. Entry into trials had no effect on survival. Survival rates were similar at teaching and non-teaching hospitals &amp; at hospitals treating different numbers of study patients per year. For AML survival rates 42% at 5 yrs after diagnosis &amp; 39% at 10 years. Survival did not vary with category of hospital. Trial effect was equivocal.</td>
<td>Historical case series</td>
<td>3++</td>
<td></td>
</tr>
<tr>
<td>14. Wilkinson JR (2001) <em>Will the creation of an adolescent centre lead to improved outcomes in Yorkshire?</em> Edinburgh: University of Edinburgh. Unpublished thesis.</td>
<td>Patients aged between 10 to 24 years of age with cancer.</td>
<td>Evaluation of the proposal for creation of a teenage and young person’s cancer unit in Leeds.</td>
<td>Needs assessment of young people with cancer in Yorkshire. Qualitative work examining the needs of young people with cancer.</td>
<td>The evidence is equivocal that place of treatment improves survival. There is insufficient evidence to state that the quality of care which can be offered by specialist teenage units is superior to that offered by smaller local hospitals.</td>
<td>Thesis</td>
<td>4*</td>
<td></td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review
Q.2 WHAT EVIDENCE IS THERE FOR THE EFFECTS OF ACCESSIBILITY AND CENTRALISATION OF CANCER SERVICES FOR CHILDREN AND YOUNG PEOPLE?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Campbell NC, Ritchie LD, Cassidy J et al. (1999) Systematic review of cancer treatment programmes in remote and rural areas. <em>British Journal of Cancer</em> 80:1275-1280.</td>
<td>All cancers.</td>
<td>Identification of problems and effectiveness of oncology service provision in remote and rural areas.</td>
<td>Patient and physician satisfaction. Survival.</td>
<td>The authors concluded that there was some evidence to support the safety of shared outreach care. Such care could make specialist care more accessible to outlying patients.</td>
<td>All studies were small and had methodological problems. Little evidence of relevance to the question.</td>
<td>Systematic review</td>
<td>++</td>
</tr>
<tr>
<td>2. Cosford P, Garrett C, Turner K (1997) Travel times and radiotherapy uptake in two English counties. <em>Public Health</em> 111:47-50.</td>
<td>Registered cancer patients who received radiotherapy from 14 local authority districts in UK in 1991. Residents recorded at a single cancer centre as receiving palliative or radical radiotherapy at that centre in 1991.</td>
<td>To examine whether longer travel times for radiotherapy are associated with reduced overall uptake of radiotherapy treatment, or with reduced uptake of palliative as opposed to radical radiotherapy.</td>
<td>Uptake of radiotherapy.</td>
<td>There was no significant correlation between travel times for treatment and overall radiotherapy uptake (correlation coefficient r=0.40, 95%CI -0.19 to 0.78, p=0.18). The non-significant trend towards increasing uptake with increasing travel time disappeared with the exclusion of the four districts where treatment after six months was included in the data (r=0.08, -0.61 to 0.70, p=0.84). There was no significant change in the ratio of palliative to radical radiotherapy at one cancer centre with increasing travel time to that centre (r=-0.29, -0.72 to 0.31, p=0.34).</td>
<td>Considerable variability was observed between local authority districts for both measures of uptake. Longest travel times were about one hour. Total study population not stated.</td>
<td>Survey</td>
<td>3/4</td>
</tr>
<tr>
<td>3. Ferguson B, Place M, Posnett J (1996) Accessibility and *Accessibility and</td>
<td>All cancer services.</td>
<td></td>
<td>3000 articles were identified. and approximately 300 were screened against inclusion</td>
<td>93% of studies were cross sectional and thus</td>
<td>Systematic review</td>
<td>2/4</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/ QUALITY</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------</td>
<td>------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------</td>
<td>------------------------</td>
</tr>
<tr>
<td>centralisation in cancer services. A report by the Yorkshire Collaborating Centre for Health Services Research. Leeds: Nuffield Institute for Health 57p.</td>
<td></td>
<td></td>
<td></td>
<td>criteria of relevance, outcome and design. 243/300 papers were rejected. The quality of the evidence was generally poor with a lack of properly controlled trials. Direct evidence of the relationship between distance and mortality or morbidity was rare, although 2 studies of cancer patients indicated that outcomes are not affected by distance. Data for other outcome measures such as QOL was lacking. The author concludes that there is not widespread agreement about what constitutes specialist care. Specialist care should not be equated with centralised care.</td>
<td>vulnerable to confounding. There were no RCTs. Useful review of all literature to 1995.</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>4. Kearney P (2003) The burden of travel in paediatric oncology. Cork: University College, Cork 131p. Unpublished thesis.</td>
<td>22 parents (5 fathers and 17 mothers) of children with cancer.</td>
<td>Investigation of the experience of travelling to paediatric oncology centres and to identify the burdens of travel. Analyses of transcripts using a grounded theory approach.</td>
<td></td>
<td>There were 2 paediatric units associated with centres that had different policies of decentralising care. Four focus group interviews performed by an experienced sociologist were recorded. The experience of having a child with cancer was very intense for both groups. Travel was not an issue for the decentralised group. The parents using a more centralised service identified several burdens of travel: • Exhaustion with uncertainty of travel arrangements &amp; huge round trips.</td>
<td>Thesis</td>
<td>3/4</td>
<td>+</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>All cancer patients.</td>
<td>Identification of evidence on impact of travel on cancer patients’ experiences of treatment.</td>
<td>Patients views on the burden of travel for cancer treatment.</td>
<td>296 papers were identified. 11 papers, from 6 countries, fulfilled the inclusion criteria. Most studies had methodological flaws. The evidence that travel distance and difficulty increases psychological distress and reduces compliance with treatment and take up of treatment is inconclusive. The author concludes that the literature is contradictory but travel for cancer treatment appears an inconvenience for patients and may be perceived as a barrier to compliance.</td>
<td>Well designed and reported review with adequate description of methodology. No specific child and adolescent studies.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Q.3 IS THERE EVIDENCE FOR AN ASSOCIATION BETWEEN THE NUMBER OF CASES OF CHILDREN AND YOUNG PEOPLE WITH CANCER SEEN AND OUTCOME?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Halm EA, Lee C, Chassin MR (2002)</td>
<td>All types of health care.</td>
<td>Organisation. To review systematically the research evidence linking volume and outcome in health care.</td>
<td>Health outcomes e.g. death, stroke or clinical complication.</td>
<td>135 studies met the inclusion criteria. No child and adolescent cancer studies. Overall 71% of all studies of hospital volume and 69% of studies of physician volume reported statistically significant associations between higher volumes and better outcomes. Differences in case mix and processes of care between high and low volume providers may explain part of the observed relationship between volume and outcome. The authors discuss the methodological problems with some of the primary studies and emphasise about making policy decisions based on the evidence.</td>
<td>Systematic review</td>
<td>2++</td>
</tr>
<tr>
<td>2.</td>
<td>Hillner BE, Smith TJ, Desch CE (2000)</td>
<td>All types of cancer care.</td>
<td>Evidence to support that hospital or physician volume or specialty affects outcome of cancer care.</td>
<td>Consistent literature was identified that supports a volume-outcome relationship for cancers treated with technically complex surgical procedures. These studies identified 30 day mortality and used the hospital as the unit of analysis. For cancer treated with low-risk surgery there were fewer studies and there was only an association.</td>
<td>Search limited to Medline 1989-1999</td>
<td>Systematic review</td>
<td>2++</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
</tr>
<tr>
<td>3. Stiller CA, Draper GJ (1989) Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia. <em>Archives of Disease in Childhood</em> 64:657-661.</td>
<td>Children with acute non-lymphoblastic leukaemia, Hodgkin’s disease, non HL, neuroblastoma, Wilms’ tumour, osteosarcoma, Ewing’s tumour &amp; rhabdomyosarcoma</td>
<td>Comparison of survival rates between UKCCSG patients and non-UKCCSG patients</td>
<td>Survival</td>
<td>Children with acute non-lymphoblastic leukaemia, non HL, Ewing’s tumour, rhabdomyosarcoma and osteosarcoma treated at paediatric oncology centres had significantly (p= &lt; 0.05) higher survival rates than those treated elsewhere.</td>
<td>Relevant to question.</td>
<td>Historical case series</td>
<td>3</td>
</tr>
<tr>
<td>4. Stiller CA, Eatock, EM (1999) Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994. <em>Archives of Disease in Childhood</em> 81:202-208.</td>
<td>4998 children aged between 0 and 14 years.</td>
<td>Effect of patterns of care.</td>
<td>Survival. Hospitals were classified as:</td>
<td>5 year survival improved from 67% in 1980-84 to 81% in 1990-94. The authors conclude that survival did not vary systematically with hospital case load or between paediatric oncology centres and other hospitals. Trial entry had an effect on survival.</td>
<td>Large well designed multicentre study.</td>
<td>Historical case series</td>
<td>3 ++</td>
</tr>
<tr>
<td>5. Stiller CA, Benjamin S, Cartwright RA et al. (1999) Patterns of care and survival for adolescents and young adults with acute leukaemia-a population-based study. <em>British Journal of Cancer</em> 79:658-665.</td>
<td>879 patients, aged 15-29 years with acute leukaemia during 1984-1994.</td>
<td>Effect of patterns of care.</td>
<td>Survival. Hospitals were classified as:</td>
<td>For ALL actuarial survival rates were 43% at 5 years after diagnosis and 37% at 10 years. Survival improved significantly between 1984-88 and 1989-94 for those aged 15-19 at diagnosis. Entry into trials had no effect on survival. Survival rates were similar at teaching and non-teaching hospitals &amp; at</td>
<td>Historical case series</td>
<td>3 ++</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td>DESIGN</td>
<td>EVIDENCE LEVEL/QUALITY</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>--------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>6. Stiller CA (1994) Centralised treatment, entry to trials and survival. <em>British Journal of Cancer</em> 70:352-362.</td>
<td>All cancer patients.</td>
<td>Review of published literature from 1984-1993 (Medline, Embase) on patterns of care.</td>
<td>Survival</td>
<td>For children with ALL, there was a significant trend towards higher survival rates in children being treated at high volume centres. Children entered into MRC trials had a significantly higher survival rate. Trial entry had little effect on survival at high volume centres. For children with acute non lymphoblastic leukaemia entry to a trial and treatment at a teaching hospital were both associated with a higher survival rate. In 2 studies of children with retinoblastoma, survival rate was highest at the national referral centre. For children with Wilms’ tumour, survival rates were higher for those included in MRC trials than those who were eligible but not included. Patients, who had surgery at a specialist centre had higher survival rates.</td>
<td>The papers are not critically appraised. The author discusses the possible sources of bias. Other possible outcome measures are discussed.</td>
<td>Literature review</td>
<td>3/4</td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review 206
**Q.4 IS THERE EVIDENCE THAT SHARED CARE IMPROVES PATIENT OUTCOMES?**

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Campbell NC, Ritchie LD, Cassidy J et al. (1999) Systematic review of cancer treatment programmes in remote and rural areas. British Journal of Cancer 80:1275-1280.</td>
<td>All cancers.</td>
<td>Identification of problems and effectiveness of oncology service provision in remote and rural areas.</td>
<td>Patient and physician satisfaction. Survival.</td>
<td>The authors concluded that there was some evidence to support the safety of shared outreach care. Such care could make specialist care more accessible to outlying patients.</td>
<td>Systematic review</td>
</tr>
<tr>
<td>3. Edwards J, Hooker L (2004) Caring for the child with cancer within a model of shared care. In: Pinkerton CR, Plowman PN, Pieters R (Eds) Paediatric Oncology (3rd Edition) London: Arnold.</td>
<td>Children with cancer.</td>
<td>Description of shared care.</td>
<td>The authors conclude that: • Centralised care has improved outcomes, but can have negative consequences for families and is expensive for service providers. • Successful shared care requires good organisation by all parties involved. • There is a need for high quality research to evaluate outcomes.</td>
<td>Useful review chapter</td>
<td>Expert opinion</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION/ AIMS</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>-------------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>6. Nielsen JD, Palahof T, Mainz J et al. (2003) Randomised controlled trial of a shared care programme for newly referred cancer patients: bridging the gap between general practice and hospital. Quality &amp; Safety in Health Care 12:263-272.</td>
<td>248 cancer patients, &gt; 18 years.</td>
<td>To determine the effect of a shared care programme on the attitudes of newly referred cancer patients. The shared care programme included transfer of knowledge from the oncologist to the GP; improved communication between the parties and active patient involvement.</td>
<td>QOL &amp; performance status. Patients attitudes to healthcare system and GPs.</td>
<td>Shared care is defined as: when the responsibility for the health care of the patient is shared between individuals or teams who are part of separate organisations, or where substantial organisational boundaries exist. It implies personal communication and organised transfer of knowledge from hospital doctors to GPs and patient involvement.</td>
<td>Well designed and described study. Non-blinded. Power of study discussed and adequate to detect a difference. Appropriate statistical analyses. Good discussion about limitations of study – power, bias etc.. Only relevant to upper age group patients for question.</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION/AIMS</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>------------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>study (24 from each group); 17 had died. The shared care programme had a positive effect on patient evaluation of cooperation between primary and secondary care. The effect was particularly significant (p=0.003) in young (18-49) men. There were no differences in QOL. Phenomenology is often criticised as a technique but is often used in nursing to explore issues that are different to every human being. Small study of limited relevance to question.</td>
<td></td>
</tr>
<tr>
<td>7. Sepion B (2004) Shared care. In: Gibson F, Soanes L, Sepion B (Eds). Perspectives in paediatric oncology nursing. London: Whurr Publishers, p176-191.</td>
<td>6 parents of children with cancer.</td>
<td>Assessment using phenomenological method of parents feelings about shared care.</td>
<td>The major issues identified were: • Poorer facilities in the DGH compared with cancer centre. • Parents felt isolated both physically and emotionally. • Conflict between the knowledge base of some parents and the healthcare professionals caring for them in the DGH. • Communication was identified as an important problem.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. West Midlands Cancer Peer Review (2003) Shared care of children and young people with cancer: overview report. Birmingham: West</td>
<td>Children and young people with cancer.</td>
<td>Peer review visits to units that share care with Birmingham Children’s Hospital NHS Trust.</td>
<td>Adherence to standards. Adherence to standards was generally over 50% for all units apart from 1 (~47%). The authors found that there: • did not appear to be clear understanding of the type</td>
<td></td>
<td>Report</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION/AIMS</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>-------------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>Midlands Cancer Peer Review Team 24p.</td>
<td></td>
<td></td>
<td></td>
<td>of care that a SCU is able to offer.</td>
<td></td>
</tr>
</tbody>
</table>

The authors propose the following principles for the future organisation of care for children and young people with cancer:
- Equity of access to high quality services.
- A ‘critical mass’ of staff so that the quality of service does not vary unreasonably when staff are away.
- Care as near to home as possible.
- Support from Birmingham Children’s Hospital for care delivered in other hospitals and in the community.
- Access to specialist treatment and care from Birmingham Children’s Hospital when this is needed.
- Commissioning arrangements that support the agreed model of care.

Elements that make up service for care of children & young people with cancer:

**Community-based care**
- Blood counts and blood product support
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION/ AIMS</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Central venous line care</td>
<td>Hospital-based care</td>
<td>Diet diagnosis and initiation of treatment for 'low risk' acute lymphoblastic leukemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytarabine administration</td>
<td>Care for patients on an agreed list of regimes</td>
<td>In patient chemotherapy for an agreed list of regimes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nasogastric tube feeding and support</td>
<td>Out-patient chemotherapy for an agreed list of regimes</td>
<td>Treatment of febrile neutropenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Specialist care</td>
<td>Diagnosis and initiation of treatment (except for 'low risk' acute lymphoblastic leukemia)</td>
<td>Care for patients with the rarest cancers (including chemotherapy)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Care for complex cases (including chemotherapy)</td>
<td>Provision of training, including for shared care unit staff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Advice and support to shared care units, including a consultant clinic in each shared care unit and BCH Macmillan Nurse attendance at some shared care unit multi-disciplinary teams</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Communication/Information

The Question:

What is the evidence for effective means of communication and information giving?

Nature of the evidence

1 randomised controlled trial of fair to poor quality
4 systematic reviews, 3 of good quality; 1 fair to poor quality
2 qualitative studies of fair to poor quality
1 guideline of fair quality
1 policy/expert opinion of fair quality
2 surveys

Summary of the supporting evidence for the recommendations

- The results of one RCT indicate that training courses to improve communication are effective\(^3\).
- The evidence from one systematic review indicated that communication skills training programmes are effective\(^4\).
- The evidence from one systematic review indicated that communication skills training programmes are effective and that tailored information is the most effective\(^7\).
- There was good quality evidence from one systematic review on the best use of communication methods and information exchange in cancer\(^9\).
- One systematic review of RCTs indicated that the use of effective mechanisms such as audio visual aids improve patient outcomes\(^6\).
- One systematic review of randomised and non-randomised trials indicated that the evidence was poor on interventions to enhance communication
involving child and adolescent patients. Some evidence for tailored information

• One qualitative study indicated that patients recall about the information they were given by the GP was poor.  
• One qualitative study indicated that parents feel that the executive role they have to adopt vis à vis their children is a problem for effective communication.  
• One guideline specifically for paediatric cancer patients provides good recommendations for communication of diagnosis.  
• One policy document details basic principles for communication in cancer services.  
• There was evidence from a survey of teenagers that approximately 50% felt that information was not suitable for their age group (Appendix E).  
• A survey of very young children showed that they are able to express their feelings when staff skilled in communicating with them are employed (Appendix D).

There is very little high quality evidence to indicate the optimum service provision for children and young people with cancer who have very specific information requirements.
## WHAT IS THE EVIDENCE FOR EFFECTIVE MEANS OF COMMUNICATION AND INFORMATION GIVING?

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Dixon-Woods M, Findlay M, Young B et al. (2001) Parents' accounts of obtaining a diagnosis of childhood cancer. <em>Lancet</em> 357:670-4.</td>
<td>20 parents whose children (aged 4-18 yrs) had a confirmed diagnosis of cancer (leukaemia) or brain or solid tumours.</td>
<td>Semi-structured interviews.</td>
<td>The feelings of parents about the diagnosis process. Whether the narratives had implications for early diagnosis and referral.</td>
<td>Response rate 95%. There was good consistency between parent’s accounts and the medical records. Data were analysed by the constant comparison method. The signs and symptoms of younger children were first noticed by parents. Parents of older children and adolescents often had to be told of problem. Early symptoms often vague. 7/20 families had disputes in 7/20 families with the GP.</td>
<td>The study is limited to 1 paediatric oncology unit. There were few examples of the types of tumour that can be prone to delays in diagnosis. Communication or information issues not addressed.</td>
<td>Qualitative</td>
<td>3 +/-</td>
</tr>
<tr>
<td>2. Eiser C, Parkyn T, Havermans T et al. (1994) Parents' recall on the diagnosis of cancer in their child. <em>Psycho-oncology</em> 3:197-203.</td>
<td>30 families with a child diagnosed with cancer (ALL, lymphomas, solid tumours and brain tumours). Determination of information parents recall being given on diagnosis and assessment of information they would have liked.</td>
<td>In 20 cases mothers were told by the GP or local hospital before they received fuller information at the oncology unit or regional centre. 2/20 mothers reported that this initial explanation was incomplete.</td>
<td>Some relevance to question. Insufficient details given for appraisal.</td>
<td>Qualitative</td>
<td>3 +/-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Fallowfield L, Jenkins V, Farewell V et al. (2002) Efficacy of a Cancer Research UK communication skills training model for 160 oncologists from 34 cancer centres in the UK, 72% male and of consultant grade (61%) 39% SpR. Videotaped consultations of consultation sin cancer patients. Behavioural changes.</td>
<td>5/160 doctors withdrew from study and were replaced. Data was presented for 640 patients. The authors conclude that: Communication problems of Method of randomisation or allocation concealment not given. Complete blinding was not Randomised controlled trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review 214
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Fellowes D, Wilkinson S, Moore P (2004)</td>
<td>Qualified health professionals within all hospital, hospice and ambulatory care settings, working in cancer care.</td>
<td>Studies in which the intervention group has communication training.</td>
<td>Changes in behaviour skills.</td>
<td>3/2524 references were included. 2/3 trials concerning communication skills training programmes did have a positive effect on the communications behaviour of experienced nurses and doctors working in cancer care. The authors conclude that further research into the long-term efficacy of communication skills training is needed.</td>
<td>Good quality review with good description of methodology. There is some evidence to suggest labour intensive communication skills training can have a beneficial effect on behaviour change in professionals working with cancer patients.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic review</td>
<td>2+</td>
</tr>
<tr>
<td>+/-</td>
<td>++</td>
</tr>
</tbody>
</table>

---

Improving outcomes in children and young people with cancer: evidence review 215
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>7. NHS Centre for Reviews and Dissemination (2000) Informing, communicating and sharing decisions with people who have cancer. <em>Effective Health Care</em> 6:1-8.</td>
<td>All patients with cancer.</td>
<td>Review of published literature.</td>
<td>Effective methods for informing, communicating and sharing decisions with people who have cancer.</td>
<td>• Limited trial data suggest that training programmes in communication for healthcare staff are beneficial for patients, with cancer. Informing patients - there is evidence (44 articles, data quality poor) to indicate that tailored information best meets the needs of cancer patients.</td>
<td>No studies specific for child and adolescent cancer. Some relevance to question.</td>
</tr>
<tr>
<td>8. NHS Modernisation Agency, Cancer Services Collaborative Improvement Partnership</td>
<td>All cancers.</td>
<td>Document setting out basic principles in communication in cancer services.</td>
<td>Useful for general principles of communication across all sectors.</td>
<td>Policy</td>
<td>4</td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/ QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institute for Clinical Excellence (2004) Guidance on cancer services - improving supportive and palliative care for adults with cancer – the manual. London: National Institute of Clinical Excellence. Available from: <a href="http://www.nice.org.uk">www.nice.org.uk</a></td>
<td>Children and adolescents with cancer.</td>
<td>Randomised and non-randomised controlled trials and before and after studies that evaluated the effects of interventions to improve communication with children and/or adolescents about their cancer, its treatment and their implications.</td>
<td>Children and adolescents knowledge about cancer and its treatment. Psychological, social &amp; behavioural outcomes and social activities. Physical health outcomes.</td>
<td>The reviewers conclude that interventions to enhance communication involving children and adolescents with cancer have not been widely or rigorously assessed. The weak evidence that exists suggests that children and adolescents with cancer may derive some benefit from specific information giving programmes &amp; from interventions that aim to facilitate their reintegration into school and socially. Nine studies met the criteria for inclusion. They were diverse in terms of interventions, study designs and outcomes.</td>
<td>Adequate description of inclusion and exclusion criteria for studies and outcomes. Search terms and databases searched comprehensive. Updated search in January 2003.</td>
<td>Systematic review</td>
<td>1**</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><em>italics</em> review comments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Young B, Dixon-Woods M, Windridge K et al. (2003) Managing communication with young people who have a potentially life threatening chronic illness: qualitative study of patients and parents. <em>British Medical Journal</em> 326:305-308.</td>
<td>Young people with cancer and their parents. 13 families comprising 19 parents and 13 patients aged 8-17 yrs. 1 paediatric oncology unit, UK.</td>
<td>Semi structured interviews analysed using constant comparison method.</td>
<td>13/20 families agreed to be interviewed. Most parents described acting in an executive-like capacity managing what their children were told about their illness. The diagnosis was usually told to the parent first without the child being present. This executive role both facilitates and constrains communication with young people. Some young people feel marginalised in consultations.</td>
<td>Well designed and reported study. Qualitative study</td>
<td>3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

programme reported improvements in knowledge & understanding about blood counts and cancer symptoms.

- One study of a CD-ROM about leukaemia reported an improvement in children’s feelings of control over their health.
- One study of art therapy during painful procedures reported an increase in collaborative behaviour in children.
- 2/2 studies of school reintegration programmes reported improvements in some aspects of psychosocial well being.
Research

The Questions:

1. Do children and young people with cancer have equal access to entry into clinical trials?
2. Does inclusion in a clinical trial improve outcomes for children and young people with cancer?

Nature of the evidence

Q.1
2 retrospective analyses, 1 of fair quality; 1 fair to poor quality
2 expert opinions, 1 of good quality; 1 of fair to poor quality

Q.2
1 prospective cohort study of fair quality
1 literature review of good quality
1 literature review of selected cancer trials (8 trials in child and adolescent age range), of fair quality
2 historical case series of good quality
1 expert opinion of fair to poor quality

Summary of the supporting evidence for the recommendations

Q.1
- One large retrospective analysis indicates that adolescents do not have equal access to clinical trials.\(^6\)
- The evidence from one retrospective analysis indicates that adolescents are more likely to enter a clinical trial if treated at a paediatric centre.\(^8\)
• It is concluded in one expert opinion that recruitment to clinical trials is low in children with some types of tumour (e.g. brain) and in adolescents ¹. Another expert opinion emphasises that adolescents do not have equal access to clinical trials ⁷.

Q.2
• The evidence from one prospective cohort study indicates that 3 year survival is improved in children with nephroblastoma entered into a clinical trial ⁵.
• There was no difference in survival in adolescents with ALL entered into a clinical trial in one historical case series ¹¹, but in children with ALL survival was improved in those treated within a clinical trial ¹⁰.
• A statistically non-significant increase in survival was noted in one historical case series of children with ALL entered into clinical trials ¹⁴.
• One review of the literature indicated that for children with ALL, clinical trial entry resulted in a significantly higher survival but there was no effect at high volume centres. Trial effect however, was demonstrated in children with Wilms’ tumours ¹³.
• An investigative literature review compared trial subjects with non-trial subjects to investigate the possible confounding effect. Eight paediatric oncology trials were included and the results indicated that trial entry produced improvement in outcomes in 1/8 paediatric cancer trials after correction for confounding factors ⁹.

It is accepted that, while there is currently insufficient high quality evidence to definitely conclude that entry into a clinical trial improves outcomes in children and young people with cancer, patients should be encouraged to enrol in trials. There is observational evidence to indicate that adolescents and young people do not have as good access to clinical trials as children.
**Q.1 DO CHILDREN AND YOUNG PEOPLE WITH CANCER HAVE EQUAL ACCESS TO ENTRY INTO CLINICAL TRIALS?**

**Q.2 DOES INCLUSION IN A CLINICAL TRIAL IMPROVE OUTCOMES FOR CHILDREN AND YOUNG PEOPLE WITH CANCER?**

<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Ablett S, Pinkerton CR (2003) Recruiting children into cancer trials - role of the United Kingdom Children's Cancer Study Group (UKCCSG). British Journal of Cancer 88:1661-1665.</td>
<td>Children with cancer ≤ age 15 years.</td>
<td></td>
<td></td>
<td>Author concludes: • Referral into specialist centres for children with cancer &amp; recruitment into trials is very high and exceeds the targets currently being set by the NCRN for adult cancer trials in the UK. • Recruitment is low in children with e.g. brain tumours, and adolescents. • There is also geographical variation in centre facilities which may lead to differences in recruitment. • Issues remain about randomisation rates to certain studies compared with European centres.</td>
<td></td>
</tr>
<tr>
<td>2. Benjamin S, Kroll ME, Cartwright RA et al. (2000) Haematologists approaches to the management of adolescents and young adults with acute leukaemia. British Journal of Haematology 111:1045-50.</td>
<td>Adolescents and young adults (15-29 years) with acute leukaemia. UK</td>
<td>Questionnaire survey of haematologists from 121 hospitals, entering patients into clinical trials.</td>
<td>Types of hospital treating the patients; haematologists perceived practice for trial entry and reasons for non entry.</td>
<td>There was a 79% response rate (96 hospitals). 82% of haematologists stated that they entered patients ‘always’ or ‘whenever possible’ for AML and 76% for ALL but actual entry rates were 46% of 239 AML patients and 38% of 182 ALL patients. The respondents gave 3 main</td>
<td>The data obtained were linked to the MRC trials data to determine the actual proportion of patients treated in MRC leukaemia trials in the 5 years prior to the questionnaire.</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>3. Boissel N, Auclerc MF, Lheritier V et al. (2003) Should adolescents with acute lymphoblastic leukaemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. <em>Journal of Clinical Oncology</em> 21:774-80.</td>
<td>Adolescents with ALL aged 15 to 20 years. 77 treated in paediatric FRALLE-93 trial (1993 to 1999). 107 treated in adult LALA-94 trial (1994 to 2000), 100 with complete follow-up were analysed. Treatment groups were similar apart from median age (15.9 years for FRALLE versus 17.9 years for LALA).</td>
<td>To compare treatment of adolescents with acute lymphoblastic leukaemia (ALL) using paediatric and adult protocols. Adolescents diagnosed by paediatricians are treated in paediatric trials. Adolescents diagnosed by GPs or internists are treated in adult departments. Treatment regimens for both trials were reported. Higher doses of all major ALL drugs were given in FRALLE-93 within shorter time period compared with LALA-94. Country: France.</td>
<td>Complete remission (CR); disease free survival (DFS); event free survival (EFS); relapse free survival (RFS). Predictors of EFS at 5 years</td>
<td>Treatment with the paediatric protocol (FRALLE-93) significantly improved CR rates compared with the adult protocol (LALA-94) especially for patients with BCP-ALL: CR for ALL: 94% with FRALLE versus 83% with LALA, p = 0.04. CR for BCP-ALL: 98% with FRALLE versus 81% with LALA, p = 0.002. Treatment with the paediatric protocol (FRALLE-93) significantly improved EFS and DFS at 5 years compared with the adult protocol: EFS: 67% with FRALLE versus 41% with LALA, p &lt; 0.0001. DFS: 72% with FRALLE versus 49% with LALA, p = 0.0004. The only prognostic factors for EFS were white blood cell count (p &lt; 0.0001) and the trials (p = 0.004).</td>
<td>Adequate response rate; well described study. No discussion of study limitations.</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>4. Estlin EJ, Ablett S (2001) Paediatric update: practicalities and ethics of running clinical trials in paediatric oncology - the UK experience. <em>European Journal of Cancer</em> 37:1394-1401.</td>
<td>UK authors.</td>
<td>Clinical trials.</td>
<td></td>
<td>The authors conclude: • Small patient numbers. • Increasing subdivision by clinical and biological prognostic factors. • Increasing complexity of trials. • Collection of large amounts of patient data often justified due to rarity of disease and lack of knowledge about long-term effects of the tumour and its treatment. • Need for explicit consent, age specific information sheets and good clinical practice guidelines. Need realistic expectations for toxicity and benefit (e.g. 7.9-10% objective response rate, 0.6-0.7% drug related toxicity).</td>
<td>Expert review</td>
</tr>
<tr>
<td>5. Lennox EL, Stiller CA, Jones PH et al. (1979) Nephroblastoma: treatment during 1970-73 and the effect on survival of inclusion in the first MRC trial. <em>British Medical Journal</em> 2:567-69.</td>
<td>UK. 313 children diagnosed with nephroblastoma in 1970.</td>
<td>98 children were entered into the MRC nephroblastoma study between October 1970 – December 1973. 288/313 (92%) children had a nephrectomy, 248 (79%) received a course of RT and 267 (85%) were given at least 4 days CT.</td>
<td>3 year survival.</td>
<td>The 3 year survival rate was 58%. The rate in the children entered into the trial (77%) was significantly better than that among children who were eligible for the trial but not included (58%) p&lt;0.01. This result was more pronounced when allowance was made for the distribution of age and tumour stage (p&lt;0.001).</td>
<td>Trial participants and non trial controls were not matched for prognosis variables but statistical adjustment was made. Recruitment rates not given. Appropriate use of statistics.</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>6. Liu L, Krailo M, Reaman GH et al. (2003) Childhood cancer patients’ access to cooperative group cancer programs: a population-based study. <em>Cancer</em> 97:1339-1345.</td>
<td>10,108 children &lt;20yrs old with cancer, identified by the 11 SEER registries between 1992-1997.</td>
<td>Analyses of Children’s Oncology Group (COG) to determine whether it would serve as a resource for identifying children with cancer.</td>
<td>Not all children are registered by the cooperative groups. The annual age-adjusted registration rate (AARR) was 71% for children &lt;15yrs, 24% for adolescents 15-19 years, and 57% for children &lt;20 years. Registration rates varied by geographic region and were higher among children with advanced disease. Registration rates were highest for children (&lt;15yrs) with leukaemia (84%), hepatic tumours (82%) &amp; renal tumours (80%) and were lowest for carcinoma (26%) and retinoblastoma (30%).</td>
<td>US. Confirms UK studies of low registration for older children and adolescents and differences with tumour type.</td>
<td>Retrospective analysis</td>
</tr>
<tr>
<td>7. McTiernan A (2003) Issues surrounding the participation of adolescents with cancer in clinical trials in the UK. <em>European Journal of Cancer Care</em> 12:233-239.</td>
<td>Adolescents (15 - 19) with cancer.</td>
<td>Consideration of issues about participation of adolescents in trials.</td>
<td>Author concludes: • Clinical trials imperative to improve treatment and prognosis. • Adolescents do not have equal access to trials due to fragmentation of care between paediatric and adult settings. • Compliance is less in adolescents and needs research.</td>
<td>Age definition of adolescents not given.</td>
<td>Expert opinion/ overview</td>
</tr>
<tr>
<td>8. Mitchell AE, Scarcella DL, Rigutto GL et al. (2004) Cancer in adolescents and young adults treatment and outcome in Victoria. <em>Medical Journal of Australia</em> 180:99-62.</td>
<td>All adolescents &amp; young adults, aged 10-24 yrs. Diagnosed with cancer (leukaemia, lymphoma, germ cell tumours, brain tumours and bone tumours) between 1992-1996.</td>
<td>Questionnaire survey of referring physician. Treatment regimen. 5 year survival. Compliance with protocol.</td>
<td>Questionnaires completed for 576/665 eligible subjects (87%). Recruitment into trials decreased with increasing age. Adolescents aged 10-19 yrs were more likely to be recruited into a trial if treated at a paediatric hospital (38% and 3% respectively; p&lt;0.005; 95% CI for Australian study of relevance to UK situation. Well designed and described study. Appropriate use of statistics. Authors discuss limitations of small numbers in each age group to</td>
<td>Australian study of relevance to UK situation. Well designed and described study. Appropriate use of statistics. Authors discuss limitations of small numbers in each age group to</td>
<td>Retrospective analysis</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>9. Peppercorn JM, Weeks JC, Cook EF (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. <em>Lancet</em> 363:263.</td>
<td>Cancer patients enrolled and not enrolled in clinical trials.</td>
<td>Literature review of studies comparing trial with non-trial subjects. Reviewed 8 major paediatric oncology trials.</td>
<td>21 comparisons used retrospective cohort designs. 14 comparisons provided some evidence that trial patients have improved outcomes. A third of the studies were restricted to children. Only 8 comparisons restricted non-trial patients to those meeting trial eligibility criteria. Of these three noted better outcomes in trial patients than in non-trial patients; one of these (Lennox et al – nephroblastoma) was in a paediatric population. Strategies to control for confounding were frequently inadequate. Positive studies were more likely than negative studies to involve children, patients treated before 1986.</td>
<td>difference 25%-41%). Only 4% of young adults aged 20-24 years were treated within clinical trials. There was no significant difference in overall 5 year survival between the three age groups (10-15, 16-19 &amp; 20-24 yrs). Brain tumours had the lowest trial entry. 1% of patients did not complete treatment.</td>
<td>make conclusions about differences in survival. Examination of figures for 5 year survival suggest differences in survival between age groups for brain and bone tumours.</td>
</tr>
<tr>
<td>10. Stiller CA, Eatock EM (1999) Patterns of care and survival for children</td>
<td>4998 children aged between 0 and 14 years.</td>
<td>Effect of patterns of care. Survival. Hospitals were classified as:</td>
<td>5 year survival improved from 67% in 1980-84 to 81% in 1990-94.</td>
<td></td>
<td>Large well designed multicentre study.</td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>11. Stiller CA, Draper GJ (1989) Treatment centre size, entry to trials and survival in acute lymphoblastic leukaemia. <em>Archives of Disease in Childhood</em> 64:657-61.</td>
<td>Children with acute non-lymphoblastic leukaemia, Hodgkin’s disease, non HL, neuroblastoma, Wilms' tumour, osteosarcoma, Ewing's tumour &amp; rhabdomyosarcoma.</td>
<td>Comparison of survival rates between UKCCSG patients and non-UKCCSG patients.</td>
<td>Survival.</td>
<td>Children with acute non-lymphoblastic leukaemia, non HL, Ewing’s tumour, rhabdomyosarcoma and osteosarcoma treated at paediatric oncology centres had significantly (p&lt; 0.05) higher survival rates than those treated elsewhere.</td>
<td>Relevant to question.</td>
</tr>
<tr>
<td>12. Stiller CA, Benjamin S, Cartwright RA et al. (1999) Patterns of care and survival for adolescents and young adults with acute leukaemia-a population-based study. <em>British Journal of Cancer</em> 79:658-665.</td>
<td>879 patients, aged 15-29 yrs with acute leukaemia during 1984-1994.</td>
<td>Effect of patterns of care.</td>
<td>Survival.</td>
<td>For ALL actuarial survival rates were 43% at 5 years after diagnosis and 37% at 10 years. Survival improved significantly between 1984-88 and 1989-94 for those aged 15-19 at diagnosis. Entry into trials had no effect on survival. Survival rates were similar at teaching and non-teaching hospitals &amp; at hospitals treating different numbers of study patients per year. For AML survival rates 42% at 5 yrs after diagnosis &amp; 39% at 10 years. Survival did not vary with category of hospital. Trial effect was equivocal.</td>
<td></td>
</tr>
</tbody>
</table>

Improving outcomes in children and young people with cancer: evidence review
<table>
<thead>
<tr>
<th>STUDY</th>
<th>POPULATION</th>
<th>INTERVENTION</th>
<th>OUTCOMES</th>
<th>RESULTS</th>
<th>COMMENTS</th>
<th>DESIGN</th>
<th>EVIDENCE LEVEL/QUALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>13. Stiller CA (1994) Centralised treatment, entry to trials and survival. <em>British Journal of Cancer</em> 70:352-62.</td>
<td>All cancer patients.</td>
<td>Review of published literature from 1984-1993 (Medline, Emerge) on patterns of care.</td>
<td>Survival.</td>
<td>For children with ALL there was a significant trend towards higher survival rates in children being treated at high volume centres. Children entered into MRC trials had a significantly higher survival rate. Trial entry had little effect on survival at high volume centres. For children with acute non-lymphoblastic leukaemia entry to a trial and treatment at a teaching hospital were both associated with a higher survival rate. In 2 studies of children with retinoblastoma survival rate was highest at the national referral centre. For children with Wilms’ tumour survival rates were higher for those included in MRC trials than those who were eligible but not included. Patients who had surgery at a specialist centre had higher survival rates.</td>
<td>The papers are not critically appraised. The author discusses the possible sources of bias. Other possible outcome measures are discussed.</td>
<td>Literature review</td>
<td>3/4 +</td>
</tr>
<tr>
<td>14. Stupnicki A, von der Weid N, Imbach P et al. (1995) Incidence of childhood acute lymphoblastic leukaemia (ALL) and population-based treatment results in Switzerland: experiences with 507 study and 149 nonstudy patients. <em>Medical</em></td>
<td>656 children &lt; 15 years with acute lymphoblastic leukaemia entered into protocols (1980-1983; 1984-1987; 1988-1991).</td>
<td>Number entered into trials.</td>
<td>507/656 were entered into trials and 149 were not. The authors conclude that the true incidence of ALL in Switzerland in children &lt; 15 is higher than that reported. The rate of survival at 4 years for both trial and non-trial patients increased but the increase was greater in trial</td>
<td>Confounding not discussed adequately. Study period 11 years.</td>
<td>Historical case series</td>
<td>3 +</td>
<td></td>
</tr>
<tr>
<td>STUDY</td>
<td>POPULATION</td>
<td>INTERVENTION</td>
<td>OUTCOMES</td>
<td>RESULTS</td>
<td>COMMENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&amp; Pediatric Oncology 25:79-83.</td>
<td>included patients, although this difference was not statistically significant.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix A

Main Child and Young People with Cancer Search Strategy

Relevant studies were identified using the search strategy for Medline shown below:

Medline, Embase (a modified search strategy with different index terms was used for Embase) and the Cochrane Library were searched as core databases - Cinahl, British Nursing Index, Psychinfo and Amed were searched, if relevant to the subject of the search.

1. exp Adolescent/ or exp Child/ or exp Child, preschool/ or exp Infant/ or exp Infant, newborn/ or exp Minors/ or exp Pediatrics/
2. (child$ or paediatric$ or pediatric$ or perinat$ or neonat$ or newborn$ or infan$ or baby or babies or toddler$ or boy$ or girl$ or kid$1 or schoolage$ or juvenil$ or young).mp.
3. (underage$ or teen$ or youth$ or pubescen$ or adolescen$).tw. or (infan$ or child$ or pediatric$ or paediatric$ or adolescen$).jw.
4. or/1-3
5. exp neoplasms/
6. (cancer$ or neoplas$ or tumo?r$ or oncol$).tw.
7. leuk?emi$.tw.
8. lymphoma$.tw.
9. (Hodgkin$ or non Hodgkin$).tw.
10. reticulosarcoma$.tw.
11. lymphosarcoma$.tw.
12. granuloma$.tw.
13. astrocytoma$.tw.
14. glioma$.tw.
15. glioblastoma$.tw.
16. medulloblastoma$.tw.
17. ependymoma$.tw.
18. craniopharyngioma$.tw.
19. neuroblastoma$.tw.
20. ganglioneuroblastoma$.tw.
21. meningioma$.tw.
22. neuroepithelioma$.tw.
23. neurilemmoma$.tw.
24. neuroma$.tw.
25. oligodendroglioma$.tw.
26. pineoblastoma$.tw.
27. primitive neuroectodermal tumo?r$.tw.
28. pnet.tw.
29. retinoblastoma$.tw.
30. (wilm$ or nephroblastoma$ or nephroma$).tw.
31. (hepatoblastoma$ or hepatoma$).tw.
32. (renal adj (carcinoma$ or tumo?r$)).tw.
33. sarcoma$.tw.
34. angiosarcoma$.tw.
35. dermatofibrosarcoma$.tw.
36. ewing$.tw.
37. (askin$1 adj1 tumo?r$).tw.
38. osteosarcoma$.tw.
39. (haemangioepityoma$ or hemangiopericytoma$).tw.
40. (haemangiosarcoma$ or hemangiosarcoma$).tw.
41. (haemangioendothelioma$ or hemangioendothelioma$).tw.
42. oligodendroglioma$.tw.
43. histiocytoma$.tw.
44. rhabdomyosarcoma$.tw.
45. rhabdosarcoma$.tw.
46. fibrosarcoma$.tw.
47. desmoid$.tw.
48. kaposi$.tw.
49. leiomyosarcoma$.tw.
50. liposarcoma$.tw.
51. myosarcoma$.tw.
52. angiosarcoma$.tw.
53. mesenchymoma$.tw.
54. neurofibroma$.tw.
55. neurofibrosarcoma$.tw.
56. schwannoma$.tw.
57. chondrosarcoma$.tw.
58. choriocarcinoma$.tw.
59. dysgerminoma$.tw.
60. (germ cell or germimoma$).tw.
61. teratoma$.tw.
62. seminoma$.tw.
63. carcinoma$.tw.
64. exp adrenal gland neoplasms/
65. adenocarcinoma$.tw.
66. exp thyroid neoplasm/
67. phaeochromocytoma$.tw.
68. exp nasopharyngeal neoplasms/
69. melanoma$.tw.
70. or/5-69
71. 4 and 70
Appendix B

High Level Search Strategy

The following sites were searched:

| Automated Childhood Cancer Information System |
| Agency for Healthcare Research and Quality (AHRQ) |
| Appraisal of Guidelines for Research & Evaluation (AGREE) Collaboration |
| AltaVista |
| Audit Commission |
| Agency for Quality in Medicine (AZQ) |
| Cancer and Public Health Unit |
| Cancer and Public Health Unit, London School Hygiene & Tropical Medicine |
| Cancer Care Ontario Practice Guidelines Initiative |
| Cancer links - Cancer guidelines and standards |
| Cancer Management Guidelines British Columbia Cancer Agency |
| Cancer Research UK - Science and Research |
| Cancer Research UK Home |
| Cancer Services Collaborative Group |
| Cancer.gov - Cancer Information |
| Cancer.gov - Cancer Literature in PubMed |
| CancerBACUP |
| Canadian Coordinating Office for Health Technology Assessment (CCOHTA) |
| Centre for Evidence Based Medicine |
| Centre for Evidence-Based Child Health |
| Centre for Health Services Research - Population and Health Sciences - University of Newcastle |
| Centre for Reviews Dissemination |
| Childhood Cancer Research Group |
| Children's Cancer Centres and Units |
| College of Health |
| Commission for Health Improvement |
| Department of Health |
| Department of Health - Cancer |
| Department of Health National Specialist Commissioning Advisory Group (NSCAG) |
| Eastern Cooperative Oncology Group (ECOG) |
| Effective Professional Practice Initiative |
| Evidence Network - The UK Centre for Evidence Based Policy |
| Evidence-Based Medicine |
| Finnish Medical Society Evidence-Based Medicine Guidelines for primary care |
Improving outcomes in children and young people with cancer: evidence review
| Swiss Network on Health Technology Assessment |
| Trent Research Information Access Gateway |
| Turning Research Into Practice (TRIP) Database |
| UK Cancer Links |
| United Kingdom Childrens’Cancer Study Group UKCCSG |
| UpToDate |
| World Health Organisation |
| Young Adults & Cancer WebSite |
### Appendix C

**Evidence Levels and Quality Grading**
(modified from NICE Methodology Manual)

<table>
<thead>
<tr>
<th>Level of evidence</th>
<th>Type of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1**</td>
<td>High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias</td>
</tr>
<tr>
<td>1+</td>
<td>Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias</td>
</tr>
<tr>
<td>1-</td>
<td>Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*</td>
</tr>
</tbody>
</table>
| 2**               | High-quality systematic reviews of case–control or cohort studies  
High-quality case–control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal |
| 2+                | Well-conducted case–control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the relationship is causal |
| 2-                | Case–control or cohort studies with a high risk of confounding bias, or chance and a significant risk that the relationship is not causal* |
| 3                 | Non-analytic studies (for example case reports, case series) |
| 4                 | Expert opinion, formal consensus |

**Quality grading**

++ = good quality  
+  = fair  
+/- = fair to poor  
-  = poor
Appendix D

Consultation with children with cancer, their siblings and parents for the NICE child and adolescent cancer service guidance

Commissioned by the National Collaborating Centre for Cancer

Jessica Datta, Claire Lanyon, Lucy Read, Emma Sawyer, Janine Shaw, Ben Street

July 2004
Contents

Acknowledgements 238
1. Summary of report 239
2. Introduction 243
3. The National Children’s Bureau 244
4. Aims of the consultation 245
5. Methodology 246
6. The views of children affected by cancer 250
7. The views of siblings 277
8. The views of parents and carers 283
9. Conclusion 308
Glossary of terms 311
List of appendices 312
Acknowledgments

We would like to thank the children and parents who participated in the four consultations and who shared their experiences, views and aspirations for cancer services. We hope this report accurately reflects these.

Thanks are due to Dr Andrew Champion at the National Collaborating Centre for Cancer who commissioned the National Children’s Bureau to facilitate the consultation days and to Rachel Hollis and other members of the Child and Adolescent Cancer Guidance Development Group sub-group for their support for this work. We would also like to thank staff at the regional cancer centres who were so helpful in organising and co-facilitating the days and whose expertise and professionalism were invaluable. We would particularly like to thank Jeanette Hawkins, Louise Soanes, Rachel Hollis and Judith Armstrong for their support.

A special vote of thanks goes to catering staff at Birmingham Children’s Hospital who provided a fabulous lunch. Thanks also to the two clowns from Theodora Children’s Trust who provided entertainment at Great Ormond Street Hospital. We would also like to thank staff at Wolf+Water Arts Company (www.wolfandwater.org) for their advice in developing some of the consultation activities.

We would like to thank Julie McLarnon who facilitated the sessions with very young children and Young NCB’s Hannah Gibney, Seun Fajolu and Graham Duffy who co-facilitated the siblings groups.
1. Summary of report

Background to the consultation
The National Institute for Health and Clinical Excellence (NICE) commissioned the National Collaborating Centre for Cancer (NCC-C) to develop child and adolescent cancer service guidance early in 2003. In spring 2004 the NCC-C commissioned the National Children’s Bureau (NCB) to facilitate this consultation. It was agreed that the consultation would consist of four one day events in four cities in England held in May and June 2004.

Aims of the consultation
The broad aims of the consultation were to examine the perspectives and to elicit the views of children with cancer, their siblings and parents in relation to the relevant criteria within the scope of the NICE guidance (see http://www.nice.org.uk/pdf/Child_Adolescent_Final_Scope.pdf), in order to inform its development.

The participants
In all 114 people took part in the four consultation days. These included 49 parents, 39 children with cancer and 26 siblings. Children’s ages ranged from two to 14 years. Participants at each consultation event were assigned to a group of either children with cancer (differentiated by age), siblings or parents.

Programme of activities
A programme of activities and areas for discussion was developed for each group. These included games and creative activities as well as ideas for discussion. Although participants were given the opportunity to set the agenda to some extent, topics for discussion were relevant to the development of the guidance and were agreed in advance by staff at NCC-C.
Key points

The broad areas covered by the consultation were the diagnosis of cancer and how families are told, access to health services, hospital treatment and care, families’ information needs, communication, community and home care and family support. Participants shared their experiences and opinions about health services and the key points for improvements in services raised by both children and parents are listed below. The consultation’s findings are given in more detail in the following chapters.

Diagnosis of cancer

- Primary care professionals should be well informed about childhood cancers and take parental concern seriously.
- Diagnostic tests should be undertaken quickly.
- Families should be warned if a diagnosis of cancer is suspected.
- Families should be told about a diagnosis of cancer in a comfortable, private room by one or two professionals with plenty of time available for discussion.
- There is no uniform way of telling family members about a diagnosis – children and their parents should be treated as individuals.
- The diagnosis and its consequences should be explained to children in simple, direct language.
- Children should be given the opportunity to contact another child or children of a similar age and with the same condition.
- Families should have opportunities to ask questions more than once and be given access to support by telephone.
- Parents are likely to search the internet for information and would like consistent advice on how best to do this and how to interpret their findings.
- Both parents and children suggested a ‘buddy’ system which would give families the opportunity to support each other after diagnosis.
Access to health services

- Services should be located near home.
- Hospitals should be near other facilities which families could visit.
- Free or affordable parking should be available.
- Access to more responsive and better organised hospital transport service.
- Appointment systems should be designed to meet individuals’ needs.
- Shorter waiting times at outpatient appointments.
- Children with cancer should have access to beds on specialist wards.
- Speedy, consistent procedures for referral to specialist wards.
- Consistent, universal access to home care and social work support.
- Effective pharmacy services.

Hospital treatment and care

- **Hospital environment and facilities**
  - Wards should be colourfully decorated and comfortable with opportunities for privacy.
  - Space for older children separate from babies and toddlers.
  - Separate visiting and resource rooms were suggested.
  - Play facilities outside the wards including access to outdoor play space.
  - Facilities (such as showers) for family members.
  - All groups mentioned entertainment wanting more age appropriate toys, games, art materials, television and DVD.
  - Easy access to free or affordable telephones.

- **Food**
  - Hospital food should reflect what children like to eat while not being consistently unhealthy. Younger children wanted pizza, burgers and chips while older ones sometimes preferred lighter meals.
  - Food should be well prepared.
  - Opportunities to eat outside normal mealtimes.
o Opportunities to eat with family members.
o Affordable food available for family members.
o The provision of a ward snack trolley.
o Easy access to cold drinking water.

• **Education**
o Teaching in hospital to be appropriate for age and ability.
o Effective hospital/school liaison.

• **Relationships with staff**
o Staff should talk honestly to children and not just to their parents using accessible language.
o Children should be given opportunities to be involved in their care whenever possible.
o Children appreciated reward systems after treatment.
o Staff in shared care centres should be trained in specialist cancer care and treatment.

• **Treatment and care**
o Consistent quality of care across services.
o Consistent treatment protocols across services.
o Parents’ involvement in care to be valued and training offered to parents when appropriate.

**Providing and sharing information**

- Information about all aspects of cancer and cancer treatments should be made available to children, parents and other family members in a range of formats and appropriate for their age and circumstances.
- Information should be made available about rare conditions.
- Information about medication and its effects.
- Regular updates on a child’s progress which parents can understand.
• Clear lines of communication between professionals.
• Information provided to GPs about a child’s progress.
• Regular consultation with patients and parents about services.
• Wider understanding of childhood cancer and its effect on families.
• A sensitive approach to sharing information about the death of a child.

Community and home care
• Consistency in the availability and quality of home care services.

Family support
• Consistent, easily accessible advice about welfare benefits.
• Support for siblings of children with cancer.
• Access to psychological and family support when needed.

2. Introduction

The National Institute for Health and Clinical Excellence (NICE) commissioned the National Collaborating Centre for Cancer (NCC-C) to develop child and adolescent cancer service guidance early in 2003.

To help inform the development of the guidance, NCC-C was asked by the child and adolescent cancer guidance development group (GDG) to commission a consultation with children and young people with cancer and their parents, carers and siblings. The GDG considered input of patient experience into the guidance a high priority. In spring 2004 the NCC-C commissioned the National Children’s Bureau (NCB) to facilitate such a consultation. It was agreed that it would consist of four one day consultation events in four cities in England held in May and June 2004. Young people aged 15 and over were consulted separately in collaboration with the Teenage Cancer Trust.
The NCC-C was responsible for the administration of the days which included booking the venues, recruiting participants, transport, catering and providing rewards for participants. NCB’s Project Team was responsible for planning and facilitating activities. This included developing a programme of activities and games, preparing discussion topics, facilitating activities and discussion, collecting and analysing information and preparing a report for the GDG. The topics covered in the consultations were agreed between NCC-C and NCB.

3. The National Children’s Bureau

The National Children’s Bureau is a national voluntary organisation. It promotes the voice, interests and well-being of all children and young people across every aspect of their lives. It advocates the participation of all children and young people in all matters affecting them. It challenges disadvantage in childhood. Young NCB is a membership organisation for young people with its own magazine and website.

NCB achieves its mission by:
• ensuring the views of children and young people are listened to and taken into account at all times
• playing an active role in policy development and advocacy
• undertaking high quality research and work from an evidence based perspective
• promoting multidisciplinary, cross-agency partnerships
• identifying, developing and promoting good practice
• disseminating information to professionals, policy makers, parents and children and young people

NCB has adopted and works within the UN Convention on the Rights of the Child.
The consultation team included staff from NCB’s Participation Unit, Research Department and Family Support Unit. An early years consultant was employed to undertake the work with children aged two to four. The team also included three young facilitators (aged 16-18) who are members of Young NCB and who have trained as group facilitators.

4. Aims of the consultation

The broad aims of the consultation were to examine the perspectives and to elicit the views of children with cancer, their siblings and parents/carers in relation to the relevant criteria within the scope of the guidance (http://www.nice.org.uk/pdf/Child_Adolescent_Final_Scope.pdf), in order to inform its development. These criteria included access to health care, experiences of health care and treatment and how information needs are met.

The consultation focused on the following aspects of cancer care:

- Diagnosis of cancer
- Hospital treatment and care
- Meeting information needs
- Community and home care
- Family support

The report covers these subjects and key points based on the views of participants are included after each section.
5. Methodology

The participants

The sampling frame for participants was children aged two to 14 years, their siblings and parents or carers. The children who were recruited were or had been patients at participating regional cancer centres and had malignant disease, including leukaemia and related conditions (as defined by the International Classification of Childhood Cancer) or benign cancer. The GDG stipulated that there should be a mix of boys and girls in each age group and that recruitment from black and minority ethnic groups should be included at each event. It was agreed that a maximum of 48 children would take part in the consultation.

The four consultation events were held in different cities in England (Birmingham, London, Leeds, and Bristol) in collaboration with the regional cancer centres. NCB produced a recruitment flyer (see Appendix A*) and staff at the regional centres made contact with a wide range of potential participants from individuals, families and local groups already known to them. Details of each local centre’s recruitment strategy are not known.

Participating children with cancer were grouped by age and it was planned that approximately 20 families would participate in each event. In order to cover the wide age range identified by the GDG, it was agreed that there should be two consultations for each age group. Age groups included children aged two to four, five to eight, nine to 11 and 12 to 14 (see table 1).

Table 1: Age groups planned for the consultation

<table>
<thead>
<tr>
<th>Hospitals</th>
<th>Groups consulted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birmingham Children’s Hospital</td>
<td>Parents, siblings and children with cancer aged 5-8 years</td>
</tr>
<tr>
<td></td>
<td>and children with cancer aged 9-11 years</td>
</tr>
</tbody>
</table>
Great Ormond Street Hospital, London Parents, siblings and children with cancer aged 2-4 years and 12-14 years

St James's Hospital, Leeds Parents, siblings and children with cancer aged 2-4 years and 12-14 years

Bristol Children’s Hospital Parents, siblings and children with cancer aged 5-8 years and 9-11 years

Altogether 114 individuals (including children with cancer, siblings and parents) took part in the consultation days. There were 39 children with cancer of whom 22 were boys and 17 girls. There were 26 siblings and 49 parents of whom 31 were mothers and 18 fathers (see table 2). Although it was planned that a group aged 12 to 14 would be included in the London consultation, only one child of that age group attended and so that group did not take place.

Table 2: Numbers and sex of participants

<table>
<thead>
<tr>
<th>Group</th>
<th>No. of participants</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aged 2 to 4</td>
<td>15</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Aged 5 to 7</td>
<td>7</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Aged 8 to 11</td>
<td>10</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Aged 12 to 14</td>
<td>7</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Siblings</td>
<td>26</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Parents</td>
<td>49</td>
<td>18</td>
<td>31</td>
</tr>
</tbody>
</table>

The large majority of participants described themselves as ‘White British’. Only 7% of all participants were from a black or ethnic minority background.
Participants came from East Anglia, the Midlands, the south-east, south-west, north, north-west of England and from south Wales. Some participants had met each other or some of the facilitators before during hospital visits while others knew nobody else.

**Consulting with children and young people**

Over recent years there has been a growing acceptance that children and young people should be given opportunities to be involved in decisions that affect their lives. This has been driven by a number of ideas which include the increased involvement of the consumer in the development and modification of both private and public goods and services, the children’s rights agenda, which includes the right to participate in decision making, and a relatively new understanding of children – including very young children - as a competent social actors who have a role to play in shaping their own lives and those of others. In accordance with these ideas, children and young people have increasingly been asked to take part in consultation exercises and decision making in diverse areas of their lives. These include health services, the family court, community initiatives and education. The current consultation is an example of how service providers and policy makers take account of the views of children and young people. A separate report of the consultation and its findings has been written for young participants (see Appendix H*).

A consultation of this kind cannot represent the views of all family members in England and Wales who are affected by childhood cancer. However, it does provide the opportunity for a number of children and parents to share their experiences of and views about living with cancer and cancer care. The issues raised at the separate consultation days were broadly similar which points to the relevance of the information gathered and key points made.
Consultation techniques and activities

The programme for consultation days was divided into sessions with age appropriate activities organised around a theme (see Appendices for details of the programme). Children’s activities included opportunities to make pictures and play games as well as to discuss issues while the sessions with parents were more like traditional focus groups where issues were discussed and recorded in writing. Although activities and discussion were based broadly on the issues agreed with the GDG, participants were able to widen the remit and talk about other aspects of cancer services that they felt were important. Consultations with very young children used play and medical equipment to encourage interaction and discussion.

The consultation tools were carefully prepared with consideration given to age appropriate activities, the health of the children, keeping children engaged and having fun. Separate programmes were devised for children aged two to four years and five to eight years which focused on creative play techniques (see Appendices B and C*). One programme was developed for the sessions with 9 to 11 years and 12 to 14 year olds (see Appendix D*) with minor adaptations according to the age group. In this programme a series of activities was designed to engage the children, to be fun, to be participative and to ensure that relevant topics were raised and discussed. The activities included group discussions around a topic using post-it notes to record experiences and views, a reporter exercise in which children interviewed each other, and making collages to express views and suggestions. All the activities were designed to promote discussion and enable children to give their views in fun ways. The programme for siblings was similar to the programme for 9 to 14 year olds but included slightly different exercises (see Appendix E*). The programme for parents was much more discussion-based in order to allow participants as much opportunity as possible to talk about their individual experiences and express their views in addition to creating a group consensus about issues of importance (see
Appendix F*). All participants were asked to stick ‘leaves’ on a wish tree at the end of each day on which they had written a ‘wish’ for improvements in cancer services.

In order to establish a friendly, informal atmosphere at the consultations, each group session (including parents’ sessions) began with a brief fun game which gave participants the opportunity to familiarise themselves with each other and with facilitators. Ground rules were introduced and agreed by participants. These included an agreement that personal experiences were confidential and should not be repeated outside the sessions and that children should not leave a session without letting facilitators know. Children were able to leave a session and go to their parents at any time.

Collecting and analysing information
Members of the Project Team with the invaluable help of local facilitators made copious notes of what participants said on flipchart paper and notepads. These notes, with the post-it notes, drawings, etc., produced at the consultation days, were written up into reports of each session. The resulting reports were collected together for each group of participants (i.e. for each age group and for parents and siblings) and themes relating to the main issues covered by the guidance scope were drawn and compiled together to produce this report. As noted above, another report was produced for young participants.

6. The views of children affected by cancer

This section presents the experiences and views of children with cancer who were consulted about their health care and treatment. It is divided into three sections which detail the responses from each age group. These were children aged two to four, five to seven, and eight to 14. Each section describes the activities, consultation findings and key points.
Younger children affected by cancer aged 2-4 years

The consultations with children aged two to four took place in hospitals in London and Leeds. An early years consultant facilitated the sessions with this group of children.

Methods

An outline of the day’s activities was planned and intended to be used as a guide for the kinds of age appropriate activities that could take place on the day rather than as a rigid schedule (see Appendix B*). To ensure that the process was both child-led and child-focused the children dictated the pace of the consultation and how it developed. The different activities were integrated into an ordinary play session so that the children could choose what they wished to play with, how they played and could join in activities only if they wanted to. Flexibility was essential in order to work with the children’s normal routines. This meant that sessions did not always go according to plan – for example, at one hospital children were too tired to participate in all the sessions. Discussions with co-facilitators highlighted the many different techniques used to support these children through the different stages and circumstances of their treatment. Examples include at initial diagnosis, during treatment, when in remission or isolation, terminally ill children and those at the transition stage between illness and becoming well. Because children of this age can be wary of being separated from parents or other familiar adults, the facilitator felt that meaningful consultation with this age group would be more effective on an ongoing (rather than one-off) basis.

The topics for consultation were simplified so that they were meaningful to those taking part. Written observations were made on the day. The topics became:

- I know I am not well – drawing around each child’s body and prompting discussion about how they felt;
• **Making me better** – a sensory walk around the hospital setting, the children being prompted to talk about what they saw and smelt and what happens in particular areas of the hospital;

• **The very worried doctor** - an interactive story and rhyme session about a newly qualified doctor and what a wise child with cancer taught him.

In pre-consultation discussion, play specialists recommended the following:

• **Concentrating on free play with medical equipment**
  It was decided that the most useful play equipment would be real medical equipment (i.e. drips, bandages and syringes etc.), closely supervised by adults to ensure safety of the participants.

• **Using a ‘blood doll’**
  These are dolls with Hickman lines, nasogastric tubes and portocaths in place and who have removable hair to represent a child undergoing treatment for cancer.

• **Collecting background information from parents**
  To understand the context of what the children expressed, questionnaires about the child and his/her condition were distributed to parents (see Appendix G*). Where appropriate, information from individual children was shared with parents to ensure that what their child expressed was accurately represented.

**Younger children’s awareness of their medical needs**
These very young children were capable of clearly expressing their experience of living with cancer through their play, body language and spoken explanation. The free play enabled the children to be in control of what they played with and how. Playing with real and Playmobile medical equipment helped them to make links between what was happening to them in hospital and at home. The play and
conversation reported below illustrate young children’s awareness of illness and how it is treated.

The children referred to their cancer in simple terms - ‘bad blood’, ‘when your blood is up’ and ‘bad tummy’. They used colloquial terms to refer to their treatment such as ‘wiggly’ or ‘noodle’ for the central venous line. Those children who had a portocath fitted were quite happy to show them to the facilitator. One explained that the port in her arm was for ‘the medicine [which] goes in your tummy and makes you better’. One child administered ‘treatment’ to the facilitator in a calm, efficient and professional manner, putting on gloves, using and then carefully disposing of antiseptic wipes, injecting into a line and taking temperature. Another child’s mother reported that her child was capable of asking medical staff specific questions about treatment.

Two children applied ‘magic cream’ (local anaesthetic cream used for painful procedures) to dolls. The magic cream appeared to be important and great care was taken to rub it in carefully and give it time to work before applying a dressing. The syringes were used to administer medication into the Hickman line or as medicine into the mouths of the dolls. One child described her medicine as ‘orange’ and she administered it slowly and carefully. One child asked another what else could the syringe be used for. The child replied, ‘medicine’. A third child sitting nearby touched his tongue and said, ‘Yuk’.

A child asked, ‘Where else do we put the tube?’ and then placed the tube in the doll’s nose. A second child shook his head emphatically and said, ‘no!’ A third, who had a nasogastric tube inserted, said, ’like me!’ and the first child very solemnly said, ‘Only on dollies’. The children seemed to be wary of the nasogastric tube.

During another session children were happy to show the facilitator the waiting and consulting rooms and show her where they sit and where the doctor sits.
They lay down on the bed and one used a stethoscope to listen to another’s chest. In the treatment room one of the children administered medication to a blood doll. When he forgot to undo the clip, the others reminded him what to do and he rolled his eyes at his own omission.

In their responses to the pre-consultation questionnaire (see Appendix G*), it seems that parents underestimated the level of awareness that their children had about cancer believing they were too young to be able to participate effectively in the consultation. However, it was clear through play that the children did have an awareness and demonstrated quite clearly that they had an understanding both of cancer and of cancer treatment.

Play specialists involved with the consultation did not think that any of the literature for children with cancer that they had seen was suitable for very young children. The books are too wordy and lack the pictures required to help a young child’s understanding. There is perhaps a need to develop early years literature on cancer that is suitable for very young children.

**Relationships with staff**

*Continuity and familiarity are important to children*

The younger children said that continuity is important to them and that separation from main carers worries them. This was reflected in some of the children’s discomfort at being separated from their parents and the relief shown when the children recognised individual co-facilitators. One child immediately recognised a member of the hospital’s support staff and sought her company while another child who did not know anyone wanted to leave early. They were familiar with particular doctors and appeared pleased when they discovered that another child in the group also knew a doctor by name.
Waiting for treatment

An interesting observation of this consultation process was that children appeared to be used to waiting and accommodating delay. Although anxious to return to their parents, they appeared resigned to the fact that treatment would take a long time.

Key points for services for children aged two to four

- The development of effective listening and observation techniques for supporting very young children with cancer
- Dedicated information about cancer and cancer services in the form of picture books (or other media) for very young children

Children affected by cancer aged 5-7 years

The consultations for children aged five to seven years took place in hospitals in Birmingham and Bristol.

Methods

Sessions for this age group were based on play and creative techniques. A plan for each session was developed with advice from the arts organisation, Wolf+Water, and used as a flexible guide. First, the children were asked to give a name to a cut-out cartoon ‘alien’ which was used to help establish children’s understanding of their illness. This character was used to represent a child with cancer. Participants were asked to imagine this character’s favourite activities and to specify its illness. They used the same character to provide information on their experience of being treated for cancer.
Hospital treatment and care
Generally, the children seemed to have few complaints about hospitals and hospital care. Hospital staff received the most praise, and the facilities available for children were also appreciated.

Hospital location and environment
Children were asked to discuss what makes an ‘ideal’ (or improved) hospital environment. They suggested that an ‘ideal’ hospital would be located near their home to make visits easier (one child made a drawing of a hospital with his family home inside it) or near a town centre so there would be things to do on family visits. Most children wanted children’s wards to be brightly coloured with plenty of toys and art materials available. Children emphasised their wish for privacy (‘a door you can lock’, ‘curtains around you’).

Treatment and care
The children discussed the good and bad aspects of their own experiences. Most children were happy with the treatment they had received from hospital staff. Doctors and nurses were described as ‘funny’, ‘friendly’ and ‘happy’. One child was concerned about hospital staff not getting enough sleep and consequently being grumpy.

‘The doctor was funny - that made me happy.’ (7 year old)

‘The nurses were really kind and friendly. They let me choose a toy from the treasure box after the injection.’ (6 year old)

A few children said they liked to know exactly what was going on and knew what all the medical apparatus was used for. The majority, however, preferred discussing their illness in a more opaque way.
‘It's best to know all about the medicines and what's happening to you. My mum and dad told me what's going on.’ (8 year old)

Reward systems such as letting children play with toys or have sweets after injections or operations were regarded as positive.

**Hospital facilities**

**Play away from the ward**

Some children said they wanted to play outside the hospital ward in either separate playrooms or in playgrounds in the hospital grounds. Many said they wanted to have more time outside the hospital building but recognised that this was dependent on their treatment.

**Food**

Most children enjoyed the food they ate in hospital, although a few said they disliked it and suggested having McDonalds meals instead. Most children of this age said they preferred pizza, burgers and chips to other options.

**Communication**

Contact with family and friends was considered important by participants. Children thought that patients should be given mobile phones to call home, friends should be able to visit more often, and there should be a school in the hospital.

**Key points:**

**Access to services**

- Hospitals should be located nearer children’s homes and near other facilities which families could visit.
**Hospital facilities:**

- Hospital rooms should be colourful and there should be toys and art materials to play with.
- There should be places to play outside the ward including outside play space.
- Young children said they would like to eat pizza, burgers and chips.
- There should be a hospital school.
- Telephones should be made available to patients.
- Friends should be able to visit more often.

**Relationships with staff**

- Children liked ‘funny’, ‘happy’ doctors and nurses.
- They liked to be offered rewards after treatment.
- Some wanted to know about treatment in detail while others did not. Staff should treat children as individuals.

**Children affected by cancer aged 8-11 and 12-14 years**

The consultations with children affected by cancer aged 8 to 11 took place in the Birmingham and Bristol hospitals. It was noted that the group of children in the Bristol group were generally less well than the Birmingham group and consequently there were more breaks in the sessions. One group of young people aged 12 to 14 participated in Leeds. The one young person in this age group who attended the London consultation joined the siblings group. The findings from both age groups are described below.

**Methods**

A schedule of activity-based exercises was created to be used at each consultation day for these age groups (see Appendix D*). The same schedule was used for both the 9 to 11 and 12 to 14 age groups. The activities were designed to encourage the children to express their views and to promote
Facilitators recorded children’s views and comments on flipchart paper.

The activities were planned to involve participants as much as possible and included sessions entitled (see Appendix D*):

- What’s Important to You?
- Picture Perfect Diagnosis
- Your Care, Your Views
- The World’s Worst/Best Nurse
- Receiving You Loud and Clear

**What’s Important to You?**

The children were asked to identify issues that were of most importance to them in relation to having cancer, write them on post-it notes and stick them to a full-sized body shape. The themes below are those identified as most important by participants.

**Family and friends**

Children talked about how their family and friends reacted to their illness. Many said that their friends and family members acted differently towards them since their diagnosis, were far too protective of them and did not understand their illness. They also said that they missed friends and family while they were ill and in hospital. Some said their siblings were nicer to them. Many said that they did not like always being asked how they were.

‘*It is difficult to see my sister ‘cause she’s scared of hospitals and gets upset.*’
**School**
The main issues children highlighted about school were feeling ‘different’ and missing school because of clinic appointments, being unwell or undergoing treatment.

‘I have to have a stool, cushion and file thing on my desk and no-one else has.’

Older children reported falling behind with schoolwork and getting poorer grades in tests and exams.

**Hospital treatment and care**
Participants had the most to say about this subject. They talked about being scared, being tired, their hair falling out, having to be on specific diets and being woken up in the night to receive medication.

‘Radiotherapy is scary especially the mask over your face.’

‘People should make chemotherapy so your hair doesn’t fall out.’

However, they also made positive comments about hospital staff and effective treatment.

‘My portocath has helped because I can swim. It’s better than a Hickman.’

**Being bored**
Overcoming boredom in hospital was an issue raised by a number of participants. They wanted more things to do and to entertain them in the wards including books, Sky TV and games consoles.

‘My treatment is boring and annoying.’

‘Books for when I can’t run about.’
Other people

Many children felt uncomfortable with how they were regarded by adults or other children when they were out or at school. They did not like the way that people stared at them. Girls explained how they were often mistaken for boys because of hair loss and how other children did not want to play with them.

‘People in the ladies call me a boy.’

Sports and hobbies

Children said that they were upset that they could not take part in the physical activities that they used to enjoy such as swimming and other sports.

Personal support

Older children talked about the importance of people around them who offered support. In particular, they cited parents and other family members, friends, nurses, doctors and teachers.

Picture Perfect Diagnosis

The aim of this exercise was to provoke discussion about diagnosis and what could be better through the creation of a collage. All comments were recorded. For this session, each group was given a selection of materials, including pens, pictures, magazines and speech bubbles, to create a picture of how and where they thought children should be told they have cancer.

The feelings that a diagnosis of cancer provoked were evident in the pictures created by the children. The facial expressions of their parents (shocked) and themselves (unhappy) demonstrated how emotive diagnosis was for children and families. Different forms of support and solace such as pictures of teddy bears and adults comforting children were also used. One young person said, ‘when I got told it was strange because my heart went strange’ and drew a picture of a broken heart.
There were broad similarities in the rooms that the children designed as the place where they would prefer to hear about a diagnosis of cancer. The rooms were colourful with sofas or comfortable chairs, pictures and toys. Children did not want to be told in a clinical, impersonal environment. Many stressed that they wanted to be told in a private room with only their parents and the consultant present.

‘Tell, me, my parents and consultant and no one else about my health.’

One child thought there should be a room specifically designated for the purpose of giving diagnosis. Another said that he would prefer to be told in his own bedroom at home with his family.

Children were concerned with who told them and who was present. Some commented that they would like to be told at the same time as their parents although a small number said they would like to be told afterwards by their parents. One wanted her friends to be there as well as her family and another chose her favourite uncle to be with her. Another child wanted a nurse present who would be able to explain medical terms and treatment.

Children wanted to be given an explanation of their illness in simple terms and in a direct manner. One child wrote in a speech bubble, ‘OK [child’s name], let’s get straight to the point…you have leukaemia’. Several children said that they would like to be treated with respect and not like small children who could not understand what was happening. They felt that if they were given a clear and simple explanation they could understand their diagnosis from a very early age.

‘Doctors shouldn’t explain it [treatment and diagnosis] to someone in a rush and they don’t explain enough.’
Some said that a diagnosis of cancer should be explained more sensitively with enough time allowed for questions and answers. It should not be given over the telephone which was one young person’s experience. Many had not understood the medical terms or realised that treatment would begin immediately after diagnosis. The older group agreed that having another young person who had undergone cancer treatment or a liaison nurse to explain and help them understand procedures and terms would have improved their experience. Many children felt that there were too many people involved at the early stages of treatment and all thought that there was too much information to digest.

Some children said that they wanted to be told by a consultant who was friendly, fun and kind. One child thought that a play specialist, rather than a consultant, should have explained her diagnosis to her. She liked the way that play specialists used toys in their work. The pictures created showed how much children need to be supported and comforted by their parents and other hospital staff.

‘See a consultant rather than a registrar because they explain things better.’

Many of the children talked about the length of time it took to be diagnosed and how upsetting this was for them and their families. Only one of those in the older age group had been diagnosed quickly. They also talked about when the diagnosis was made. One child, for example, said, ‘I spent all Christmas waiting to hear’.

Your Care and Support: Your Views

This exercise was designed to investigate children’s experiences of cancer services in hospital, at outpatients clinics and at home. Children were also asked for suggestions for how services could be improved. Children acted as roving reporters and interviewed each other with a questionnaire about their care in
hospital, as outpatients and at home and also took part in a group discussion about their involvement in their care

**Hospital treatment and care**

**Location of care**

All but one child expressed a preference for being treated at a regional cancer centre rather than a local centre even though it often involved a long journey to hospital. Children thought that the treatment they received at the regional centre was superior, centres were better equipped and staff had more specialist knowledge about cancer treatments as well as knowing children and families better. When being treated in local hospitals children felt that themselves and their family had more knowledge about their condition than the staff. They also liked being in contact with other children who had cancer in the regional centres and felt isolated on general wards.

Some children said that staff in shared care hospitals were ill informed about their current treatment and that they had to explain their needs again and again. They would be happier to attend the local hospital for routine appointments if records were maintained and staff kept up to date with their treatment. They suggested that a specialist liaison nurse attending all appointments could improve communication and that local hospitals kept up to date copies of medical notes.

**Hospital environment**

The majority of children had stayed on a children’s ward and only one on an adolescent ward. All children said that the ward they stayed on was OK or good. The older ones contrasted their experiences of general paediatric wards in local hospitals with specialist wards at regional cancer centres, preferring the latter. The majority of children said that they ‘sometimes’ had enough space and privacy. They requested more space between beds, more cubicle style rooms and less curtained ones.
Half the children thought that it was ‘always easy’ for friends and family to visit them and the other half thought it was ‘sometimes’ easy. They suggested that a separate room should be provided where they could meet with family and friends. They also wanted a mechanism to ensure that friends came to visit when they looked well. Those who lived far from the hospital and whose families had been able to stay with them or close by appreciated the availability of accommodation attached to the hospital.

Children said that different age groups have different needs and cancer services should reflect this. In particular, older children stated said that they did not like to hear babies crying. Specific activities (such as wig and pyjama parties) and environments designed for teenagers were appreciated as were things like a painted ceiling in one ward which was ‘fantastic’ for patients who were bed bound.

_Treatment_

Most children had had chemotherapy and some had had radiotherapy, surgery, bone marrow and peripheral stem cell transplants, biopsies, steroids and lumbar punctures. Children felt that their treatment could have been made better if they had been better informed beforehand, had pre-medication and smaller tablets that were easier to swallow.

_‘They told me what to do but not what it would do to me.’_

_Hospital facilities_

_Food_

All the children reported that they were unhappy with hospital food. Nearly all stated that it was ‘not good’. They said that it was not hot, it was often burnt and they would like more menu choice. Many children preferred food like burgers and chips while some of the older ones would like the option of lighter meals when they are not very hungry. Children also wanted food to be available all day and
not just at mealtimes so they did not have to go to the shop. Older children liked a family Sunday lunch which was provided at some hospitals when families could eat together and requested more opportunities to share meals like this.

**Telephone calls**
Young people talked about the high cost of making and receiving telephone calls in hospital using Patientline. Although they greatly valued having a personal phone, the cost was prohibitive. It was suggested that costs should be reduced for long-stay patients.

**Parking**
Children reported that it was often difficult to find a parking space and that car parks were expensive. This sometimes meant that there was a long walk to the hospital making them late for an appointment which added to the family’s frustration. Only one child knew about a free parking scheme.

**Activities**
Children reported that, although there were some activities and things to do available in hospital, such as age appropriate videos, games and Playstation, they get very bored and requested more activities for older children and teenagers including more computers, exercise equipment and art activities.

**Education**
All the children who had spent time in hospital had done some schoolwork. Children of both age groups said that lessons they had in hospital were not suitable for their age and ability and schooling would have been more effective and interesting if they had been set more demanding work.
Making things better

Each child was asked to think of two things that would make being in hospital better for them. The most common answer was entertainment such as television, Playstation and playing games. Other individual answers were:

- No pain
- Nurses making sure that you went to the toilet to prevent constipation
- Having family around you
- To bring a pet in with you
- Nice nurses, doctors and play specialists
- A garden
- More play ladies

Children were also asked to think of two things that made being in hospital worse for them. Their responses included poor food, the lack of games and things to do and being far from home and/or in isolation.

Outpatient care

Most children received the majority of outpatient care at a regional centre but were sometimes treated locally. All the children estimated that it took them up to an hour to travel to the clinic.

The majority of children said they had weekly or fortnightly appointments. When asked whether they had enough time with staff at appointments, most children said that they did ‘sometimes’. The majority said that they were only seen quickly sometimes and usually had to wait. When asked what would improve appointments, they all requested shorter waiting times. Most children wanted more entertainment in the waiting room and requested television and videos or more toys and activities. They also suggested that having more doctors and
nurses would speed up the process. One child requested a bed so he could sleep while waiting.

**Home care**
Children were asked who helps care for them at home, at school and in the community. All the children said their ‘mum’. Nearly half also mentioned a community nurse. Other family members, teachers and a summer camp for children were also mentioned.

**Involvement in decision-making**
When asked how they are be involved in decisions about their treatment for cancer, the children recognised that ultimately they did not have many choices because they were often in a life or death situation.

‘Treatment is more important than anything because you could die.’

Many children felt that staff talked to their parents and treated them as though they were invisible. Older children hated being seen as ‘cancer victims’ and not as individuals living with cancer who were able to make informed decisions.

‘Don’t treat us like we don’t know anything – we know more than they think.’

Children felt that sometimes doctors offered choices to their parents which they felt they could have made themselves. However, some had had more positive experiences of being consulted and listened to.

‘I really like that they ask me when they could ask my parents. It makes me feel like I’m the important one.’

Children and young people also talked about times when they did have some choice over their hospital care. One, for example, was asked whether she wanted a portocath or a Hickman line. She said, ‘I got a choice but the other children
didn’t’. Another had been asked whether she wanted her mother to help with her treatment at home. She said she did not and so a community nurse was assigned to her. Others talked about the timing of treatment. Some had good experiences of doctors being flexible about the timing of non-urgent treatment in order to allow children to enjoy holidays or a birthday while others felt that they had been denied opportunities because of a rigid adherence to treatment regimes.

One area in which children felt they would like more say was in the meals provided in hospital and mealtimes. Children in hospital often missed a meal because they were having treatment and so were hungry afterwards. This meant that parents had to bring in food for children. They also requested more choice over when they were able to eat.

**The World’s Worst Nurse**

A cartoon picture of a nurse was drawn on to the flip chart. Children were asked to describe the world’s worst nurse. They were also encouraged to describe a nurse’s good qualities. The aim of this exercise was to engage participants in a fun discussion about what qualities they would like nurses and other health professionals to have and how they could be supported better. The answers produced were very general but most were related to the experiences of each individual child.

Some children talked about the way nurses explained the treatment they were given and remarked that they were often not told clearly about what was happening to them.

‘They do things without explaining and leave you with things you don’t understand.’

‘Not telling me about the machines.’
Children most commonly said that nurses were either not very helpful or hurt them whilst carrying out treatments. It should be noted that they said that this was more likely to happen at a local hospital rather than at a regional centre.

‘Doesn’t wash hands – ‘cause you might get an infection.’

‘Doesn’t give you ‘magic cream’ to stop the needles hurting.’

‘Pulls ‘wiggly’ and it hurts.’ [NB: ‘Wiggly’ refers to the central venous line used to administer medication.]

The second most prevalent topic was how nurses communicate with children. Children said that nurses often did not look at them when they were talking to them or did not listen. They also raised the difficulties they had experienced communicating with nurses whom they did not understand.

‘If they are foreign and you can’t understand what they are saying’.

Another theme was the amount of time nurses dedicated to children. A number of children said that nurses were either with them too much or too little. They did not want to talk to nurses when they were feeling tired, although they did joke about this aspect.

‘Always with you too much or not enough.’

‘Always wanting to talk when you’re tired.’

Children were unhappy with nurses who talked about them and their illness in front of others on the ward.
Children listed the members of staff who they found most helpful while they were receiving treatment. These were the pain nurse, the community CLIC nurse, ward sister, professor, consultant doctor, surgeon, anaesthetist, physiotherapist, play specialist and home tutor.

Receiving You Loud and Clear

In this session, children were asked to design a website, using a cut out of a computer and collage, to include all the different kinds and ways of giving information they wanted about cancer. Children also discussed the information they had actually received. All those in the 12 to 14 year old group thought that the leaflets they had been given had not been appropriate for their age. They recommended more suitable literature, information aimed at them rather than at parents, guidance on helpful websites, being asked for their opinions on care and treatment and a wider understanding of cancer in children and young people which might be prompted by a storyline in a television soap opera.

Children wanted their websites to contain the following pages:

- My illness
- My messages to you
- Photo board
- Research on leukaemia
- Send me an email
- Message board
- Cancer cartoons
- Other people’s stories/diaries
- Link to send messages between hospital and home.
  Access to your results on the screen (accessed by a password, only used by you and your family)
- Chat rooms
- Links to more detailed information on cancer.
Children thought that the best ways of giving children and others around them information were:

- Doctors talking to them/talking to your consultant - ‘Consultants give the best information.’
- Talking to your counsellor
- Receiving good information and then explaining it to your friends.
- Videos on childhood cancer
- Books on childhood cancer
- Leaflets about leukaemia and all types of cancer for children and for adults
- Chatting to other people who have cancer
- Activities for children with cancer
- Camps and special activity days
- Gifts and goodies about cancer – to help children with cancer
- Blood dolls
- In school – advice on how to return to school and what might happen, more education about cancer in schools and information for teachers to tell them about a child with cancer. Asking parents to go to your school and explain to your class what is wrong with you.
- Talking to family – ‘Sisters are very good at explaining things’.
- Using accessible language

**Meeting information needs**

Just over half the children felt that they had not been given enough information about their illness and treatment. The comments below show that children did not always feel well informed.

*I thought after the transplant it would be over but it wasn’t. I still have to have drugs and come to hospital. I didn’t know I would have to go into isolation.*
‘They didn’t inform me that I might go sterile and not be able to have children because of radiotherapy.’

‘I was diagnosed aged three but given no information because I was too young. I was given the basics but it was really weird because I was so small so why bother?’

‘I wasn’t told that I couldn’t go to school or it will be a while until I can go out.’

‘I did not realise it would take so long for my T cells to come back.’

‘You should be told what all the tests are for.’

‘I should have been told more about treatment before it started.’

**Key points**

**School**

- Schools should be provided with information about a child’s condition and how it will affect his or her work.
- Information and education about cancer should be provided for all school students to help overcome children with cancer feeling ‘different’ from peers.
- Better school/hospital liaison to support children’s learning.

**Diagnosis**

- Hearing about a diagnosis of cancer should take place in a private room, preferably one specially designated for diagnosis which is comfortable and informal and with some toys available.
- Most children requested that only the consultant and their parents should be in the room. Some would have also liked a nurse to be present.
• The diagnosis and its implications should always be explained to the child in simple and realistic terms.
• Further support, such as play therapy, should be available to children and parents.
• Symptoms should be taken seriously and tests undertaken quickly so that a diagnosis can be made as soon as possible.
• Families should be told about a diagnosis of cancer face to face and not on the telephone.
• Some children would like to make contact with another child with cancer of the same age.

Shared versus regional care
• Children did not have confidence in shared care centres. Staff in shared care centres should have better training in specialist cancer care and treatment and have the correct equipment.
• There should be effective communication and information sharing between staff.

Hospital care
• Children want more entertainment in hospital including games and activities specifically for teenagers.
• There should be more resources available on wards such as satellite television, a wide range of books, art materials and games consoles.
• A separate visiting room (like the one at a specified hospital) was suggested.
• Children should be given some say in when they want to see visitors.

Food
• The food available in hospital should reflect what children like to eat (such as burgers and chips as well as more healthy options and lighter meals). Food should also be well cooked and hot.
• Food should be available at alternative times for children who are undergoing treatment or who are ‘nil by mouth’ and who therefore miss conventional mealtimes.
• Opportunities to eat with family members sometimes.

Education in hospital
• Teaching should be appropriate to children’s age and ability.
• Educational activities could help address children’s boredom.

Activities
• The provision of a wide range of age appropriate activities and entertainments in hospital including books, videos, computer games, toys and opportunities to play.

Clinic appointments
• Waiting times should be reduced.
• There should be entertainment available in waiting rooms.
• Health professionals should make the necessary time available to discuss issues with children and families.

Children’s involvement in decision-making
• Children should be involved in their care whenever possible. Children understand the serious nature of their treatment but should be involved in smaller decisions that could make their lives easier. Where possible, medical staff should accommodate children’s wishes which might include acknowledgement of birthdays and other important events.

Staff issues
• All health professionals should explain to children what they are doing to them and what the equipment is that they are using.
• Health professionals should use age appropriate language.
• Nurses should be able to speak and understand English well enough to communicate effectively with children in their care.
• Children should be treated with respect regardless of age.
• When parents are present, health professionals should talk to both the child and the parents and remember that the child is the patient.
• Health professionals should be aware of how a child is feeling and disturb them as little as possible when they are tired or feeling ill.
• Children with cancer are concerned about lack of cleanliness and the risk of infection. Staff should be aware of the importance of scrupulous cleanliness.

Information needs
• All children with cancer should be given adequate information about their illness, treatments (before they begin), how treatment will affect them, how long it will go on for and any side effects.
• Information should be age-appropriate. This is a particular problem for teenagers.
• Children can be given information in a variety of ways:
  o Websites – other people’s stories and chat rooms were popular and a useful method of providing information.
  o Information from health professionals provided in clear, fun and sensitive ways.
  o Videos/books/leaflets
  o Cancer related projects and camps
  o Information-based toys such as blood dolls
  o Information support from health professionals
7. The views of siblings

Four sessions for siblings took place at each of the consultation days. Siblings’ ages ranged from 5 to 17 years.

Your sibling’s illness

The first activity aimed to establish the extent of participants’ knowledge about their brother or sister’s illness. Despite the inclusion of young children in some of the groups, all participants were able to articulate the name of their sibling’s cancer and what part of the body it affected. They drew around a person’s body and marked the areas where they knew their sibling’s cancer was.

This exercise showed brothers and sisters’ understanding of how their siblings with cancer feel and its effect on these children. The children talked about their sibling’s hair loss, big scars on their bodies, pain and its location, the position of the ‘wiggly’ and marks made by it, the danger of infection, the fact that they may swell or bruise easily, weight loss or gain and other effects of medication. Some explained how illness and medication can prevent them from participating in activities and, in some cases, losing their sense of taste and appetite. They talked about the effect of treatment on their brother or sister and said it could make them scared, grumpy, cry a lot, moody, sleepy, sick, angry, unhappy, different, sad, stressed, mad and ‘a pain’.

An ‘ideal’ hospital

Working in pairs each group was given a selection of pictures and magazines to create a picture of where they thought their brother or sister could have best been treated.
Participants designed colourful rooms with pictures of Scooby Doo and Thomas the Tank Engine on the walls which they thought would make brothers and sisters feel at home. They thought the rooms should be private and comfortable with facilities like DVD and video players to keep their older siblings occupied and more toys and books for their younger siblings. They wanted comfortable chairs for them and other family members as visits lasted a long time.

Siblings proposed that the rooms have free phones so they could make contact with their brothers or sisters whenever they wanted as many said they missed them while they were in hospital. They also suggested having tables and chairs so that their siblings could get out of bed to eat if they were able. They wanted a wider range of food to be available and for it to be of better quality.

Children suggested having baths with bubbles which would comfort their siblings. Some children wanted colourful, soft carpets on the floor and access to swimming pools to allow their siblings to stay fit and not get bored.

They thought doctors and nurses should be available at all times and that siblings should have immediate access to a member of staff especially if they were in pain. They suggested smaller pills be developed which were easier to swallow and tasted better. They wanted someone to look after their brother or sister so their parents could take a break every so often. They wanted staff to explain the medical equipment to them so that they could understand more about their sibling’s treatment.

More fantastic suggestions included a stunt show to fly past their sibling’s windows, a big wheel to ride on and daily entertainment by clowns. They wanted their siblings to have pets in hospital which would provide comfort and company for them.
What makes a difference?

Siblings were asked to write suggestions for things that would make things better for them, their brother or sister and for their parents. Their ideas are listed below:

For siblings

- Somebody to help me with spellings and homework when mummy and daddy are away
- Support from people at school like friends or teachers
- Hospital closer to home so I can see him more
- People to tell me what’s wrong
- Have someone to talk to when I’m alone
- Lots of entertainment for children and adults
- Help at home when mum and dad are at hospital
- Someone to go out on my bike with me
- Mum doesn't leave me out if my brother goes to hospital
- More attention for me

For brothers and sisters with cancer

- Better food and advice on diet
- Less painful treatment
- Play specialists so you don’t get bored at home or the hospital
- Hospital nearer home
- A study room in hospital
- Toys, games and videos and more things to do in hospital
- For my brother to wait only a year not three years for the ‘all clear’
- More doctors and nurses to cut waiting times
- A quicker, easier and less painful way of curing cancer

Parents/carers

- Someone to give my mum or dad a break
- Information sheets for adults to understand
o Having meals delivered free to home
o To be able to get to the clinic quickly instead of having to drive so far
o Helping mum and dad stop being upset

Meeting information needs
Participants were asked to design a web page that would give them all the information they needed for themselves and their family. They discussed what they knew about cancer and cancer treatment and what they wished they had known. Many said they would like to have access to information and support via the internet and suggested how this could be made available with games, quizzes, case studies, information pages, fund raising ideas and chat rooms. They wanted websites that could answer questions and provide links to other useful sites.

Suggestions included:

Games and quizzes
- The battle of the cells - a game where you are a good red blood cell and you have to shoot the bad cells
- Education games such as naming parts of the body
- A wig game
- A quiz about cancer
- Golf with pills. Each pill has a different name to help different cancers
- A bone game
- Create your perfect medicine

They wanted information on:
- Create your perfect medicine
- Cancer – what is it and why do you get it?
- Diagnosing cancer
- Different types of cancer
- Platelets and blood cells
o Medication and how it works
o Cancer research
o Different hospitals
o Curing cancer
o What treatment their siblings have
o What doctors actually do (with pictures)
o How to comfort people with cancer
o How to cope with cancer

Suggestions for support:
o A free support telephone line
o An agony aunt to listen to people with cancer by e-mail or telephone
o Answers to specific questions
o Real life stories
o Meeting other people

Key points:
Access to services
• Hospitals should be located nearer home to enable families to visit easily.

Hospital facilities:
• Hospital rooms should be colourful, comfortable, private and large enough to accommodate enough seating space for visitors and somewhere to eat.
• Rooms should include toys, books, television and DVD players so patients can entertain themselves.
• Hospitals should have luxurious bathrooms and a swimming pool.
• Patients should be able to play with pets.
• Telephones should be freely available to patients.
• Food should be of good quality.
Hospital staff

- Medical staff should be instantly available to patients particularly when they are in pain.
- There should be enough play specialists to provide play opportunities.

Treatment

- Pain should be well managed and pain free treatments developed.
- Smaller, easy to swallow pills should be developed.

Information needs

- Siblings and parents should be provided with information about cancer and cancer treatments via age appropriate websites.
- Siblings should be told about medical equipment and what it is used for.

Family support

- Parents should have access to both emotional and practical support.
- Siblings’ need for attention and support should be acknowledged and met.
8. The views of parents and carers

Methods
Parents were invited to share their experiences, views and suggestions in pairs and small groups. Individuals then reported back to the whole group and the data was either written up on a flipchart or in note form by one of the facilitators. Participants were given the opportunity to add to flipchart notes during the breaks. The broad topics covered were diagnosis of cancer, inpatient and outpatient hospital care, information needs, community and home care and family support. Although participants were keen to talk about their own experiences, they were also encouraged to evaluate the treatment their child received, comment on what they thought worked well and what was not helpful and make suggestions for improving services. These topics were covered in all sessions but the level of detail provided by each group varied depending on experiences, time available and the interests of those present. This section covers all four consultations drawing together the issues discussed into broad themes.

Diagnosis
This was an emotive topic for parents, all of whom could remember being told that their child had cancer or leukaemia with horrible clarity. They were, however, able to distinguish between a ‘good’ diagnosis and a ‘poor’ one. These were differentiated by the time it took to get a positive diagnosis and how, where and by whom parents and their children were informed. Participating parents had experienced both speedy and slow diagnoses. Some felt these had been handled with professionalism and sensitivity while others described how ‘there were eight or nine doctors in the room’. However, parents also recognised their own important role in the treatment of their child’s cancer. One said:
‘The context of the diagnosis is not that important. It is still going to hurt however you are told. It’s who you are that defines what happens next.’

**Time taken**

In some cases children were diagnosed on the day that parents took them to their GP while some parents described how they had been made to feel overprotective or neurotic by GPs before they agreed to send them to hospital for blood tests. Many cited delays in the process of undergoing tests and receiving a diagnosis. One mother described how she was told her child was ‘lazy’ and suffered from glandular fever and had to wait over two months for a correct diagnosis. In some cases it took some time to be referred to specialist services for tests and results of blood tests were sometimes slow in being returned to the GP.

Although immediate diagnosis was a huge shock to some (but not all) parents, being taken seriously by a GP who acted quickly and decisively was much appreciated. In some cases, parents were intuitive and guessed that their child had a serious condition but others found it very difficult to take in because the child seemed so well.

**Rare conditions**

The experiences of the few participants whose child had a rare form of cancer were particularly painful. One mother waited 8 months for a positive diagnosis of her child’s cancer after ‘fighting’ for a second biopsy as the first one undertaken was inconclusive. Another parent who had experienced similar frustrations said,

‘I’m still mad at them. I still don’t understand why they couldn’t admit that they didn’t know and consult with more experienced doctors.’

**How parents and children were told about diagnosis**
All parents found the experience of being told about their child’s illness traumatic. It was described as ‘a bombshell’, ‘a bad dream’, ‘hits you like a ton of bricks’ and ‘the world falling away’.

Some parents described being told about their child’s illness in a private room with only one or two people present. This was preferable to being told in an open paediatric ward which some experienced but being asked to go ‘to a quiet room where we can talk’ implied bad news to parents. One parent said this was made more difficult by ‘the nurse following me in with a box of hankies’. At all sessions parents talked about the emotional shock they felt in trying to get to grips with the diagnosis (even if it had already been suspected). Some were told ‘straight’ and many struggled to understand medical terms which one father described as ‘Latin and Greek’. One described being ‘summoned into a room where the consultant was surrounded by staff who weren’t introduced’. There they were ‘told the science and sent out. It was really awful’. This was some time ago, however, and the parent thought things have now improved. Parents appreciated staff who were approachable and offered to explain things more than once and who seemed to understand that shock made it difficult for parents to take in the details of what they were being told.

Another parent described how distressed hospital staff themselves were to discover that her child had cancer. They knew the child well because he had another condition and were ‘upset for us’.

The early stages of treatment – which in many cases started immediately after a child was diagnosed – were also disturbing for parents. Parents described their shock at first going into the cancer ward where seeing ‘children with no hair, grey and ill’ helped them take in what they were dealing with. Even seeing the sign saying ‘Oncology’ was described as a shock.
Parents had a variety of stories to tell about how their children were told they had cancer. Many of the children were very young at the time of diagnosis and parents told them themselves but appreciated staff who explained medical procedures to their children. One parent was advised to tell her child herself. One mother, however, said that her child had been ‘stuck on a side ward and avoided’ because staff knew that she had leukaemia and were avoiding telling her – perhaps because they were waiting for a more senior member of staff to arrive. Play specialists and other staff helped to explain what having cancer meant to children using drawings, story books, teddies or dolls. In one regional centre, the support offered in how to tell a child was described as ‘great’.

Parents agreed that there is no ‘correct’ way of telling a child but that sensitivity, consideration and showing friendliness towards the child all help to make it easier.

**Information and the internet** (and see **Meeting information needs** on page 60)

Most parents were supplied with literature in the form of booklets from CancerBACUP and other organisations by hospital staff and found this useful although certain rare conditions were omitted from these publications. Many parents whose child had been diagnosed with cancer felt they needed as much information as they could absorb immediately in order to try to make sense of what was happening to them and surfed the internet to find out more. In some cases, medical staff discouraged them from using the internet, warning them that information available there might be inaccurate and anecdotal and that they might find themselves more distressed by an overload of information that they could not make sense of. In others, parents were encouraged to access particular sites which were recognised as reliable. Some staff offered to help parents interpret information they found. Some parents found information on the internet was useful while others were frightened by it. A mother whose child had
a rare condition was encouraged by the consultant to seek information from an American website which provided more detail than the equivalent British one.

**The role of other parents**

Some parents had found contact with other parents whose children had cancer unhelpful and even distressing at the time of diagnosis. They felt that these ‘experienced’ parents were too free with their (sometimes negative) advice at a point when they were unable to take in what was happening or too vulnerable to rebuff unwelcome approaches. Others, however, welcomed the support of other parents. One mother described other parents in the cancer ward as ‘helpful, supportive and nice’ and another parent said, ‘the most helpful thing was talking to other parents in similar positions’. One couple described how they found that advice from other parents was useful particularly in relation to making an application for Disability Living Allowance (DLA). Parents at all consultations did, however, say that they had felt that they had needed to be pushy on some occasions on behalf of their child and that their child (and not other people’s children) had to be their first concern.

**Practical and emotional support**

Some parents described practical support that was offered to them and their families at the time of diagnosis, particularly when treatment was urgent and based in another town. One mother appreciated the help of the chaplain in one hospital, for example, who rang her husband at work to tell him and offered a lift in his car. Some parents were offered advice about welfare benefits soon after their child’s diagnosis. The timing of this advice, however, was sometimes inappropriate. When parents were trying to come to terms with their child’s illness, they felt they could not cope with completing complicated forms.

Parents appreciated ‘little personal touches’ offered by staff which they felt made a difference to how they felt. They said they took comfort from the smallest examples of encouragement, kindness and ‘bits of hope’.
Key points regarding diagnosis

- GPs and Accident & Emergency (A&E) departments should be well informed about symptoms of childhood cancer. Staff at health clinics and A&E departments should take seriously and be responsive to parents’ concerns about their child’s health in order to aid early diagnosis. Parents do not want to be made to feel neurotic or paranoid by doctors.

- If staff suspect that the diagnosis will be cancer but it has not been confirmed, parents would appreciate some warning which might prepare them for a definite diagnosis.

- When staff tell parents about their child’s diagnosis, it should be done in a quiet, private place and there should be plenty of time available. Staff should be sensitive and honest and be prepared to answer questions. There is, however, no ideal or uniform way of ‘telling’. All circumstances and individuals are different.

- Staff should be willing to provide information more than once as parents find it impossible to take everything in immediately. They should expect parents to use the internet, suggest reliable websites to visit and be prepared to help them interpret information found there.

- Parents would value access to a telephone number in the period immediately after diagnosis which they could ring for help - medical, emotional or practical.

- Some parents wanted their child to be present and involved throughout the initial diagnosis and for staff to explain it to them in accessible language. Others – particularly those of very young children - felt they wanted to tell their child in their own way. Individual preference should be respected.

- Parents would appreciate some warning about what the cancer ward is like before going there for the first time.

- Many parents suggested that a parent ‘buddy’ system based in the paediatric cancer ward would be helpful, particularly because nurses are very busy and parents sometimes feel isolated. Parents whose child was
already being treated and who were willing could provide advice and support to those whose child was recently diagnosed. Parents of children who had been recently diagnosed would welcome the option to use such support but it should not be thrust upon them.

Hospital treatment and care

Location and access

Although some parents said they would prefer to use services that were closer to home than the nearest regional cancer centre, the majority also felt that care at the regional centre represented the ‘gold standard’ and preferred their child to be treated there. Regional centres were seen to have more staff in the oncology department and to have greater expertise in treating cancer patients. Some parents reported being prepared to travel much longer distances to ensure their child received the quality and continuity of care available at the regional centre despite the negative impact on other aspects of their lives.

Access to hospital services depended on where families live and, for those living far from regional care centres, could be difficult. One couple, for example, described the long drive from north Norfolk to Cambridge. Public transport is not a feasible option for children who are neutropenic and so access to affordable parking is important to families. One mother said she had no choice but to take her child to London via public transport regardless of the child’s blood count or health status. Parents raised concerns about parents who cannot drive or who do not have access to a car as the cost of taxis is high.

Some parents described having to leave home early for appointments in order to find a parking space which ‘added stress to an already stressful situation’. Parking half a mile away from the hospital was not feasible for a sick child so one parent would drop off the child and the other parent (and possibly siblings as well) and then find a space. Parking could also be expensive. Some security staff
allowed parents to park in the staff car park at one hospital but others were not prepared to waive the rules.

Parents in more than one centre said that outpatient appointments were not staggered and all patients were asked to arrive at nine a.m. This was difficult for those who lived far away who had to leave home very early and for all families because it meant travelling during rush hour.

Parents who had used hospital transport services had found them unsatisfactory. One reason is that transport is shared and parents are concerned about cross infection with other patients. There are also organisational problems. One mother described, for example, how she had used the ambulance service to go to hospital appointments an hour’s drive from home. She and her child had to wait to be picked up and then the journey was extended as other patients were collected from a wide area. The ambulance was then ready to pick them up for the return journey before chemotherapy treatment was completed and there were further delays on the way home. She had since started driving into town for appointments, having got a disabled parking badge which allowed her to park easily. However, she was embarrassed about using the badge when her child was well enough to walk feeling that she was somehow cheating the system. There was a perception from parents at another centre that different wards worked to different protocols on access to transport and this could lead to delayed discharge from hospital.

The hospital environment

There was little discussion of the environment as parents were more interested in discussing staffing and treatment. However, parents in one centre were unhappy with aspects of the environment at the regional centre. This was not a dedicated children’s hospital and they did not like the A&E department where at night there were ‘disreputable types’ in the waiting room. They also objected to having to walk past smokers who hang around outside the hospital and having to wait in
clinics with a neutropenic child where 'all sorts of bugs and germs were being spluttered about'.

Some thought there was not enough space in wards although the cubicle arrangement available in some hospitals was liked because of the space and the privacy provided. Parents at one session described the wards as very clean. The wide age range of children accommodated in the oncology ward was commented upon and it was suggested that there might be a dedicated space for teenage patients. Parents at one session said they would have liked access to showers in the hospital and others said they would like a dedicated resource room for parents where they could learn more about cancer and cancer treatment. Some parents had used a suggestion box located in the ward and thought this was a good idea.

**Getting a bed**

Most parents preferred their children to be treated at a regional cancer centre (particularly in the early stages of treatment) and, at the centres, wanted them to be accommodated in the cancer ward which they regarded as the right place for them. They valued the specialist care and the contact with other families facing the same issues and were concerned that treatment in other wards or hospitals was not of as good quality as that available in the paediatric cancer ward. Because of caseload sizes, however, it was not always possible for children to have a bed in the cancer ward and parents found this frustrating and, in some cases, were unhappy with the treatment received in other wards. They described having to wait hours in A&E (where their child was exposed to others’ coughs and colds) for a bed when a child was ill and then being disappointed when they were eventually allocated to a different ward. Some parents said it seemed that some families were able to go straight into a ward when a child was sick while others had to wait in A&E and wondered whether this was an issue of protocol or lack of communication. In one hospital, parents were also frustrated by the effect
the lack of beds or a bed booking system had on treatment plans. If a bed was not available, treatment was put off which meant that the plan was not followed.

Continuity of care

As noted above, parents wanted their child to be treated in the cancer ward at the regional cancer centre where they and their child had built up relationships with staff and were confident about the care available. Some felt that staff in other paediatric wards did not understand the needs of their child and some had been offended by comments from staff in other wards who implied that they thought cancer patients were given special treatment which was not ‘fair’. Some felt that other parents had not respected their ‘space needs’ and had generally felt uncomfortable in other wards. In some hospitals there simply is not the capacity to provide beds for all the paediatric cancer patients in specialist wards.

Parents said that the skill with which staff worked was an important aspect of treatment because if chemotherapy was administered well, for example, it caused less distress to a child than being carried out by someone who was inexperienced or clumsy. A shared understanding of policies and procedures for treatment by both staff members and parents was also highly valued by parents. Parents had had mixed experiences of care and treatment in shared care hospitals. Some felt that the nurses were not experienced or skilled enough in medical procedures and therefore did not inspire confidence in them or their children while others thought that shared care was well organised and that staff did have the necessary knowledge and would ring the regional centre for advice if necessary.

Parents reported hospitals having different protocols and techniques for, for example, changing a Hickman line and using different equipment (such as bungs) which caused distress to their children. They reported that the anti-emetic drugs offered to patients also varied between hospitals. Parents had experienced a variety of advice about bringing newborn siblings into the ward.
One mother said that she had been asked not to breastfeed her baby in the ward while another mother who attended another centre said breastfeeding had been welcomed.

Problems raised about the relationship between regional centres and their shared care partners included inflexible protocols that set down, for example, when a child with an infection had to be moved from one setting to another and poor communication and lack of note sharing between partners which resulted in parents – and in one case a child - having to take responsibility for knowing a child’s current medication needs. Appointments were sometimes double booked for the same reason.

One parent felt that there was some competition between staff at the regional centre and shared care hospital which was unhelpful. More than one complained about a particular surgical ward where it was felt that there was a lack of understanding of children’s needs and a reluctance to seek advice from specialist staff. According to one parent, this resulted in a child being left in pain for much longer than necessary.

Parents did not raise many instances of discontinuity in the specialist cancer ward although they preferred to see the same consultant which was not always possible. One said, ‘he is always away. We never see him’. Parents reported that at one hospital the staff rotation system meant that registrars left the ward with no warning which led to lack of continuity.

In general, parents reported that they and their children found discontinuity stressful. Reasons given for this were difficulties in finding their way around unfamiliar hospital buildings, having to build relationships anew and learn to trust new members of staff, having to ‘tell the story’ again and again and getting used to different protocols and ways of carrying out procedures.
Parental involvement in care

Parents reported having limited choices about treatment because of inflexible protocols. Some children had been offered the choice of using a Hickman line or a portocath but others had not.

Parents appreciated it when staff acknowledged their own expertise although, in some cases, they felt that information was not shared with them because it was assumed that they already knew everything. Sometimes they felt that it was difficult to get staff to listen to them because their knowledge was not recognised. One parent, however, said:

‘They tell us everything. We can’t fault it.’

Parents did not appreciate having to be responsible for informing staff about their child’s treatment. One mother described how, when her child was facing liver failure, a doctor asked her, ‘how big is his liver normally?’ Another was asked by a nurse with regard to medication, ‘have I made this up right?’.

Although parents did become well informed about their child’s care and were accustomed to monitoring machines, etc., most did not actually take responsibility for administering medication. One mother had been trained to take blood and administer chemotherapy and antibiotics by staff as her very young child was resistant to being treated by anyone else and other parents present admired her for taking such an active part in her child’s care. They had not, however, been offered the same opportunities. Another mother had been asked to contribute to induction training for new staff at one of the regional centres and, although she was nervous about addressing a large group, appreciated being asked for her perspective and felt that the views of parents were valued.
**Relationships with staff**

In general, both mothers and fathers reported having good relationships with members of staff although they agreed that to some extent these depended on personalities and that there was an element of individual preference in developing relationships. In some cases, they felt dependent on a particular person, often a consultant, whom they felt could 'make things happen' when there were problems with their child's care. They trusted staff who were honest about their child’s condition and appreciated the kindness, friendliness and thoughtfulness of nurses who would take time to comfort them if they were upset. One parent also said that hospital cleaners were also friendly and supportive to families and another described how staff were ‘brilliant’ when she was pregnant. Another mother said that as she got to know the personalities, ways and skills of different members of staff she was able to use this knowledge to her child’s advantage – for example, she knew that the community nurse was more confident with a portocath than the hospital nurse and so made sure that she was the one to look after it.

Skills in actually treating children were valued and parents reported good treatment in some hospitals. They were not happy with trainee doctors 'poking around' in their attempts to insert a cannula. They felt that the child – who has become familiar with how procedures are carried out - should be listened to more. One parent said that her three year-old child had told a doctor to wash his hands before touching her line! The example of a consultant who had put in a cannula himself was unusual and welcomed by both parent and child.

Some had experienced rudeness and incompetence from doctors and nurses and thought that some nurses had showed favouritism towards some children and families. Others felt that their own knowledge and the fact that they were acting as advocates on behalf of their children had a negative effect on their relationship with doctors. One described being devastated when 'people don't listen and you have to fight to be heard'. Doctors’ communication style could
worry parents – one wondered, ‘what does it mean when they just shake their heads?’ Others talked about the ‘mega-egos’ of some medical staff in teaching hospitals while others said they had not experienced egotism nor had they felt there were imbalances of power between staff and families. One, for example, was reassured by being given the mobile phone number of her child’s consultant.

Relationships with staff may depend on how the child’s treatment is progressing. One parent said that the attitude of staff might change if the child is not responding as expected and that this might create a barrier between staff and parents. Others had learned that less senior doctors erred on the side of caution about, for example, sending a child home whereas a more experienced doctor would consider all the child’s needs and make a decision based on those. A holistic approach to caring for the child which takes into account his or her wish to lead a ‘normal’ life and family circumstances was welcomed.

**Hospital facilities**

**Food**

The choice, quality and cost of food available for both child patients and other family members were all raised by parents. As families had to travel to the hospital and, in many cases, stayed there, it was not possible for them to eat at home. Food was expensive in hospital and there was no discount available for inpatients’ families and, because regional centres were based in town centres, it was not always easy to find a suitable shop to buy reasonably priced food.

Parents were concerned about the quality of the food provided for children saying that it was hard to provide a healthy diet. They also found it difficult to eat with their children without complicated organisation. They welcomed the snack trolley where this was available in the ward. Parents reported some positive experiences of staff being prepared to get hold of a particular food that a child craved outside normal eating times.
Parents complained that in one hospital the parents’ kitchen was not conveniently located or secure and food was taken by others. The kitchen was not well-equipped or clean and no one took responsibility for it. Canteen facilities were also criticised for dull, badly prepared food although parents who had stayed at another hospital would have welcomed a canteen as there was only a snack bar which closed in the early afternoon. One mother said that she always brought food with her to hospital or went out to get it locally and found that the limited opening times of restaurants sometimes posed a problem.

The lack of easy access to cold drinking water was mentioned by parents at more than one session.

**Telephone**
Access to a telephone was a problem for some parents. The patients’ phone service – Patientline – was described as good but expensive and not available by the child’s bed. Some parents found phones by the beds where they could receive incoming calls only a better and more useful facility. In another hospital, phones were not available in the ward. Parents used the nurses’ phone because the pay phone was outside the ward and felt that this arrangement was not ideal.

**Accommodation for parents**
There was little discussion about the availability and quality of accommodation for parents. One mother described how she shared her child’s bed which was the child’s wish. Although she enjoyed privacy she was woken in the night by nurses checking the equipment. Others had appreciated family accommodation provided close to the hospital.

**Play facilities**
Parents appreciated play therapy and play facilities and talked about ‘wonderful’ play workers. Some, however, said that playrooms were not open at weekends and, in some hospitals, toys were ‘tatty’ and broken especially those available on
other wards (i.e. not the cancer ward). One mother explained how they brought their own toys into the hospital. Parents whose children were very young at diagnosis said there were few toys available for this age group as did those whose children were aged between eight and 12. Parents thought that there were not enough Playstations or computers.

*Hospital education*

Many of the children who attended the consultation were very young and so had not been taught in hospital. At one session, mixed views were expressed about the necessity of specialist hospital teachers. It was felt that flexibility was important in assessing individuals’ circumstances, capabilities and needs. Some parents felt that teachers had been too forceful in encouraging children to take part in lessons when parents felt they were too ill. One father said that he felt the teaching offered to his child was inappropriate given her age and condition but that it was offered in a friendly way.

Despite thinking that school work was offered initially when her son was too ill, the mother of an older child felt that education was of value as his health improved and that teachers and work engaged him which was a good thing. Liaison between the specialist nurse and secondary school was helpful when he returned as staff and students were informed about his illness (and his hair loss) and could anticipate his needs. A simple arrangement like being allowed to wear a hat in class made the return to school easier.

As there were few older children participating in the sessions, there was little discussion of school/hospital liaison. One family, however, described their child’s school as ‘useless’ because staff there would not make contact with hospital school staff and another father said that his child had got behind at school because of illness but did not blame the hospital for this. It was also thought important that children kept in touch with their peers and this could be done through internet messaging.
Outpatient services
As noted above, outpatient appointments may be preceded by an early start, a long drive and frustrating parking. This might be followed by a long wait in a busy, cramped clinic. Not surprisingly, parents described outpatient appointments as stressful. Some did not understand the appointment system which seemed to book all patients at nine o’clock in the morning. Others said a new system with staggered appointments was being tested at one hospital but that it had not yet made a difference to waiting times. In some cases parents had been asked to arrive at the clinic as early as seven a.m. although their child was not treated until midday. This was seen as a particular problem if the child was not allowed to eat which happened when they were told that ‘procedures’ would be carried out before treatment. Delays can also occur because medical notes have not been updated.

In some hospitals there was a day unit attached to the ward and this was seen as a good idea. Parents would appreciate somewhere for children to play while waiting.

After the clinic appointment many had experienced waiting for hours for medication to arrive from the pharmacy. Parents thought that doctors did not realise how long this could be. One hospital had a pharmacy in the oncology department and medication was provided more quickly.

Key points regarding hospital care
- Access to free or affordable parking at or near the regional cancer centre.
- Better organised hospital transport.
- An appointment system which takes journey time into account and which does not mean long periods of waiting.
- More capacity at regional centres so that children can be accommodated on the specialist ward.
• A speedy, consistent and clear system for referring ill children to specialist wards.
• Parents would like access to showers in hospital and a dedicated resource room for educational and social purposes.
• Consistent quality of care across all hospital services including general paediatric wards.
• Consistent protocols for treatment across services.
• Opportunities for parents to be involved in children’s treatment when appropriate.
• Staff to respect children and treat them accordingly by listening to them, consulting them and taking account of their wishes.
• A range of good quality, affordable hospital foods available to patients and their families. Some flexibility about mealtimes for children undergoing chemotherapy and other treatments. Ward snack trolley welcomed.
• Easy access to an affordable telephone service.
• Play equipment for a wide range of age groups.
• Sensitive, age appropriate teaching and access to educational resources including computers and the internet.
• Effective hospital/school liaison where appropriate.
• Quicker pharmacy service for both outpatients and inpatients.
• Parents appreciated the opportunity to talk about the care their child had received and suggested that more consultation days across the country should be organised which would bring together hospital management staff and parents.
• Suggestion boxes on wards were thought to be a good idea.

Meeting information needs
Parents said they wanted information about ‘everything’ although they were sometimes frightened by what they learned. Parents learned about cancer and its treatment from the consultant, community nurse, CancerBACUP, the UKCCSG, the internet and voluntary groups such as the Leukaemia Research Fund. They
had received booklets and fact sheets produced by CancerBACUP when their child was first diagnosed. Parents reported that sometimes information (for example, about the time scales for disease development) provided was not consistent. They were, however, positive about the way professionals explained their child’s condition and treatment to them. Parents whose child had a rare condition were more likely to feel frustrated with the amount of information available to them.

Parents felt that they were less well informed about the emotional needs of their children and siblings and the need for emotional support for themselves. Some said they had not been told what the side effects of radiotherapy might be.

Accessing information from the internet was seen as both positive and negative. Although some parents had come across misleading information which they felt was potentially dangerous, those whose children had a rare condition found the internet particularly useful. Parents at one session suggested hospitals provide a parents’ resource room where parents could access selected websites. This could also be used as a library of information and a place where parents could meet each other informally.

Initially parents felt that professionals were willing to provide as much information as they were able to take in – and repeat it if necessary - which they found helpful. However, a number of parents felt that as their child’s treatment progressed and they themselves became involved with the child’s health care, information was withheld from them because it was assumed that they were experts themselves and no longer needed it. They also felt that they were told bad news but were less likely to be informed when treatment was progressing well. They found it hard to ‘read’ blood or bone marrow test results because they did not have baseline information to compare them with so did not know if results were normal or not.
It was felt that information should be available at transitions in treatment and that perhaps there could be checklists available to help normalise adjustments to new aspects of treatment. Parents could be helped to support their child by being well informed about what was going to happen next.

The extent to which parents were provided with information about medication varied and it was felt that this should be consistent across centres. Parents felt they needed to know what effects to expect from medication so that they could effectively monitor their child’s response. Some hospitals provided all parents with a loose leafed book which included useful telephone numbers, treatment plans and details of medication. These included sections that could be updated over time (such as blood test results) as well as space to record feelings and note down questions. The book was much appreciated and well thumbed copies were passed around.

Some parents felt that their own knowledge had had an effect on how they were treated by staff. One mother who was training to be a midwife felt that her medical knowledge had a positive effect as did another whose mother worked in an oncology department. Another, whose child had a rare disorder and who had to ‘push’ for a diagnosis, felt that her specialist knowledge gained from her own work was not respected or welcomed by staff.

Information for children
Parents felt that there was a lack of written information for children and siblings. The parents of children who had leukaemia were provided with (or given information about) a storybook but there was not something similar for other types of cancer. Parents also said that a book on having a ‘wiggly’ (central venous line) was helpful but that books on other aspects of treatment such as anaesthesia would be useful. Members of staff who drew pictures and took time to explain to children in simple language what was happening to them were valued.
**Sharing information**

Children were seen by a number of health professionals both in the regional centres and shared care hospitals. Parents reported lack of communication and information sharing between professionals in different departments, wards and hospitals and described this as both frustrating and potentially dangerous. They described how medical notes and X rays had been lost and it was perceived that professionals ‘don’t talk to each other’. It is not possible, however, for parents to hold a copy of medical records as these are simply too big.

Parents thought that it was important that GPs were kept informed about a child’s treatment which did not always happen. They felt that GPs could advocate on behalf of families when necessary and that, because childhood cancer had an effect on the whole family, GPs should be kept up to date with a child’s progress.

It was also suggested that information and support should be available for other family members which would help take the burden of continually having to share information. It would be helpful if grandparents, for example, could access information from professionals.

Parents felt that there should be wider understanding of childhood cancer and its effects which might mean that in general people would be more understanding.

**Death**

Parents said that it was very difficult for all families when a child died on the ward. They felt that this was exacerbated by staff avoiding talking about it. They thought that this information should be shared sensitively and then parents would be able to talk about it without feeling that they were not allowed to.
Key points regarding the provision and sharing of information

- A wide range of information available on all aspects of childhood cancer including medical, treatment, medication and its effects, emotional, practical and financial.
- Opportunities to ask questions and have information repeated.
- Advice on reliable websites and how to use information from the internet effectively.
- Regular updates on child’s progress.
- Interpretation of information about treatment and sharing of positive progress with parents.
- Information in advance especially at points of transition (e.g. before changes in treatment regime).
- Consistent information about medication and its effects.
- More written information for children and siblings including storybooks for very young children.
- Acknowledgement and respect for parents’ own knowledge and skills.
- Clear lines of communication between professionals across departments, hospitals and community services including GPs.
- Information available for other family members such as grandparents.
- Wider understanding of childhood cancer.
- A sensitive approach to sharing information about the death of a child.

Community and home care

There was wide variation in participants’ experience of receiving home care. Some families had not been assigned a community nurse while others found home services hugely valuable. One mother said she had not used the community service until the end of her child’s treatment because she did not know about it. Others had had few visits from a specialist outreach nurse because they lived so far from the regional centre.
CLIC and Macmillan nurses and the ‘Diana team’ were described as providing excellent services. They treated children at home, liaised with other services such as physiotherapy, offered practical advice to parents, helped access equipment and visited schools to discuss children’s health with school staff and fellow students. One mother received support with antenatal care when she was struggling to cope with spending time with a child in hospital and attending appointments herself.

These nursing teams were described as having ‘emotional intelligence’ which was defined as being understanding, approachable, actively sympathetic and working well together as a team. These qualities were highly valued by parents.

Parents reported a range of experiences with GPs too. As noted above, they felt that GPs should be kept ‘in the loop’ with information about their child’s health, treatment protocol and progress and some valued GPs’ role in caring for the whole family and for advocating on their behalf when they experienced problems. Some parents, however, preferred hospital care as they felt ‘safer’ in secondary care than they did with non-specialist services.

**Key points regarding community and home care**
- Consistency in the availability of home care services.

**Family support**
Parents talked about the huge effect cancer and cancer treatment has on the whole family and how normal life is put on hold for the period of treatment. Some suggested that parents need support to make decisions about all aspects of their lives including work, finance and other practical issues as they are so overwhelmed with immediate concerns. Sometimes they felt they needed to be reminded that there is life outside the hospital.
**Benefit advice**

The availability of advice about welfare benefits was raised at all sessions. In many cases parents felt that they had not been well informed about their eligibility for Disability Living Allowance (DLA), travel allowances and special equipment or, if they had, the advice had been offered at an inappropriate time. Many had received the most useful advice from other parents who had already made an application for benefits. There was inconsistency about the availability of professionals able to provide help with form filling and a feeling that the application process was a lottery. The advice of Sargent social workers was welcomed but these were not available at all hospitals. Nurses in some areas were willing to fill in forms but not all were well informed about how to make a good case.

Parents who had been refused DLA and then reapplied felt humiliated by having to ‘prove’ how ill their child was. One family had approached the Citizens Advice Bureau because there was no advice available at the hospital.

**Siblings**

Parents said that there were few services provided for siblings. Some said they would like siblings to have the opportunity to talk to each other. They also wanted advice on behaviour management for their child’s siblings. One hospital provided outings for siblings of children who were undergoing treatment and this was much appreciated.

**Voluntary groups**

One couple said they were involved with a local support group for families and set up by parents. The group raised funds to help with equipment (including pushchairs), parking costs, etc.

**Stress**

Parents talked about the stress of having a child with cancer. This is caused by constant worry as well as the practical issues of spending most of the time in
hospital while also caring for other children. They said that financial difficulties and pressures from employers exacerbate stress.

There seemed to be regional variations in the availability of social work and psychological support. Some parents were uncomfortable about using social work services because of the stigma it implied for them. It was suggested that hospital social workers are given another title. One mother said she found seeing a psychologist essential while others had not been offered a service. However, parents reported that nurses provided support although they did not always have time. Parents in one hospital had taken part in research on stress and how families cope with childhood cancer and felt that the needs of all family members should be taken into account.

Parents talked about the difficulties they faced. One said she felt like she was permanently living under a cloud. One hospital provided aromatherapy massage sessions for parents one day a week. These were appreciated for giving parents the opportunity to relax but they also liked feeling they were being given ‘permission’ to take a break from caring for their child. Others had been offered antidepressants by GPs when they felt that what they needed was time to themselves (just to cry or think) and practical support such as child care for their other children, help with housework and someone to talk to.

**Key points regarding family support**

- Consistent, freely available advice about welfare benefits and access to specialist equipment.
- Support for siblings of children with cancer which could include opportunities to meet each other.
- Easy access to psychological and family support.
- Sensitive, flexible support which could help with practical solutions, emotional support or financial advice.
9. Conclusion

One of the most significant issues raised by the consultation was the difference in quality of services perceived by participants between services available at regional cancer centres and shared care hospitals. This was mentioned by many (but not all) children and parents who both expressed their preference for the care received in regional centres. Parents were prepared for the extra travelling involved in attending a regional centre despite the difficulties this caused but both children with cancer and their siblings were unhappy that the hospital was far from home. The reasons that participants preferred the regional centres were because they felt that staff were better informed and that treatment was more effective and less likely to be painful than in shared care. They also appreciated the resources available and culture of care developed at these centres which included the advice of experienced consultants and senior nurses and support from social workers and psychologists. The specialist nature of the centres means that participants felt they were getting ‘the best’ services and, having experienced it, were disappointed by the quality of care on offer elsewhere. It may also be that they were initially referred to the regional centre after diagnosis and preferred not to use other services for less tangible, more emotional reasons. One mother, for example, said that her child was not known by name on general paediatric wards either in the regional centre or in her local shared care hospital.

Although children and their parents were positive about the care they had received in general and many were full of praise for hospital staff, another finding of the consultation was that staff sometimes fail to take children’s views into account. As can be seen from the consultation’s findings, even very young children have an acute awareness of what is going on around them and how they are being treated and young cancer patients should be given the opportunity to discuss their needs and feelings with staff as well as to be informed about their illness, treatment and how it will affect them. Parents’ knowledge of their
children’s condition and their skills in caring for them should also be acknowledged and valued by staff and they too should be informed about all aspects of their child’s treatment and care so that they can actively co-operate with it.

Children at all consultation days said that they get bored in hospital and wanted more and better entertainment. They wanted toys, games and books as well as electronic equipment including Playstations, DVD players and television. Play specialists were much appreciated by children and parents for providing both opportunities for play and accessible information about cancer and cancer treatment to young patients. Participants said that school work had not been appropriate for their age and ability and would prefer to be challenged more by hospital teachers. Parents felt that schools could do more to liaise with hospital staff to support the education of children in hospital.

Food was mentioned by both children and parents. Some complained that hospital food was not to their taste and poorly prepared while parents found eating in hospital could be expensive or difficult because of lack of catering facilities. Children wanted a range of different foods with some flexibility about mealtimes and the opportunity to eat with family members at least some of the time.

Children with cancer, their siblings and parents want consistent, detailed and accessible information about cancer and cancer treatment and for this to be available to siblings and other family members. Children wanted more understanding about cancer amongst peers and the general public in order to normalise their experience as much as possible. Effective hospital/school liaison would support this. Parents’ lives are completely changed when their child is diagnosed with cancer and they need access to financial advice as well as practical and emotional support and community health services. Although these are provided in some areas, participants reported that these were not consistent.
Some had had no access to any of these services while others praised them for their helpfulness.
Glossary of terms

A&E: Hospital Accident and Emergency department
DLA: Disability Living Allowance
GDG: Child and Adolescent Guidance Development Group
NCC-C: National Collaborating Centre for Cancer
NICE: National Institute for Clinical Excellence
## List of appendices

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appendix A</td>
<td>Recruitment flyer</td>
</tr>
<tr>
<td>Appendix B</td>
<td>Programme of activities for children aged 2-4 years</td>
</tr>
<tr>
<td>Appendix C</td>
<td>Programme of activities for children aged 5-8 years</td>
</tr>
<tr>
<td>Appendix D</td>
<td>Programme of activities for children aged 9-11 and 12-14 years</td>
</tr>
<tr>
<td>Appendix E</td>
<td>Programme of activities for siblings</td>
</tr>
<tr>
<td>Appendix F</td>
<td>Programme for parents</td>
</tr>
<tr>
<td>Appendix G</td>
<td>Questionnaire for parents of very young children</td>
</tr>
<tr>
<td>Appendix H</td>
<td>Report for children and young people</td>
</tr>
</tbody>
</table>

* All Appendices are available from the NCC for Cancer on request.
Appendix E

Teenage Cancer Trust Conference 2004

Analysis of Teenage Cancer Patient Questionnaire Responses

The following is a summary of the responses to an electronic questionnaire carried out at the TCT Conference in 2004.

Demographics

There were up to 271 Teenage and Young Adult (TYA) respondents, aged 14 to 23; 71% of which were 14 to 18 years old, with 49% male and 51% female (n=271).

22% were 12 or less and 68% were 13 to 18 years old, at start of treatment (n=203).

12% came from Scotland, 33% from the North of England, 26% from the Midlands and 15% from the South East and London. There were few respondents from the South West and Wales (n=261 total).

Diagnosis

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphoma</td>
<td>14%</td>
</tr>
<tr>
<td>Hodgkins</td>
<td>13%</td>
</tr>
<tr>
<td>Leukaemia</td>
<td>30%</td>
</tr>
<tr>
<td>Bone cancer</td>
<td>21%</td>
</tr>
<tr>
<td>Brain cancer</td>
<td>11%</td>
</tr>
<tr>
<td>Testicular cancer</td>
<td>2%</td>
</tr>
<tr>
<td>Skin cancer</td>
<td>0.5%</td>
</tr>
</tbody>
</table>
Bowel cancer  1%
Soft tissue sarcoma  4%
Rhabdomyosarcoma  3%
Breast cancer  0.5%
Cervical cancer  0.5%  (n=205)

N.B. The incidence of these distributions should be qualified by the likelihood of survival to becoming a TYA from diagnosis, particularly with brain tumours.

**Referral and Treatment**

**Question:**  *Did you visit your GP and, if so, how many times before they referred you to the hospital?*

<table>
<thead>
<tr>
<th>Visits</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-2 times</td>
<td>43%</td>
</tr>
<tr>
<td>3-5</td>
<td>28%</td>
</tr>
<tr>
<td>More than 5</td>
<td>29%  (n=193)</td>
</tr>
</tbody>
</table>

17-40% (mean=29.7%) of patients approximately evenly across the age range 14-22 required more than 5 GP visits before referral, with 64% (n=11) of 23+ year olds.

16-35% of haematological cancers require more than 5 GP visits, with considerable variation between leukaemia and Hodgkin's lymphoma. E.g. only 15.8% (n=57) of leukaemias are diagnosed with more than 5 visits, as opposed to 34.6% (n=26) of Hodgkins. Furthermore, 52.6% of leukaemias, but only 26.9% of Hodgkins are diagnosed within 2 visits. Lymphoma (n=25) shows intermediary data.

60% (n=15) of brain tumours, 31% (n=39) of bone cancers, 43% (n=7) of sarcomas and 40% (n=5) of rhabdomyosarcomas, require 5 or more visits. In
addition, only 20% of brain tumours, and 26.9% of Hodgkins, are referred within 2 visits, compared to e.g. 40% of lymphoma and 57.1% of sarcomas.

There is little variation between areas of the country.

*Interpretation:* Childhood cancers, especially Hodgkins lymphoma, brain tumours and sarcomas, are slow to be identified in primary care.

**Question:** Were you on your own (12%) or with a parent (88%); n=205.

**Question:** How long after you first visited hospital did it take for someone to tell you that you had cancer?

<table>
<thead>
<tr>
<th>Time Period</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 2 weeks</td>
<td>60%</td>
</tr>
<tr>
<td>3-4 weeks</td>
<td>14%</td>
</tr>
<tr>
<td>1-2 months</td>
<td>14%</td>
</tr>
<tr>
<td>3-5 months</td>
<td>5%</td>
</tr>
<tr>
<td>6-8 months</td>
<td>3%</td>
</tr>
<tr>
<td>Longer</td>
<td>5%</td>
</tr>
</tbody>
</table>

(n=212)

80% of 14 year olds know they have cancer within two weeks of visiting the hospital.

25-68% of 15+ year olds know within 2 weeks.

80% of leukaemics know within 2 weeks, but only 25-57% of lymphomas, Hodgkins, bone, brain sarcomas know in 2 weeks.

Generally, 48-62% of patients in the areas know within 2 weeks, with some areas reaching 82-100%.
40% of brain tumours, 33% lymphoma, 34.6% Hodgkins and 25% of bone cancer patients know in more than 4 weeks, with leukaemia at only 10% not knowing within 4 weeks.

Patients knowing in more than 4 weeks varied from 15.4% in London and Home Counties, to 43.3% in the North East.

*Interpretation:* There is wide variation in time to confirmed diagnosis of most childhood cancers in secondary care, both in respect to cancer type and area of the country.

**Question:** Who told you that you had cancer?

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>GP</td>
<td>6%</td>
</tr>
<tr>
<td>Hospital Doctor</td>
<td>70%</td>
</tr>
<tr>
<td>Nurse</td>
<td>3%</td>
</tr>
<tr>
<td>Mum</td>
<td>15%</td>
</tr>
<tr>
<td>Dad</td>
<td>6%</td>
</tr>
</tbody>
</table>

(n=212)

Hospital Doctors inform the patient they have cancer 54-83% of the time, with Mum the next frequent, particularly with leukaemia and brain tumours (24 and 36% respectively).

**Question:** Were you told you had cancer before or at the same time as your parents?

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>10%</td>
</tr>
<tr>
<td>After</td>
<td>40%</td>
</tr>
<tr>
<td>At the same time</td>
<td>50%</td>
</tr>
</tbody>
</table>

(n=214)
**Question:** Once they told you that you had cancer, how long was it before you started treatment?

<table>
<thead>
<tr>
<th>Duration</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-2 days</td>
<td>32%</td>
</tr>
<tr>
<td>3 days - 2 weeks</td>
<td>44%</td>
</tr>
<tr>
<td>3 weeks – 2 months</td>
<td>20%</td>
</tr>
<tr>
<td>3 – 4 months</td>
<td>2%</td>
</tr>
</tbody>
</table>
| Longer                 | 2%         | (n=207)

13-25% (mean= 16.4%; n=137) of patients aged 14-18, started treatment more than 2 weeks after diagnosis; compared to 8-50% (mean= 36.3%; n=58) of 18+ year olds.

Only 6% of leukaemias had not started treatment within 2 weeks, compared to 20-38% of other cancer types.

Scotland, NW England, NE England, E Midlands, London and South England had between 17 and 34% of patients not starting treatment within 2 weeks of diagnosis, whereas in other areas, between 0 and 9% are not treated within 2 weeks.

**Interpretation:** There are a significant proportion of patients who do not start treatment within 2 weeks, especially in the 19 to 23+ year olds, and this varies from area to area.

**Question:** After you were told that you had cancer, how much help did you get to help you understand what was happening?

<table>
<thead>
<tr>
<th>Help Received</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Everything I needed</td>
<td>48%</td>
</tr>
<tr>
<td>A bit more than I expected</td>
<td>15%</td>
</tr>
<tr>
<td>What I expected</td>
<td>20%</td>
</tr>
<tr>
<td>A bit less than I expected</td>
<td>12%</td>
</tr>
</tbody>
</table>
| Little or nothing                  | 5%         | (n=204)
**Question:** What choices, if any, were you given for treatment options?

- All choices were given: 19%
- Some choices were given: 25%
- No choices were given: 56% (n=206)

No choice was given in 39-67% of 14-18 year olds, and in 25-86% of 19+ year olds.

Between 33% (rhabdomyosarcoma) and 62% (bone cancer) of tumour types offered no choice of treatment.

Across the health regions, between 30 and 67% of patients had no treatment choices.

**Interpretation:** There is considerable limitation of choices of treatment in childhood cancers.

**Question:** Did you have the choice of entering a clinical trial?

- Yes: 43%
- No: 57% (n=197)

40-66% (mean= 53.1%) of 14-18 year olds did not have the choice to enter a clinical trial, with 25-86% (mean=64.3%) of 19+ year olds.

48% (bone) to 84% (brain) of patients were not offered a clinical trial.

Variation was essentially independent of the area of the country.

**Interpretation:** The availability of trials for TYAs is/has been variable.
**Question:** Did you feel that you were involved enough in making decisions about your treatment and any options that were open to you?

- Always 24%
- Most of the time 29%
- Some of the time 24%
- Not much of the time 13%
- Never 11% (n=208)

Between 34 and 75% of all ages were involved all or most of the time in decision making about treatment.

There was little variation across cancer types ranging from 45 to 62% being involved all or most of the time.

There was little variation across areas of the country (43-69%).

**Question:** What type of treatment did you have?

- Chemotherapy 32% (n=202)
- Surgery 28% (n=173)
- Radiotherapy 16% (n=98)
- Other 25% (n=157)

**Where treated**

**Question:** Where did you receive most of your treatment?

- A Main Cancer Hospital 49%
- A Local Hospital only 13%
- A Main Cancer Hospital and a Local Hospital 38%
36-48% (mean= 41.7%; n=132) of 14-18 year olds were treated at both a local hospital and a main cancer hospital, with 40-70% (mean= 24.1%; n=58) of 19+ year olds being treated at a main cancer hospital only.

29-65% of all cancer types, with 29.1% Hodgkins, 30.9% bone, 42% leukaemia and lymphoma and 65% brain, being treated in both local and main cancer hospitals.

Scotland, NW England, E Midlands, E Anglia, South Wales and London and Home Counties had 26-35% patients treated in both local and main cancer hospitals, whereas NE England, W Midlands and North Wales had between 50 and 64% of patients treated in this way.

**Interpretation:** There is considerable variation in providing shared care treatment, based on cancer type and area of the country.

**Question:** When you were in hospital for your treatment, were you usually treated on a:

- Children's ward 53%
- Adult ward 11%
- TCT ward or other adolescent unit 22%
- Children’s ward and adult ward 2%
- Children’s ward and TCT or other adolescent ward 6%
- TCT ward and adult ward 6% (n=208)

**Question:** Was the Cancer Centre ward or day care facility that you were treated on suitable for a person of your age?

- Completely 38%
- Mostly 26%
- Partly 20%
- Hardly 12%
- Not at all 4% (n=194)
Across all ages, the ward was completely or mostly suitable for between 50 and 70% of patients.

Hodgkins and rabdomyosarcoma (42 and 40% respectively) were completely or mostly suitable least, with lymphoma (55%), leukaemia (60%), bone (81%), brain (70%) and soft tissue sarcoma (71%) suitable all or most of the time.

Regional suitability all or most of the time varied between 39% and 46% (E Midlands and E Anglia) to 70% (W. Midlands) and N and S Wales 100% suitable all or most of the time, with other areas in this last group.

**Interpretation:** There is considerable variation in suitability of treatment facilities for TYAs and at least 30% of TYAs are treated in facilities that are less than suitable.

**Question:** If you received any of your treatment at a local hospital, was the ward you were treated on suitable for a person of your age?

<table>
<thead>
<tr>
<th>Response</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Completely</td>
<td>25%</td>
</tr>
<tr>
<td>Mostly</td>
<td>18%</td>
</tr>
<tr>
<td>Partly</td>
<td>18%</td>
</tr>
<tr>
<td>Hardly</td>
<td>18%</td>
</tr>
<tr>
<td>Not at all</td>
<td>22% (n=159)</td>
</tr>
</tbody>
</table>

Between 30% and 50% of local hospitals were ages suitable for all or most patients, with 17 to 86% of 19+ patients treated on suitable wards.

Between 20% (Hodgkins) and 57% (bone) of local hospitals were suitable all or most of the time.
In most areas, local hospitals were suitable all or most of the time for 34% to 50% of the time, but North Wales (100%), S Wales (0%) and South England (17%) were outliers for suitability of local hospitals.

**Interpretation:** There is considerable variation between local hospitals in suitability for some cancers and in some areas of the country.

**Question:** When you received your treatment, did everyone on your ward have cancer?

- All 56%
- Mostly 30%
- Partly 9%
- Hardly any 4%
- Only you 1% (n=193)

Between 79% and 100% of patients of all ages were treated on wards that had only, or mostly cancer patients.

All tumour types were at least 86% cancer patients on the ward, except brain (65%), soft tissue sarcoma (66%) and rabdomyosarcoma (80%).

Most areas of the country had over 92% of patients on cancer or mostly cancer wards, except Scotland (68%) and London and Home Counties (79%).

**Interpretation:** There are outliers in terms of cancer type and region, in the inclusion of non-cancer patients on the same treatment wards.
**Question:** How long would you be prepared to travel for your treatment?

- Up to a couple of hours: 37%
- Half a day: 8%
- A day: 3%
- Travel needing overnight stay: 3%
- Any distance any time: 50% (n=189)

**Question:** If you had a choice about the environment you were treated in, where would it be?

- Adult ward: 10%
- Teenage and Young Adult ward: 90%
- Children’s ward: 9% (n=201)

**Question:** Were you treated in a single sex area?

- Yes: 17%
- No: 83% (n=190)

**Question:** Which would you prefer?

- A single sex area: 8%
- A mixed sex area: 92% (n=200)

*Interpretation:* TYAs prefer mixed sex wards.

**Support and Information Needs**

**Question:** During your treatment, has there been a particular member of staff that you could confide in about your treatment and any concerns you had?

- Yes: 87%
- No: 13% (n=191)
**Question:** What was there role?

- Activity co-ordinator: 7%
- Cleaner: 4%
- Doctor: 13% (0-27% across the age range)
- Specialist nurse: 23% (9-67% across the age range)
- General nurse: 31% (14-53% across the age range)
- Physiotherapist: 1%
- Play therapist: 5%
- Religious representative: 1%
- Social worker: 7%
- Teacher: 1%
- Other: 1%
- None: 8%

Psychiatrist, Psychologist, Radiographer and Volunteer did not score.

**Interpretation:** Nurses are key communicators and supporters of TYAs with cancer.

**Question:** How important was it to have a staff member to help you stay occupied with activities, education and interests?

- Essential: 28%
- Very important: 29%
- Quite important: 26%
- Not that important: 12%
- Unimportant: 5% (n=185)

**Question:** Was the written or audio information given to you about your cancer easy to understand and suitable for your age?

- Aimed at people older than me: 27%
- Aimed at people my age: 55%
- Aimed at people younger than me: 18% (n=172)
Between 53% and 70% of 14-17 year olds thought the information was directly suitable for their age, with between 20 and 57% of 18+ year olds recording similarly.

Over 57% of most cancer type information was considered suitable for the patient’s age, except for testicular cancer and soft tissue sarcoma where the direct age suitability was 33% for both, and more suitable for older patients.

The level of suitability of the information for the patients in the areas of the country was between 46 and 75%, with Scotland at 35% and South England 83% as outliers.

**Fertility Counselling**

**Question:** Were you provided with fertility counselling?

- Yes 34%
- No 66% (n=184)

**Question:** If counselling was given, was it?

- Before treatment 29%
- During treatment 38%
- After treatment 33% (n=100)

**Question:** Were you satisfied with the counselling?

- Yes 52%
- No 48% (n=110)

**Question:** Were you told about the risks to your fertility before you started treatment?

- Yes 64%
- No 36% (n=171)
Interpretation: The majority of TYAs did not receive fertility counselling, and when they did, it was not consistent in terms of timing and quality. If this is a reflection of the provision of fertility support and treatment, then it is far from satisfactory in all respects.

**Life Issues**

**Question:** What is the most challenging issue you face with cancer today?

- Communicating about my illness 20%
- Returning to school 16%
- Dealing with my appearance 26%
- Managing the side effects of cancer 38% (n=183)

30.7% of leukaemics, with 52.2% of lymphomas, as opposed to 40.9 to 45.7% of Hodgkins, bone and brain, cited managing the side-effects of treatment as the most challenging issue.

Interpretation: Late effects of treatment are a significant burden for many TYAs.
<table>
<thead>
<tr>
<th>Question:</th>
<th>Do you have difficulty with?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel insurance</td>
<td>Yes 41%</td>
</tr>
<tr>
<td></td>
<td>No 20%</td>
</tr>
<tr>
<td></td>
<td>Don't know 39%</td>
</tr>
<tr>
<td>Life insurance</td>
<td>Yes 8%</td>
</tr>
<tr>
<td></td>
<td>No 11%</td>
</tr>
<tr>
<td></td>
<td>Don't know 81%</td>
</tr>
<tr>
<td>Medical insurance</td>
<td>Yes 16%</td>
</tr>
<tr>
<td></td>
<td>No 11%</td>
</tr>
<tr>
<td></td>
<td>Don't know 73%</td>
</tr>
<tr>
<td>Mortgage</td>
<td>Yes 5%</td>
</tr>
<tr>
<td></td>
<td>No 5%</td>
</tr>
<tr>
<td></td>
<td>Don't know 90%</td>
</tr>
<tr>
<td>Bank account</td>
<td>Yes 13%</td>
</tr>
<tr>
<td></td>
<td>No 47%</td>
</tr>
<tr>
<td></td>
<td>Don't know 40%</td>
</tr>
<tr>
<td>Obtaining a place at school</td>
<td>Yes 14%</td>
</tr>
<tr>
<td></td>
<td>No 56%</td>
</tr>
<tr>
<td></td>
<td>Don't know 30%</td>
</tr>
<tr>
<td>Obtaining a place at University</td>
<td>Yes 6%</td>
</tr>
<tr>
<td></td>
<td>No 23%</td>
</tr>
<tr>
<td></td>
<td>Don't know 71%</td>
</tr>
<tr>
<td>Obtaining a job</td>
<td>Yes 34%</td>
</tr>
<tr>
<td></td>
<td>No 26%</td>
</tr>
<tr>
<td></td>
<td>Don't know 40% (n=168-177)</td>
</tr>
</tbody>
</table>

**Interpretation:** There is a notable level of discrimination against TYAs with cancer in terms of insurance, access to education and employment, particularly when adjusted for the numbers who
respond yes or no, assuming that the don’t knows were age excluded.

**Question:** Do you feel that the National Health Service does enough for teenagers with cancer?

- Yes 25%
- No 53%
- Don’t know 22% (n=220)
Appendix F

Position paper on Compliance

Geraldine Mynors, Head of Projects
Task Force on Medicines Partnership

1. What is known about non-compliance with cancer therapy amongst children and adolescents?

Prescribed medication is the most common form of therapeutic intervention in child and adolescent oncology. New and more effective treatments are constantly being introduced, with an emphasis on developing orally administered agents and moving away from intravenous therapies where possible. Using medicines to best effect is therefore of critical importance in successfully managing child and adolescent cancer. In the past, most attention has been devoted to guiding treatment decisions rather than involving patients in these decisions and monitoring whether the medicines selected are actually taken as prescribed. However, until issues of medicine taking are addressed, as well as questions of what to prescribe, a significant proportion of drugs will be wasted and the potential therapeutic gain envisaged by NICE in drawing up its guidelines will not be realised.

The literature on medication compliance in cancer patients is limited, because most treatment is administered in hospital under the direct supervision of health professionals. However, with increasing use of oral therapies, the issue of compliance may become more important in the future. Currently, most research on compliance in cancer patients has been conducted in the context of clinical trials, and uses dropout rates as the measure of ‘compliance’, which is problematic. Measures and definitions of compliance vary widely between studies. Nevertheless, a review of published studies of compliance in cancer
therapy by Partridge et al (2002) review revealed poor compliance in the paediatric oncology population (see Figure 1 below). The review showed that adolescents were the least compliant cancer patients.

**Figure 1: Non-compliance rates to oral antineoplastic agents in paediatric populations**

<table>
<thead>
<tr>
<th>Type of cancer</th>
<th>Measure of non-compliance</th>
<th>Definition of non-compliance</th>
<th>Non-compliance rate</th>
<th>Number of patients in study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leukaemia or non-Hodgkin’s lymphoma</td>
<td>Level of drug metabolite in urine</td>
<td>Lower than expected levels</td>
<td>33%</td>
<td>52</td>
</tr>
<tr>
<td>Leukaemia, Hodgkin’s disease, non-Hodgkin’s lymphoma, other malignancies</td>
<td>Self-report and parent report Serum bioassay</td>
<td>More than one missed dose per month Not described</td>
<td>35%</td>
<td>46</td>
</tr>
<tr>
<td>Hodgkin’s disease, acute lymphocytic leukaemia (ALL)</td>
<td>Biological markers</td>
<td>Lower than expected levels</td>
<td>50%</td>
<td>50</td>
</tr>
<tr>
<td>ALL</td>
<td>Level of drug metabolite in urine</td>
<td>Less than expected level</td>
<td>42%</td>
<td>31</td>
</tr>
</tbody>
</table>
Research into non-compliance more generally has shown that as much as 50% of medicines for long term conditions are not taken as prescribed (Haynes 2002), and that non-compliance rates can be high even with medicines which are seen as being ‘life-saving’. This area, therefore, deserves attention within the NICE guidance being produced.

2. Reasons for non-compliance

The most recent systematic review of compliance by McGavock and colleagues (1996) showed that most non-compliance is almost always the result of conscious choices made by patients rather than simply ‘forgetfulness’.

A large variety of factors are predictive of, or associated with, non-compliance with medication regimens (Carter and Taylor 2003). They include:

- Demographic indicators (e.g. age, gender and socio-economic status)
- Medication characteristics (e.g. side effects, complexity of regimen)
- Psychosocial issues (e.g. social support, family functioning, self-esteem).

However, the most consistent predictor of compliance appears to be individuals’ attitudes, beliefs and perceptions about their illness and treatment. Horne & Weinman (1999) reported a study which linked patients’ beliefs about medication to compliance. Specific beliefs about particular medications include whether the

<table>
<thead>
<tr>
<th>ALL</th>
<th>Level of metabolites in blood</th>
<th>Less than expected level</th>
<th>10%</th>
<th>327</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL</td>
<td>Level of metabolites in blood</td>
<td>Less than expected level</td>
<td>2%</td>
<td>496</td>
</tr>
</tbody>
</table>
medication is perceived as necessary for maintaining health, and concerns about adverse consequences such as side effects or becoming dependent.

The authors looked at whether beliefs affected compliance in four different chronic illness groups (people with asthma, cardiac conditions, and renal failure demanding haemodialysis, and oncology patients). They found that specific beliefs about medicines were the strongest predictor of compliance, accounting for 19 per cent of the observed variance. Demographic variables were less significant. Patients who believed that their medication was necessary for good health reported a higher rate of compliance, whereas those who had more concerns about medicine use reported poorer compliance. This study highlights the importance of exploring and addressing patients' beliefs about medication when addressing compliance issues.

These observations are consistent with the limited research which has been done on compliance amongst children and adolescents with cancer. According to Spinetta et al (2002) the reasons for refusal, non-compliance and abandonment of anticancer treatment in children and adolescents include:

- physical discomfort;
- misunderstanding and uncertainty about benefits of medication;
- poor communication regarding diagnosis and regimen;
- frustration with length of treatment;
- fear of side effects; and
- poor understanding of the seriousness of the illness.

The review by Partridge et al (2002) showed that those most at risk tended to have a poorer understanding of their illness than their peers, and to have less perceived vulnerability and higher levels of denial compared to those who were compliant. The relationship between parental involvement and compliance also appeared to be important.
3. The concordance model as the basis of service improvements to improve compliance

Past approaches to improving compliance have focussed on cues and reminders. More recent approaches have instead tried to implement ‘concordance’ - a two way process of prescribing that recognises that patients are not the passive recipients of prescribing decisions, but have their own views about their condition and treatment. Numerous studies in adults have shown that patients’ beliefs and views about medicines are a key influence on whether and how they take them. Patients are much more likely to follow treatment if they have been active partners in prescribing decisions and their views and preferences have been recognised and taken into account (Cassileth 1980). This in turn is only possible if they have sufficient information and understanding about the medicines available to them.

Three elements need to characterise the health system if concordance is to be achieved (see Figure 2 overleaf).

For children and adolescents with cancer, some of the practical aspects of concordance which should be implemented within services are as follows:

(i) Patients have enough knowledge to participate as partners

Information about different treatment options must be made available both to patients and their families in accessible formats. Patient information leaflets have been shown to be too narrow, too negative and too late to help patients understand treatment options (!Raynor et al 2004). The available patient information can be sometimes be particularly unhelpful for children where medicines are prescribed outside their licensed indications, and parents and children need particular help to understand what this means.
Information for patients and families should make clear the potential benefits, but also the risks and side effects associated with treatment, so that these can be fully explored in the prescribing consultation. Such information should also be ‘user tested’ with real patients to assess whether it meets their needs and what they would like to hear about. (Dickinson 2001)

Patients often appreciate hearing directly from peers who have been through similar experiences, and this can be achieved either by linking up patients on a one-to-one basis or in small groups, or through initiatives such as DIPEX (the Database of Individual Patient Experience), a web-based collection of video clips of patients describing their experiences – which is currently only available for adults but could be extended to children and young people.

**Figure 2**

![CONCORDANCE: a process of prescribing and medicine taking based on partnership]

<table>
<thead>
<tr>
<th>Patients have enough knowledge to participate as partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Patients are offered information about medicines which is clear, accurate, accessible and sufficiently tailored.</td>
</tr>
<tr>
<td>- The information provided is tailored to individual patients' needs.</td>
</tr>
<tr>
<td>- Education programmes empower patients to take responsibility for their own health.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prescribing consultations involve patients as partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Patients are invited to talk about their priorities, preferences and concerns about medicine taking and the proposed treatment, and these are explored openly.</td>
</tr>
<tr>
<td>- Professionals explain the rationale for, and the characteristics of, the proposed treatment.</td>
</tr>
<tr>
<td>- Patients and health professionals jointly agree on a course of treatment which reconciles as far as possible the professional’s recommendations and the patient’s preferences.</td>
</tr>
<tr>
<td>- The patient’s and professional’s understanding of what has been agreed is checked.</td>
</tr>
<tr>
<td>- The patient’s ability to follow the agreed treatment is checked.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients are supported in taking medicines</th>
</tr>
</thead>
<tbody>
<tr>
<td>- All appropriate opportunities are used to discuss medicines issues (e.g. patients’ interactions with doctors, pharmacists and nurses).</td>
</tr>
<tr>
<td>- Health professionals share medicines information effectively with each other.</td>
</tr>
<tr>
<td>- Medications are reviewed regularly, with patients’ participation.</td>
</tr>
<tr>
<td>- Practical difficulties in taking medicines are addressed.</td>
</tr>
</tbody>
</table>
(ii) Prescribing consultations involve patients as partners

Consultations between health professionals and patients should explore the extent to which patients want to be involved in treatment decisions and allow them this degree of involvement. In particular, patients should be given the opportunity to discuss their own priorities and concerns within the conversation. Research has shown that many patients do not voice their agendas and concerns during consultations unless these are explicitly brought out. Tools and techniques for doing this should be used where helpful – for example in adults, significant improvements in patient experience have been achieved by using patient self-completed agenda forms prior to consultations (Barry 2000). Similar approaches could be tested with younger patients – perhaps using pictures or simple diagrams with younger children to help them to express their views.

Once patients have voiced their concerns and beliefs, it is essential that this information is shared between different members of the multi-disciplinary team so that all members can work together to build the trust and knowledge of the patient and his or her family.

It is recognised that there are ethical issues surrounding the extent to which a child or young person below the age of 16 can decide to decline treatment considered to be ‘optimal’, and therefore the extent to which negotiation about prescribing decisions is possible. However, it must be recognised that failing to involve patients fully in prescribing decisions is likely to lead to poorer compliance and poorer outcomes.

Two way communication of this nature is difficult, and it is likely that many practitioners will need additional training and/or opportunities to reflect on consultations in order to review and improve their practice.
(iii) Patients are supported in medicine taking

Once a prescribing decision has been made, it is important that patients are not simply left to take, or not take, the medicine, but have access to ongoing support and additional information, should they need it. For many people, it is only when they start using a new medicine for them that concerns and issues arise – for example if it gives rise to side effects, they don’t feel that it is ‘working’, or the Patient Information Leaflet raises concerns. Ready access to someone at the end of a telephone who can answer questions – even out of hours - and offer support is vital, and in this area hospital pharmacists and nurse specialists can often play a particularly valuable role.

In adolescent medicine, new approaches to ongoing support for patients taking medicines are currently being tried out using new technology such as SMS messaging and by e-mail, focussing on Type 1 diabetes (see http://www.diabetes.org.uk/good_practice/innovative/examples/innovate1.htm). In reviewing such innovations, Medicines Partnership has found that they are most likely to be successful when they offer the opportunity of a two way conversation with someone who the patient knows – rather than being just one way ‘prompts’ to aid compliance. Nevertheless, these kinds of approaches, which tap into technology with which most young people are now very comfortable, could be a useful adjunct to face-to-face support.

In summary, then, young people with cancer are in particular need of appropriate care and support to enable them to get the most out of medicines. There is evidence that people who are really aware of the risk that cancer presents to them and the possible benefits of treatment are often willing to persist with therapy, despite sometimes unpleasant side effects. Involving patients and their families fully in decisions, proactively offering them opportunities to discuss their fears, concerns and expectations, and supporting them on an ongoing basis through the whole multi-disciplinary team are all important. Approaches which
allow individuals to feel confident and make informed decisions in what may be testing personal circumstances are more likely to promote desirable outcomes

References


Raynor DK, Savage I, Knapp PR, et al. We are the experts: people with asthma talk about their medicine information needs. *Patient Education and Counselling* (in press).

Background on the Task Force on Medicines Partnership

The Task Force on Medicines Partnership is a Department of Health funded programme, which aims to help patients to get the most out of medications by involving them as partners in prescribing decisions (including those decisions where an informed patient decides to decline the treatment offered) and supporting them in medicine taking where the decision is to accept treatment. The Task Force is a truly multi-disciplinary collaboration of 25-30 members involving doctors, pharmacists, nurses, patients, the NHS, the pharmaceutical industry and academics, supported by the Medicines Partnership Centre, an executive team carrying out the programme of the Task Force. Medicines Partnership was set up at the beginning of 2002 as part of the Pharmacy in the Future programme under the NHS plan. More details are available at www.medicines-partnership.org.
Appendix G
Position Paper for the Guidance Development Groups
Work on Child and Adolescent Cancer in the Specialist Area of Blood and Marrow Transplantation

Dr Paul Veys
Consultant in Charge of BMT

Between 300 and 350 blood and marrow (BMT) procedures are performed on children and adolescents under the age of 18 years in the UK each year. About 2/3 of these procedures are for haematological/oncological malignancies. The number of procedures has remained fairly static over the last ten years. Work is carried out in 19 centres throughout England and Wales. All centres perform autologous transplant procedures whereas 13 also carry out allogeneic BMT procedures. Over a ten-year period 6 of the transplant centres performed over 200 procedures, and to give an idea of the geographical provision of services these major centres are Bristol Children’s Hospital, Birmingham Children’s Hospital, Great Ormond Street Hospital for Children in London, Manchester Children’s Hospital, Newcastle General Infirmary and Royal Marsden Hospital in Surrey. Together these 6 units perform more than 2/3 of the BMT procedures in the UK. The allogeneic work within the UK is closely monitored by the United Kingdom Children’s Cancer Study BMT sub-group.

This group is made up of representatives from all the major BMT centres in the UK. It is mandatory that all BMT procedures performed in the UK are reported to this group. The annual report for 2003 from this group illustrates the overseeing activity performed currently by the group (Enclosure 1*). Most autologous procedures are performed at UKCCSG cancer centres and within National/International collaborative studies, but this work is not as closely
monitored, as for allogeneic procedures, by a reference group. This is currently being addressed within the general body of the UKCCSG organisation.

The UKCCSG BMT Group provides an “always open” network for communication between professionals for discussion of difficult cases. The Group regularly updates its list of indications for BMT (Enclosure 2*), and has recently produced consent forms to ensure that full communication has occurred between families and professionals in preparation for these complex procedures (Enclosure 3*). This process of consent seeks to confirm that adequate information has been given to the family about the procedure itself, storage and/or future use of any stem cells that may have been collected around the procedure, and the use of data collected from any individual BMT procedure.

The UKCCSG BMT group has also produced guidelines governing BMT protocols and the management of post-BMT complications (listed in Enclosure 1*). Consequently any team in the UK performing paediatric BMT has ready access to nationally agreed guidelines covering the whole area of their practise.

Transplantation procedures will soon come under close scrutiny from the Joint Accreditation Committee of ISHAGE and EBMT (JACIE) accreditation process. The necessary standards required to perform BMT procedures are stringently defined in Section B of the JACIE accreditation manual. (Enclosure 4*). These standards closely define both the facility and staff requirements to conduct BMT within the immediate multi-disciplinary team as well as necessary supporting teams.

These standards have been modified by the UKCCSG BMT group so that they specifically address the Paediatric population. A remaining grey area concerns adolescents aged 16 and 17 years where, on an individual basis it may be better for such older children to be cared for either in a paediatric BMT unit or indeed in an adult unit. It is not envisaged at this time that there will be sufficient resources
to provide BMT units specifically for adolescent patients. The other remaining grey area is follow-up of children post BMT. It is necessary to continue follow-up of BMT patients lifelong to address a number of late sequelae that may occur many years after transplant. Such sequelae include infertility, growth retardation, neuropsychometric problems, endocrine dysfunction, cataracts, and secondary tumours. It will be necessary to forge links between Paediatric and Adult centres such that long-term survivors can pass seamlessly from one group to the next. Clearly this connection is also very pertinent to Paediatric Haematology and Oncology.

The complex nature of BMT procedures and the considerable expense incurred in performing BMT necessitates that expertise and resources are focussed within designated centres. Currently, in England and Wales, there are 13 centres performing allogeneic BMT and it is likely after the JACIE accreditation process and other on-going reorganisations this number may be reduced to 10. Clearly this means that a number of children may have to travel reasonable distances for their BMT procedure. This may be acceptable for the acute period of hospitalisation, usually 1-3 months in duration, however, travelling distances may complicate the necessity for frequent post-BMT clinic attendances. This is currently being addressed with 2 models of care. Firstly some centres particularly outside London have near hospital accommodation where patients and families may remain outside the BMT ward but close to the Hospital for prolonged periods of time. Secondly some centres have developed comprehensive shared-care models whereby much of the post-BMT care is carried out by local hospitals and community teams in constant liaison with the specialist BMT centre

Further work will be required to ensure that one of these two models is fully operational in all 10-13 Paediatric BMT units.

* If required, Enclosures 1-4 are available from the NCC for Cancer upon request.
Appendix H

Nutrition and Childhood Cancer

Mrs Evelyn Ward
Paediatric Oncology Dietitian
St James’ University Hospital, LEEDS

Background

With continued improvement in the treatment of children’s cancers the role of nutritional support has become more important. Children differ metabolically from adults and continued growth and development is desired throughout treatment, therefore with more curable children being treated the more children there are subject to the nutritional problems caused by their disease and treatment.

Malnutrition and cancer cachexia are a frequent consequence of paediatric cancer and its treatment. A clear understanding of the metabolic alterations with malignancy leading to nutritional depletion and the value of maintaining nutritional equilibrium are a valuable part in managing these children. [Andrassy RJ, 1998]

The incidence of malnutrition in childhood cancer ranges from 6-50% depending on the type, stage and location of the tumour. [Donaldson SS, 1981, Van Eys, 1979] Malnutrition at diagnosis is often the exception rather than the rule, however malnutrition is more severe in later stages of malignancy, occurring in up to 37.5% of newly diagnosis children with metastatic disease. [Smith DE, 1991] The initial problems resulting from the tumour may soon be compounded by the iatrogenic nutritional abnormalities, the consequence of the treatment and its side effects. [Mauer AM, 1990]

As therapies have increased in both complexity and intensity leading to increased survival rates, so to has the severity of the complications including nutritional depletion secondary to prolonged anorexia, nausea, vomiting, mucositis and
significant infectious complications. Other common side effects impacting on nutritional intake include taste abnormalities, dry mouth, constipation, renal impairment and food aversion.

Children who are malnourished at diagnosis have a significant poorer outcome compared with children who are well nourished at diagnosis. [Donaldson SS, 1981]

Malnutrition contributes to a reduced tolerance to therapy. Dose adjustments in chemotherapy have been seen most frequently in patients during a time of malnutrition. [Van Eys, 1979] There appears to be differences in the metabolism of chemotherapy agents between adequately nourished and inadequately nourished patients. [Van Eys, 1984] Malnutrition is associated with a higher risk of infectious complications and higher infection rates have been documented in malnourished children. [Van Eys, 1980]

Nutritional support will therefore improve immune competence, tolerance to therapy, quality of life and promote growth and development. [Van Eys, 1998] Nutritional support must be designed to provide adequate protein and calories for all children taking into account their condition and age whether this be oral supplementation, enteral nutrition or parenteral nutrition.

Continued monitoring of nutritional status is an essential component of care. Children at a higher risk of malnutrition include younger children, solid tumour patients, especially abdominal. The risk of malnutrition increases with greater treatment intensity.

It is now well recognised that nutritional support in childhood cancer is an important part of supportive care and the development of ever more intensive protocols highlights the need for aggressive nutritional support. A multidisciplinary team approach is the best way of providing safe, appropriate
and effective nutritional support for this group of patients. Along with the emergence of early and late treatment related morbidity in survivors e.g. osteoporosis, elevated fat mass, the role of nutrition remains challenging.

References


Service provision

1 – Training
Currently the majority of registered dietitians working in paediatric oncology will have worked in general paediatrics and therefore done basic nutritional support.

The majority will be Senior I grade and will have completed the basic paediatric dietitics module 1 run by the paediatric group of the BDA, but will not necessary have a specific knowledge on childhood cancers and their treatments unless they have completed that part of module 2 run by the paediatric group of the BDA.

It is recommended that they should undertake some of the following training
   a) Attend module 2 part, which includes paediatric oncology.
   b) Orienteering with different members of the MDT.
   c) Support from the paediatric oncology dietitians interest group.
   d) Spend time with a dietitian who has experience in paediatric oncology.

2 - Recruitment and retention
Generally in dietetics there is a shortfall of trained registered dietitians leading to problems with recruitment and retention. Problems specific to paediatric oncology include:
   a) Depending on size of centre the dietitian may not just cover paediatric oncology but other areas of paediatrics making it harder to specialise in oncology.
   b) Some centres have rotational posts where dietitians rotate around different specialities and therefore only gain a limited experience in oncology.
   c) In most centres dietetic activity has increased due to:
      - An increasing number of patients requiring more aggressive nutritional support due to an increase in the use of more intensive protocols.
- Better recognition that nutritional status has a prognostic effect on the outcome of children with cancer.

- Increased monitoring of patients requiring nutritional support due to toxicity affecting tolerance to enteral feeds or parenteral nutrition.

- Increase in the number of Teenage Cancer Trust Units opening requiring dietetic input.

This has often been without any increase in dietetic staffing leading to:

- Less follow up and monitoring of patients deemed to be of a lower nutritional risk.

- Less outpatient follow up.

- Less time available to spend on continuing education, research and audit.

- Difficulty finding time to update patient information advice leaflets and other patient orientated documentation.

This can have an adverse effect on staff morale due to an ability to provide a good service to paediatric oncology patients due to increasing work loads and will have an effect on staff recruitment and retention.

3 - Staffing

A recent questionnaire undertaken by a member of the paediatric oncology dietitians interest group showed diversity within UKCCSG centres as to how much dietetic time is allocated to paediatric oncology.

   a) Range = 0.4 –1.3 WTE. Mean = 0.65 WTE with 50% of centres having 0.5-0.6 WTE.


   c) Input into outpatient clinics varies from centre to centre.
Recommended staffing levels

It is difficult to estimate accurately the correct staffing levels and it is possibly easier to estimate on average number of newly diagnosed patients referred to the UKCCSG centre. Ideally a maximum of 80% of available hours should be spent on patient-related work [direct and indirect casework] with 20% on practice-related work [staff meetings, professional development, training, audit/research, resources and quality assurance].

A reasonable estimate to allow adequate service provision to both inpatients and outpatient clinics would be 1.0WTE per 85 newly diagnosed patients or per 18 beds.

Support staff

As well as members of the MDT other staff involved in the provision of adequate nutrition for the child with cancer include;

a) Diet cooks and catering staff.

b) Pharmacy technicians for supply of oral sip feeds, enteral feeds and manufacturing of TPN.

c) Milk kitchen staff to make up specialised feeds.

4 - Equipment

In order to provide adequate and effective nutritional support to paediatric oncology the following equipment is needed:

a) A good range of oral sip feeds and calorie supplements suitable for paediatric patients and older children/adolescents.
b) Enteral nutrition – Wide range of feeds suitable for infants, young children, older children/adolescents
   - elemental
   - peptide based
   - whole protein standard calorie
   - whole protein high energy
   - fibre containing feeds
   – Nasogastric feeding tubes, nasojejunal tubes
   – Gasrostomy tubes
   – Enteral feeding pumps.

c] Parenteral nutrition – Able to provide tailor made regimens for infants, young children, older children and adolescents.

d] I.T. facilities – to enable patient administration
   – audit
   – individualised patient information
   – research.

5 – Multidisciplinary approach to nutritional support in paediatric oncology

A multidisciplinary approach to cancer therapy is well established and this includes a multidisciplinary approach to the nutritional care of the children with cancer. A multidisciplinary approach is the best way of providing safe, appropriate and effective nutritional support.

A team is able to function more effectively than individual members in the following areas:
   a) Identification of present or potential nutritional problems
   b) Nutritional assessment
   c) Recommendations for therapy
d) Supervision and monitoring of recommended therapy

e) Communicating more effectively and quickly with patients, parents and other team members

It is therefore paramount that dietetic staff attend MDT meetings.

6 - Future

The following will have implications for dietetic services in the future:

a) Development of more intensive treatment protocols highlights the need for more children requiring aggressive nutritional support.

b) As the overall cure rate continues to rise early and late treatment related morbidity is coming to the fore. Consequences such as loss in bone mineral mass resulting in osteopenia and osteoporosis, growth problems, altered body composition with a reduction in lean mass and increase in fat mass leading to obesity, type 2 diabetes and ischaemic heart disease can impact on dietetic services.

c) An increasing number of centres are now siting gastrostomies in patients impacting on surgical, dietetic and nursing staff.

d) Increased research need into the role of specific nutrients e.g. glutamine, antioxidants.

Guidelines for the nutritional management of the childhood cancer

1) Identification of nutritional risk

Criteria for identifying children with cancer who are malnourished differ, however determination of the nutritional risk of a child with cancer can be associated with the diagnosis of certain tumours and stages of the disease. Table 1.
The following criteria can be used to identify children with cancer who are likely to require supplementary nutritional support.

a) Total weight loss of >5% relative to pre-illness body weight.
b) Weight for height <90% or BMI < 20 in adolescents aged 18 years and above.
c) Decrease in current percentiles for weight [or height] of 2 percentiles.
d) Food intake <70% of estimated average requirement for more than 5 days.
e) Anticipated gut dysfunction for > 5 days.
f) High nutritional risk patients based on tumour type and treatment regimens [Table 1].
g) Mid upper arm circumference and/or triceps skinfold thickness < 5th percentile.

2) **Nutritional support**

The aim of nutrition support is to

a) Reverse any malnutrition seen at diagnosis.
b) To prevent malnutrition associated with treatment.
c) To promote growth and development throughout treatment.
d) To enhance quality of life.

Nutritional support therefore must be designed to provide adequate calories and protein intake for children with cancer by an experienced dietitian with the expertise to tailor make such individualised regimens.
3) **Methods of nutritional support**

a) **Oral feeding**

For children of a low nutritional risk, oral feeding is the best method, if they are able to consume sufficient nutrients. However advice with regard to the use of high energy foods and specific advice on eating problems related to the side effects of treatment should routinely be given by the dietitian.

The dietitian can also advise on the use of proprietary sip feeds and calorie supplements with regard to quantity, type and modification depending on the child's age and current oral intake. Due to changes in the child's appetite and taste perception this needs to be frequently reviewed.

b) **Enteral nutrition**

Whenever nutritional intervention is indicated it is highly preferable to use the enteral route.

Studies report that nasogastric feeding benefits children with cancer and that it is practical, acceptable and tolerated in children with newly diagnosed advanced malignancy who are commencing intensive treatment protocols. It improves their energy intake, wellbeing and their nutritional status as measured by mid upper arm circumference. [Smith DE, 1992]

Even in children undergoing bone marrow transplant where the nutritional insult is complex as is its management, enteral nutrition when tolerated is effective in limiting the nutritional insult leading to a better response and fewer complications. [Papadopoulou A, 1997, Papadopoulou A, 1998]

Generally a whole protein will be tolerated. However following chemotherapy or radiotherapy a hydrolysate or elemental feed may be more appropriate if
malabsorption occurs. Careful monitoring of these patients by an experienced dietitian is essential with regard to feed tolerance during and following chemotherapy when it is often necessary to manipulate the feed volume, type and flow rate taking into account the age of the child and clinical condition.

Until recently it would have been rare to place a gastrostomy in a child with cancer as concerns over site infections and placement timing during chemotherapy. However an increasing number of centres are now siting gastrostomies particularly in brain tumour patients, Osteosarcoma patients, Ewing's sarcoma patients, nasopharyngeal tumour patients and adolescent patients.

Enteral feeding can be done easily at home with minimal disruption to the child's normal daytime activities.

c) Parenteral nutrition

Parenteral nutrition is required when enteral feeding alone cannot provide adequate nutrients or for those patients with abnormal gastrointestinal function related to their tumour or following chemotherapy, radiotherapy, bone marrow transplant or high dose therapy and peripheral blood stem cell rescue. This form of nutritional should ideally only be used if the gut is not functioning or accessible. [Pencharz PB, 1998] It is however often the only means of nutritional support in children with severe mucositis.

Parenteral nutrition may be used as an adjunct to enteral nutrition or as a sole source of nutrition. This method of support is expensive, carries a high risk of infection and is not easily carried out at home. [Szeluga Dj et al, 1987] Metabolic complications associated with parenteral nutrition are well documented [Glynn J, 2001].
Summary

Nutritional support to prevent loss of lean body mass is an integral part of treatment of paediatric oncology patients. It will improve tolerance of therapy, immune competence, quality of life and promote growth and development. [Van Eys, 1998] It is necessary to choose the most appropriate method of nutritional support taking into account the child’s age, condition and treatment. It is imperative that the effect on nutritional status is monitored to ensure the optimum support is being given and a multidisciplinary team approach is the best way of ensuring this.

References


### Table 1

Types of childhood cancers associated with high or low nutritional risk

<table>
<thead>
<tr>
<th><strong>High Nutritional Risk</strong></th>
<th><strong>Low Nutritional Risk</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced diseases during initial intense treatment.</td>
<td>Good prognostic Acute Lymphoblastic Leukaemia.</td>
</tr>
<tr>
<td>Stages III &amp; IV Wilm’s tumour</td>
<td>Non- metastatic solid tumours</td>
</tr>
<tr>
<td>Ewing's sarcoma</td>
<td></td>
</tr>
<tr>
<td>Osteosarcoma</td>
<td></td>
</tr>
<tr>
<td>Stage IV Rhabdomyosarcoma</td>
<td></td>
</tr>
<tr>
<td>B-cell Non Hodgkins Lymphoma</td>
<td></td>
</tr>
<tr>
<td>Acute Myeloid Leukaemia</td>
<td></td>
</tr>
<tr>
<td>Poor prognostic Acute Lymphoblastic Leukaemia</td>
<td></td>
</tr>
<tr>
<td>Medulloblastoma</td>
<td></td>
</tr>
<tr>
<td>Children undergoing BMT or high dose therapy and P.B.S.R.</td>
<td></td>
</tr>
</tbody>
</table>
Appendix I

The Role of Psychological Service in Supporting Children and Adolescents with Cancer

Dr Deborah Christie
Consultant Clinical Psychologist and Honorary Senior Lecturer
University College London and Middlesex Hospitals

Biography
Dr Deborah Christie has a Ph.D in neurobiology and a background in experimental psychology before joining Great Ormond Street Hospital as a Leukaemia research funded psychologist for 4 years, documenting the effects of the UKALL10 protocol for leukaemia on cognitive outcome in long term survivors. As part of the research project she provided clinical back up to families who were struggling to access adequate special needs support for their children who had been affected by their treatment. Subsequently Dr Christie worked for 5 years as liaison psychologist to the haematology/oncology and neuroncology services. She has provided short and long term input to young people and families at point of diagnosis, as part of the GOSH late effects services and worked with the palliative care team. Dr Christie is currently Consultant Clinical Psychologist at University College London and Middlesex hospitals where she is a member of the multidisciplinary psychological services team and head of service for paediatric and adolescent psychology. She is a member of the joint hospitals late effects re-design task force.

Acknowledgements
Several colleagues working in paediatric cancer across the country provided information about their service. Several chose not to contribute. Therefore the
opinions, views and suggestions from other psychologists working in paediatric cancer have been incorporated where possible but not the views of those that didn’t contribute!!

This document has been written to identify clinical issues and potential gaps providing psychological input to children and families living with cancer. The paper aims to summarise the issues from the perspective of a practising clinician and reflects the personal challenges that are created by current resources and service level planning. The document contains suggestions and ideas, which are entirely those of the author and are based on clinical and personal research experience. It is hoped therefore that the suggestions reflect a general and reasonable perspective on needs. As it has not been reviewed by a committee there may be those that feel that it does not reflect a consensus opinion although it is questionable if one could ever be achieved. This paper does not reflect the view of any institution. The document aims to identify how young people can and would benefit from a psychological service that provides a range of therapeutic support from individuals who are trained in these approaches, methods and techniques and does not specifically identify a particular discipline as being inherently more or less appropriate.

Introduction

What is the difference between a psychiatrist, a psychologist and a psychotherapist? This question may sound like the beginning of a bad joke but it is an often asked question by managers trying to understand the difference - real or imagined - between the many professionals that provide psychological support to young people, families and medical teams dealing with cancer. The main differences are located in training, approaches, method and technique. A child and adolescent psychiatrist (CAP) is a medical doctor who works with children and young people who have serious emotional or mental health problems. CAPs can prescribe medicine for these problems - if this is appropriate - and are often trained in individual and family therapy as well. The therapeutic approach can
range from the biological to a family systems approach. Limited resources mean that the majority of psychiatrists will tend to work with the more severe end of the spectrum of psychological distress. Traditionally the psychotherapist will train in a single therapeutic model that will aim to offer individuals or families a space to explore their thoughts and feelings and integrate their internal and external ‘worlds’. As a generalisation the approach taken is non-directive and self-reflective. However once again within this single discipline there are a range of models that inform the kind of questions and approaches that may be used to ameliorate distress in an individual. Finally, clinical psychologists have a scientific training (at a doctorate level) in the understanding of behaviour within the context of normal developmental processes, and the relationships between thoughts, emotions and behaviours. They will be trained in the assessment of emotional distress, behavioural difficulties and levels of cognitive ability. Some have additional specialist training (e.g.; neuropsychology). They can offer a wide range of therapeutic intervention techniques.

To add further confusion family therapists, counselling and health psychologists are also able to provide support and advice to young people and families in distress whilst play/activity specialists and specialist social workers are often key members of the wider psycho-social team. All of these professions offer a combination of unique and overlapping skills using different psychological models and different approaches but have the same goal - that of helping young people and families living with and surviving the challenge of cancer.

**Cancer Treatment**

Around 200,000 children worldwide are diagnosed with cancer each year. There have been significant advances in treatment for cancer over the last two decades and in the developed countries some 70 - 80% of these children will be cured. Although teenagers and young adults are no more likely to survive than they
were 25 years ago, the five year survival rate in younger children has risen\(^5\).

There has also been an increase in the number of paediatric cancer nurses and specialist developmentally appropriate treatment centres, mostly due to the work of the Teenage Cancer Trust. Despite these improvements in medical care and increases in survival rates, a diagnosis of cancer remains a traumatic and terrifying experience for children, young people, parents and other family members. It can also create a significant challenge for the multidisciplinary treatment teams.

**So what’s the problem?**

*The problem is not that there are problems. The problem is expecting otherwise and thinking that having problems is a problem.* T. Rubin

It is important to acknowledge that many young people and families show remarkable resilience as they begin their journey from diagnosis to treatment and ultimately survival. Some families seem able to cope with minimum intervention and use coping strategies previously developed or learned to ‘get on with’ their life.

Should we be encouraging families to ‘be miserable’ and face their worst fears or is denial a useful strategy? Different psychological models would have different responses to this question.

One of the challenges for clinicians is to find ways to acknowledge and respect those that prefer to do without additional support whilst remaining sensitive to coping styles that no longer appear to be helpful. The skill for the clinical team is to be able to offer support that fits for families when they need it. Identifying risk factors at the beginning of contact with families can help teams identify who may

require input. Ensuring that psychological and social support is a resource that is available to all families as and when it is needed can reassure families who struggle at certain times that they should not feel that they have ‘failed to cope’.

A comprehensive review of the psychological impact of cancer has been published by Rowland (1990)\(^6\). The model acknowledges the importance of developmental stages and the impact of cancer on these stages. The disruption caused by illness and treatment is specific to each developmental stage however there are five common sources of problems that Rowland and Holland identify as the 5 D's.

1) *Distance* in interpersonal relationships  
2) issues of *Dependence* and independence  
3) *Disability* in social or school achievement  
4) *Disfigurement* or physical impairment  
5) fear or anxiety about *Death*.

Other factors that can affect a family's relationship to cancer will be their developmental stage, communication style and previous experience of illness. Cultural, economic and social factors are additional influences on how a family understand and cope with diagnosis, treatment and the ultimate outcome.

**The role of psychological services in supporting people living with cancer**

Psychological services have an important role to play at all stages of the patient pathway. This includes at the time of diagnosis, coping with different stages of treatment and providing long term support in rehabilitation and palliative care and for those that survive. Input should be available for the young person, their families and the clinical treatment teams, who are sometimes forgotten.

**Diagnosis**

However well communicated, bad news can be extremely difficult to hear. The distress can have a significant impact on the ability to process and remember information. Parents sometimes say that they were never told the diagnosis or cannot remember information that has been repeated several times.

In some teams a psychological team member will join the consultant in order to hear what the family is told and will then meet with the family again to go through the information and help them assimilate what they have heard. The role here is not to discuss the medical information but to think about the emotional impact of the diagnosis. It also provides an opportunity to assess the thinking style of the family and help them identify ways they have coped in the past with bad news, previous experiences of serious illness and what psychological resources they have available. Cultural and/or religious beliefs about illness and treatment can be important to explore in order that teams have a greater understanding of a families responses to a diagnosis or how they manage whilst on the ward. The communication style of the family can also be considered at this point and then fed back to the clinical team to help enhance future communications with the family.

**Coping with treatment**

There are a range of difficulties associated with treatment that psychological services can offer specific support for, using a range of evidence based treatment techniques.

These include:

- Procedural distress
  - Treatment refusal e.g.; Chemotherapy, surgery, medication compliance
  - Needle Phobia
• Medication tolerance and associated distress e.g.
  - Anticipatory anxiety
  - Anticipatory vomiting
  - Food Aversion
• Body Image
  - Hair loss
  - Amputation
• Emotional distress
  - Depression
  - Anxiety
  - School avoidance

There is evidence to suggest that Cognitive Behavioural Therapies are the most effective in the support and treatment of these conditions. Cognitive behaviour therapy (CBT) is an approach that aims to help an individual identify underlying negative thoughts that have developed in response to their environment. These thoughts create distressing emotions which then drive behaviours that are usually maladaptive or unhelpful. CBT includes a range of techniques that can be helpful in many different anxiety related conditions. A child who is refusing to allow chemotherapy to be started on time or who becomes acutely distressed when they need to have catheters inserted or bloods taken can be helped to use relaxation techniques (including guided imagery and hypnotherapy). Graded exposure is another way to reduce the distress associated with procedures. CBT has also been shown to be effective in the management of panic attacks, eating disorders, body image, anxiety disorders and depression and is a relatively brief, symptom focussed, practical and effective therapy.

In addition to CBT, family based solution-focused approaches are being increasingly seen as helpful in the clinical setting. These view the patient as the expert and focus on “what works” e.g. identifying “what helped” during periods
when their illness was in control. The approach is non-pathologising and normalising. The author has found it to have significant promise with young people with a wide range of chronic illness who are reluctant to engage with more traditional psychological approaches. Solution focussed therapy begins from where the young person and their family wish to be in the future and identifies strengths, abilities and resources that can be used to achieve the preferred future. It introduces the possibility that no matter how difficult the situation, change is possible. Families are invited to see themselves as experts who already have solutions but just need support in recognising and identifying exceptions to the problem being the rule.

There is a small but growing number of research papers describing these approaches in children and increasing clinical evidence that these approaches are effective and liked by families.

‘a 12 year old girl had not expressed any concern about hair loss to her family or the medical team however was withdrawn and resistant to treatment at the beginning of each treatment cycle. In a conversation she was able to identify bravery as the ability that allowed her to challenge the effects of her disease and its treatment on her life. She told me she had needed bravery be able to go out in public without her hair’.

Bravery was therefore identified as a unique strength and ability and discussions followed that helped her identify how she could use this ability to help her in other aspects of her treatment. Members of her nursing team were interviewed and invited to join her bravery team and were asked to look out for any times they spotted bravery hanging out on the ward with her.

---

The meaning of the long term consequences of treatment can also impact on how a young person copes with the acute treatment phase. An example of this would be discussions about limb amputation. The effect on a young person's life will be unique and have a meaning that is specific to their hopes and ambitions. For example a young teenager with an ambition to be footballer that loses a leg or a musician who loses an arm may believe that they no longer have any future and that it is not worth surviving. Thoughts about the amputation become increasingly catastrophic and are accompanied by increasing distress and depression. CBT can focus on addressing these catastrophising thoughts and help young people think about creating alternative futures. It is important to point out that these are just two approaches and some families will find other models of psychotherapy, general support and non-specific counseling to be as helpful. The role of psychological services is to work with the clinical team to find out what works best for whom and fit the intervention to the family, not the other way round.

**Communication problems**

Difficulties in communication during treatment can arise between the child and their family, between the clinical team and the family, and very often within the team where different views about how best to treat the child are held.

In any complex system it is important to take an approach which can consider the views of the different members of the wider system. It may be important to think about the role of school, the church or local community. Religion, race, and cultural views may influence a family's attitude to treatment and how they communicate with or are perceived by staff (e.g.; Jehovah's Witness).

Some of the above issues may be embedded in communication difficulties between different parts of the system. The role of the psychological team is to enable and understand where the difficulties are located and to think about how to enable more productive conversations between these different parts.
Systemic approaches offer a perspective which allows an understanding of the family's relationship to help and, when problems occur, offer opportunities to think in a positive way about who wants help from whom.

**Relationships**

Perhaps one of the most immediate consequences of treatment is its impact on dependence-independence. The specific nature of the impact is influenced by the child's developmental stage. In healthy children there is a gradual and complex renegotiation of their relationship with their parents as they grow from new-born to young adult. For young children the parent is seen as having complete authority and control whilst a key developmental task of adolescence is achievement of independence and autonomy.

The process of separation in the healthy family begins slowly as children begin to feel confident with being left with other carers, start school and learn to take responsibility for personal care. There is an increasing need for physical and emotional privacy. Successful negotiation requires parents to allow adolescents to make safe mistakes, reviewing and revising consistent and reasonable negotiated boundaries, which adolescents are required by their adolescent job description to ignore and step over!

Personal privacy is often difficult to maintain on busy wards. Weakness or incapacity requires levels of personal and intimate care that may not have been required since early childhood. Teenagers used to personal space and privacy find cancer hijacks their journey towards independent living as they once again become dependent on parents and nurses for physical and intimate care.

Psychological services can offer a family meeting to explore these anxieties and offer space to think about the way that cancer has knocked them off track. Family

---

therapy creates opportunities to explore previous strengths in families that can be built on to help them recreate previously negotiated independence.

Unpleasant but necessary treatment may be ‘enforced’ by parents and medical teams, who ‘know what is best’. Ultimately decisions about treatment may challenge the ability of parents (and doctors) to allow children choice. Parents can feel their role as protecting children challenged when they are required to encourage children to accept treatments that are unpleasant or distressing.

In family meetings parents can explore their feelings of powerlessness in the face of cancer and complicated medical decisions. Young people may find it difficult to ask for or accept independence post treatment. Therapy can focus on uncovering how young people were previously successful and introduce possibilities of rediscovering these previous successes and ways to get their life back on track.

**Social relationships**

Cancer is usually a condition that is unpleasant and debilitating, that requires treatment in hospitals, perhaps a long way from home and can cause dislocation from family, friends and peer groups. There are particular time points, (transition stages) in a child’s life that increases the difficulties, for example the child just about to begin reception or transfer from junior to secondary school. Children may miss the critical first class and the opportunity to establish new developmentally appropriate peer relationships. Absence from school will mean difficulty establishing or maintaining peer networks.

For many young people returning to school during treatment can feel like an impossible hurdle. Treatment induced sickness, pain or discomfort may result in not wanting to meet friends or play with siblings in between treatment cycles. Hard won friendships may be dislocated and hard to repair. Young people talk about feeling like an outsider.
R was 16 when she was diagnosed with a brain tumour. After a year off school for treatment she felt her friends had all moved on without her. When she went to school she didn’t have the confidence to approach groups of girls and believed that nobody was interested in her. R was encouraged to find ways to answer back these negative thoughts about people not wanting to talk to her. We also decided that confidence had gone into ‘hibernation’ and strategies for waking confidence up and getting it to help her reawaken old friendships were tried out.

Research has shown lower social competence in children treated for brain tumours⁹. These problems may be due to deficits in physical appearance (e.g. hair loss) increased physical limitations (surgery or treatment effects) and missed school days and social activities. Cognitive deficits may also underlie social skills deficits due to white matter damage secondary to cranial radiation therapy.

A group intervention Social skills training (see Barakat et al) has been found to be potentially effective in mediating these effects and could be delivered in all services both as part of on-treatment and follow up clinics.

**Late effects**

The impact on long term cognitive functioning has been extensively documented in the research literature¹⁰. Monitoring the impact of treatment and liaising with educational services is a key function of cancer psychological services. A team in Birmingham is currently running a regular workshop for teachers of recently diagnosed children to inform and educate them about the acute and long term effects of treatment.


However, very few services have sufficient resources to offer a regular screening programme. In the majority of clinics neuropsychological assessment can only be offered some years after treatment when problems become severe and remediation or rehabilitation is much more difficult. Butler and Copeland (2002) have recently developed a cognitive remediation programme that has reported improvement in attention and concentration skills\(^{11}\). At the present time this is an expensive resource however the increasing number of children surviving cancer demands that the cost of cure must also now be addressed as intensively as the search for new and more effective treatments has been. A challenge for cancer services must be to ensure that current levels of cognitive functioning at time of diagnosis are determined and monitored over time. In this way treatment induced deficits can be addressed quickly and appropriate special needs support can be put in place. The establishment of specialised rehabilitation and remediation programmes is also essential.

**Palliative treatment**

Despite heroic efforts by clinical teams, for a number of children and young people treatment is not successful. Death remains a possibility for a percentage of children who are diagnosed.

Failure to respond to treatment may occur early on in the treatment cycle whilst for others there is an ongoing risk of relapse and decreasing treatment options. This ‘sword of Damocles’ feeling is often reinforced by the need to attend long term survivor or late effect clinics where continual tests ‘just to check’ do little to reassure children that they no longer have cancer.

There are many views as to how and when families should be told about treatment ‘failure’ and who should be involved in this process. These views are influenced by personal beliefs and professional experience as much as evidence

based practice. Decisions as to when to introduce palliative care teams differ widely across services and may be different within a single service\textsuperscript{12}.

The developmental stage of a child and their family may determine the kind of anxieties that surface in response to bad news. For younger children the concerns may be specific and concrete.

\textit{J was 5 and suffering from terminal skin cancer. In conversations with him about what might happen if he didn't get better he talked about needing to be sure that someone was going to look after his goldfish and his play station and how he knew his mummy and daddy were going to be sad that he was going to heaven without them.}

His parents felt able to begin having these conversations with him once they were reassured that he could tolerate the idea of not getting better. They also asked for the psychologist to talk to his sister about what was happening to get sense of what she understood and was able to talk about with them.

For teenagers a need to protect themselves from distress may mean they choose not to talk or acknowledge what is happening and throw themselves into activities whilst they are still physically able to do so. In contrast other young people may find it helpful to discuss their anxieties about unfulfilled futures and loss of future relationships and unlived lives. The psychological team can often have a role here reassuring the clinical team that the young person has made a personal choice about how they have chosen to live with their potential death. Their way of coping may fit for them and our ideas about what should or shouldn't happen

may not always be helpful\textsuperscript{13} (see Griffin and Christie, 2004 for a description of working with a palliative care nursing team).

The psychological team can also offer input to bereavement services and work with bereaved parents and siblings.

\textit{L’s husband had died of cancer 12 months before her oldest daughter was diagnosed. E died on the ward. Meeting with L helped her think about what strengths and abilities she needed to cope with this second terrible loss and how to support E’s younger sister.}

\textit{J’s parents asked for his sister to meet with the psychologist after he died. She talked wanting to feel it was OK to be happy without being disloyal to J.}

**The state of play**

Psychological services across the country offer a range of in patient and out patient services which include:

- Individual, family and parental therapy
- Individual counseling and support for staff
- Clinical training to the Multi-disciplinary team
- Staff Consultation to the Multi-disciplinary team
- Young person and parent groups
- Staff Groups (for nurses, play specialists, junior doctors)

There appears to be very little consistency around provision of psychological services to child and adolescent cancer services in the UK. The majority of services primarily use clinical (or health) psychology and/or social workers as the main discipline. Very few have dedicated child psychotherapy or psychiatry

although most can access or refer to if needed. The majority of services respond to specific referral requests and few are able to see all the young people admitted to the service. This role is often left to specialist social workers. The number of psychology sessions specifically allocated to haematology/oncology ranged from 0 to 10 (full time) at larger specialist teaching hospitals. However even at some of the specialist centres there is a relatively small number of sessions of dedicated psychological input although support may be provided through the general paediatric psychology service.

It was very difficult to obtain an accurate breakdown of referral patterns across services however about half of the referrals seem to be for emotional and behavioural problems, including procedural anxiety. About 25% are for parental support (including bereavement). The remainder were for cognitive assessments, sibling problems or school problem. A number had been seen for long term emotional sequelae. The majority were referred during the initial hospital admission although services that offered specialist late effects service often had larger number of referrals for rehabilitation and cognitive support.

One of the challenges expressed by those who work in different services is the paucity of thought given to managing communication between shared care teams. There is also a feeling among psychologists who work in cancer that there is an enormous amount of potential work that could be being provided. This includes being able to work proactively rather than just responding to distress, offering a range of group work and supervision of other members of the clinical team (e.g. communication skills with nurses, teaching procedural anxiety methods to play specialists/activity co-ordinator). There are also opportunities to oversee the broader aspects of psychological care to ensure coherence and clinical governance that psychology expressed a wish to be involved in. For others the frustration is that limited sessions can make it difficult to carry out research unless they have dedicated funding.
**A gold standard service**

The ideal psychological service should be able to offer flexible and creative ways to think about how families are living with a diagnosis of cancer. Patients should have access to individual and family interventions that fit their way of thinking and is coherent with their cultural and religious beliefs.

The psychological team should be able to offer

- A range of individual approaches including brief solution and cognitive behavioural therapies
- Systemic consultation and family therapy
- Anxiety management
- Guided imagery and visualisation
- Hypnotherapy
- Relaxation training
- A range of groups (age appropriate and family based) including social skills training.
- Neuropsychological assessment, cognitive rehabilitation and remediation support

Managers must recruit individuals that have the skills and training to offer these services rather than focussing on specific disciplines.

Different clinicians have different views as to what works best for their service. Should the psychologist meet and greet every child (usually the remit of cancer charity funded social workers) or should they only provide targeted interventions specifically requested by the clinical team?

In an ideal world this is not an either/or situation. Initial screening and assessment of a family’s beliefs, strengths abilities and potential risks should inform a positive watch and wait approach. Teams should be transparent and
open with families informing them of the range of support that is available and is as much a part of the treatment as the chemotherapy.

Job plans for psychological services should follow a planned activity format where regular supervision, professional development and training are incorporated into the job plan.

Planned activity should include (in order of priority)
- Attending ward rounds and multidisciplinary team meetings,
- Offering assessment and consultation to families and the team
- Brief and long term therapy
- Working with a family consultation/family therapy team
- Monitoring treatment effects
- Educational liaison
- Neurocognitive rehabilitation treatment programme (acute and long term treatment effects)
- Audit, Research and Service Development

**What is the formula?**
Sadly there is no magical formula that allows us to say for ‘x’ number of patients ‘x’ sessions of psychological support will be able to offer all of the above. The staff on wards have a fairly clear view of what they want from their psychological support teams\(^{14}\). However resources will dictate the model that can be provided. When patient numbers and allocated time are well balanced a process consultation model allows a rapid, flexible, and frequent service. In contrast limited resources may mean that an indirect consultation model can only offer indirect consultation at ward rounds with minimal direct patient contact.

The end – or the beginning?

Guidelines for patient care often tread a middle ground once the extremes of evidence have been sifted through. A basic minimum of psychological delivery should be agreed and incorporated into the care pathways just as certain medical procedures are agreed and provided for. However, recommendations often say ‘all patients should have access to psychological support’ but do not say what for or what that support should look like. We should ask the young people and families that we work with what they found helpful and what they would have liked more or less of. It is the patients that are the experts not us. Different interventions will be relevant at different times in a young person’s treatment and what seems to fit for us as a clinical team may not make sense to them.

In some teams introducing different ideas or working in a different way rather than increasing the number of sessions can be helpful. We should be identifying effective models of good practice and build on what works.

As clinicians the guidelines you are developing will provide an opportunity to develop creative and collaborative answers to the challenges created by cancer for children and adolescents.
Appendix J

NICE Child and Adolescent Cancer.
Special Report on Late effects and long-term follow up of young people treated for cancer

Dr W. Hamish Wallace
Consultant Paediatric Oncologist
Royal Hospital for Sick Children, Edinburgh EH9 1LF
Hamish.Wallace@luht.scot.nhs.uk

Summary Points

• Long-term morbidity risks in childhood and adolescent cancer survivors largely relate to treatment modality and the challenge remains to further improve survival rates whilst reducing the incidence and severity of such treatment-induced late effects.

• Treatment-related morbidity is diverse, with potential effects on the endocrine system (growth, puberty, fertility, pituitary, thyroid and other disorders), cardiovascular, second tumours, pulmonary and renal complications, and cognitive, educational, psychological, social and quality of life manifestations.

• Morbidity can be anticipated and monitored to optimise prevention and treatment – ideally through multidisciplinary follow-up.

• Evidence-based and graded recommendations provide a basis for the effective, informed and pragmatic follow-up of a cohort of patients who, it is estimated, will make up 1 in 715 of the adult population by the year 2010. The further development of evidence-based, therapy-based guidelines for follow-up are an important prerequisite for an effective and cost-effective follow-up strategy.
**Introduction**

The incidence of Childhood cancer is 100 – 130 per $10^6$ per annum and 1 in 600 children under the age of 15 years will develop cancer which is now curable in 65 – 70% (Campbell et al, 2003). It has been estimated that by the year 2010 1 in 715 of the adult population will be a long-term survivor of childhood cancer. Leukaemia makes up approximately one third of childhood cancers and brain and spinal tumours about one quarter. Childhood cancers are diverse in their site of origin and histological type but long term morbidity in survivors relates more to the treatment – surgery, chemotherapy, radiotherapy, bone marrow transplantation – than the cancer type or site.

With increasing understanding of the effects of these treatment modalities on tissues and organ systems, many of these treatment-related sequelae are predictable – and many are preventable or treatable with informed and careful follow-up. For the majority of those treated for cancer in childhood and adolescence, the goal is not merely long-term survival but high quality of life.

Nevertheless there is still an 11-fold increased overall risk of death in five year survivors of childhood cancer (Mertens et al 2001, Moller et al 2001) with still higher risks in females (18.2- fold), those diagnosed under the age of 5 years (14-fold) and those with an initial diagnosis of leukaemia (15.5-fold) or CNS tumour (15.7-fold). The commonest cause of death amongst 5 year survivors is a second malignancy (19.4-fold increased risk). Other common causes include cardiac problems (8.2-fold) and pulmonary problems (9.2-fold). Whilst cancer recurrence is the cause of death in about two thirds between 5 and 9 years after diagnosis, treatment related causes of death account for about 1 in 5 deaths (second cancer, cardiac toxicity, pulmonary complications).

Treatment-related morbidity is diverse with potential effects on the endocrine system (growth, puberty, fertility, pituitary, thyroid and other disorders), cardiovascular, pulmonary and renal complications, and cognitive, educational,
Improving outcomes in children and young people with cancer: evidence review 377


Growth and endocrine function following treatment of childhood malignant disease and the effects of chemotherapy are also reviewed by Wallace (1996) and Wallace and Kelner (1996a, b) respectively

Whilst there is still a dearth of prospective longitudinal interventional large-scale studies of therapies designed to prevent, modify or treat morbidity in long-term survivors, there is an increasing body of evidence (descriptive, case control or cohort studies) on which scientifically sound recommendations for monitoring and follow-up can be based. The development of the SIGN guideline "Long term follow-up of survivors of cancer in children and young people" (SIGN No 76, 2004) in which I was involved as chair, has provided a systematic review of the evidence in many (although not all) of these areas. Its evidence-based and graded recommendations provide a basis for the effective informed and pragmatic follow-up of a cohort of patients who, it is estimated, will make up 1 in 715 of the adult population by the year 2010.

Areas covered by the SIGN guideline are 1) the assessment and achievement of normal growth, 2) the achievement of normal progression through puberty and factors affecting fertility, 3) the assessment of thyroid function, 4) the early identification, assessment and treatment of cardiac abnormalities and 5) the assessment and achievement of optimal neurodevelopment and psychological health. Important areas not covered by the SIGN guideline include second malignancy, renal, respiratory and liver dysfunction.

Thus long-term morbidity risks relate to treatment modality and the challenge remains to further improve survival rates whilst reducing the incidence and severity of such treatment-induced late effects. These can be anticipated and monitored to optimise prevention and treatment – ideally through multidisciplinary
Improving outcomes in children and young people with cancer: evidence review

follow-up involving paediatric oncologist, paediatric endocrinologist, paediatric neurologist, radiation oncologist, paediatric neurosurgeon, clinical psychologist, specialist nurse and social worker.

**Growth impairment**

Long-term effects of radiotherapy (RT) and chemotherapy (CT) on growth and endocrine function have become more obvious and important as survival following childhood cancers has improved (Sklar et al 1993). Adverse effects on growth may result from radiation-induced hormone deficiencies, impaired spinal growth from spinal RT (and from CT), primary hypothyroidism from spinal RT, precocious or delayed puberty from abnormal gonadotrophin secretion, gonadal failure from RT or CT, and problems with nutrition or obesity (Didi et al 1995, Shaw et al 2000, Reilly et al 2000).

At diagnosis of acute lymphoblastic leukaemia (ALL), there is already low bone turnover with reduced levels of collagen formation and resorption markers (PICP, PIIINP and ICTP) (Crofton et al 1998). In remission, there is further bone synthesis suppression (low levels of PICP and PIIINP) and growth suppression (Ahmed et al 1997, 1999, Crofton et al 1999, 2000) which probably relates to glucocorticoid (prednisolone) and high dose methotrexate therapies. This suggests that there may be an increased risk of long term osteoporosis and fractures. Comparison between countries suggests that the degree of growth impairment is proportional to the intensity of the CT regimen. CT has a disproportionate effect on spinal growth impairment perhaps because of the large numbers of spinal epiphyses. High dose cranial irradiation is associated with a significant potential height deficit because of the combined effects of precocious puberty and an impaired pubertal growth spurt.

The hormone deficiency effects of RT will depend on the site of irradiation, total dose of irradiation, fractionation schedule and the child’s age at treatment. Growth impairment will result from RT to the hypothalamo-pituitary axis (the
hypothalamus is more radiosensitive than the pituitary and the GH axis the most radiosensitive followed by the gonadal axis). RT to the spine (in the treatment of medulloblastomas, ependymomas, germinomas) will result in late pubertal growth failure (the spinal growth spurt occurs towards the end of secondary sexual development) and primary hypothyroidism due to a direct effect on the thyroid gland. CT (glucocorticoids, methotrexate) will also impair growth.

RT doses of >24 Gy will be associated with precocious (especially in young girls) or delayed puberty and GH deficiency within 5 years (Ahmed et al 1986). Higher RT doses (eg ~54 Gy used in craniopharyngioma) will cause GH deficiency within 2 years. Lower doses (<24 Gy) may be associated with precocious puberty, an impaired pubertal growth spurt due to relative GH insufficiency in that context (Crowne et al 1992) and reduced pubertal spinal growth. Total body irradiation (TBI) used as preparation for bone marrow transplantation (~7.5 – 15.75 Gy) may also be associated with pubertal GH insufficiency, thyroid dysfunction and a radiation-induced skeletal dysplasia.

The same total dose of RT given in several fractions minimises GHD and growth impairment and fractionated TBI produces less damage to normal tissues. Younger children (especially girls) are more likely to develop precocious puberty and a pubertal growth spurt can be mistaken for ‘catch-up’ growth. Obesity can normalise growth at the expense of disproportionate bone age advance and reduced height prognosis.

Clinical growth assessment should consist of the regular measurement of sitting and standing height, skinfolds, weight and calculation of BMI, and puberty staging. It is recommended that all children who have survived childhood cancer should have their height and weight measured regularly, on and off treatment, until they reach final adult height. Sitting height should be measured in children who have received craniospinal irradiation (SIGN Grade B recommendation).
Chemotherapy is also likely to have a deleterious affect on spinal growth which may be particularly manifested by growth failure in late puberty.

Children with impaired growth velocity should have growth hormone levels measured after appropriate stimulation tests (SIGN Grade C recommendation). Other causes of poor growth, including potential deficiencies of other pituitary hormones or problems related to early or delayed puberty, should be considered and treated as necessary (SIGN Grade B recommendation). Children with craniopharyngioma should be tested at presentation for growth and other pituitary hormone deficiencies and at regular intervals thereafter (SIGN Grade B recommendation). Young girls receiving cranial radiotherapy should be closely monitored for signs of precocious puberty (SIGN Grade B recommendation).

Children who have been treated with low dose cranial radiotherapy are at risk of precocious puberty and growth hormone insufficiency (GHI), while those treated with higher doses are at risk of an evolving endocrinopathy with GHI developing early and in some children gonadotrophin, thyroid or cortisol deficiency developing later on (Shalet et al 1988). Thus laboratory assessment (baseline free thyroxine, cortisol, testosterone / oestradiol, IGF-I etc), physiological profiles (GH, GTs, cortisol etc) and dynamic tests (insulin hypoglycaemia, GNRH, hCG, TRH, synacthen etc) will be relevant. Nevertheless, integrating clinical and anthropometric information (plotting on appropriate growth charts, calculation of height velocity, calculation of body mass index and plotting on age-related BMI standards) as a prelude to appropriate investigation and treatment is an important role for the paediatric endocrinologist in a multidisciplinary team. Much information can be gleaned from careful anthropometry and pubertal assessment in the context of knowledge about the anti-cancer treatment received so as to minimise investigations in children who have already been through many unpleasant treatments and investigations. Interpretation of biochemical (hormonal) information must be on a background of thorough understanding of growth and puberty so that treatments can be used timeously and appropriately.
Available treatment modalities include the use of GH for growth failure, pubertal suppression and thyroxine, glucocorticoid and sex steroids as indicated.

If a child has a good prognosis from the underlying condition two years from treatment, GH therapy should be given when indicated on biochemical and anthropometric grounds. (SIGN Grade B recommendation). There is a high relapse rate in the first 2 years after diagnosis and it seems inappropriate to treat children with daily injections if the prognosis is poor or whilst the chance of relapse is still high. There is no evidence that GH is associated with reactivation of the primary lesion (Swerdlow et al 2000) but GH may well be ‘blamed’ for any relapse. Where the cause of growth impairment is unclear, a trial of GH may be appropriate (SIGN Grade C recommendation). In cranipharyngioma there is every reason to start GH therapy without delay once deficiency is identified – the response is excellent and on a par with that seen in other causes of GH deficiency. Management of the growth disorders secondary to treatment of childhood cancers is reviewed by Bath et al (1998).

There is accumulating evidence that childhood cancer survivors (particularly of leukaemia, but also of brain tumours and cranipharyngioma), however they were treated, are at risk of obesity in adolescence and adult life (Davies et al 1995). The aetiology is likely to be multifactorial (nutritional, psychological, lifestyle including lack of exercise, endocrine and neuroendocrine) and is difficult to prevent or treat. There are potentially severe consequences: childhood obesity may affect educational attainment and interpersonal relationships adversely, especially in boys (Wake et al 2000, Gortmaker et al 1993), may persist into adulthood and is associated with an increased risk of hypertension, stroke, myocardial infarction or type 2 diabetes mellitus, osteoarthritis, breast and bowel cancers, skin disorders and asthma and other respiratory problems. Hypertension, dyslipidaemia and hyperinsulinaemia are increasingly found in obese children with two or more risk factors found in 58% of obese children (Freedman et al 1999) with significantly increased Odds ratios for raised diastolic
BP (2.4), raised LDL cholesterol (3.0), raised HDL cholesterol (3.4), raised systolic BP (4.5), raised triglycerides (7.1) and high fasting insulin (12.6).

Treatment for childhood cancer may result in reduced bone mineral density (Nysom et al 1998). An increased fracture rate remains to be demonstrated, but the observed decrease in bone mineral density would be expected to predict for increased fracture risk.

Children who are about to undergo head and neck cancer treatment, should be advised about the possible effects (particularly from radiotherapy) on oro-facial growth and teeth – eg facial growth, tempero-mandibular joint function, enamel defects, mineralisation and development of crowns and root stunting. Specialist dentists have a role in the care of these children (SIGN Grade D recommendation). Whilst levels of decay seem no worse than control children, treatment such as radiotherapy which reduces saliva may increase caries risk (see SIGN Dental Caries Guideline 2000).

**Thyroid disorders**

Abnormalities of thyroid gland structure and function may occur following treatment for childhood cancer either due to primary damage to the thyroid gland itself, particularly from neck irradiation, or secondary to damage to the hypothalamo-pituitary-thyroid axis. Chemotherapy is an independent risk factor for thyroid dysfunction.

Groups particularly at risk of thyroid dysfunction include those treated for thyroid cancer (which is very rare in childhood) and survivors of neuroblastoma who have received 131-I-MIBG. All will require thyroxine replacement therapy. Children with Hodgkin’s disease treated with radiotherapy to the neck have a significantly increased risk of hypothyroidism, thyroid nodules and thyroid cancer compared to those treated with chemotherapy alone. Transiently abnormal
thyroid function tests are common in the first few years after treatment but hypothyroidism may develop many years later.

Children treated with craniospinal radiotherapy are also at increased risk of primary hypothyroidism. Cranial radiotherapy is not associated with an increased risk of primary hypothyroidism but may cause 2ry/3ry hypothyroidism by damage to the pituitary/hypothalamus.

In the past children were treated with low-dose radiotherapy for a variety of non-malignant disorders (eg skin conditions or lymphoid hyperplasia). The risk of thyroid cancer in such groups is significant (<10% over 35 years (Pottern et al 1990, Favus et al 1976)). That radiation is indeed an important cause of thyroid cancer in children (Brill & Becker 1986) has been demonstrated by the effects of the short-lived radioactive fallout from the 1986 Chernobyl nuclear power plant accident (Shibata et al 2001).

The prevalence of thyroid dysfunction in survivors treated with total body irradiation seems variable, may be transient and can be secondary to thyroid or hypothalamo-pituitary dysfunction (Borgstrom and Bolme 1994, Katsanais et al 1990, Thomas et al 1993).

Survivors who have received radiotherapy to the neck, brain or spine should have their thyroid function checked after completion of treatment and regularly thereafter – surveillance should be life-long (SIGN Grade B recommendation). There are no good quality studies which address the question of screening for thyroid nodules or second primary thyroid cancers. Although ultrasound may detect more abnormalities than simple clinical examination, their clinical significance is unclear. Survivors at risk should be advised accordingly and asked to seek urgent medical advice if they notice a palpable neck mass.
Thyroid hormone replacement is safe and effective in a dose of approximately 100mcg/m²/day. Although there is no high quality evidence to support or refute the use of thyroxine in compensated primary hypothyroidism (clinical euthyroidism with normal free T4 but raised TSH levels) it is arguably sensible to treat such patients with thyroxine as persisting high TSH levels may theoretically predispose to malignant change due to thyroid hyperstimulation in these patients.

**Puberty and fertility problems**

The impact of combination cytotoxic chemotherapy on gonadal function is dependent on gender and age of the child undergoing treatment and the nature and dosage of the drugs received. Drugs known to cause gonadal damage include procarbazine, cytosine arabinoside, and the alkylating agents, particularly cyclophosphamide, chlorambucil, mustine, melphalan, busulphan, and the nitrosoureas. Both the testis and ovary are vulnerable to radiation damage (Waring and Wallace (2000)).

High dose (>24 Gy) radiotherapy to the hypothalamus/pituitary (eg for brain tumours) may result in delayed puberty whereas lower doses (<24 GY) are more commonly associated with early/precocious puberty especially in children treated when they are very young (Quigley et al 1989). Thus early puberty (in boys) and precocious puberty (in girls) are common sequelae in young children who have received cranial irradiation as CNS directed treatment for ALL. The pubertal growth spurt can be mistaken for ‘catch-up’ growth.

The majority of childhood cancer survivors are fertile. There are low risks of infertility following chemotherapy for Wilms’ tumour and ALL and following cranial RT <24 Gy. Abdominal, pelvic and total body irradiation may all result in ovarian damage (Saunders et al 1996). The human oocyte is sensitive to radiation (LD<sub>50</sub>&lt;2Gy) and the risk of ovarian failure increases with increasing doses of radiotherapy (Wallace et al 1989, Wallace et al, 2003). Infertility or subfertility is common after CT for Hodgkin’s disease RT (Thomson et al 2002). Ovarian failure
after TBI is common with the risk relating to age at treatment (younger children are at lower risk). Sex steroid replacement therapy is necessary if there is evidence of ovarian failure, from puberty through to at least the fifth decade, for bone mineralisation and cardiovascular protection.

In young adult women, physiological sex steroid replacement therapy (Critchley at al 1990,1992) improves uterine function (blood flow, endometrial thickness) so that these women could potentially benefit from assisted reproductive technologies (Bath et al 1999, 2001). However they have reduced uterine distensibility with increased risk of small-for-gestational-age infants and miscarriage or preterm delivery (Saunders et al 1996). They should be counselled appropriately and managed as high risk pregnancies by an obstetrician aware of the potential problems.

In boys, the germinal epithelium is much more sensitive to radiation than Leydig cells – 1.2 Gy to the testis will result in azoospermia, whereas >20 Gy (in prepuberty) or >30 Gy (post puberty) is necessary before Leydig cell function is damaged significantly (Shalet et al 1985). Thus spontaneous progression through puberty does not necessarily indicate subsequent fertility. Permanent azoospermia is likely in most patients receiving more than 4Gy.

The current management of ALL in children in the UK includes cyclophosphamide. Although the long term fertility for this group of patients is not known, the available evidence suggests that the total dose of cyclophosphamide (2-3g/m²) is unlikely to be sterilising (Wallace et al 1993). Treatment for Hodgkin’s disease in the UK with “ChlVPP” (Chlorambucil, Vinblastine, Procarbazine, Prednisolone) is known to cause gonadal damage particularly in the male and the agents implicated are chlorambucil and procarbazine. In a recent long-term follow-up study 89% of the males treated before puberty had evidence of severe damage to the germinal epithelium and recovery of spermatogenesis is unlikely. Around 50% of girls treated for Hodgkin’s disease
prepubertally with 6 or more courses of ChlVPP had raised plasma
gonadotrophin levels, but longer follow-up is needed to determine whether these
women have recovery of function or go on to develop a premature menopause
(Mackie et al 1996).

As part of their monitoring, childhood cancer survivors should have routine
assessment of gonadal function. Counselling is necessary for young people at
high risk of infertility and sperm cryopreservation must be made available for
post-pubertal boys at risk of infertility before treatment starts. Ovarian cortical
strip cryopreservation may allow preservation of ovarian function in the future but
remains entirely experimental (Wallace et al. in press). The Royal College of
Obstetricians and Gynaecologists and the British Fertility Society have provided
reports from working parties on the storage of ovarian and prepubertal testicular
tissue (refs) providing standards for best practice in the cryopreservation of
gonadal tissue. Strategies to protect the prepubertal testis from damaging effects
of CT or RT are under investigation (Meistrich et al 2000, Kelnar et al 2002).

**Cardiovascular morbidity**

Cardiovascular disease can occur as a consequence of cancer treatment and
contribute significantly to the late morbidity and mortality of disease-free survivors
(Truesdell et al 1994). The majority of cardiovascular damage is the result of a
direct effect by radiation and chemotherapeutic agents (particularly
anthracyclines), but an indirect contribution can occur from injury to other organs.

There are no randomised controlled trials examining the cardiotoxic effects of
chemo- and/or radiotherapy in the treatment of children and young people with
cancer. However there is strong evidence that anthracyclines such as
daunorubicin and doxorubicin cause cardiac damage in a cumulative dose-
related fashion (Pihkala et al. 1996). The mechanism appears to be focal
myocyte death with replacement fibrosis (Truesdell et al 1994). There is probably
no ‘safe’ dose – cardiac dysfunction can occur with relatively low anthracycline

Mediastinal irradiation increases the risk and incidence of coronary artery disease and myocardial infarction. Specific risk factors are high dose (>30Gy), minimal protective cardiac blocking, young age at irradiation and length of follow-up (Hancock et al. 1993). Patients receiving Total Body Irradiation for BMT conditioning must also be considered at risk. Whilst mediastinal radiotherapy appears to induce atheromatous lesions of the proximal coronary arteries (and similar lesions can be seen in the carotid bulb after cranial irradiation) there is no strong evidence that radiotherapy alters HDL blood lipid levels. Radiation damage has an additive effect to anthracycline cardiotoxicity.

The balance between useful and pragmatic assessment for cardiac dysfunction in those at risk is not easy to determine. The literature supports echocardiographic assessment at diagnosis and at regular intervals during treatment.

Children who have satisfactory left ventricular function on simple echocardiographic measures, and who have received modest cumulative anthracycline doses (<250 mg/m²) may benefit from three-yearly echocardiogram surveillance. There is no evidence on which to base recommendations for the monitoring of patients who receive larger doses.

Survivors of childhood cancer who are pregnant, considering becoming pregnant and those wishing to take part in competitive sports should have a detailed cardiological assessment.
Protective drugs (such as ICRF) are under investigation and may improve the prognosis in subclinical cardiotoxicity (Wexler et al. 1996). The data currently available do not support the routine treatment of the damaged heart with angiotensin converting enzyme (ACE) inhibitors such as captopril or enalapril. Although short term improvements have been demonstrated, studies are uncontrolled and not blinded and long term outcomes are unknown (Wexler et al. 1996).

Lifestyle changes (smoking cessation, improved diet, appropriate exercise) should be encouraged. There is no evidence to suggest restricting employment or limiting activities is beneficial. However the risks from competitive sporting activity and pregnancy are likely to be considerable and pre-pregnancy counselling is important so that women patients understand the risks involved.

**Renal morbidity**

Renal toxicity after successful treatment of childhood cancer is common and leads to a wide range of manifestations of variable severity, and may be irreversible. There are many causes of nephrotoxicity in children treated for malignancy, including the disease itself, chemotherapy, radiotherapy, surgery, immunotherapy, and supportive treatment. Assessment of renal toxicity should include both glomerular and tubular function. The two most commonly implicated agents are ifosfamide and cis-platinum. Ifosfamide nephrotoxicity usually affects predominantly the proximal tubule (causing a Fanconi syndrome), but may also impair glomerular function. Platinum nephrotoxicity (commoner after cis-platinum than carboplatin) causes glomerular impairment and hypomagnesaemia due to tubular damage. Unfortunately an incomplete understanding of the pathogenesis of ifosfamide or platinum nephrotoxicity has hindered attempts at developing protective strategies.
Cognitive, education, social, quality of life and psychological outcomes

Although during the course of cancer treatment children can miss substantial amounts of schooling, a decline in cognitive function is neither a frequent nor inevitable consequence of treatment for childhood cancer (Eiser 1998, 2002). There is a strong observed association between cranial irradiation and structural brain abnormalities (disruption of frontal lobe/basal ganglia connections, temporal lobe calcification and cortical atrophy). Their functional significance is more difficult to determine but impairment may be associated with vasculopathy, calcification and EEG abnormalities (Mulhern et al. 1999). Both structural abnormalities and cognitive impairment correlate positively with dose of brain irradiation and negatively with age at irradiation.

Thus, in the treatment of childhood cancer, cranial irradiation is an important risk factor for cognitive decline particularly in high dosage and young children. Regular review for such deficits should be part of follow-up for patients at risk (SIGN Grade D recommendation). This is likely to have significant resource implications. Screening annually using the Wechsler Intelligence Scale for Children (WISC) may be practical – if a problem is suspected, the patient’s cognitive function should be assessed more comprehensively.

The treatment of childhood cancer is likely to impact on educational, psychological and social functioning and thus the impact on overall quality of life may be considerable. Studies addressing these issues are largely observational and outcome measures assessed range from formal psychiatric and psychological assessments through self-completed questionnaires to socio-demographic variables (eg marriage or employment). Adverse outcomes with regard to employment and marriage are, indeed, common findings but the risk of bias in the studies is high. Frank psychiatric disorders seem uncommon but survivors do seem to be at risk of anxiety, low mood and low self-esteem. Again,
brain tumours and treatment with cranial irradiation are frequently reported risk factors for adverse psychological and social outcomes.

There are currently no prospective studies using standardised assessment measures which address particular interventions for preventing or managing adverse quality of life outcomes in these groups of patients.

2nd primary tumours and tumour recurrence

Current knowledge of the longer term risks of second cancers are based on treatments used many years ago, and there will be an inevitable delay before we can assess the longer term consequences of current therapies with confidence. Nevertheless, in the UK, there is a 1 in 25 risk of childhood cancer survivors developing a second primary cancer within 25 years of the primary diagnosis – an approximately 6-fold increased risk (Hawkins et al 1987). It is likely that this relates both to carcinogenic effects of anti-cancer therapies and genetic predisposition to cancer development. Thus the excess risk after all childhood cancers (except retinoblastoma) is related to the carcinogenic effects of radiotherapy and alkylating agents (Hawkins et al 1996, Tucker et al 1987a) and there is likely to be some element of genetic predisposition which would include, for example, constitutional mutations of the p53 gene (Neugut et al 1999).

The large second cancer excess after heritable retinoblastoma is attributable to the carcinogenic influence of both constitutional mutations in the RB gene and exposure of bone to radiotherapy and alkylating agents (Hawkins et al 1996, Tucker et al 1987a).

Second primary bone cancer affects about 1 in 100 survivors by 20 years from the original diagnosis (Hawkins et al 1996). Bone cancers, mostly osteosarcomas, are the most common solid second cancers observed after both heritable retinoblastoma and all types of childhood cancer except retinoblastoma (Hawkins et al 1996). About 7% and 0.5% (respectively) of these two groups of
survivors are affected by 20 years from diagnosis of the original childhood cancer. This corresponds to about 380 and 25 times the expected number of bone cancers respectively, and is attributable to the carcinogenic influence of both constitutional mutations in the RB gene and exposure of bone to radiotherapy and alkylating agents (Hawkins et al 1996, Tucker et al 1987a).

Second primary leukaemia is diagnosed in about 1 in 500 of UK survivors of childhood cancer by 6 years from diagnosis of the original childhood cancer, about 8 times the number expected (Hawkins et al 1992). Increased cumulative exposure to alkylating agents (Tucker et al 1987b) or epipodophyllotoxins (Hawkins et al 1992) increases the risk of subsequent leukaemia. In addition other topoisomerase II inhibitors, including the anthracyclines, appear leukaemogenic.

Second cancer is the leading cause of death in long-term survivors of Hodgkin’s disease, with exceptionally high risks of breast cancer among women treated at a young age. Breast cancer risk increases with increasing radiation dose up to at least 40 Gy. A radiation dose of 4 Gy or more delivered to the breast was associated in one study with a 3.2 fold (95% CI 1.4-8.2) excess risk. The risk increased to 8 fold (95% CI 2.6-26.4) with a dose of more than 40 Gy (Travis et al 2003). Young age at treatment has a major effect on risk of second malignancy after Hodgkin’s disease (Swerdlow et al 2000). Although absolute excess risks are greater for older patients, relative risks of several important malignancies are much greater for patients who are treated when young.

There is still considerable uncertainty concerning the long-term risks of the adult carcinomas observed most commonly in the general population, including carcinomas of the lung, large intestine and breast.
Follow-up of childhood cancer survivors

With improving survival rates there is an urgent need for effective and cost-effective long-term follow-up strategies to be developed (Wallace et al 2001). There is good evidence of wide variation in the extent to which survivors of childhood cancer are discharged from hospital follow-up (Taylor et al 2004).

Much of the evidence base in these areas is necessarily derived from descriptive longitudinal studies. Such studies are handicapped by the lack of appropriate control groups and small numbers of patients in individual studies. Whilst this introduces much greater risks of bias than from conclusions drawn from and recommendations based on well conducted randomised controlled studies, this should not devalue the importance of the recommendations derived from such studies. Indeed, many of the studies are distinguished by meticulous attention to detail and report patients enrolled into national and international clinical trials – high quality information describing potential late effects of childhood cancer therapies is available. A corollary of the current dearth of high quality interventional studies to prevent, modify or eradicate such late effects is that collaborative research will, in the future, need to be on a national or international scale.

Who should these patients be seen by? How often should they be seen? How should they be assessed and investigated? Adult cancer specialists are overwhelmed by the large numbers of patients with breast, lung and bowel cancers. In addition, the expertise for dealing with such problems is very different from that required for the appropriate follow-up of childhood cancer survivors.

It will be clear from the above discussion that the degree and nature of adverse long-term morbidity risk will depend on the site of the underlying malignancy, the type and intensity of the treatment given and the age of the child at treatment. Whilst most childhood cancer survivors will require long-term follow-up, this has major practical (e.g. geographical) and resource (e.g. expertise and financial)
implications. The British Cancer Survivor Study has been developed to obtain estimates of the risks of particular adverse health outcomes amongst survivors and their offspring and to investigate the variation in risk in relation to the types of treatment received. Such national population-based studies will provide a basis for the further development of long-term clinical follow-up strategies. Clinically-based research will require the maintenance of regular patient contact.

In the context of such developments it is likely that appropriate follow-up strategies will vary between patient / treatment groups. At one extreme, there are survivors for whom the benefit of clinical follow-up (beyond 5 years from treatment completion which equates with “cure”) is not established and for whom annual or even 2 yearly postal or telephone contact may be all that is necessary. Such patients would include those treated with surgery alone (eg stage I or II Wilms’ tumour survivors, some germ cell tumours) or low risk chemotherapy (eg single system disease such as Langerhans Cell Histiocytosis) – level 1 follow-up (table 1).

At the other extreme would be patients who have received radiotherapy (other than low dose (<24GY) cranial irradiation), bone marrow transplantation, or megatherapy (eg brain tumours, stage IV patients of any tumour type). They should be seen in a medically supervised late effects clinic at least annually and, until final height is achieved 3 to 4 times per annum – level 3 follow-up (table 1). The majority of patients on current protocols (eg chemotherapy-treated or those who received low dose (<24GY) cranial irradiation) would fall somewhere in between. In theory, nurse- or primary care-led follow-up on an annual basis might be appropriate – level 2 follow-up (table 1).

What is clear is that if late adverse effects are to be anticipated and monitored to optimise prevention and treatment outcomes this requires a wide spread of expertise. Multidisciplinary follow-up involving paediatric oncologist, paediatric endocrinologist, paediatric neurologist, radiation oncologist, paediatric
neurosurgeon, clinical psychologist, general practitioner, specialist nurse and social worker is necessary but, with so many health care professionals potentially involved, it would seem logical that there should be a particularly important role for a key worker for each patient. The primary area of professional expertise will vary with the nature of the patient and their treatment, the intensity (level) of follow-up required and local resources and practicalities. It could be a hospital specialist (e.g. paediatric oncologist), primary care doctor or specialist nurse. The latter could be a particularly appropriate co-ordinator for many of these patients but there is currently no formal training programme or career structure for such an individual.

The further development of evidence-based, therapy-based guidelines for follow-up (Kissen and Wallace 1995) are an important prerequisite for an effective and cost-effective follow-up strategy. Further information to guide and inform the future follow-up and management of childhood cancer survivors will come from national population-based cohort studies and large multi-centre clinical studies. Future randomised childhood cancer treatment trials should address systematically not only survival outcomes but also long-term treatment morbidities.

Follow-up outcomes should be audited carefully. As knowledge accumulates, it will be increasingly possible to determine and deliver appropriate levels of surveillance in relation to clinical need so as to deliver high quality care in a targeted, and thus effective and cost-effective, manner.
References


Kissen GKN & Wallace WHB (1995) Therapy based guidelines for long-term follow up of children treated for cancer. Published by PHARMACIA on behalf of the late effects group of the UKCCSG.


### Table one

Possible levels of follow-up more than 5 years from completion of treatment.

<table>
<thead>
<tr>
<th>Level</th>
<th>Treatment</th>
<th>Method of Follow-up</th>
<th>Frequency</th>
<th>Examples of Tumours</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>♦ Surgery alone  ♦ Low risk chemotherapy</td>
<td>Postal or telephone</td>
<td>1-2 years</td>
<td>♦ Wilms’ Stage I or II  ♦ Langerhans Cell Histiocytosis (Single system disease)  ♦ Germ cell tumours (surgery only)</td>
</tr>
<tr>
<td>2</td>
<td>♦ Chemotherapy  ♦ Low dose cranial irradiation (&lt;24Gy)</td>
<td>Nurse or Primary Care led</td>
<td>1-2 years</td>
<td>♦ Majority of patients (eg ALL in first remission)</td>
</tr>
<tr>
<td>3</td>
<td>♦ Radiotherapy, except low dose cranial irradiation  ♦ Megatherapy</td>
<td>Medically supervised late effects clinic</td>
<td>Annual</td>
<td>♦ Brain tumours  ♦ Post BMT  ♦ Stage 4 patients (any tumour type)</td>
</tr>
</tbody>
</table>
Appendix K
Position paper to the Guidance Development Group for
Child & Adolescent Cancer in the Specialist Area of
Paediatric Endocrinology

Helen A Spoudeas
D.R.C.O.G  F.R.C.P.C.H  F.R.C.P  M.D
Consultant in Neuro-Endocrine and Late Effects of Cancer Treatment in Children
& Adolescents and Honorary Senior Lecturer in Paediatric Endocrinology,
University College London Hospitals & Great Ormond Street

Title

Key issues and concerns raised by the Scope within the specialist area of paediatric and adolescent endocrinology and transition to adult endocrine needs.

Areas of particular input requested on

Composition of MDT’s and their skill mix
- Age transitions and transitions between different patient pathways
- Continuity of care
- Communication between professionals as well as families
- Involvement in decision making
- Access to information (for professionals & patients)
Biography

Dr Spoudeas has 15 years experience in Paediatric Endocrinology in a tertiary centre and has supported the endocrine late effects of cancer survivors at 3 centres (Great Ormond Street Hospital, University College Hospitals and The Royal Marsden Hospital) over that time. She completed her thesis on this topic in 1995 and continues to work in this area leading the neuro-endocrine support service to oncology at the North London Cancer Network, and solely servicing some 1000 patients with a large cohort of brain (>700), bone (100) tumours and bone marrow transplant (>50) patients.
SCOPE

Background
The Institutes’ service guidance states it will cross reference other documents as well as those mentioned in 2B of the Scope. It is important that these include:

- The NICE technology appraisal guidance No 42 (May 2002) on the use of human growth hormone in children with growth failure.
- NICE technology appraisal 64 (August 2003) on the use of human growth hormone in adults with growth hormone deficiency.
- Guidelines on adult clinical osteoporosis currently being developed by NICE.
- All the Type II Diabetes clinical guidelines (NICE) (Feb-Oct 2002) and the accompanying technology appraisal for insulin infusion, glitazoma and insulin glorgine (Dec 2002-Aug 2003).
- Guidelines on rare endocrine tumours currently being developed by multidisciplinary groups under the auspices of the UKCCSG and BSPED (available from Dr Spoudeas) to be published end 2004.
- Thyroid cancer society guidelines on thyroid cancer.\(^{(1,2)}\)
- Royal College of Physicians guidelines – pituitary tumours – which include references to childhood disease\(^{(3)}\).
- Fertility preservation strategies 2003 – report of BFS multidisciplinary group\(^{(4)}\).

References


**Comments**

- The current SIGN guidelines on long-term follow-up after childhood cancer (released 2004), although helpful in many areas, do not, in my opinion include adequate representation from the multiple stakeholders, professional organisations and patient groups consulted by NICE currently.

- As a result, although largely robust, they carry some important areas of potential disagreement in the recommendations made, particularly with what I would see as the ideal patient care pathway for the endocrine & neuro-endocrine follow-up of childhood cancer survivors.

- These discrepancies pertain to the key areas of age appropriate transitional adolescent and adult services, which groups of patients should be routinely assessed in an endocrine or reproductive setting (both paediatric and/or adult), and at which point in the patient pathway.

- In particular, the endocrine input to SIGN appears limited to the involvement of one individual who has also functioned as the methodologist for that group, without wider endocrine paediatric and adult specialist consultation. Given that 85% of the late effects witnessed in cancer survivors are potentially
(neuro) endocrine or reproductive in origin\(^{(1,2)}\) and can be pre-symptomatically detected and treated, this is a potentially important omission.

- Since this is an adult survivors issue\(^{(3,4)}\), the apparent absence of representatives from adult specialist experts or stake holders and allied professionals (particularly psychology, psychotherapy, educationalists, occupational therapists and physiotherapists), is also a weakness of the SIGN guidelines, although there is good representation from nurses and primary care.

**References**


**Summary of this Position Paper**

**Needs-Led Services**

- To service the needs of an increasing and accruing number of young adult survivors of childhood cancer, an appropriate age transition needs to be effected with collaboration from dedicated adult ambulatory services.

- Ambulatory and multidisciplinary one-stop cross-sectional and/or prospective assessment needs to be made available equitably to all cancer survivors as determined by their needs and requirements.
• Effective community, educational and job employment advice needs to be co-ordinated and facilitated through carers, counsellors, youth workers and social workers in these services for young adults.

• Endocrinology, fertility and secondary consequences of obesity are the most important and largest health-related consequences of cancer survival and need to be prioritised in age-appropriate endocrine and reproductive settings.

• Neuro-disability and/or cognitive impairment are particular challenges to long-term mental health, independence and employment and appropriate rehabilitative services need to be developed to detect and support those with brain injury, at an early stage.

• To facilitate prospective and complete detailed outcome data for future audit, investment needs to be prioritised towards developing electronic health care records available to multiple users at multiple sites, (including the patients themselves and doctors in primary care), facilitating electronic health follow-up by questionnaire and developing appropriate educational tools for professionals caring for these patients.

• Both professional and patient information needs enhancing and should be targeted to age-appropriate groups as videos, CD ROM’s, advertisements and web-enabled (as well as written) information for multidisciplinary collaboration.

• Governance issues and special standards frameworks preclude the follow-up of these children indefinitely in paediatric oncology centres. The development of new ambulatory services bringing in multiprofessionals and interfacing with both those adult survivors treated as adults, as well as those adult survivors treated as children, needs to be effected in tertiary/quaternary cancer centres.
• All children with cancer should be assessed by endocrinologists and/or reproductive health specialists at least once in their childhood (peri-pubertally 11-12yrs) and once in their young adult (at adult height 16-18yrs) lives. Preferably this should again occur at the end of their treatment and at adult transition (19yrs), so that patients can fully understand what benefits may accrue, and have contacts which they can re-activate as necessary.

• In my opinion every high risk patient who has a brain or CNS tumour, has received craniofacial, spinal, pelvic or thyroid irradiation, bone marrow transplantation, high dose or multiple therapy for relapse should be seen prospectively and regularly from diagnosis or the end of treatment on a 6 monthly basis to adult height in an endocrine setting. This should be mandatory for all patients with tumours involving an endocrine gland or situated close to it (including all central, optic, sella/suprasellar, pineal, hypothalamic tumours).

• All minors (<16yrs) multiply-treated or receiving known significantly gonadotoxic agents, as defined by UKCCSG recent guidelines, should be seen and counselled by an appropriately trained professional for fertility preservation techniques before treatment and followed subsequently in an endocrine and reproductive setting at the end of treatment, and at intervals thereafter, for reproductive counselling and HRT.

• The ideal multidisciplinary team should include age-appropriate professionals (paediatric, adolescent and/or adult), facilitating transitions at ages 12-13yr and 20-25yrs, and access to appropriate services. The core team should ideally include neurological, (neuro) endocrinological, (neuro) psychological, oncological, reproductive, cardiac and renal medical expertise, appropriate diabetic, psychotherapeutic, occupational and physiotherapy support, a dedicated CNS practitioner trained and experienced in endocrine, reproductive as well as, oncological counselling issues, and allied
professionals (including alternative and homeopathic therapists as appropriate), providing play therapy, career counselling, schooling advice and social work. Age-appropriate psychiatry would be a helpful addition and should at least consist of access to an identified individual with appropriate family therapy, systemic or cognitive behavioural skills, responsible for supporting those at risk of significant mental health issues and/or family break-down.
CONCERNS RAISED BY SCOPE

Redesign of services to meet need

- Infants, young children, adolescents, and young adults in their early 20's are considered in the scope. Thus, by definition, patients may present to adult specialists, making a better collaboration between paediatric and adult specialists in a multidisciplinary setting, vital. This collaboration might exist in both acute oncological care and rehabilitation. It is my impression that these two aspects of healthcare are better separated into 2 settings. On occasion they will need to occur hand in hand, as is the case in young people with brain tumours, (particularly those centrally positioned), those receiving high dose gonadotoxic chemotherapy (where fertility preservation and counselling will be required), and those undergoing heavy treatments (such as bone marrow transplants or high dose therapy). In others, it is possible that an end of treatment or 5 yr MOT type assessment will suffice. Importantly endocrine referral should be virtually routine at, 1) end treatment, 2) pubertal age, 3) end of growth and 4) adult transition.

- Professionals involved in acute oncological care may wish to be part of the late MDT rehabilitation team. This makes for good continuity of care but can sometimes inadvertently prevent non-oncological specialist and expertise information being equitably accessed by all patients. To avoid this, it is likely that those participating in the late follow-up MDT require adequate funding and recognition of their roles, under an identified key late-effects coordinator; this could be a paediatric late-effects nurse or late-effects consultant, responsible for the necessary timely referrals for specialist expertise. Once the referral has been made, certain basic recommendations for follow-up should be made, e.g. 5 yearly assessments for those who are at least risk, cross sectional assessments at age-appropriate transitions, or annual (6-12 monthly) intervals for those at sufficient risk of growth and endocrine abnormalities (see appendix 1*). However it is likely that endocrinologists
would prefer to follow patients on a 3-6 monthly basis to obtain a more
detailed picture of the risk-benefits balance of earlier intervention, particularly
in high risk patients.

- Benign as well as malignant tumours are considered as part of the scope,
where treatment is complex, including chemotherapy and radiotherapy. This
will include many tumours which currently present to neuro-surgeons or
endocrinologists rather than paediatric oncologists, (eg craniopharyngiomas,
thyroid tumours, adrenal tumours and rarer pituitary and parathyroid tumours
which form part of the MEN syndromes). These tumours are the current topic
of our multidisciplinary collaboration to develop consensus best practice
guidelines between the BSPED and UKCCSG aimed at improving the
outcome and survival of these rare cases. In these cases it may be more
appropriate that the key coordinator leading the treatment care pathways and
late effects pathways is an endocrinologist, (rather than an oncologist)
collaborating with oncology. In other cases, radiotherapists and/or neuro-
surgeons may wish to take the lead, but a multidisciplinary team also able to
deliver ophthalmological, auditory and neuro-psychological and neuro-
developmental assessments is important.

- This multiprofessional contribution is at least as vital, if not more so, than the
coordination of care by a key worker and currently remains unrecognised and
unfunded in the complex cancer care service provision. More resources
should be allocated up-front towards rehabilitation as well as acute therapy.

- Another model is the empowerment of the patient himself to drive his own
rehabilitation pathway through appropriate information and/or electronic
health record as necessary, or through a primary care physician.

- It would seem appropriate that the information technology develops to a
capacity to support the centralisation of this very important aspect of cancer
care and survival. This model needs considering under the ideal health care setting and services provision & whether or not this is delivered in secondary, tertiary or community care. I would favour a “spoke & wheel” service (see later).

**Key areas of Clinical Supportive Management**

It is an omission in the current scope that paediatric endocrinologists, endocrine surgeons and neurosurgeons are not mentioned as practitioners involved in the diagnostic services. Their particular relevance to those children presenting with brain tumours involving the pituitary area, or other endocrine tumours, cannot be underestimated.

Similarly under oncology treatment services, specialised endocrine/reproductive and late-effects nursing is not mentioned. This omission underlines the reasons for the under-funding of such support services to acute and chronic oncological care and requires rectification.
CLINICAL NEED FOR THE GUIDANCE

Age–Appropriate and Needs–Led Service

General Comments
This scope clearly defines the importance of community support staff and social care and the need for specific age-appropriate services.

- Age-appropriate services are also a stated aim of the Children’s NSF framework with an increasing awareness that children (<12yrs), adolescents (12-20yrs) and possibly also young adults (20-30yrs), should be seen in their own specific age-appropriate and needs-led services, in separate areas from older or younger age groups. The current practice of seeing survivors of childhood cancer in paediatric services, usually paediatric acute oncology services, I would see as inappropriate both for their long-term specialist and non-oncological rehabilitative needs and for meeting those needs in age-appropriate services.

- There are clearly governance issues if paediatric specialists continue to see patients well into adult life without appropriate training or support services in those areas, or without adult colleagues and their specialist expertise. The current SIGN guidelines suggest that patients’ needs are not adequately met solely by adult specialists, specifically adult oncologists, and highlight the need for appropriate training in this area, but they do not adequately consider the establishment of one-stop, age-appropriate multidisciplinary specialist rehabilitative surveillance services, which I would wish to see endorsed. The skill mix of such a service should be targeted to meet patient needs - based on disease and treatment related criteria (see later). For example psychological and/or psychotherapeutic services (with access to psychiatry and fertility) are an important part of the rehabilitation service for patients and their families whilst dedicated neuro-rehabilitative support to those with
significant brain injury from disease, treatment or treatment-related complications, carry evidence-based benefits in the longer term. Such early rehabilitative support has long been advocated for children & young people with brain and spinal tumours \(^1\) and more recently in adults with brain injury \(^2\), but access to such services is likely to be confined initially to specialist tertiary centres with dedicated funding streams. Equitability of access for all eligible patients becomes of real ethical concern, but patients themselves could be better empowered and demand these services through information about service provisions & follow-up/surveillance choices.

- The NHS needs to prioritise funding for better multidisciplinary preventative and rehabilitative care of such patients and develop collaborative services between adult and paediatric sub-specialists and between primary, secondary and tertiary care. In this way, better training and research in this area can be effected, patients needs can be identified and patient choice can be enhanced.

- Prospective national registries and audits of detailed, comprehensive, functional, endocrine and quality of life outcomes should be encouraged, to better determine levels of need, treatment-and-disease related toxicity and the as yet undefined contribution of social adversity. Such prospective outcomes have been lacking to date in UKCCSG clinical trials which have prioritised survival alone, without addressing the quality of that survival. In the absence of such data, changes to cancer therapeutic protocols have been driven by assumption rather than evidence as to treatment-related toxicity.\(^{3&4}\)

**References**


A) **Age-appropriate transitional services**

I would support the development of

a) **Integrated**, needs-led and assessment-based services for specific groups of childhood cancer survivors according to degrees of late injury.

b) In age-appropriate, one-stop, multidisciplinary settings in order to maximise knowledge and efficiency.

c) Such services should be delivered from tertiary centres in a “spoke & wheel” design with centralised data collection for the purposes of audit, education and treatment recommendations to primary and secondary care centres.

d) These services could conceivably interface well with late effects/neuro-rehabilitative services for young adult survivors of cancer treated in adulthood as well as childhood; such adults may have lesser levels of need, but likely similar issues and experiences.

e) Since long term cancer survival is very much poorer in adults than in children, the large majority of survivors of adult onset disease will have been treated for breast cancers, lymphomas and leukaemias and will have similar late effects.
issues to young adults treated in childhood for these conditions. An example of such a pilot development service is attached (appendix 2").

f) An interface between the adult and paediatric services, with professionals from both represented in the multidisciplinary ambulatory setting separate from acute oncology, would be ideal for future research, service provision and training of future health professionals. Such a service might be better termed a “SUCCESS” service (SUrviving Childhood Cancer, Empowerment, Surveillance & Support) than a “Late-Effects” or “After-Cure” service which lacks specificity.

B) Childhood & adolescent population

Schooling, Neuro-disability Liaison & Endocrine Need (85% of the “late” problem)

- A single screening tool devised to identify endocrine and (neuro-) psychological needs in a dedicated multidisciplinary “after-cure” rehabilitative and surveillance service should be a necessary part of the end of treatment assessments for all children with cancer. Leaving these assessments for a period of 5 years until “cure” has been defined, may be too late for some, compromising quality of life issues such as (HRT) hormone replacement therapy, obesity, peak bone mass, or age-appropriate puberty(1), sexual(2), reproductive(3) potential and schooling & employment(4).

- Given that survival rates are high(5) each child cured of cancer has a further 68 yrs of potentially reduced quality of life ahead (compared with 10yrs for each adult). The vital importance of early (neuro)-rehabilitation back into their community, education & future employment cannot be understated. This process is currently neither streamlined according to need nor equitable for all groups of patients across the UK. The “after-cure” care services for long-term survivors have traditionally been seen as of secondary import to those of
acute cure and received consequentially less attention, NHS prioritisation and funding \(^{(6)}\). This needs to change.

- In particular the liaison with schools and with further educational colleges for the identification and support of specific learning needs, (up to the age of 19), should be a vital part of services for every child\(^{(4)}\).

References


- Those deemed at particular risk, high dose therapies, identified from screening assessments\(^{(1)}\), or brain-injured, (ie: CNS tumours, cranially irradiated or multiply treated) should be prioritised for additional support and assessments from psychologists, (eg: clinical, educational or neuro-psychologists) physiotherapy and occupational therapy, visual and hearing assessments to aid in targeting support and concessions in school and prepare them for adult transitions. These assessments should be prioritised at important age and maturational transitions, such as entry into primary and
secondary schooling, prior to GCSE's and between the ages of 16-19yrs for young adult transitions. *(see example of pathway for neuro-oncology appendix1*)

• Career advice and support, from youth workers and/or career counsellors or social workers is vitally important at these adolescent transitional stages above. The input to adult transition is currently woefully absent, many patients and families struggling to access neuro-disability services, sheltered accommodation and structured employment, retraining and rehabilitation schemes\(^{(2,3)}\).

• To achieve the independence and employment which survivors require, certain high-risk individuals and their families may also need accessible child & family psychiatric/psychological/psychotherapeutic support and/or a period of inpatient assessment and neuro-rehabilitation in a dedicated special facility, particularly in young adult life.

• Those most in need with motor, sensory and neurological deficits, multiple pituitary deficits, visual and hearing impairments, cognitive impairments, which may progress with time, will require longitudinal assessments as they mature and particular help at adult transition.

• In some late-evolving or severe cases, appropriate assessments and support will be necessary in young adulthood and access to the appropriate brain injury and neuro-disability services, currently extremely difficult, could be better enhanced for those with significant brain injury and/or other physical and psychiatric disabilities. This small but important and growing group of brain injured survivors (some 30-40%of all survivors) has repeatedly been neglected in the many reports of late effects, which have largely concentrated on cross sectional hormonal and growth assessments in other survivors,
(potentially treatable and preventable) rather than more in-depth analysis of causation of specific organ dysfunction \(^{1-3}\)

**References**


**C) Need - Adult Population of Survivors**

- Prospective national data registries of endocrine, quality of life, functional & neuro-psychological assessments from diagnosis to adult life which include all relevant treatment protocols and account for missing data are becoming increasingly important to identify needs for “rare” tumours, such as children’s cancer generally, not withstanding specific very rare tumour groups within this category. This is especially the case as cancer treatments become more intensive and prolonged with heavier chemotherapy and its multiplicity of late side effects, as well as the potential for additive toxicity where two treatment modalities co-exist. There is a widespread belief that systemic chemotherapy has no central neuro (endocrine) toxicity, but this is clearly not the case as exemplified by growth hormone abnormalities\(^1\) and platinum ototoxicity in children with brain tumours. All children will require careful endocrine surveillance beyond adult life as deficiencies evolve\(^5\). There is assumption that chemotherapy alone has little neuro (endocrine) toxicity, but this is clearly not the case\(^{1,4}\).
• Whilst we are in a position to only accrue retrospective data on those who survive and are seen comprehensively in the above tertiary endocrine and rehabilitative settings, we are unable to document the size of any problem or determine the best interventional therapy. New treatment strategies change the picture; fertility protection strategies are increasingly available on an "ad hoc" basis but they are currently not funded and their risk benefit profile or cost efficiency is unknown\(^{(6&7)}\). Randomised studies in this area have never been performed and without adequate documentation of the outcome of both those who do and those who do not undergo such treatments, we will be unable to determine this in the future. The current endeavour (Nov’03) by the late-effects group of the UKCCSG to collect such data prospectively over 1 year is therefore important, particularly as only 30% accrual to a national retrospective study of fertility after Ifosfamide regimen, has been achieved, but at best this can only be a single cross sectional snapshot of what exists at a given time. This is why prospective very long-term longitudinal data should be encouraged and collected anonymously.

• In the absence of prospective detailed endocrine and neuro-psychometric evaluations from diagnosis, before and after each therapeutic modality, much late toxicity in this area is blamed on the treatment itself, particularly cranial irradiation\(^{(8&9)}\). Arguably, however, it could be just as much due to the tumour itself, the surgery employed, the peri-operative complications and circumstances of psycho-social adversity, and inadequate rehabilitation as to the chemotherapy or radiotherapy employed to effect a cure. Recent studies have not confirmed previously held beliefs\(^{(10)}\) as to the causation of endocrinopathies observed after cranial irradiation.

• The “moving baseline” of constantly changing cancer therapies and the long lead time necessary for documenting late post-maturational organ toxicity\(^{(5)}\), means that much of today’s evidence of late-effects come from already outdated treatment regimens used 10-20 yrs ago in existing adult survivors.
This demonstrates the importance of comprehensive prospective longitudinal data collection on all treated patients whether or not they be survivors or on randomised trials within the UKCCSG, ensuring detailed treatment datas are available to all professionals caring for these survivors. The BSPED is working currently to try to achieve more comprehensive endocrine & QoL data collection through national endocrine registries for endocrine and brain tumour with the UKCCSG.

References


D) Make up of MDT

- Depending on the mix and needs of patients, different MDT’s could be established. The role of a new specifically trained CNS Practitioner to this service with oncological, endocrine and reproductive diagnostic counselling skills should be developed(1). Additional medical and allied professional expertise in neuro-oncology, neurology, including epilepsy, neuro-rehabilitation, (neuro)-surgery, (neuro)-endocrinology, (neuro)-psychology, occupational and physiotherapy as well as psychotherapy and career advice from a youth worker, teacher or educational psychologist may all be required for brain injured survivors of CNS tumours or CNS directed therapy (eg: intrathecal or systemic chemotherapy, cranial irradiation and/or cerebrovascular accidents, high dose or multiple intensive therapy) with subsequent cognitive impairment, and potential neuro-psychiatric disorders. The latter has been particularly under-investigated but is potentially treatable, and is the subject of a recent grant proposal submitted to the CRUK from UCLH (Paediatric Endocrine Dept) Cambridge (Department of Neuro-psychiatry) and Birmingham (British Childhood Cancer Survivor group).

- Specific rehabilitative inpatient assessment units (eg: the multi-disciplinary teenage assessment service at UCLH) need to be made more available to
specific groups of needy individuals, with a view to better in-depth assessments of need, and enhancing independence.

- The ultimate aim of this service guidance is to improve quality as well as quantity of survival. As children mature it is clearly important to obtain their own perspective, (increasingly shown to be different from that predicted by parents’ and professionals) and ascertain their needs.

- I would argue that a paediatric endocrinologist (and ultimately a reproductive or adult endocrine specialist) should be involved from an early stage in the assessment of growth, development, puberty, and reproductive health after cancer and that any multidisciplinary team supporting long-term rehabilitation and surveillance for childhood cancer survivors should at least include these two members of the team.

E) Professional/Specialty expertise – the importance of endocrinologists

- Whilst it is clear that many paediatric oncologists are developing expertise in the area of late toxicity, given that 85% of late effects are hormonal in nature and affect up to 70-90% of survivors, most patients would benefit from an independent expert assessment of growth, puberty, fertility and future bone and reproductive health from an endocrine and reproductive specialist at least once.

- To be equitable, these services should be accessible to all survivors at preferably 4 cross-sectional periods (eg; a) at the end of treatment, b) onset of pubertal age, c) at the end of growth, d) as a young adult), this being combined with a psychological/psychotherapeutic, Quality of Life or functional assessment questionnaire at the same time. In other words, certain MOTs could be performed in the tertiary setting (“spoke”) with recommendations
made to secondary and primary care ("wheel"). *(Recommendations for assessment and earlier referral could be made as per appendix 3)*.

- Other more intensively treated high risk groups of brain tumours, especially where centrally positioned, those receiving high dose therapy, bone marrow transplantation or cranial irradiation should be prioritised for expert assessment from an endocrinologist soon after treatment has finished and at least annually thereafter.

- Those with tumours in endocrine glands or very closely situated to them or tumours positioned centrally in the brain, which can have life threatening effects from pituitary dysfunction *(2)* should be assessed at *diagnosis* by endocrinologists as well as oncologists; a collaboration to achieve better registration and treatment for these rare diseases is currently in progress (UKCCSG rare tumours group and the BSPED endocrine tumours group) & will report by the autumn of this year.

- Those whose treatment protocols put them at significant risk of sub-fertility should be pre-pubertally assessed and counselled regarding fertility preservation techniques by someone suitably trained in all the pertinent areas of counselling, pubertal assessment, legal aspects of consent and gamete cryopreservation & storage *(3)*.

- As children mature, their information and development needs change. By nature of their speciality, endocrinologists are very used to issues of adolescent transition, Quality of Life (as opposed to life saving decision making), and counselling (eg: with respect to short stature and infertility), the dangers of hypothalamic hypopituitarism, thirst & sleep disorders, obesity and secondary glucose intolerance. The latter is a likely consequence for the large majority of survivors *(4&5)*.
• Adult endocrine transition services for monitoring consequent endocrine problems which include adult growth hormone deficiency\(^{(6)}\), osteopenia, hormone replacement therapy, assisted reproductive technology, secondary insulin resistance & diabetes, panhypopituitary, cardiac, renal & other health-related risks are necessary to alleviate and potentially prevent these important consequences (see attached articles for review).

• Hypopituitarism and hormone replacement therapy also impact on quality of life. HRT even in the pre-symptomatic patient, can prevent decline in health & well being, decrease mortality from hypopituitarism and its related complications\(^{(7,8)}\). The effects of hormone deficiency are subtle and difficult to recognise and the interpretation of endocrine tests in different centres, using different methods of assessing hormonal reserve, require interpretation by those appraised of its difficulties and pit falls\(^{(9,10)}\). Equally, to the untrained eye, advanced rates of growth from precocious sexual maturation, or obesity, can be mistaken for catch up growth and their underlying endocrine implications missed depriving the patient of potentially beneficial treatment intervention to enhance growth and sexual reproductive capacity.

• Many of the late-effects of treatment relate to oncology therapies; however they can equally reflect primary as well as secondary neuro-endocrine issues which might pre-date treatment as well as result from it. Thus specialised endocrine nurses are likely to be of enormous help particularly in the management of neuro-endocrine conditions in the MDT setting (eg: in the assessment of the adipsic and hypopituitary patients, in the assessment of growth & puberty and in the education of patients and families in the management of hypopituitarism and diabetes insipidus and emergency Hydrocortisone rescue. Age-appropriate and adult specialist endocrinology and endocrine nursing support should be a part of the MDT late-effects service. This is especially required for brain tumours, tumours of the endocrine glands or treatment related endocrine toxicity, or where high dose
steroids are used as part of treatment and may cause adrenal suppression (1&11).

References


F) Information technology development - The need for audit

Audit – Suggested Requirements to Identify need

- The audit of long-term quality of survival and toxicity issues after childhood and adolescent cancer needs to be prospective and long-term. Most existing studies lack the denominator of patients and are retrospective in nature. There are few, if any, detailed prospective and longitudinal outcomes and these registries are currently being discussed for rare endocrine tumours with pump-priming pharmaceutical company support. Since there are only about 300 brain tumours and endocrine rare tumours annually in the UK, it is not an impossible task to collect endocrine data on all such patients over a 5-10yr period at 6 monthly intervals. This could potentially be combined with functional and quality of life measurements at appropriate longer intervals. Such endocrine outcomes would include detailed weight, height, sitting height, skin fold thicknesses, puberty staging, thyroid, gonadal and pituitary function tests and their relation to functional status, health-related quality of life, HRT treatment, adult bone mineral density, body mass index, reproductive status, thyroid and pituitary function, systolic cardiac function, lipid status, & potential for atherogenesis. Quality of life & tubular renal function would be added because of their relationship to adult growth hormone deficiency and osteoporosis respectively. Semen analysis, ovarian and uterine size and other pelvic assessments are appropriate in adult life in patients contemplating pregnancy and pre-pregnancy risk assessment.
Specific other endocrine data will be required on patients with adrenal disease and/or panhypopituitarism.

- The whole service could be better streamlined with a specifically tailored, web-enabled and password protected, electronic health care record for the centralisation of all data, the standardisation of any treatment recommendations, streamlined access to the personal cancer treatment history for multidisciplinary professionals (potentially at many sites) and providing information to patients, schools, employment and community networks. This needs to be given priority as a currently achievable goal, given the NHS IT strategy. This is a recommendation of the NSF Diabetes framework, another long-term chronic illness with similar issues of transition and self-empowerment.

- This endeavour would support standardised prospective and longitudinal data collection of outcomes of interest to ascertain the best interventional strategies for preventing and/or curing late organ dysfunction. Specific endocrine, cardiac, renal, respiratory, quality of life, psychometric and psychiatric screening evaluations, undertaken nationally in a few dedicated centres, could improve the future quality of survival, just as national collaboration through the UKCCSG has improved the quantity of survival. (An example of a data driven form for such services viewed in a paediatric setting (appendix 4*) and adult setting (appendix 5*) are included.)

- The recognised difficulties in collecting prospective data over many years mean that innovative ways of collection through collaboration with interested other societies and their professionals (e.g. the endocrine, fertility and neurological societies) could benefit patients, particularly those at greatest risk. The latter could most helpfully be considered as those who are most intensively or multiply treated or where disease involves a vital organ such as the brain or reproductive tract.
Palliative care

- It is my understanding that palliation includes the alleviation of suffering in those living with, as well as dying from, an incurable disease. Several patients surviving brain tumours, high dose therapy, total body or spinal, craniofacial or pelvic irradiation, will have incurable and possibly painful secondary consequences which require long term support. This potentially palliative service should not be underestimated in its importance. An increasing number of survivors are being recognised to suffer from chronic fatigue symptoms (anecdotal case reports), (currently unexplained) severe hypothalamic disturbances (1), obesity, thirst and water imbalance and the secondary consequences which follow (diabetes and heart disease being of particular concern) (2&3). Services established to support these disabilities might also be considered palliative, particularly where suffering becomes extreme, limits quality of life, self esteem and adult independence and perhaps causes the suicides noted(4). This is a particularly under-researched area of cancer survival and one which has potentially very important funding implications. Inpatient or ambulatory assessment services may need to be developed to support those with chronic disease and the role of complimentary or alternative therapies is still to be explored.

References


**Support services**

**Information & Access:**

- Better community, primary and secondary care liaison and information is necessary. If we are to enhance ultimate independence in those most at risk, we might require access to family therapy, behaviour and intervention strategies, improve school awareness of the needs of children, enhance access to neuro-disability services & social housing, career advice & job opportunities in adulthood. An example of how this might look for a child with a brain tumour is attached (Appendix 1*). This aspect of transition is particularly poor are present, many families being unaware and unable to easily access specialised services for the visually or hearing impaired or distressed young adult. Part of this arises from the fragmentation of care of survivors in different specialities and in age inappropriate settings (an example of endocrine and sperm banking leaflets are in Appendix 6&7*).

- Although we know survivors are less likely to be employed, form sexual and peer relationships or become parents, and lack self esteem and confidence (1), the necessary career counselling and psychometric evaluation to inform and support future employment & rehabilitation in the adult work place is severely lacking. Long term adult depression is a potential concern in those cognitively impaired (2) but it is treatable and could improve function and quality of life. More psychotherapeutic, diagnostic and therapeutic strategies are necessary to effect adult transition and independence. A specific information-giving MDT assessment is potentially beneficial at this stage for all young adult survivors.
• These MDT assessments are not easily available or appropriate in the paediatric oncology departments where these patients are currently predominately seen. It is my view that a few tertiary/quaternary specific young adult services need to be developed which should be reasonably accessible through self or GP referral (e.g. via newsletters to survivors or Internet). These services could provide information (see earlier IT section also) and perform needs assessments to deliver appropriate information and rehabilitative strategies to survivors, including hormone replacement, +/- career advice, independence skills and access to information, and social health care. Individuals could thus be empowered to make their own choices at times appropriate to them.

• The voluntary sector may be able to assist in some of these areas and better information and links need to be established to specific existing units.

• In addition, 5 yearly ‘MOT’ assessments could be offered to all patients, if their record of care could be centralised and accessed remotely by primary and secondary care services. The necessary IT software could be developed to support this and the data collection, questionnaires and standardised hormone assessments, and treatment could be forwarded from the centre to the primary and secondary services as necessary, according to individual patient preference and funding. The most important development which would need to occur to facilitate this for all survivors, (rather than just those with high priority) is the development of a web-enabled, password protected, electronic health care record which meets the data protection criteria of the European union, is accessible by patient, primary, secondary and tertiary health care professionals, and carries levels of alert to the physicians involved. This could also provide information for the patient and feed data back through a centralised collection system to primary care so that appropriate appointments can be sent out as necessary for those patients deemed needy. A similar model has been proposed for diabetes. A local grant
proposal has been submitted from our Trust but at present no funding has been identified and this model does not exist elsewhere.

References

* Appendices are available from the NCC for Cancer upon request
Appendix L

Paediatric palliative care
A position statement

Dr. Richard Hain, Senior Lecturer in Paediatric Palliative Medicine, Department of Child Health, University of Wales College of Medicine

Sources 438

1. The nature of paediatric palliative care 438

2. The nature of children who need it 439
   2.1 Who are they? 439
   2.2 Where are they? 440
   2.3 What do they need? 440
   2.4 How should we ideally meet their needs? 441

3. What do we have in the UK at the moment? 442
   3.1 Strengths 443
   3.2 Weaknesses 443

4. What could we have in the future? 445
   4.1 Opportunities for development 445
   4.2 Practical challenges to developing good palliative care in children 447
   4.3 Summary 450

5. Recommendations 451
   5.1 Urgent needs 451
   5.2 Long term goals 451

6. References 453

7. Tables 455

8. Figures 465
Sources

This document draws largely on two sources of evidence:

1. That provided by families and professionals to the Association of Children with Terminal or Life-threatening illnesses and their families (ACT) in collaboration with the Royal College of Paediatrics and Child Health regarding palliative care for children, and for adolescents and young people (1-4).

2. Selected data from a recent regional research project (5) regarding children needing paediatric palliative care in Wales. The data (table 6, figures 1 and 3) included children referred for specialist paediatric palliative care, those who were reported by paediatricians to need palliative care but were not referred, and those who were referred to a children’s hospice. The full report is being prepared for publication as a scientific paper and can be made available to the Committee if required.

1. The nature of paediatric palliative care

“Palliative care for children and young people with life-limiting conditions [LLC] is an active and total approach to care, embracing physical, emotional, social and spiritual elements. It focuses on enhancement of quality of life for the child and support for the family and includes the management of distressing symptoms, provision of respite and care through death and bereavement.” (3)

Palliative care for children differs significantly from the adult specialty. Where adult services predominantly focus on cancers, children’s palliative care services must cater for a wide spectrum of very different conditions. Furthermore, in comparison with adults, the palliative phase in childhood is usually characterised
by greater uncertainty, and often by intermittent or fluctuating need for specialist involvement over many years or decades. The families of children with life-limiting conditions may in effect experience many ‘terminal’ phases.

2. The nature of children who need it

2.1 Who are they?

The range of conditions needing specialist paediatric palliative care is very wide. The Royal College of Paediatrics and Child Health, in association with the Action for Children with Life-Threatening diseases (ACT), has identified four groups of conditions (table 1). Cancer is an important example, and the single commonest condition, but a greater number (table 6) of children have life-limiting conditions that are not malignant (5).

By reviewing the available evidence, the ACT/RCPCH Guide concludes that around 10:10000 children aged 0-19 in the UK have life-limiting conditions (3), of whom 10% per annum will die from their condition. This approximates to 12000 children in England and Wales of whom 120 are likely to die from the condition in any one year. According to the Guide, 40 will die of cancer, around 20 from heart disease and 120 from other conditions. These figures are generally accepted, but may even be an underestimate (6-12).

A recent study (5) suggests that many are not recognised. The study also confirmed the ACT/RCPCH finding that for every one child with cancer, there are three with non-malignant life-limiting conditions with palliative care needs. Even among those who were recognised, for over one third of patients (36%) their paediatricians felt palliative care was inadequate. The usual reason was too little respite provision.
2.2 Where are they?

Flexible palliative care means that care should be available to children in whatever environment they find themselves. In practice, there are four main areas: home, school, hospital and children’s hospice (table 2). A specialist paediatric palliative care team should ideally be able to support all carers in all environments (fig 2). The exact nature of support will vary according to the needs of the individual child, family and team of professional carers (2).

2.3 What do they need?

A 1998 pilot palliative care project for the Department of Health (13) identified 17 specific needs for children and families with LLC (table 3). Paediatricians identified similar issues in their patients (5):

1. Coordination of services in community (97%)
2. Physical symptom control (95%)
3. Emotional etc. support for family (95%)
4. Respite (82%)
5. Discussing prognosis with family (79%)

These findings emphasise the multidimensional nature of PPC, and consequently the need for an approach that combines the skills of many different disciplines having in common expertise in working with children for whom cure is not, or is no longer, possible.

The RCPCH/ACT Guide authoritatively set out the scope of conditions that may limit the life of a child (table 1) but left some definitions unclear. It did not, for example, distinguish respite from other aspects of palliation, or define ‘active’ or ‘specialist’ paediatric palliative care. A working glossary for this document is given in table 4.
Doctors and nurses have a long history of working closely together in pediatrics and child health. Children’s palliative care in particular is a field in which the skill sets of doctors and nurses often overlap. It is often assumed that symptom control is the purview of doctors, and psychosocial issues are best dealt with by nurses. In managing children with LLC, while doctors are often skilled at physical symptom control and nurses at other aspects of holistic symptom management, both sets of skills can be found in members of both professions.

The skills in Table 4 therefore apply equally to nurses and to doctors. They do not abolish professional boundaries; doctors remain accountable to their profession for their own prescribing practice, irrespective of the degree of expertise of the nurse advising them.

2.4 How should we ideally meet their needs?

After wide consultation throughout England, Wales, Scotland and Northern Ireland, the RCPCH and ACT made recommendations regarding the ideal provision for pediatric palliative care in British regions (1, 3), which are summarised in Table 5.

In summary, they emphasise the need for a network with three key elements:

- A sound community children’s nursing infrastructure.
- Skilled medical support from general pediatricians with an interest and some training in pediatric palliative care (one per NHS trust) and from tertiary specialists in pediatric palliative care (one per region).
- Coordination and continuity of care through:
  - a system of named key workers and dedicated coordinators liaising with primary, secondary and tertiary care and also between statutory and voluntary providers of pediatric palliative care.
  - multidisciplinary teams
- an appropriate documentation system based on parent or patient-held records.

3. What do we have in the UK at the moment?
Services were recently audited against these ACT/RCPCH recommendations (table 5) in Wales. It seems likely the results are representative of the UK as a whole, suggesting that while there are some areas which are progressing, there are others in which improvement is still needed even five years on.
### 3.1 Strengths

- A small number of tertiary specialists in paediatric palliative medicine.
- A small number of general paediatricians developing a special interest in PPM.
- A small number of general practitioners working within children’s hospices developing a special interest in symptom control.
- Well-developed subspecialty outreach models of care, involving highly trained and experienced Clinical Nurse Specialists in a variety of subspecialities including oncology, respiratory, neurology and neonates.
- A network of 20 – 30 children’s hospices providing high-quality respite care, generic and semi-specialist palliative care (2).
- Diana Teams in many parts of the UK, providing nursing care to dying children at home (14).
- Beacon developments in community provision of generic palliative care.

### 3.2 Weaknesses

- Still very few consultant specialists in paediatric palliative medicine.
- Weak research and evidence base: practice often anecdotal or drawn from adult practice.
- Very small academic base. There is only one medical senior lecturer in paediatric palliative medicine in the UK, and few academics from nursing or other disciplines.
- Very few training opportunities for doctors, nurses or other disciplines wanting to make care of dying children their main interest.
- Tendency of each provider of palliative care to children to see themselves as the only, or the main, providers rather than as part of a group of services.
- Inconsistent provision of community paediatric nursing teams across the country.
- Slow (though often well coordinated) access to continuing care funds.
- Little specific provision for adolescents.
- Clinical record-keeping and audit
palliative care such as the Avon Lifetime Service (10, 15).

- Numerous voluntary and charitable services providing resources that overlap, sometimes substantially, with palliative care.
- Unified community and hospital trusts in many health districts, facilitating transfer of inpatients into home.
- Well-developed adult palliative care services serving as a model from which the paediatric specialty can learn.
- Increasing numbers of paediatric palliative care training programmes for nurses and one course for doctors. There is a larger selection of resources for adult palliative medicine which are of less relevance but may still be useful to those working with children.

system do not cross boundaries.

- Inconsistent professional supervision of carers.
- Lack of regional or national databases of children needing palliative care.
- Lack of consistent child psychiatric support in most regions.
- Lack of child bereavement facilities.
- Lack of therapeutic supervision for carers.
4. What could we have in the future?

4.1 Opportunities for development

4.1.1 Paediatric palliative medicine
The multidimensional nature of palliative care means that it cannot be provided exclusively by any one profession. Traditionally it is an area of care that nurses have taken more seriously than their medical colleagues. Increasingly, however, doctors are recognising the role that they can play in supporting nursing and other colleagues in caring for dying children. There are currently six consultant specialists in paediatric palliative medicine, of whom one is a nurse and five are doctors. They are dispersed as follows: Great Ormond Street, London (2), Cardiff (1), Alder Hey, Liverpool (1 nurse, 1 doctor) and St.James’ University Hospital, Leeds (1). There is a paediatric oncologist in Southampton with two sessions dedicated to palliative medicine in children with cancer. There is an increasing number of consultant paediatricians taking on palliative medicine as a special interest, and some children's hospice GPs who are undergoing further training in order to become ‘GPs with a special interest’. Numbers are not exactly known, but based on current membership of the British Society for Paediatric Palliative Medicine are probably around 40 or 50.

4.1.2 Education
There is no recognised postgraduate clinical training for nurses in paediatric palliative care. There are, however, academic MSc courses at Oxford Brookes, King’s College and Newcastle among others. Most of these are open to doctors but in practice do not meet the needs of those wishing to specialise in paediatric palliative medicine.

Postgraduate training for paediatricians is available in two centres: Great Ormond Street London, and Cardiff. Both are 12-month SpR posts for paediatric trainees who have completed their core paediatric training. There is a post in
children’s hospice medicine at Helen House Children’s Hospice designed for GP trainees, which could also be accessed by paediatric trainees at the discretion of their Deanery.

There is a paediatric option for the distance-learning Diploma in Palliative Medicine based in Cardiff.

4.1.3 Research
Both paediatrics and palliative medicine rely heavily on the use of therapeutic approaches that may have little evidence base. The use of medications for unlicensed indications illustrates this and is common in both (16-18). It is doubly difficult to find a good evidence base on which to build good palliative medicine in children, yet a rational and therefore compassionate approach requires that one should be found. There are very few academic centres of research excellence in palliative care in children, and only one consultant senior lecturer.

The need for education and research emphasises the importance of developing academic support for PPC and indicates a need for academic departments that combine both nursing and medical academics (1-3).

4.1.4 Children’s Hospice
Children’s hospices represent an important resource for children with LLC (2). Between 25% and 50% of children referred for specialist palliative medicine (fig 1) have also used a children’s hospice (2, 5). Children’s hospices can provide high-quality specialist respite in a comfortable ‘home from home’ environment, and are staffed in such a way as to allow them to address many of the psychosocial and spiritual needs of the child and family that are difficult to approach in more acute hospital settings. They therefore provide much-needed generic and semi-specialist palliative care. With appropriate specialist medical and nursing input, children’s hospices can also potentially provide specialist palliative medicine for cases where families choose not to remain at home during the palliative phase.
Properly supported, hospices could potentially provide a wide range of other services such as child bereavement services and complementary therapies. Links with hospital and community services could be developed further, particularly with hospices that offer a community nursing service. Allowing nurses on a community paediatric nursing team to rotate through children’s hospices would increase flexibility and continuity as nurses could be deployed there according to the child and family’s need. The experience of staff at children’s hospices is a resource for developing palliative care education.

The hospices themselves are a resource which should be valued and developed through political and professional dialogue. Robust and fair contractual arrangements should take account of regional needs. Simplified access to continuing care packages that include hospice care would improve utilisation.

4.2 Practical challenges to developing good palliative care in children

4.2.1 Commissioning
The impact of suboptimal care for a dying child is very significant, most obviously on the family but also on professionals and society as a whole. Most individual PCTs will, however, encounter relatively few children with life-limiting conditions and there is a risk that they will accord paediatric palliative care an inappropriately low priority for commissioning. Like many tertiary specialities in children, paediatric palliative care services may need to be commissioned on a different basis from their adult equivalents (1-3).

4.2.2 Continuing care
Current mechanisms for accessing continuing care funds are unwieldy and can result in a delay in providing services (1-3). The main cause for this is the lack of a tripartite funding agreement between Social, Education and Health services.
All children with LLC need all of medical, educational and social support (19). Much time and effort are wasted drawing arbitrary distinctions between them. While the exact proportions are of course different for each child, they are to a large extent predictable on the basis of the diagnosis. Incomprehensibly, the presence of a medical condition is sometimes taken to imply less of a need for educational or social service funding. Furthermore, there are particular difficulties getting funding across administrative boundaries, especially where the three are not coterminous.

One solution is a nationally centralised Tripartite Fund for children with LLC, to which all three budgets would contribute on the basis of average need in the region. Access should be automatic at diagnosis of a LLC, and be based largely on the anticipated needs of a child with that condition.

4.2.3 Record-keeping
The nature of paediatric palliative care is that it takes place in a number of different clinical environments. The same child may need the same sort of care to be delivered at home, school, hospital and hospice within the same week. CNS and consultants in paediatric palliative care, other CNS and consultants, GPs, and therapists will all need to add to the notes. It is essential that a robust system of record-keeping be developed that allows the records to be available to all professionals who are involved in the care of the child. The best way to achieve this is through patient-held records, paper or electronic. In order to minimise the risks as part of clinical governance, these must be subjected both to clinical review as necessary by the responsible consultant and to regular audit.

4.2.4 Access
In practice, access of children to palliative care services is also potentially limited by a number of other factors including:
**Culture**
Palliative care services for children, particularly children’s hospices, are often poorly accessed by those from ethnic minorities (unpublished data), who because of inherited conditions are over-represented especially in RCPCH group III. Culturally-appropriate support for families with children with LLC should be developed.

**Geography**
Children in rural areas in particular may be difficult to access by specialist nurses and/or doctors. A flexible system for supporting local primary care teams is therefore particularly important (fig 2). The importance of geography in influencing the likelihood of an appropriate referral (fig 3) has been shown in Wales (5).

4.2.5 Clinical governance - the need for specialist support and training
Nurses caring for dying children can acquire considerable experience and many become *de facto* prescribers through their advice to medical colleagues. This raises important issues regarding clinical governance. It is likely that NHS trusts would be criticised for allowing nurses to remain in this vulnerable position without providing them with appropriate specialist paediatric palliative care training and support. Furthermore, there is little formal provision for clinical supervision. To address these clinical governance issues, it will be necessary to develop adequate structures for training and supervision, as well as patient care pathways and guidelines. These will need to originate from specialist nurses and paediatricians in paediatric palliative care.

4.2.6 Lack of facilities for adolescents
It is becoming clear that there is a dearth not only of respite facilities for those over eighteen, but also of services for adolescents and young adults with more specialised palliative care needs. This has been the subject of a recent detailed survey by ACT (4). Its recommendations are summarised in table 7.
4.3 Summary

Children with life-limiting conditions, malignant and otherwise, have needs that are in common, and mark them out as a group distinct from other children. It is our experience that this is not yet widely recognised, and that boundaries too often cut across their care. The result can be provision that is poor and patchy or simply delayed by division and duplication.

Paediatric palliative care is expanding in the United Kingdom. There is considerable semi-specialist skill among doctors and nurses, and enthusiasm among a wide range of other professionals who have a part to play in developing a seamless service that is flexible enough for the needs of individual children and families. At the same time, interested doctors and nurses are increasingly taking forward more specialist skills. Such development could be threatened by a weak infrastructure in generic medical and nursing skills, particularly by poor community paediatric nursing provision.

Respite provision by children’s hospices is of extremely high quality but can cater for only relatively small numbers. Children’s hospices are rarely the sole providers of palliative care to a family. There is a need to consolidate the position of children’s hospices in the wider framework of care to children with LLC, through professional contact and fair funding arrangements, and to expand statutory home and inpatient respite provision.
5. Recommendations

5.1 Urgent needs

- Establishment of commissioning arrangements for a palliative care network for children.
- Establishment of multidisciplinary teams in paediatric palliative care as per ACT/RCPCH model (table 8).
- Expansion of consultant-led tertiary services as per ACT/RCPCH model.
- Establishment of multiprofessional academic departments of paediatric palliative care in order to:
  - Expand teaching opportunities for doctors and nurses in particular.
  - Expand research and evidence base for palliative care in children.
- Expansion of SpR training opportunities:
  - More numbers.
  - Broader training to include children’s hospice work as well as specialist palliative medicine in children.
- Expansion of nursing training opportunities:
  - To combine paediatrics and palliative medicine.
  - Beyond oncology (‘non-cancer oncology outreach nurses’).
- Establishment of community paediatric nursing teams (including further Diana Teams) where they do not exist currently.
- Robust and fair funding arrangements with children’s hospices, including appropriate sessional commitments from professionals employed in statutory sector such as specialist physios, speech and language therapists and consultants.
- Formal provision of clinical supervision and psychology services for those working with dying children.

5.2 Long term goals

- Development of adolescent and young people’s palliative care services.
• Record-keeping and audit system that crosses home/hospital/school/hospice boundaries.
• National register of children needing palliative care.
• More inpatient respite provision.
• Development of primary care paediatrics.
• Review of continuing care funding arrangements.
• Education resources for professionals allied to medicine, educationalists and other carers.
• Development of child-specific chaplaincy.
• Expansion of child psychology and psychiatry service.
• Unification of community and hospital paediatric services.
6. References


### 7. Tables

**Table 1:** Conditions that may need paediatric palliative care (1, 3).

| **Group 1:** Life-threatening conditions for which curative treatment may be feasible but can fail. Palliative care may be necessary during periods of prognostic uncertainty and when treatment fails (e.g. cancer, cardiac anomalies). | **Group 2:** Conditions in which there may be long periods of intensive treatment aimed at prolonging life and allowing participation in normal childhood activities, but premature death is still possible (e.g. cystic fibrosis, muscular dystrophy). |
| **Group 3:** Progressive conditions without curative treatment options, in which treatment is exclusively palliative and may commonly extend over many years (Batten’s disease, mucopolysaccharidosis). | **Group 4:** Conditions with severe neurological disability which may cause weakness and susceptibility to health complications, and may deteriorate unpredictably, but are not considered progressive (e.g. severe cerebral palsy). |
Table 2: Clinical environments in which children needing palliative care may be found (CNS – clinical nurse specialist, SN – school nurse, LSA – learning support assistant, NNEB – nursery nurse, SW – social worker).

<table>
<thead>
<tr>
<th>Environment</th>
<th>Royal College Groups</th>
<th>Main Primary Carers (not exhaustive)</th>
<th>Palliative care offered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Home</td>
<td>All</td>
<td>Parents</td>
<td>Respite Generic palliative</td>
</tr>
<tr>
<td></td>
<td></td>
<td>District nurses</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CNS (groups 1 &amp; 2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>GPs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SW</td>
<td></td>
</tr>
<tr>
<td>School (Special and mainstream)</td>
<td>1, 2, 3, some 4</td>
<td>Teachers</td>
<td>Respite Generic palliative</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LSAs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nurses (SNs, CCNs)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>NNEB</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Community therapists</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Community paediatricians (groups 2, 3 &amp; 4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SW</td>
<td></td>
</tr>
<tr>
<td>General inpatient paediatric unit</td>
<td>Mainly 1 &amp; 2 3 &amp; 4 occasional visits</td>
<td>General/subspecialty paediatricians</td>
<td>Generic palliative Semi-specialist palliative (especially symptom control)</td>
</tr>
<tr>
<td>Specialist inpatient paediatric unit</td>
<td></td>
<td>Ward paediatric nurses</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital therapists</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CNS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical psychologist</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SW</td>
<td></td>
</tr>
<tr>
<td>Children’s Hospice</td>
<td>2 &amp; 4 Occasional 1 &amp; 2</td>
<td>Carers</td>
<td>Respite Generic palliative</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Children’s nurses</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>GP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Often SW</td>
<td></td>
</tr>
</tbody>
</table>
Table 3: Main needs of children with LLC summarised from pilot projects in England (13).

<table>
<thead>
<tr>
<th>Needs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normalisation of life as far as possible, e.g. continued access to play and education, and contact with friends and peers</td>
</tr>
<tr>
<td>Information and advice about the condition and its treatment</td>
</tr>
<tr>
<td>A 24-hour helpline</td>
</tr>
<tr>
<td>Benefits advice</td>
</tr>
<tr>
<td>Practical help in the home</td>
</tr>
<tr>
<td>Help with transport</td>
</tr>
<tr>
<td>Psychological support</td>
</tr>
<tr>
<td>Support for siblings</td>
</tr>
<tr>
<td>Pre and post-bereavement advice</td>
</tr>
<tr>
<td>Continuity of staff, at least one of them, i.e. the key worker</td>
</tr>
<tr>
<td>Education and/or special education</td>
</tr>
<tr>
<td>Social work input</td>
</tr>
<tr>
<td>Play, art, music etc. therapies</td>
</tr>
<tr>
<td>Record keeping mechanisms and facilities</td>
</tr>
<tr>
<td>Administrative, clerical and information and communication technology support</td>
</tr>
<tr>
<td>Provision of aids, equipment, housing modifications etc.</td>
</tr>
<tr>
<td>Complementary therapies</td>
</tr>
</tbody>
</table>
### Table 4: Glossary of terms used to describe some of the skills needed in paediatric palliative care.

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paediatric palliative care</strong></td>
<td>the sum total of respite and all forms of palliative expertise in children.</td>
</tr>
<tr>
<td><strong>Symptom management</strong></td>
<td>the preferred use of this term is in a holistic sense to include attention to physical, psychosocial and spiritual aspects of symptoms. In many documents, the term is often used in a more restricted fashion to mean only control of the physical aspects of symptoms. To distinguish between the two this document uses the term ‘holistic symptom management’ for the former and ‘symptom control’ for the latter. Thus symptom control is a part of holistic symptom management, as are psychological and bereavement support.</td>
</tr>
<tr>
<td><strong>Respite care</strong></td>
<td>care whose main function is to relieve the family of the burden of care by providing support in the home or an alternative ‘home-like’ environment such as a children’s hospice. Respite care will often incidentally address some aspects of holistic symptom management.</td>
</tr>
<tr>
<td><strong>Generic palliative care</strong></td>
<td>palliative care skills that might be expected to result from medical or nursing training in paediatrics or child health.</td>
</tr>
<tr>
<td><strong>Semi-specialist paediatric palliative care</strong></td>
<td>skills in holistic symptom management that may be expected from any specialty paediatrician or paediatric clinical nurse specialist with expertise in one particular condition or a narrow range of conditions. Examples include paediatric oncologists, CNS in cystic fibrosis. Adult physicians with palliative medicine training would be a special category within this.</td>
</tr>
<tr>
<td><strong>Specialist paediatric palliative care</strong></td>
<td>skills in holistic symptom management that may be expected from paediatricians with specialist training in palliative medicine, or CNS in paediatrics and palliative care.</td>
</tr>
<tr>
<td><strong>Recommendations by RCPCH/ACT</strong></td>
<td><strong>Current Provision</strong></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td><strong>1.</strong> The needs of children with life-limiting conditions have been thoroughly assessed in a number of recent studies. Commissioners should use this research which is unlikely to need further validation for local applicability (section 5 introduction).</td>
<td>No unnecessary research being undertaken. (6/12)</td>
</tr>
<tr>
<td><strong>2.</strong> Children with life-limiting conditions should be recognised as a discrete group and commissioners should work with NHS trusts to set up a robust local database of these children (sections 4.3.1,8.1.1 ).</td>
<td>No specific database, but overlap with Special Needs Registers being developed in different regions (5/12)</td>
</tr>
<tr>
<td><strong>3.</strong> A flexible children's palliative care service, recognising each family’s individual needs, should be provided in each district. It should be available over a long term as well as when death approaches (section 8.3.4).</td>
<td>Flexibility very limited: Inconsistent community paediatric nursing team cover ‘Palliative care’ not well defined Palliative care team often poorly defined. (6/12)</td>
</tr>
<tr>
<td><strong>4.</strong> Every district should have a senior paediatric professional as coordinator of children's palliative care. The need for coordination of the network of services should be included in purchasing specifications (section 8.3.1 - 8.3.6).</td>
<td>Coordinator for continuing care but not palliative care. Multidisciplinary specialist paediatric palliative care ‘teams’ not yet in a position to take on this role. Specialist nurse(s) in paediatric palliative care needed. (6/12)</td>
</tr>
<tr>
<td><strong>5.</strong> Community children's nursing teams are essential for the management of children with palliative care needs. Commissioners should facilitate their establishment and/or development to address the needs of this caseload (section 9.3.1 iii).</td>
<td>Established CCNS in Gwent and Bro Taf., under development in Iechyd Morgannwg. (8/12)</td>
</tr>
<tr>
<td><strong>6.</strong> Occupational therapy and physiotherapy are a crucial part of children's palliative care and children should have access to them in the community (section 9.3.1 iv).</td>
<td>Inconsistent provision in the community. Better for children in III and IV as often coordinated through special school. Play specialist available to oncology children at Llandough. (5/12)</td>
</tr>
<tr>
<td><strong>7.</strong> In addition to respite provided by social services and social work departments, respite with medical and nursing input should be available locally or within a short distance.</td>
<td>Very little residential respite care. Monday to Friday, Ty Hafan and Ty Gobaith/Hope House provide inpatient ‘specialist respite’ (6/12)</td>
</tr>
<tr>
<td><strong>Commissioners should ensure a choice of such health-based respite by purchasing or commissioning a variety of services both within and outside the district's boundaries (sections 9.8, 9.8.3).</strong></td>
<td><strong>Most patients have a care plan, but often fragmented in absence of coordinated palliative care team. (5/12)</strong></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>8. Each child and family should have a care plan, drawing together the provision of all components of care; where appropriate, voluntary agencies should be recognised as integral to the care plan. (section 9.2.1).</strong></td>
<td><strong>Inconsistent. Many specialist services (especially neonates, oncology, respiratory and renal paediatrics) have Clinical Nurses Specialists who are experienced, but not usually formally trained, in palliative care (4/12)</strong></td>
</tr>
<tr>
<td><strong>9. Each family should have its own named keyworker who is responsible for the coordination of the care plan, ensuring that total care, not just healthcare, is available (sections 8.4.1, 9).</strong></td>
<td><strong>Inconsistent. Usually poor. Patient-held records not widely used, but are being developed. (5/12)</strong></td>
</tr>
<tr>
<td><strong>10. Continuity of care is vital. Speedy communication and clear documentation of management plans and treatment sheets are essential; parents should hold the record in case emergency care is required (section 8.4.2).</strong></td>
<td><strong>Continuing care guidelines clear but access often too slow for urgent palliative care needs. (4/12)</strong></td>
</tr>
<tr>
<td><strong>11. NHS trusts, purchasers and general practitioners need to develop a clear mechanism for the accessibility and funding of medications, disposable medical and nursing supplies and medical equipment (section 9.3.3iii).</strong></td>
<td><strong>Still an obvious problem in most areas. Local implementation of flexibilities under the Health Act 1999 (e.g. pooling of resources) likely to improve current situation eventually. (2/12)</strong></td>
</tr>
<tr>
<td><strong>12. Families should not be caught up in a financial and bureaucratic trap caused by disagreement between health, education and social services/social work departments over the provision and funding of aids, respite care and housing adaptations. The agencies must not delay in reaching urgent agreement over funding and timely provision (section 9.3.4).</strong></td>
<td><strong>Few teenagers access adult palliative care services. Access to specialist paediatric services inconsistent (NB many teenagers still seen by adult physicians e.g. haematology) (1/12)</strong></td>
</tr>
<tr>
<td><strong>13. Services should be developed to meet the needs of older teenagers and young adults requiring palliative care. Partnerships between children's and adult services should be developed to help with the transition (section 9.8.5).</strong></td>
<td></td>
</tr>
</tbody>
</table>
14. A tertiary network of children's palliative care specialists should be developed as a resource for local professionals and a basis for advice, training and research (section 10.2.2v).

<table>
<thead>
<tr>
<th>Table 5:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>14. A tertiary network of children's palliative care specialists should be developed as a resource for local professionals and a basis for advice, training and research (section 10.2.2v).</td>
<td>Single tertiary specialist in post. His academic and clinical roles cover all of Wales, in direct clinical or advisory capacity. (6/12)</td>
</tr>
<tr>
<td>15. Children's palliative care courses for nurses need to be developed. Training should be provided for all other professionals in the field (sections 10.2.3, 10.2.4).</td>
<td>Medical diploma available. Nursing diploma under development (4/12)</td>
</tr>
<tr>
<td>16. All staff working closely with families should have formal psychological support and supervision written into their job descriptions (section 10.2).</td>
<td>Psychologists generally supportive, but constraints on staff numbers mean arrangements are informal and ad hoc (4/12)</td>
</tr>
</tbody>
</table>

**Table 5:** Recommendations of ACT/RCPCH guidelines (3) for Paediatric Palliative Care Services, and how, in the view of a multidisciplinary group, services matched up to them in November 2002. Scores are out of 12, where 12=fully met and 0 =not met at all. Although this study was done in Wales, it is likely that the results are illustrative of the situation in the United Kingdom as a whole.

It can be seen that the most pressing concern was services for teenagers, adolescents and young adults.
Table 6: Diagnosis of patients reported by paediatricians in the WPSU study or referred to specialist PPM (5). Patients in group 1 (mainly cancer) are an important group, but more children did not have cancer. Children with non-malignant conditions were less likely to be referred for specialist palliative medicine.

<table>
<thead>
<tr>
<th></th>
<th>Reported by paediatrician to have palliative care needs, but not referred for specialist PPM.</th>
<th>Referred to specialist paediatric palliative medicine service</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>4</td>
<td>35</td>
<td>29</td>
</tr>
<tr>
<td>Group II</td>
<td>3</td>
<td>15</td>
<td>18</td>
</tr>
<tr>
<td>Group III</td>
<td>10</td>
<td>5</td>
<td>15</td>
</tr>
<tr>
<td>Group IV</td>
<td>16</td>
<td>13</td>
<td>29</td>
</tr>
</tbody>
</table>
Table 7: recommendations made by Joint Working Group of ACT and National Council for Hospice and Specialist Palliative Care Services for palliative care among adolescents (4).

- Recognition as a distinct group
- Involvement in decision-making
- Multidisciplinary, multi-agency services
- Link and key workers
- Joint Health/Social Service planning
- Psychological, spiritual services
- Transition planning from children’s services
- Specific training in
  - palliative care
  - management of young people
Table 8: Potential members of a multidisciplinary team in paediatric palliative care.

- Senior lecturer/consultant in paediatric palliative care and SpR hold the ring by advising, supporting and training locally, regionally and centrally.
- Community or other sub-specialised paediatrician with special interest in paediatric palliative care, and admission rights
- Clinical nurse specialist in paediatric palliative care (when available)
- Community children’s nurse(s) with wide networks with other nurses working with children in community, hospitals and hospice
- Clinical nurse specialists, eg. oncology, respiratory, neonatal care
- Clinical psychologist
- Chaplaincy
- Therapists
- Social worker
- Others, such as NNEBs, healthcare and care assistants, etc. according to need
- Administrative, clerical and ICT support staff
Fig 1: Children needing palliative care. It can be seen that although the skills of general paediatrician, children’s hospice and specialist palliative medicine paediatrician (PPM) overlap, they are far from the same.
Fig 2: Supporting the supporters. The challenge for specialist paediatric palliative care is to provide support to many different professionals in several different clinical environments. Current interprofessional, interdisciplinary and internecine boundaries mean that families are typically cared for by a number of teams working independently. While this model works well for some children, for others the specialist can optimise the delivery of palliative care in part by providing common ground on which to base these vertical supports.
Fig 3: Relationship of referrals to geographical location in Wales. The ratio of children reported by paediatricians to have PPC needs but not referred (bnr) to those actually referred for specialist PPM is related to distance from Cardiff, (•) where specialist services are based. Children with palliative care needs who are at some distance from Cardiff are less likely to be referred even when their needs are recognised. This supports the ACT/RCPCH recommendation (1, 3) for a national network of tertiary specialists.